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Summary 
Triple-negative breast cancer (TNBC) is defined by the lack of expression of the 
oestrogen and progesterone receptors and the overexpression of HER-2. Recently, 
carbon monoxide (CO) was found to behave as an important endogenous signalling 
molecule and interestingly, to suppress vascular endothelial growth factor receptor-2 
(VEGFR2) and protein kinase B (AKT) phosphorylation. Given that anti-angiogenic 
drugs exist as one of the few available therapies against TNBC, CO-releasing molecules 
(CORMs) could be used as part of a combination therapy, in order to reduce cancer-
driven angiogenesis. Therefore, the aim of this project was to study any potential anti-
angiogenic properties of four commercially available CORMs and after the selection 
and structural modification of one of them, new analogues would be synthesized and 
evaluated in vitro. The four commercially available CORMs were screened for 
cytotoxicity against TNBC, epithelial and endothelial cells and found to be moderately 
toxic. They were also shown to reduce the glycolytic metabolism of TNBC cells, 
decrease VEGF excretion from both TNBC cell lines tested and downregulate the 
expression of the cytoprotective enzyme haem oxygenase-1 (HO-1). They were finally 
reported to moderately inhibit the activation of VEGFR2 and other downstream 
proteins upon stimulation with VEGF and reduce the tube formation ability of 
endothelial cells. These results were crucial for the selection of one lead compound, 
which was subjected to structural modifications and 15 new analogues were 
produced. The new molecules showed a more favourable cytotoxicity profile, with 
two of them being selectively toxic against TNBC. All the 15 analogues retained the 
ability to reduce VEGF excretion from TNBC cells and two of them were chosen for 
further studies. These two complexes downregulated the expression of HO-1 at 
similar levels and reduced the phosphorylation of some VEGFR2 downstream proteins 
more than the parent compound. Finally, both CORMs decreased the tube formation 
activity of endothelial cells. In summary, two of the commercially available and two 
of the newly synthesized CORMs showed promising anti-angiogenic properties and 
should be pursued further, in order to identify a mechanism of action for these 
organometallic complexes.  
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1.1 Breast cancer 
1.1.1 General characteristics of cancer 
Cancer is a family of diseases that involves abnormalities in cell growth, with the 
potential to invade or spread to other parts of the body. The malignant progression 
from normal cells to cancer cells is a complex cascade with many steps, where the 
rate of cell division is disrupted and dysregulated (Sharma et al. 2010). Rapidly dividing 
and growing tumour cells progressively accrue mutations that help them deviate even 
more from normal behaviour. There are six hallmarks of cancer, which are required 
features for a cell to be able to form a malignant tumour and be characterized as 
cancerous. These hallmarks include:   
• Sustaining proliferative signalling 
• Evading growth suppressors 
• Resisting cell death 
• Enabling replicative immortality 
• Promoting angiogenesis 
• Activating invasion and metastasis 
Four novel hallmarks have also been described during the last decade. The first is 
reprogramming of energy metabolism, referring to the ability of cancer cells to 
reprogram their glucose metabolism, even in oxygen abundance, favouring glycolysis 
for their energy production. The second emerging hallmark is genome instability and 
mutation, indicating the abundant genome maintenance and repair defects found in 
many tumours, combined with the destabilization of gene copy number and 
nucleotide sequence. Genome instability is an enabling characteristic associated with 
the acquisition of the other hallmarks, since these defects have been proven 
advantageous by accelerating the rate of favourable genotype accumulation. The 
third hallmark is tumour-promoting inflammation that supplies necessary molecules 
to the tumour microenvironment, mainly growth factors, survival factors, pro-
angiogenic factors and inductive signals for EMT. The final hallmark is evading immune 
suppression. Immunogenic cells such as cancer cells can evade the immune response 
by disabling eliminating components of the immune system, expressing 
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immunosuppressive molecules and recruiting immunosuppressive inflammatory cells 
(Hanahan and Weinberg 2011). 
The causes of cancer progression are various, but around 40% of them are 
preventable by changing lifestyle factors. A small percentage of 10% are due 
to hereditary genetics.  Common factors that contribute to cancer initiation according 
to the US National Cancer Institute (www.cancer.gov) include age, smoking, alcohol 
consumption, unhealthy diet and obesity, infections, radiation (both ionizing and non-
ionizing), cancer-causing substances, chronic inflammation, hormones, 
immunosuppression (linked also to stress) and sunlight (Anand et al. 2008). 
Carcinogenesis is a process divided into three defined stages: initiation, promotion 
and progression. During initiation irreversible changes alter the genotype of the target 
stem cell leading to immortality. The main process responsible is the interaction of 
the carcinogen or its active metabolites with nucleic acids leading to mutations in 
oncogenes and tumour suppressor genes. During the second stage of promotion, an 
immortalized cell acquires the phenotype and abilities of a malignant cell and can 
provoke tumour progression. The carcinogen interferes also with the 
microenvironment of the target stem cell in order to promote the immortalized cell. 
The stage of promotion requires prolonged exposure to the carcinogen and may be 
reversible, otherwise it leads to tumour progression. Therefore, carcinogenesis could 
be described as a cascade phenomenon, resulting in the serial activation of multiple 
oncogenes and/or the inactivation of tumour suppressor genes. As expected, age 
decisively contributes to carcinogenesis, as the accumulation of several mutations 
through the years facilitates both the initiation and promotion of cancer, so aging is 
characterized as a major risk factor (Anisimov 2007).  
Management of the different types of cancer involves a combination of treatment 
techniques such as radiation therapy (radiotherapy), surgery, chemotherapy – 
sometimes in the form of targeted therapy –, immunotherapy and palliative care 
(Maughan et al. 2010; Kaufmann et al. 2013). 
Most cancer patient deaths occur due to metastasis of their primary tumour to vital 
organs. Metastasis is defined as the spread of cancer to other parts of the body 
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discontinuous from the primary lesion. It is mostly encountered during the late stages 
of tumour progression and it can occur via the bloodstream or the lymphatic system. 
The metastatic cascade includes local invasion of the primary tumour 
cells, intravasation into the bloodstream or lymph, migration to the target 
site, extravasation and invasion into the target tissue, and establishment of a 
proliferating secondary tumour assisted by induced angiogenesis. Different subtypes 
of cancer have a propensity towards particular organs, but overall the most common 
sites for metastases to occur are the lungs, liver, brain and bones (Keller 2002). 
1.1.2 Breast cancer  
Cancer deriving from the mammary gland (breast cancer, BC) is the most common 
cancer type in women and the second most common cancer type worldwide. With 
almost two million newly diagnosed cases every year, it remains the most frequent 
cause of cancer-related death in women globally, whereas the new cases of invasive 
breast cancer in the UK exceed 55,000 per year (Cancer Research UK). The increasing 
occurrence, the complexity and the heavy economic impact of the required treatment 
to the overall health system expenditure make breast cancer one of the most urgent 
health problems in our society (Wehland et al. 2012; Kalimutho et al. 2015). 
However, from the early 1990’s onwards, the mortality rate has decreased by more 
than 30% in the western world and especially in the UK, breast cancer survival has 
doubled in the last 40 years (Figure 1.1). This was a result of several measures 
implemented either concerning the prevention or the management of early breast 
cancer, as well as the introduction of adjuvant and neoadjuvant therapies and 
targeted treatments for oestrogen receptor positive breast tumours (Jemal et al. 
2010; Kaufmann et al. 2013). 
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Figure 1.1: Observed and projected mortality rates of breast cancer in the UK from 1979 to 2035. 
Source: Cancer Research UK. Access date 1/2/2018. 
The most common histological type of breast cancer is breast adenocarcinoma, which 
requires a long evolution period from normal to invasive carcinoma. The first stage of 
malignant transformation of the normal epithelium is characterized by excessive 
proliferation, known as hyperplasia. At the later stage of carcinoma in situ, cells 
progress to have a fully malignant phenotype, except for the ability to invade 
surrounding tissues through the basal membrane. Finally, carcinoma cells acquire 
invading activity and spread to surrounding areas through the basal membrane (Allred 
et al. 2001; Adeyinka et al. 2002). 
Since breast cancer is a complex and highly heterogeneous disease regarding tumour 
morphology and gene expression, it is logical to expect that the response to the 
administered treatment would also vary among patients. Recent classification 
attempts revealed a diverse profile for breast cancer, thus the molecular subtypes 
established include; Basal-like (including triple negative breast cancer), Luminal A, 
Luminal B, HER2-amplified, Normal breast-like, and Claudin-low tumours (Figure 1.2 
A). However, for prognostic and everyday clinical classification purposes the 
expression of only three surrogate key proteins (–biological markers) is assessed; the 
oestrogen receptor (ER), the progesterone receptor (PR) and the human epidermal 
growth factor receptor 2 (HER2). According to their expression, breast tumours can 
be categorized in the clinic as hormone receptor (HR)-positive/ HER2-negative, HR-
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positive/ HER2-positive, HR-negative/ HER2-negative and HR-negative/ HER2-
positive, following immunohistochemical analysis. These subtypes differ greatly in 
incidence, survival rates and overall response to treatment (Yamamoto and Iwase 
2010; Wehland et al. 2012; Jansson et al. 2014; Kalimutho et al. 2015). Regardless of 
molecular subtype, advanced age, severe comorbidity, advanced stage at diagnosis, 
lobular carcinoma and urban residence were correlated with higher mortality rates. 
As for each subtype, HR-positive/ HER2-negative had the longest survival, followed by 
HR-positive/ HER2-positive, whereas the HR-negative/HER2-negative had the poorest 
observed survival (Fallahpour et al. 2017) (Figure 1.2 B). 
A.   
 
B.  
 
Figure 1.2: A. Molecular classification of breast cancer. (The Luminal B subtype can vary in marker 
expression but is generally ER-positive and HER2-positive or HER2-low with a high Ki67 ≥14%.)  
Source: (Malhotra et al. 2010). B. Overall breast cancer survival by molecular subtype. Source: 
(Fallahpour et al. 2017). 
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Both oestrogen and progesterone (Figure 1.3) are crucial hormones for the female 
organism. They are responsible for the development and correct function of the 
female reproductive system, menstrual cycle and secondary sex characteristics, as 
well as pregnancy and embryogenesis. Their receptors (ER and PR respectively) both 
act by binding to specific DNA regions (hormone response element – HRE) to activate 
target genes and regulate gene expression (Li et al. 2004; Lin et al. 2004). 
            
Progesterone               Oestrogen (17β-Oestradiol) 
Figure 1.3: Chemical structures of progesterone and oestrogen 
More specifically, ER can be found in tissues such as the ovary, uterus and breast, 
having an important role in promoting the proliferation of the tissues’ cells. This 
receptor is also responsible for cholesterol level control and preservation of bone 
density. However, oestrogen could also prove harmful, since its gene expression 
regulatory activity could have adverse effects on the cells, increasing the chance for 
malignant mutations (Arsenyan et al. 2014). It is a fact that the vast majority of breast 
cancers present a marked dependence on oestrogen to grow, and they are 
characterized as hormone-sensitive or HR-positive cancers (Lin et al. 2004). The 
mechanism of ER activation is schematically depicted in Figure 1.4. 
On the other hand, the human epidermal growth factor receptor (HER) family 
comprises tyrosine kinase receptors responsible for the growth and development of 
the breast, along with other organs. Ligands binding to their corresponding HER result 
in homo- or hetero-dimerization of the receptor, which subsequently activates 
downstream signalling involving trans-phosphorylation of tyrosine residues. HER2 is 
the most important receptor in breast tumours, since it does not have a known ligand 
and it acts upon cross-activation by a partner receptor bound to its ligand. Moreover, 
it is also the preferred heterodimerization partner for the other HERs. HER2 
overexpression can lead to signal activation regardless of the ligand binding status, 
thus initiate the downstream signalling pathway in a ligand-independent manner. This 
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pathway eventually leads to cell progression, proliferation and survival, promoting 
tumour growth and perseverance (Creedon et al. 2014). Indeed, HER2 gene 
amplification is found in 15–20% of patients with invasive breast cancer, and is linked 
with increased risk of metastasis and death.  
 
Figure 1.4: ER and HER activation mechanisms and downstream signalling pathways. Source: 
(Johnston 2010). 
1.1.3 Therapeutic interventions 
Breast cancer management usually depends on clinical and histopathological 
characteristics, such as tumour size, tumour grade, node status, age of the patient, 
metastasis staging and most importantly, hormone receptor expression status 
(Maughan et al. 2010; Reddy et al. 2012; Westbrook and Stearns 2013). 
The usual treatment options combine surgery, radiation therapy and chemotherapy. 
The surgical treatment includes removal of the whole breast (mastectomy), removal 
of one quarter of the breast (quadrantectomy/ partial mastectomy) or removal of only 
a small part of the breast (lumpectomy).  
In most cases, surgery is followed by radiation therapy, which inevitably involves 
exposure to radiation of normal tissues along with the tumour area. This may lead to 
severe side effects caused by the incidental exposure of the heart and the lungs, 
currently minimized by more modern precisely targeted application techniques.  
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Chemotherapy involves cytotoxic agents, referred to as adjuvant or neoadjuvant 
therapies, according to their administration simultaneously or prior to the main 
treatment.  In that scope, there are more personalized biological treatment options 
including endocrine therapies for ER-positive tumours, and tissue-targeted therapies 
for tumours overexpressing HER2 (Maughan et al. 2010; Kaufmann et al. 2013). 
However, all these therapies have potential side effects and limited efficacy in most 
of the cases. It is also evident that tumours lacking HR expression and HER2 
overexpression are even more challenging to treat. Therefore, HR- and HER2- negative 
breast tumours have very few treatment options, and for these cases doctors usually 
exploit combination regimens (Reddy et al. 2012). 
1.2 Triple negative breast cancer 
1.2.1 General characteristics 
Triple negative breast cancer (TNBC) is a subtype of BC defined as lacking the 
immunohistochemical expression of ER, PR and not showing overexpression of 
HER2/neu protein or HER2/neu gene amplification. It accounts for 15 – 20% of all 
invasive breast cancers and occurs more commonly in younger women and women of 
black race or Hispanic ethnicity (Andreopoulou et al. 2015). Other risk factors include 
higher parity, young age at the time of first birth and diagnosis, use of oral 
contraceptives by women less than 40 years old, lower socioeconomic status, 
increased body weight and the existence of metabolic syndrome (Yamamoto and 
Iwase 2010). 
Although "triple negative" is not synonymous to "basal like", the molecular signature 
of TNBC frequently overlaps with basal like, in approximately 80% of the cases, based 
on PAM50 intrinsic subtype classification (Bertucci et al. 2008). Indeed in most cases, 
TNBC has a basal-like molecular phenotype by gene expression profiling, and shares 
clinical and pathological features with hereditary Breast Cancer 1 (BRCA1)-related 
breast cancers (Yadav et al. 2014; Andreopoulou et al. 2015). It is, in fact, associated 
with a higher probability of BRCA1 mutation (breast cancer susceptibility gene). The 
clinical and molecular characteristics of TNBC subtype are summarized in Table 1.1.  
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Clinical 
• Accounts for ~ 15% of all breast cancers  
• More common in women of black race and/or Hispanic ethnicity 
• Younger age at presentation (<40 years old) 
• Higher risk of visceral metastases, including brain metastasis 
• Associated with germ-line BRCA mutations in ~ 50% of patients with a strong family 
history of breast and/or ovarian cancer, and up to 20% of unselected patients 
Molecular 
• Basal-like subtype and claudin-low subtypes are the most common ‘intrinsic subtypes’ 
by gene expression 
• When present, BRCA mutations are associated with defective DNA repair and sensitivity 
to DNA damaging agents and poly-ADP-ribose-polymerase inhibitors 
• Sporadic cancers not associated with BRCA mutations are often BRCA-like due to 
methylation-induced silencing of BRCA1 and/or loss of other DNA repair proteins 
• Commonly associated with somatic p53 mutations, but ‘clinically actionable’ aberrations 
occur in < 20% (BRAF V600E, high-level EGFR amplifications, and ERBB2 and ERBB3 
mutations) and may not be driver aberrations 
• PI3K pathway activation, despite the low PI3K mutation rate, due to PTEN and INPP4B 
loss and/or amplification of PIK3CA 
Table 1.1: Summary of clinical and molecular characteristics of TNBC. Adapted from (Andreopoulou 
et al. 2015). Abbreviations used: BRCA:  Breast cancer 1, human tumour suppressor gene. BRAF 
V600E: Serine/threonine-protein kinase B-Raf gene. EGFR: Human epidermal growth factor 
receptor. ERBB2: Human epidermal growth factor receptor 2. ERBB3: Human epidermal growth 
factor receptor 3. PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase. PTEN: Phosphatase and 
tensin homolog gene. INPP4B: Inositol polyphosphate- 4-phosphatase gene. 
PIK3CA:  Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha. 
Although sensitive to chemotherapy, TNBC has an intrinsic aggressive clinical course 
associated with a 4-fold increased risk of distant recurrence, high rates of visceral (84 
vs 61%, p<0.001) and central nervous metastases and worse prognosis after 
recurrence than HR-positive subtypes. The actual risk of recurrence increases rapidly 
in the first three years, peaking between one and three years after diagnosis, and 
mostly occurs within five years of diagnosis (Dent et al. 2007; Mayer et al. 2014; 
Andreopoulou et al. 2015; Marmé and Schneeweiss 2015). More specifically, the 
expected survival of patients with metastatic TNBC is rarely over 12 months, and 
eventually all women with this disease will die of it, despite systemic therapy (Fosu-
Mensah et al. 2015). 
In fact, TNBC represents a highly heterogeneous group characterized by extreme 
genomic alterations and instability. A recent study has revealed at least seven distinct 
molecular subtypes defined by their gene expression profiles, which differ in 
important biological pathways and prognosis. Basal-Like 1 and 2 (BL1 and BL2) show 
higher expression of cell cycle and DNA response gene damage; Immunomodulatory 
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(IM), Mesenchymal (M) and Mesenchymal Stem-Like (MSL) are enriched with 
epithelial mesenchymal transition (EMT) genes; Luminal Androgen Receptor (LAR) 
highly expresses genes involved in androgen receptor (AR) signalling; while the 
unclassified is based on gene ontology analysis (Lehmann et al. 2011; Marmé and 
Schneeweiss 2015) (Table 1.2). Distinguishing the different subtypes from one 
another remains a challenging task at clinical histologic examination, and as a result 
of this heterogeneity, it is inappropriate to treat all TNBCs in a uniform fashion, as 
variations in morphology and biological characteristics result in differences in clinical 
presentation and response to therapy (Fosu-Mensah et al. 2015). 
Tumours of this subtype are almost all ductal invasive adenocarcinomas, mostly 
categorized as grade 3, with a high rate of p53 mutations. TNBCs are less likely to be 
diagnosed at screening mammography because of the age distribution, and tend to 
be diagnosed at a higher stage (Guarneri et al. 2013). 
TNBC tumour subtype 
After neoadjuvant 
chemotherapy pathological 
complete response rates (%) 
Candidate therapeutic targets 
Basal – like (BL2) 8 EGFR, MET, EPHA2, mTOR 
Luminal androgen 
receptor (LAR) 
10 AR, Hsp90, PI3K, FGFR4 
Mesenchymal stem – 
like (MSL) 
23 
SRC, PI3K, MEK1/2, mTOR, 
PDGFR, NFKβ, IGF1R, FGFR, 
TGFBRIII 
Immunomodulatory (IM) 30 
JAK1/2, LYN, STATs, IRF1/7/8, 
BTK, NFKβ 
Mesenchymal (M) 31 SRC, PI3K, Mtor, IGF1R, PDGFR, 
Unstable (UNS) 33 
PARP1, TTK, PLK1, CHEK1, 
AURKA/B, RAD51 
Basal – like (BL1) 52 
PARP1, TTK, PLK1, CHEK1, 
AURKA/B, RAD51 
Table 1.2: Nomenclature and classification of TNBC. TNBC is molecularly heterogeneous and has 
been subdivided into seven definable molecular subclasses governed by distinct sets of genes and 
pathways. Each of these subclasses shows varying pathological complete response rates following 
neoadjuvant chemotherapy and may be amenable to targeted therapies using different molecular 
targets. Adapted from (Kalimutho et al. 2015). 
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1.2.2 Current therapeutic options 
Management of TNBC remains challenging because of the lack of approved therapies, 
its aggressive behaviour and its relatively poor prognosis. There are no specific 
treatment guidelines for patients with TNBC and, unlike other molecular subtypes of 
breast cancer, there is no validated specific biomarker for TNBC, so they are just 
managed with standard chemotherapy treatments (as discussed below) (Sagara et al. 
2017). Although it has been evidenced that these tumours are more sensitive to 
chemotherapy than other subtypes and in some cases, complete pathological 
response (pCR) is achieved, the results remain unsatisfactory. This is because even 
though pCR to the neoadjuvant chemotherapy is higher in the TNBC subset of 
patients, the disease free survival (DFS) and overall survival (OS) are still lower than in 
the non-TNBC patient group. The high biological heterogeneity within the TNBC 
subtype represents the major challenge for new drug development, and has clear 
implications for clinical trial design. A better understanding of its pathogenesis onset 
and progression, including the still unclear association with BRCA1 mutations, and the 
causes of phenotypic heterogeneity will be the key to a new treatment for this 
disease. Several experiments are being carried out and while some have failed, others 
have led to an improved understanding of the biology of the disease and the tumour 
cell environment, helping to find new biomarkers and potential targeted treatments. 
However, finding an effective treatment for TNBC is still urgently needed. The 
following are the therapeutic options currently available in TNBC (Guarneri et al. 2013; 
Mahamodhossen et al. 2013; Yadav et al. 2014; Zhang et al. 2015) (Figure 1.5): 
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Figure 1.5: Potential therapeutic targets for TNBC. Current and future potential targets in TNBC 
include inhibitors of the impaired homologous recombination repair mechanism, modulation of 
the p53 signalling, antagonists of the androgen receptor and inhibitors of its pathway and inhibitors 
of the MAPK/MEK pathway. Source: (Mayer et al. 2014).  
➢ Systemic cytotoxic chemotherapy 
Due to the fact that TNBC is characterized by the loss of target receptors such as ER, 
PR and HER2, patients do not benefit from hormonal or trastuzumab-based therapies. 
Surgery, where applicable, and cytotoxic chemotherapy remain the mainstay of 
treatment for TNBC, despite the lack of long-term effectiveness. Early stage TNBC is 
usually addressed by a combination of cytotoxic agents used as an adjuvant or 
neoadjuvant therapy. Standard adjuvant and neoadjuvant regimens typically involve 
an anthracycline (doxorubicin or epirubicin) plus an alkylating agent 
(cyclophosphamide), administered either simultaneously with a taxane (docetaxel) or 
sequentially before or after a taxane (docetaxel or paclitaxel). As for their mechanism 
of action, anthracyclines can inhibit DNA and RNA synthesis obstructing the 
replication of the rapidly proliferating cancer cells, inhibit topoisomerase II enzyme 
hindering DNA transcription and provoking double-strand breaks, enhance the 
production of reactive oxygen species and deregulate DNA damage response (Pang et 
al. 2013). Cyclophosphamide has a different mechanism of action, causing toxicity due 
to its metabolite phosphoramide mustard. This metabolite is produced only in cells 
expressing low levels of aldehyde dehydrogenase, such as cancer cells. The mustard 
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can form DNA crosslinks between and within the DNA strands, leading to cell 
apoptosis (Hall and Tilby 1992). On the other hand, taxanes are mitotic inhibitors, 
disrupting microtubule function during cell division by hindering their 
depolymerisation (McGrogan et al. 2008). Unlike other types of breast cancer, few 
studies have been specifically designed for evaluating novel treatments against TNBC 
and their results remain inconclusive. Although the recurrence rate of TNBC is higher 
than other subtypes, it initially has an increased sensitivity to conventional 
chemotherapy than HR-positive breast cancers, as mentioned above (Yamamoto and 
Iwase 2010; Andreopoulou et al. 2015; Fosu-Mensah et al. 2015). 
➢ Platinum – based chemotherapy 
Platinum agents are one of the established drug classes that are considered in the 
treatment of TNBC. Platinum-based compounds, including carboplatin and 
cisplatin, are DNA interacting agents that lead to intra- and inter-strand cross links 
of double stranded DNA, prevent the formation of the replication fork and 
produce double strand breaks and replication lesions. These breaks result in 
impairment of DNA synthesis, especially in cells whose DNA repair cascade is non-
functional, like when deficient in homologous recombination repair mechanisms, 
such as BRCA1/2-mutated cells, including the majority of TNBC cases. This 
deficiency leads to an increased sensitivity to chemotherapeutic agents that cause 
DNA damage, because when a cell has reparatory defects, error-prone 
compensatory repair mechanisms step in and lead to a high degree of genomic 
instability, finally leading to its death. At present, platinum agents, as a component 
of neoadjuvant chemotherapy, cannot be recommended over established 
regimens outside of a clinical trial because none of the studies was able to detect 
disease-free or overall survival benefit (Mayer et al. 2014). Therefore, they should 
always be used in combination with taxanes or anthracyclins to increase response 
and survival rates. However, patients with BRCA1 mutation tend to have maximum 
benefit in the neoadjuvant setting (Yamamoto and Iwase 2010; Mayer et al. 2014; 
Yadav et al. 2014; Andreopoulou et al. 2015; Fosu-Mensah et al. 2015; Marmé and 
Schneeweiss 2015). 
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➢ Poly adenosine diphosphate ribose polymerase (PARP)-1 Inhibitors 
A relatively novel therapeutic target for TNBC is the enzyme PARP-1. As mentioned 
above, cells with abnormal repair mechanisms, like BRCA1/2-deficient cells, are over-
sensitized to the effects of other DNA repair mechanisms-targeting agents, a concept 
known as synthetic lethality (Fosu-Mensah et al. 2015). PARP-1 is essential for DNA 
single-strand breaks repair through regulating the DNA base excision pathway. DNA 
single-strand breaks are subsequently accumulated upon PARP-1 inhibition by RNA 
interference or with chemical inhibitors (Mayer et al. 2014). In cells with normal BRCA 
function, this leads to the activation of the homologous recombination pathway. 
However, tumour cells with BRCA dysfunctions are unable to deal with this break 
accumulation, therefore undergo apoptosis (Yamamoto and Iwase 2010).  
Some of the anticancer PARP inhibitors described in preclinical and clinical models are 
iniparib, olaparib, veliparib and rucaparib. Although PARP inhibitors have shown 
clinical activity in TNBC patients, there are still issues to be addressed such as the still 
limited experience, the selection of appropriate combinations with other drugs, the 
optimal route of administration, the duration of the therapy and the possible toxicities 
following the combination therapy (Yadav et al. 2014). PARP inhibitor resistance in 
BRCA-associated tumours has also been reported (Marmé and Schneeweiss 2015). 
➢ Tyrosine kinase Inhibitors 
A wide variety of cell surface receptors include a tyrosine kinase domain, whose 
enzymatic activity is to transfer a phosphate group from ATP to a tyrosine residue on 
a protein.  These receptor tyrosine kinases (RTKs) are critical regulators of important 
cellular processes, such as cell proliferation, differentiation, survival, metabolism, 
migration and cell cycle control. Many cancers and their metastatic progression are 
characterized by the deregulation of RTKs, therefore, they present a useful anticancer 
target. In this scope, several RTK inhibitors have been developed which block or 
constrict RTK activity to target TNBC (Fosu-Mensah et al. 2015). A few of them are 
listed below: 
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▪ Epidermal Growth Factor Receptor (EGFR) Inhibitors 
Epidermal growth factor receptor (EGFR), along with its downstream signalling 
pathway, is important for cell growth, survival and apoptosis. Since the majority of 
TNBC tumours overexpress EGFR and this high expression is linked to a poor 
prognosis, attempts have been made towards using approved EGFR inhibitor drugs. 
Gefitinib, erlotinib, lapatinib and neratinib are under investigation, however recent 
studies indicate that EFGR inhibition alone is not enough, therefore a combination 
therapeutic strategy comprising of more RTK pathways-inhibitors seems more likely 
to be successful (Guarneri et al. 2013; Fosu-Mensah et al. 2015). Monoclonal 
antibodies towards EGFR itself have also been designed, including cetuximab and 
panitumumab, but clinical data has again pointed to a modest effect on a TNBC subset 
(Marmé and Schneeweiss 2015). 
▪ Vascular Endothelial Growth Factor (VEGF) Inhibitors 
The majority of data on inhibition of angiogenesis in TNBC by targeting the vascular 
endothelial growth factor (VEGF) comes from clinical trials with the monoclonal 
antibody bevacizumab. However, more details on this category of anti-cancer agents 
can be found in section 1.3.3.  
▪ Fibroblast Growth Factor Receptor (FGFR) Inhibitors 
Fibroblast growth factor receptors (FGFRs) are a subfamily of RTKs that regulate 
several cellular and developmental processes, including apoptosis, proliferation, 
migration and angiogenesis. FGFR can promote angiogenesis along with other 
receptors, such as vascular endothelial growth factor receptor 2 (VEGFR2). The 
rationale for FGFR targeting is due to the amplification of both FGFR1 and FGFR2 in 
TNBC. There are currently no selective FGFR inhibitors in clinical testing, although 
FGFR expressing TNBC cell lines were sensitive to PD173074, a dual FGFR/VEGFR 
inhibitor, and to RNAi silencing of FGFR2 (Turner et al. 2010). The structural similarity 
between FGFR and VEGFR kinase domains may lead some inhibitors of both receptors 
to clinical investigation against TNBC. For example, lucitanib is an inhibitor of 
FGFR1/2/3, VEGFR1/2/3 and PDGFR (Fosu-Mensah et al. 2015; Papa et al. 2015). 
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▪ PI3K/AKT/mTOR pathway Inhibitors 
Phosphoinositide-3-kinase (PI3K) is part of a large family of lipid kinases that 
phosphorylate the 3-hydroxyl group of phosphoinositides, involved in cell regulation, 
proliferation and survival. Mutations in PIK3CA, the gene encoding PI3K, are among 
the most frequent in BC. Downstream of PI3K there are protein kinase-B (AKT), which 
affects downstream molecules such as mammalian target of rapamycin (mTOR), and 
3-phosphoinositide-dependent kinase-1 (PDPK1). The phospholipid produced by PI3K 
activates AKT, triggering a cascade of events responsible for cell growth and 
proliferation that can also drive tumour progression (Vivanco and Sawyers 2002). 
Apart from that, the actions of PI3K and its downstream proteins are opposed to the 
tumour suppressor gene phosphatase and tensin homolog (PTEN) (Papa et al. 2015). 
Across all TNBC subtypes, there is an elevated frequency of loss/mutation of PTEN 
expression leading to an activation of the AKT/mTOR signalling pathway. It has also 
been shown that mutation or upregulation of this pathway affects almost all its 
downstream components, resulting in resistance and cancer progression (Fosu-
Mensah et al. 2015). Moreover, phosphorylation of mTOR in early TNBC is associated 
with an adverse prognosis (Marmé and Schneeweiss 2015). Therefore, inhibition of 
the PI3K/AKT/mTOR pathway has been recognized as a promising therapeutic target.  
There are many modifiers of this pathway under ongoing research on a breast cancer 
subset, mainly as parts of a combination therapy. Temsirolimus and everolimus are 
prodrugs of rapamycin (sirolimus) and they are specific inhibitors of mTOR. 
Temsirolimus proved quite effective when combined with other anti-neoplastic 
modulators. For example, a combination of temsirolimus with letrozole for the 
treatment of advanced breast cancers was tested under a Phase III clinical trial, but 
had to be discontinued due to non-enhanced efficacy compared to letrozole alone 
(Wolff et al. 2013). Everolimus and other rapalogues seem to activate AKT in patients 
with breast carcinomas and also induce the mitogen-activated protein kinase (MAPK) 
signalling pathway leading to a shorter progression time. Therefore, a combination of 
rapalogues with AKT or MAPK inhibitors may prove more effective than the 
rapalogues alone (Cloughesy et al. 2008). Since everolimus showed mediocre results 
in breast cancer patients, other novel analogues are currently under investigation. 
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There is one clinical trial setting up to study the safety and efficacy of MLN0128, a 
selective competitive inhibitor of mTOR, in combination with hormone-therapeutics 
to treat metastatic breast cancer patients. AZD2014, another selective inhibitor of 
mTOR, is undergoing evaluation alone or in combination with AZD8186, a small-
molecule inhibitor of PI3K, in a TNBC subset (Basu et al. 2015). In addition, the mTOR 
inhibitor DHM25 was found to efficiently inhibit the growth and metastasis of TNBC 
cells in vivo (Fouqué et al. 2015). Buparlisib, a PI3K inhibitor, induced only partial 
response in patients with TNBC but no response in those with ER-positive breast 
cancer, so in another clinical trial it was studied in combination with olaparib, showing 
enhanced activity (Rodon et al. 2014; Matulonis et al. 2017). Finally, pictilisib, another 
PI3K and mTOR inhibitor, showed strong antitumour activity against xenografts of 
TNBC in combination with a dual EGFR and HER3 inhibitor (Tao et al. 2014).   
In summary, the mTOR inhibitors which exhibit antitumor effects in breast cancer 
patients emphasise the necessity for the development of novel selective and efficient 
compounds. A combination of PI3K/mTOR inhibitors with classical chemotherapeutic 
agents may be helpful in the treatment of TNBC patients and remains an attractive 
therapeutic approach (Fouqué et al. 2016). 
▪ Proto-oncogene tyrosine-protein kinase Src Inhibitors  
SRC gene is a proto-oncogene encoding a non-receptor protein tyrosine kinase (Src), 
responsible for many downstream effects of RTKs, including the EGFR family. It is 
involved in several signal transduction pathways, controlling biological functions such 
as cell growth, differentiation, migration and survival, as well as angiogenesis (Fosu-
Mensah et al. 2015; Papa et al. 2015). Cytoplasmic and membrane Src’s increased 
frequency in TNBC has been linked to a higher invasiveness towards metastasis and 
tumour progression (Guarneri et al. 2013). Gene expression studies and preclinical 
data suggested that TNBC might be susceptible to growth inhibition by the Abl/Src/c-
kit inhibitor dasatinib (Qian et al. 2017). Despite encouraging preclinical results, 
clinical trials were disappointing, with dasatinib showing only modest efficacy. Thus, 
it was deemed ineffective as a single agent in TNBC. However a gene expression 
profile is currently under investigation as a predictive marker for response to dasatinib 
and some preclinical studies suggest a synergistic effect of the combination between 
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dasatinib and chemotherapy or other RTK inhibitors. Therefore, the re-evaluation of 
this agent is still ongoing (Fosu-Mensah et al. 2015; Marmé and Schneeweiss 2015). 
▪ Mitogen-activated protein kinase (MAPK) Inhibitors 
The Raf/MEK/ERK pathway, otherwise known as the mitogen-activated protein kinase 
(MAPK) pathway, is involved in directing cellular responses to a diverse array of 
stimuli, thus important for normal human physiology (MEK=mitogen-activated 
protein kinase kinase, ERK=extracellular signal-regulated kinase). Although Ras and 
Raf oncoproteins are not frequently mutated at the gene expression level in TNBC, 
dysregulations of this pathway are common in several human cancers, including BC, 
through activation of upstream RTKs, and/or activating mutations in proteins 
upstream, such as EGFR and HER2. TNBC has been linked to higher expression of 
several gene sets related to the Raf/MEK/ERK pathway. Therefore, MAPK pathway 
inhibitors may be useful against TNBC. Trametinib, a MEK1/2 inhibitor, and 
cobimetinib, a MEK inhibitor, are currently under investigation. One of the pathways 
activated in response to MEK inhibition is PI3K/AKT, thus the efficacy of MEK inhibitors 
in combination with PI3K/mTOR pathway inhibitors is also being evaluated in TNBC 
(Andreopoulou et al. 2015; Fosu-Mensah et al. 2015). Apart from that, a recent study 
suggested that in TNBC MEK inhibition may improve recruitment of tumour-
infiltrating lymphocytes increasing tumour immunogenicity thus having a synergistic 
effect with the immune system (Dushyanthen et al. 2017).  
➢ Androgen receptor antagonists 
The androgen receptor (AR) is a particularly interesting target for TNBC. The 
association between AR pathway and TNBC is based on gene expression profiling, 
which pointed a subset of TNBCs, despite lacking ER and PR expression, being driven 
by AR expression (Andreopoulou et al. 2015). TNBC cell lines with AR-positive 
phenotype may respond to therapy with androgen antagonists (Marmé and 
Schneeweiss 2015). The androgen antagonist bicalutamide is currently under 
investigation. In a phase II study, bicalutamide was tested in a subset of AR-positive, 
ER-negative, PR-negative metastatic breast cancer and it was shown to have a 19% 
clinical benefit rate within 6 months, as well as a progression-free survival of 12 weeks 
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(Gucalp et al. 2013). Further studies of the inhibitor abiraterone in ER-positive and ER-
negative AR expressing breast cancers are ongoing. Thus, further evaluation of anti-
androgen therapies for the AR-positive TNBC is needed (Guarneri et al. 2013; Marmé 
and Schneeweiss 2015). 
It is therefore obvious that the research on novel therapies against TNBC has currently 
been very active and we hope to see some successful approaches arising soon. 
Despite the many interesting strategies proposed by researchers though, 
angiogenesis remains a very promising area of research in relation to TNBC, and many 
groups still try to better understand and tackle this process that seems to be so vital 
for TNBC progression and metastasis.  
1.3 Angiogenesis 
Angiogenesis is a multi-step process of new capillary formation from pre-existing 
blood vessels. It plays a pivotal role in physiological processes, but it has also been 
recognized as a prerequisite for tumour growth, progression and metastasis (Figure 
1.6). Especially for tumours, the ability to create new vasculature and expand the host 
vascular bed enables them to tap into the body’s blood supply and draw on oxygen 
and nutrients essential for survival, growth, progression and metastasis. Without 
angiogenesis many tumours cannot grow beyond a limited size (1 – 2mm3), and so 
tumour angiogenesis becomes a necessary and required step for the transition from 
a small cluster of faster dividing cells to a larger tumour (Carmeliet and Jain 2011; 
Bishayee and Darvesh 2012).  
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Figure 1.6: Activation of angiogenesis. Several stimuli can induce angiogenesis, including hypoxic 
conditions. Under these conditions higher VEGF levels are produced and excreted from the cancer 
cell into the extracellular environment where they bind to VEGF receptors on the surface of 
endothelial cells. This binding results in the survival, migration and replication of endothelial cells, 
ultimately promoting the formation of new blood vessels. Source: 
https://blogs.scientificamerican.com/guest-blog/the-hallmarks-of-cancer-5-sustained-
angiogenesis/ 
Angiogenesis is a complex process, which is related to the function and life cycle of 
endothelial cells, involving processes such as activation, adhesion, proliferation and 
migration from the origin blood vessels to the newly formed ones. Physiological 
angiogenesis is tightly controlled by several pro-angiogenic and inhibitory molecules 
that exist in a highly regulated balance. Imbalance of this system leads to pathological 
angiogenesis involved in tumour progression. Sprouting angiogenesis is the most 
common phenomenon that participates in tumour neovascularization (Hillen and 
Griffioen 2007; Gacche and Meshram 2014). 
1.3.1 Neovascularization process 
As mentioned before, during angiogenesis new capillaries sprout from pre-existing 
vessels via the neovascularization process, and several steps are involved. 
Adult blood vessels consist of a polarized streamlined monolayer of quiescent 
endothelial cells (ECs), called phalanx cells. At first, under multiple stress factors such 
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as ischemia and inflammation, cancer cells can activate these quiescent ECs via several 
growth factors. These factors act as stimulators of angiogenesis, activating respective 
receptors on ECs of pre-existing blood vessels, inducing more chemotaxis at the same 
time. These activated ECs initiate the production of proteases, that have the ability to 
degrade the extracellular matrix and basement membrane to allow for the migration 
and invasion of cells. These proteases include matrix metalloproteinases (MMPs), the 
most important for angiogenesis being MMP-2 and MMP-9, which can degrade all 
kinds of extracellular matrix proteins and play a vital role in cellular behaviour (Hillen 
and Griffioen 2007; Missiaen et al. 2017).  
After the degradation of the extracellular matrix, and along with an increased vascular 
permeability driven by cancer produced growth vactors such as VEGF, ECs can 
proliferate and migrate to form solid sprouts from neighbouring vessels. The selection 
of an EC as a tip cell is important, since it becomes polarized and creates numerous 
filopodia and lamellipodia, that enable the migration of this cell towards the 
angiogenic signal. The tip cell is followed by trailing proliferative stalk cells, which are 
mainly able to form tubes and branches. The sprout extends towards the angiogenic 
source and forms loops which will develop a new vessel lumen and basement 
membrane, consisting of stalk cells. As the sprouting evolves, it enables the new still 
immature vessels to grow across gaps in the vasculature and through many processes, 
such as recruitment of pericytes and deposition of basement membrane, vessel 
maturation is achieved. The now mature vessels finally reach the tumour site, where 
they will deliver nutrients and oxygen and help in the detoxification of the rapidly 
splitting cancer cells, acting as a waste pathway (Hillen and Griffioen 2007; Gacche 
and Meshram 2014; Missiaen et al. 2017). However, it must be noted that the tumour 
blood vessels have many differences compared to normal vessels in that they are 
hyperpermeable and highly heterogeneous with regards to morphology and efficiency 
of tissue perfusion (Falcon et al. 2016). A summary of the neovascularization process 
is depicted in Figure 1.7 A-D.  
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Figure 1.7:  The dinstinct steps of angiogenesis. A: Activated ECs excrete proteases (MMPs) that 
degrade the extracellular matrix. B: VEGF secreted from cancer cells reaches the vasculature and 
activates signalling pathways promoting new vessel formation. C: New immature vessels sprout 
towards the tumour site. D: Mature vessels connect the tumour with the host vasculature and 
promote its growth. Adapted from Youtube video "Introduction to Cancer Biology", channel of 
Mechanisms in Medicine. 
Angiogenesis is also important for the ability of a tumour to spread and metastasize. 
There is growing evidence that single cancer cells can be detached from an original 
established tumour site and circulate through the blood vessels towards areas where 
they can implant and begin a secondary tumour site. In fact, tumour blood vessels are 
suggested to be mosaic vessels, with irregular shapes, including both endothelial and 
cancer cells, which is also called mimicry. This heterogeneity and mosaicity may assist 
circulating tumour cells to reach distant areas and establish new tumour sites. If this 
process could be inhibited, there would be less possibility for tumour metastasis and 
possibly the primary tumour would also shrink in size (Shan et al. 2014).  
1.3.2 Angiogenic activators – Growth factors 
As discussed, tumours have the ability to induce blood vessel growth by secreting 
several growth factors. The first angiogenic growth factor to be identified in the early 
1980s was the fibroblast growth factor (bFGF or FGF-2). This family of growth factors 
includes 23 members along with four FGF tyrosine kinase receptors. aFGF (FGF-1) and 
bFGF (FGF-2) are the most well-known members and they can stimulate the 
angiogenic cascade and induce capillary growth into the tissue when expressed by 
different cell types, including cancer cells (Hillen and Griffioen 2007; Bodner-Adler et 
al. 2016; Cai et al. 2016).  
A B 
C D 
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Other pro-angiogenic growth factors which control angiogenesis physiologically but 
also during cancer include members of the vascular endothelial growth factor (VEGF) 
family, the platelet-derived growth factor (PDGF), the transforming growth factor 
(TGF), the placental growth factor (PLGF), the hepatocyte growth factor (HGF), and 
chemokines such as follistatin and angiopoietins. However, VEGF family has been 
recognized as the most potent contributor to angiogenesis, activating the basic 
signalling required for neovascularization (Gacche and Meshram 2014).  
1.3.2.1 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) or vascular permeability factor is the basic 
mediator of both physiological and pathological angiogenesis. It affects many 
endothelial related functions, such as proliferation and mobility, and it also provokes 
vessel dilatation and increased permeability of the vessel wall. Moreover, it is an 
inducer for all the steps of angiogenesis as described above, namely the expression of 
matrix metalloproteinases and other activators of the degradation of the basal 
membrane and the subsequent EC migration and new vessel establisment (Hillen and 
Griffioen 2007).  
The family of VEGF includes seven members, namely VEGF-A, VEGF-B, VEGF-C, VEGF-
D, VEGF-E, VEGF-F and the PLGF. VEGF-A seems to be the homologue that is 
responsible for EC survival and growth and is also hypoxia-inducible. It is an N-
glycosylated 35–45kDa homodimeric glycoprotein, where the two monomers 
assemble in an anti-parallel fashion with four interchain disulfide bonds that form a 
characteristic ‘cystine knot’ (Ulyatt et al. 2011; Gacche and Meshram 2014) (Figure 
1.8). There are five different isoforms of VEGF-A, namely VEGF121, VEGF145, VEGF165, 
VEGF189 and VEGF206, deriving from the alternative splicing mechanism in exon 8 of 
the VEGF-A gene (Gacche and Meshram 2014) (Figure 1.9).  
 
Figure 1.8: Structure of homodimeric VEGF-A. Source: RCSB PDB. 
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Figure 1.9: Alternative splicing of VEGF-A gene and the isoforms produced  
The receptors related to the VEGF growth factor family are cell surface RTKs and there 
are three of them: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). There is 
also a second class of non-signalling co-receptors named neuropilins (Ferrara et al. 
2003; Hillen and Griffioen 2007) (Figure 1.10).  
 
Figure 1.10: Main receptors of VEGF family and their ligands. Source: cancerpublications.com. 
VEGFR2 is the major signal transducer for the mitogenic, angiogenic and permeability-
enhancing effects of VEGF and is activated by VEGF-A, with a binding affinity as Kd of 
approximately 75-125pM, whereas VEGF-E is a selective agonist for this receptor 
(Ferrara et al. 2003; Shibuya 2004; Cudmore et al. 2012) (Figure 1.11). It is abundantly 
expressed in vascular ECs and lymphatic ECs, as well as neuronal cells, 
megakaryocytes and hematopoietic stem cells. It consists of an extracellular part with 
seven immunoglobulin–like domains, a transmembrane domain, and an intracellular 
part with two tyrosine kinase domains. A kinase-insert domain lies between the two 
tyrosine kinase domains (Zhu and Zhou 2015).  
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Figure 1.11: Structures. A: Structure of VEFGR2. Adapted from RCSB PDB. B: Crystal structure of 
VEGFR2 in complex with one of its ligands, VEGF-C. Source: (Leppänen et al. 2010). 
Binding of VEGF-A to VEGFR2 triggers the dimerization of two monomers of the 
receptor and the trans-autophosphorylation and activation of the kinase domain, with 
subsequent ligand-dependent activation of the downstream signalling cascade 
leading to proliferation and migration of ECs and pro-angiogenic signal transduction. 
The autophosphorylation of VEGFR2 occurs in two phosphorylation sites, tyrosines-
1054/1059 (Y1054/Y1059) in the tyrosine kinase domain, and this event is one of the 
earliest and most critical for the activation of the receptor upon VEGF binding. 
Another major phosphorylation site on human VEGFR2 is tyrosine-951 (Y951), which 
is in the kinase-insert domain and mediates EC permeability and migration. There are 
also two other major phosphorylation sites on VEGFR2, that are tyrosines-1175 
(Y1175) and -1214 (Y1214) in the C-terminus area (Zhu and Zhou 2015). Y1175 is 
responsible for EC proliferation and migration and Y1214 for EC migration (Falcon et 
al. 2016). Especially phospho-Y1175 binds the p85 subunit of PI3K and PLC-γ leading 
to the initiation of the PLC-γ-PKC-Raf-MEK-MAPK pathway (PLC-γ=phosphoinositide 
phospholipase C-γ, PKC=protein kinase C) responsible for the proliferation of ECs. 
Some of the main downstream proteins related to VEGFR2 activation in ECs are the 
Src kinase, the focal adhesion kinase (FAK), PI3K, AKT, PLC-γ and mTOR. The EC growth 
is related to the activation of the Raf-MEK-ERK pathway, whereas the prosurvival 
effects are mediated by the PI3K/AKT pathway (Ferrara et al. 2003; Koch et al. 2011; 
Shibuya 2013; Gacche and Meshram 2014) (Figure 1.12).   
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Figure 1.12: Cross talks between VEGFR2 and other signalling pathways in ECs. VEGFR2 is 
depicted with an extracellular domain, a juxtaposed transmembrane domain and intracellular 
kinase domains. Extracellular domain of VEGFR2 is composed of seven IgG-like domains to bind to 
its cognate ligand VEGF. Intracellular domain has two tyrosine kinase domains, which are split by 
a kinase-insert domain of 70 amino acids. Five major phosphorylation residues Y951, Y1054, Y1059, 
Y1175, and Y1214 are highlighted. SH2 domain-containing adaptor proteins are recruited by these 
phosphorylated tyrosine residues, including VRAP/TSAd, PLC-γ, SHB, and NCK. These adaptors 
mediate the downstream effects of VEGFR2 including cell proliferation, permeability, cell survival, 
and cell migration. Source: (Zhu and Zhou 2015). 
The other main receptor, VEGFR-1, is also a substrate for VEGF-A, but has much lower 
expression levels compared to VEGFR2 (Cudmore et al. 2012). VEGFR-1 is a signalling 
receptor critical for the activation of the endothelial nitric oxide synthase (eNOS) and 
the in vitro angiogenesis. It can promote EC differentiation into vascular tubes via 
nitric oxide (NO) production and the two VEGF receptors seem to be in a continuous 
cross-talk for the regulation of angiogenesis (Bussolati et al. 2001; Ahmad et al. 2006). 
The main specific ligands of this receptor is placental growth factor (PLGF), a secreted 
dimeric protein of the VEGF family, and VEGF-B, and it has been shown that PLGF can 
promote branching angiogenesis by interacellular signalling through VEGFR-1 (Cai et 
al. 2003). Although VEGFR-1 shows a many-fold higher affinity for VEGF-A than 
VEGFR2, it has poor intracellular signalling capability and weaker ligand-dependent 
tyrosine kinase activation than VEGFR2. It is thought to be mainly involved in 
inflammatory responses for the migration of monocytes, as well as the hematopoietic 
pathway and the recruitment of endothelial progenitors. VEGFR-1 expression is also 
tightly related to oxygen levels, with hypoxic conditions severely upregulating this 
receptor via a hypoxia-inducible factor 1a (HIF-1a) –dependent manner (Hornig et al. 
2000; Ferrara et al. 2003; Shibuya 2004; Ulyatt et al. 2011). 
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In addition to the homodimerization necessary for these receptors to be activated, 
there has also been reported a heterodimerization process between VEGFR-1 and 
VEGFR2. The heterodimer can negatively regulate the signalling and cellular response 
following VEGFR2 homodimer stimulation, especially during the angiogenic process, 
which adds even more complexity to the understanding and manipulation of the 
VEGF/VEGFR system (Cudmore et al. 2012).  
The last receptor VEGFR-3 is the least studied one and it does not show any affinity 
for VEGF-A, binding instead to VEGF-C and VEGF-D. It seems to play an important role 
in lymphangiogenesis (Ferrara et al. 2003).  
Another important receptor related to the angiogenic process is the soluble form of 
VEGFR-1 (sVEGFR-1). This soluble variant of VEGFR-1 is generated by differential 
splicing of the VEGFR-1 mRNA and is descibed as a natural antagonist of the VEGF and 
PLGF activity, by reducing the levels of active VEGF-A (Hornig et al. 2000; Al-Ani et al. 
2010). This splice variant that was described by Kendall et al. back in 1993 (Kendall 
and Thomas 1993), consists of 6 out of the 7 extracellular immunoglobulin-like 
domains of the full-length receptor and a C-terminal extension of 31 amino acids 
derived from an intron. Soluble VEGFR-1 has been shown to form heterodimers with 
full-length VEGFR2, leading to a dominant negative regulator complex which inhibits 
angiogenesis in vivo by eliminating receptor autophosphorylation. In specific, sVEGFR-
1 can form a VEGF-stabilized ternary complex with the extracellular ligand-binding 
region of VEGFR2 leading to inhibition of the signal transduction (Kendall et al. 1996; 
Hornig et al. 2000; Ahmad and Ahmed 2004). This receptor most probably participates 
in a paracrine regulation of local angiogenesis also ensuring a more normalized 
response to abundant VEGF presence. Furthermore, sVEGFR-1 is regulated by hypoxic 
conditions, which lead to its overexpression, whereas hyperoxia has the opposite 
effect. Therefore, sVEGFR-1 comprises a naturally expressed endogenous antagonist 
that can halt the activation of VEGFR-1 and VEGFR2 acting anti-angiogenically (Kendall 
et al. 1996; Hornig et al. 2000).  
Up to date evidence shows that the VEGF-A/VEGFR2 interaction may be the most 
important one for sprouting angiogenesis promoting cancer growth, progression and 
metastasis. It has also been shown that many human tumours show an upregulation 
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of the VEGF mRNA, and the VEGFR2 expression levels in ECs surrounding tumours 
seemed to be elevated (Shibuya 2004; Hillen and Griffioen 2007; Gacche and 
Meshram 2014). This is the main reason why targeting the VEGF-A/VEGFR2 system 
directly deemed as a promising anti-cancer approach and still attracts a lot of research 
interest.  
Especially for TNBC, the VEGF-A/VEGFR2 system seems to be upregulated and 
correlated with worse prognosis and a more aggressive phenotype. VEGFR2 
expression is crucial for breast cancer cells with mutant p53 and the activation of the 
receptor increases mammospheres and enzymatic activity in TNBC cells (Pfister et al. 
2015). Elevated VEGF-A expression was also associated with more aggressive cancer, 
as happens also with increased VEGFR2 production, which was linked to a decreased 
5-year breast cancer specific survival in TNBC patients. VEGFR2 expression, EGFR 
expression and the gene copy numbers were all significantly associated with TNBC 
(Rydén et al. 2010a; Rydén et al. 2010b). 
Targeting VEGFR2 and downstream kinases might not only help in developing better 
therapies for TNBC, but also overcome the chemo- and radiation resistance in TNBC, 
which are more common in this unique subtype (Bousquet et al. 2017).  
1.3.3 Anti-angiogenic agents 
As noted already, targeting the process of angiogenesis involved in tumour 
progression could provide a new therapeutic approach against cancer and especially 
against TNBC, where there are much fewer treatment options. Considering the 
importance of the VEGF-A/VEGFR2 system in angiogenesis, it is logical that this system 
is one of the most vital targets against carcinogenesis (Li et al. 2016).  
In the absence of neovascularization, tumour growth is limited and so is the potential 
of metastasis. Anti-angiogenic agents could potentially reduce the size of the primary 
tumour and also tumour vascularity, thus limit the number of tumour cells that can 
metastasize and the vascular surface available for extravasation. Anti-angiogenic 
treatment may normalize tumour vasculature and the resulting vessels, which now 
have a closer resemblance to the normal ones, might be harder for tumour cells to 
penetrate than the chaotic and disorganized tumour blood vessels (Falcon et al. 2016). 
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Several studies have proved that combining existing anti-VEGF agents with 
chemotherapy or radiation therapy could result in a better effect compared to 
monotherapies  (Ferrara et al. 2003). Several pharmaceutical companies undertake 
research in developing small molecular inhibitors of the tyrosine kinase activity of 
VEGFR2, even though there is also an unrelated blockade of VEGFR-1, due to the high 
structural homology. Other potential targets related to VEGFR2 are the 
autophosphorylation sites and its downstream cascade (Shibuya 2004; Hillen and 
Griffioen 2007).  
There are three main categories of anti-angiogenic agents currently in clinical trials: 
1. monoclonal antibodies against specific pro-angiogenic growth factors and their 
receptors, 2. tyrosine kinase inhibitors (TKIs) of several growth factor receptors and 
3. inhibitors of the mTOR pathway (Gacche and Meshram 2014).  
The most widely studied and currently prescribed as combination therapy for many 
cancer types is the monoclonal antibody against VEGF-A bevacizumab, which will be 
discussed in the next section. Other antibodies approved include cetuximab (target: 
EGFR), trastuzumab (target: HER2) and panitumumab (target: EGFR). Many other 
antibodies are still under research, such as HuMV833 (targets: VEGF121 and VEGF165), 
IMC-18F1, IMC-1121B and ImClone (target: VEGFR-1 or 2). The antibody MIL60 is also 
currently being developed, which has similar VEGF-neutralizing activity to 
bevacizumab and has shown promising clinical results (Gacche and Meshram 2014). 
Since bevacizumab remains quite expensive for developing countries, alternative 
antibodies were identified, and MIL60 seems to have similar antigen binding activity 
and affinity for VEGF as bevacizumab. It has also been suggested to share the same 
epitopes on VEGF with bevacizumab, therefore it could potentially have a similar 
toxicity profile. Many other candidates with stronger affinity for VEGF proved more 
toxic than the parent antibody (Yang et al. 2014). 
Approved TKIs for anti-angiogenic combination therapies are axitinib, cabozantinib, 
pazopanib, regorafenib, sorafenib, sunitinib and vandetanib. Unfortunately, most of 
the first generation anti-angiogenic TKIs such as sunitinib, sorafenib and pazopanib, 
have adverse effects unrelated to the blockade of VEGF, as they also inhibit a wide 
range of kinase targets such as PDGFRs and B-Raf in addition to the VEGFRs. The 
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second generation anti-angiogenic TKIs such as axitinib, tivozanib and cediranib 
though, have improved potency and selectivity for VEGFRs. Several of these TKIs have 
been approved by the Food and Drug Administration (FDA) in solid tumours, including 
metastatic renal cell carcinoma, gastrointestinal stromal tumours, pancreatic 
neuroendocrine tumours, unresectable hepatocellular carcinoma, advanced soft 
tissue sarcoma and advanced medullary thyroid cancer (Falcon et al. 2016).  
The majority of the ongoing clinical trials on anti-VEGF based therapies are focused 
on expanding their benefit in other approved indications, either by trying 
combinations with agents that inhibit alternative pro-angiogenic pathways or by 
combining them with cancer immunotherapy agents. In any case, the amount of 
clinical trials targeting angiogenesis (over 3000) reflects the consistent scientific and 
therapeutic interest in inhibiting this process and remains a major active area in the 
mainstream of anti-cancer research (Gacche and Meshram 2014; Falcon et al. 2016; 
Li et al. 2016).  
However, although anti-VEGF therapy for breast cancer specifically was initially 
welcomed with great enthusiasm, there are many side problems that need to be dealt 
with if higher efficacy is desired. Even though inhibition of pathological angiogenesis 
could be the answer, there should be extra consideration on the potential blockade 
of the physiological process as well. There is also the paradox that limiting the blood 
supply of the whole tumour body hinders the access of anti-cancer drugs to the 
tumour, reducing their efficacy. There are also numerous compensatory angiogenic 
feedback loops that may prevail, along with off-target toxicities and adverse effects 
that might decrease the therapeutic benefit. In any case, blocking a single pro-
angiogenic molecule or pathway may have little impact on the total tumour 
angiogenesis and growth, since there are many angiogenic factors that can be vital for 
each different development stage of a tumour.  
Other challenges include the ability of tumours to acquire resistance against anti-
angiogenic agents and aggressively recur after withdrawal of the anti-angiogenic 
treatment. The limited availability of angiogenesis-specific biomarkers for TNBC in the 
current clinical practice is also a halting factor for the success of any anti-angiogenic 
agent. Finally, different angiogenic mechanisms might be involved in the different 
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tumour subtypes and at various stages, making anti-angiogenic drug development 
even more challenging, as a combination of many agents targeting different tumour 
signalling pathways may be necessary (Ferrara et al. 2003; Gacche and Meshram 
2014).  
1.3.3.1 Anti-VEGF-A antibody (Bevacizumab) 
The first anti-angiogenic drug to be marketed was bevacizumab (Avastin®). It is a 
recombinant humanized monoclonal antibody that binds all isoforms of VEGF-A 
extracellularly, inhibiting their binding to VEGFRs, which would otherwise activate the 
angiogenic downstream signalling cascade (Figure 1.13 A).  
Bevacizumab was initially approved as a combination therapy with chemotherapy by 
FDA in 2004 against a variety of cancer subtypes, with metastatic colorectal cancer 
being the first indication. Currently bevacizumab has been approved as a 
monotherapy for recurrent glioblastoma, in combination with chemotherapy for 
metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, 
platinum resistant ovarian cancer and metastatic cervical cancer and in combination 
with IFNα for metastatic renal cell carcinoma (Hillen and Griffioen 2007; Rini 2007; 
Falcon et al. 2016) (Figure 1.13 B). It was initially on FDA "fast track" approval process 
for metastatic breast cancer (HER2-negative), for which it actually received approval 
in 2008, but it was eventually revoked due to non-significant improvement in the 
overall survival rates as first line treatment for patients with advanced breast cancer 
in November, 2011.  
Avastin® caused several side effects, such as high blood pressure and hemorrhaging. 
Other potential side effects include gastrointestinal perforations, thromboembolysis 
and impaired wound healing (Hillen and Griffioen 2007; Ebos et al. 2009a; Thomssen 
et al. 2012; Gacche and Meshram 2014; Zhu and Zhou 2015). There was evidence that 
it could slow the progression of metastatic breast cancer when combined with 
paclitaxel, but the quality of life was not enhanced and the life expectancy remained 
the same. On the contrary, some preclinical studies proved that bevacizumab could 
promote a more aggressive and metastatic behaviour of breast cancer cells. There is 
also much evidence suggesting possible acquired resistance. It has also been proposed 
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that the reduced blood supply to the tumour affects drug penetration and increases 
hypoxic stimulation with subsequent VEGF elevation in the tumour (Ebos et al. 
2009b). 
As evident from the above case, it seems more likely that a future efficient cancer 
therapy will be composed of a combination of chemotherapy and one or several other 
agents that can inhibit multiple pathways with reduction of the acquired resistance, 
as well as minimal implications to the physiological process. Novel combination 
approaches also include simultaneously targeting multiple pro-angiogenic factors that 
impact tumour growth at different stages and affect the different steps of blood vessel 
maturation. New agents in these combinations could also help in reducing the 
necessary dose of approved drugs with dose-related adverse effects. Other strategies, 
such as intermittent dosing schedules, sub-maximum tolerated dosaging to delay 
hypoxia onset thus improving oxygenation and delivery of co-administered drugs, 
seems to be the way forward for anti-angiogenic therapies. In summary, the future of 
anti-angiogenic treatment depends on identifying predictive biomarkers to monitor 
response and novel combination approaches that can overcome innate resistance, 
avoid induction of acquired resistance and provide a significant survival benefit to the 
patients (Falcon et al. 2016). 
           
Figure 1.13: Bevacizumab. A: Pro-angiogenic targets of bevacizumab, aflibercept and regorafenib. 
Bevacizumab binds to VEGF-A and interrupts the interaction with VEGFR-1 and -2. Apart from 
VEGF-A, aflibercept binds to and interrupts also the function of VEGF-B and PGF. Regorafenib is a 
small molecule, multi-kinase inhibitor, whose targets include VEGFR-1, -3, RAF, TIE-2, and mutant 
oncogenic kinases KIT, RET and BRAF. Source: (Jitawatanarat and Ma 2013). B: FDA approves 
bevacizumab for recurrent ovarian cancer. Source: Medscape. 
 
A 
B 
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1.3.4 Reactive oxygen species in angiogenesis 
Another vital mechanism taking part in angiogenesis is the production and 
homeostatic maintenance of reactive oxygen species (ROS). Cancer cells are known to 
have a different redox status compared to normal cells in most cancer types. Due to 
the high metabolic rates and signalling aberrations, cancer cells usually exhibit 
elevated levels of ROS. Therefore, modulating redox potential with new drugs could 
prove helpful in the fight against cancer (Gorrini et al. 2013). 
Recent research has shown that the angiogenic cascade is tightly interweaved with 
ROS production and signalling, and ROS can be critical regulators of angiogenic 
homeostasis (Ushio-Fukai 2006; Ushio-Fukai and Nakamura 2008; Kim and Byzova 
2014). The main sources of ROS in ECs are NAPDH oxidases (NOX) that maintain basal 
ROS levels, and the mitochondrial respiratory chain. In ECs, the production of ROS is 
continuous in low levels and different isoforms of NOX can enhance ROS production, 
which leads to stimulation of VEGFR2 auto-phosphorylation and protein kinases 
activation, therefore promoting EC migration and proliferation. ROS can also increase 
EC permeability and enhance cell adhesion surface molecule expression. The 
stimulation of VEGF itself can also increase their production in low levels, an 
important event for the subsequent VEGF-induced c-Src activation and 
phosphorylation of VE-cadherin. Thus, ROS can support growth factor signals and 
promote angiogenesis in various in vivo and in vitro tests by upregulating the synthesis 
of many molecules (such as MMPs) and transcription factors. In addition to these 
actions, NOX can also stimulate redox-sensitive signalling cascades independently (for 
example PI3K/AKT, ERK, Ras, c-Src pathways). Finally, even exogenous ROS can 
stimulate VEGF expression, which can be used as a marker of the angiogenic switch, 
and they can promote proliferation, migration, cytoskeletal reorganization and 
tubular morphogenesis in ECs (Lamalice et al. 2007; Radomska-Lesn̈iewska et al. 
2016).  
However, the effects of ROS on vascular function depend drastically on the amount 
of ROS present. Low doses of ROS were shown to promote angiogenesis via cell 
membrane damage and subsequent basic FGF-2 release. This initiates the intracellular 
production of ROS through NOX and initiation of downstream signalling for 
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proliferation, migration and tube formation. On the other hand, high doses of ROS can 
provoke oxidative stress and subsequent death of cells necessary for angiogenesis, 
thereby inhibiting the whole process. In addition to dose, timing and application 
method can also determine the pro- or anti-angiogenic potential of ROS. The complex 
role of ROS in angiogenesis is also outlined by the fact that antioxidant therapies were 
sometimes unsuccessful in inhibiting conditions characterized by over-activated 
angiogenic events (Radomska-Lesn̈iewska et al. 2016; Kruk and Aboul-Enein 2017).  
Cellular hypoxia is a key regulator of ROS production. During hypoxic events, the 
electron transport chain in mitochondria becomes uncoupled, leading to leakage of 
electrons and formation of oxygen species. Hypoxia can also upregulate NOX and 
activate hypoxia-inducible factor-1 (HIF-1), which induces proangiogenic genes. 
Cancer has been associated with abnormal ROS production and a variety of cells 
derived from human tumours demonstrate elevated ROS levels. Cancer cells 
themselves are an abundant source of ROS via their defective respiration and 
oxidative metabolism. These elevated levels are also responsible for the upregulation 
of HIF-1a and VEGF expression through activation of the PI3K/AKT pathway or the 
MEK/ERK pathway (Radomska-Lesn̈iewska et al. 2016).  
It should be noted though, that ROS are primarily formed during normal physiological 
processes such as the aerobic metabolism of molecular oxygen, inflammation and 
immune response. They act as regulators of signalling pathways, secondary 
messengers and inducers of mitogenic responses. Their involvement in carcinogenesis 
and pathological angiogenesis is coincidental and strongly related to other 
dysregulated processes and mechanisms of defence that are so common in cancer 
cells (Kruk and Aboul-Enein 2017). 
1.4 Carbon monoxide 
1.4.1 General characteristics and toxicity 
Carbon monoxide (CO) is an inert gas, colourless, odourless, tasteless and non-
irritating. It is a low molecular weight diatomic molecule (M.W. 28.01), slightly less 
dense than air and with relatively poor water solubility. The bond length between the 
carbon atom and the oxygen atom is 112.8 pm, consistent with a triple bond, making 
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it a chemically stable molecule. Its ground electronic state is a singlet state, with no 
unpaired electrons, and the oxidation state of carbon is +2, since all the bonding 
electrons are attributed to the more electronegative oxygen (Wu and Wang 2005). 
 
CO has long been known as a "silent killer", with CO intoxication potentially fatal due 
to its 210 – 250 times higher affinity for iron atoms in haemoglobin than oxygen, 
eventually forming carboxyhaemoglobin (HbCO) (Wu and Wang 2005; Ryter et al. 
2006; Maruyama et al. 2012). This binding significantly reduces the oxygen-storage 
function and the oxygen-carrying capacity of haemoglobin, consequently leading to 
tissue hypoxia and CO poisoning in humans. Most common symptoms of CO poisoning 
include headaches, dizziness, nausea, vomiting and visual confusion, eventually 
leading to coma and death, if remaining untreated (Wu and Wang 2005; Foresti et al. 
2008). The most important organs to be severely damaged by CO would be the brain 
and the heart, as proved by the increased rates of lipid peroxidation and apoptotic 
cell death (Piantadosi et al. 1997). 
 
Figure 1.14: Therapeutic use of CO. The therapeutic use of CO is impeded by safety challenges 
following non-targeted, systemic administration and the use of toxicologically critical transition 
metals. An emerging number of local delivery approaches addressing these issues have recently 
been introduced and provide exciting new starting points for translating the fascinating preclinical 
potential of CO into a clinical setting. Source: (Steiger et al. 2016). 
However, the binding of CO to haem iron centers in haemoglobin functions more like 
a detoxification mechanism than being the major reason of the observed CO 
poisoning (Schatzschneider 2015). The increase in the concentration of CO in tissues 
is more responsible for these symptoms, since elevated tissue levels lead to disruption 
of the mitochondrial function by inhibiting their respiratory system. More specifically, 
CO can bind to proteins of the mitochondrial electron transfer chain including haem, 
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such as the mitochondrial cytochrome c oxidase (complex IV), hence harm cellular 
respiration. Since the mitochondria are affected, membrane permeability is increased 
and electron leakage is consequently observed, mainly from complex III, leading to 
the formation of ROS (Lo Iacono et al. 2011; Gullotta et al. 2012; Long et al. 2014).  
1.4.2 Endogenous production and physiological functions – Haem oxygenases 
It was not only until early 1950s when CO was found in the exhaled air of healthy 
humans as a metabolite (Sjöstrand 1949b,a; SjöStrand 1951). It appears that there is 
an endogenous CO production process in every healthy human organism. This CO is 
generated as a by-product of the enzymatic degradation of haem, catalysed by the 
family of enzymes called haem oxygenases (HOs). As a consequence, there is a small 
amount of HbCO normally present in healthy human organisms. In reality, the rate of 
endogenous CO production was estimated around 0.42mL/h (18.7µmol/h), so the 
majority of blood HbCO comes from the endogenous production process, 
corresponding to blood CO levels of 0.4 –1%, which is a normal range for non-smoker 
humans (Wu and Wang 2005; Ryter et al. 2006). 
Haem oxygenases (HO) can be found as two isoforms: HO-1 is redox-sensitive-
inducible (32.8kDa), and HO-2 is a constitutive form (36kDa), controlled by post-
translational modifications and expressed mainly in the brain, endothelium and testis 
(Wu and Wang 2005; Bannenberg and Vieira 2009; Chigaev et al. 2014). There has 
been a third isoform identified, HO-3, but its physiological role still remains unclear. 
This enzyme catalyses the conversion of haem to ferrous iron, CO and biliverdin, which 
is subsequently reduced to bilirubin by biliverdin reductase (Motterlini et al. 2002) 
(Figure 1.15).  
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Figure 1.15: Endogenous production of CO from the enzymatic degradation of haem. Source: 
(Kourti et al. 2017). 
Haem oxygenase-1 (HO-1) is a well-characterized cytoprotective enzyme, which is 
widely upregulated during cellular responses to pro-oxidative and pro-inflammatory 
stimuli. These stimuli include haem, growth factors (especially VEGF), NO, fluctuations 
in oxygen levels, cytokines and peroxynitrite (ONOO-) among others. HO-1 has 
different basal expression levels in the various cell types and tissues and is responsible 
for the maintenance of cellular homeostasis, by controlling oxidative injury, 
attenuating inflammation and affecting cell proliferation. Its by-products, biliverdin 
and bilirubin, form a system that has a high antioxidant capacity, through scavenging 
ROS (Dulak et al. 2008; Ferrando et al. 2011; Loboda et al. 2015b).   
Haem oxygenase-1 is known to offer pleiotropic protection to ECs in vitro, enhancing 
their proliferation and cell cycle progression. Several human tumours, such as renal 
and prostate cancer, may overexpress HO-1 and lead to an enhanced cell survival and 
anticancer drug resistance. As a result, inhibition of HO-1 was proposed as another 
potential anticancer strategy, especially since HO-1 may also have pro-angiogenic 
effects in inflammatory conditions associated with cancer (Dulak et al. 2008; Loboda 
et al. 2015b).  
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Figure 1.16: Structures of Haem oxygenase-1 (A) and -2 (B). Source: RCSB PDB. 
Although recognised as a normal metabolite, the physiological role of the 
endogenously produced CO was yet to be identified until 1993 when CO was 
eventually proved to act as a molecular mediator, a neurotransmitter (Verma et al. 
1993). Since then, researchers classified CO with two other biologically active diatomic 
molecules, that is NO and hydrogen sulphide (H2S), forming the group of gaso-
transmitters (Romão and Vieira 2015). 
The primary cellular binding targets for CO have not been clearly identified yet, but 
haem proteins seem to be the main targets, especially soluble guanylate cyclase (sGC). 
sGC is a haem protein, which has a covalent haem co-factor anchored via a histidine 
ligation to the iron, and the trans position to the histidine is able to bind either NO or 
CO. This leads to a two- to four-fold increase in cGMP production from GTP by CO, far 
lower than the activation induced by NO, posing a question if this is indeed its real 
primary cellular target (Poulos 2006; Schatzschneider 2015). Other functions of CO, 
apart from haem catabolism and increase in cGMP production, involve activation of 
Ca2+-dependent potassium channels and MAPKs (Kaczara et al. 2015; Gessner et al. 
2017).  
A well-reported regulatory activity of CO regards the cardiovascular system. The 
vasorelaxant properties observed are justified by the elevated cGMP levels in the 
vascular smooth muscles and aorta, and have been proved to be non-endothelium 
mediated (Bannenberg and Vieira 2009). The vasodilatory mechanisms may implicate 
ion-dependent channels, as well. Additionally, blood platelet aggregation was 
reported to be inhibited by endogenous and exogenous CO (Wu and Wang 2005; 
Ryter et al. 2006; Olas 2014). As with other observations, though, the anti-coagulative 
functions of CO seem to be contradicting, since earlier research reported opposite 
outcomes (Marshall and Hess 1981).  
A B 
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The anti-inflammatory effects of CO have been well established by various studies. 
The possible mechanisms include the inhibition of lipopolysaccharide (LPS)-
dependent pro-inflammatory cytokine expression (such as tumour necrosis factor-α 
(TNFα), interleukin-1b (IL-1b), IL-2, macrophage inflammatory protein-1b (MIP-1b)), 
and the augmentation of anti-inflammatory cytokines, such as IL-10 (Otterbein et al. 
2000; Wu and Wang 2005; Ryter et al. 2006; Olas 2014). This property of CO is 
probably mediated by p38 MAPK and MKK3, independently of the cGMP pathway, as 
demonstrated for RAW264.7 macrophages (Otterbein et al. 2000). CO gas 
administration or CO-releasing molecules (CORMs) treatment reduces macrophages’ 
activation by LPS and promotes expression and stabilization of HIF-1, which regulates 
inflammatory and apoptotic genes (Motterlini et al. 2005a).  
The combination of the vasodilatory and anti-inflammatory effects of CO may 
contribute to the indicated CO protection of myocardial cells against ischemia-
reperfusion injury, myocardial infarction and cardiac rejection cases (Clark et al. 2003; 
Guo et al. 2004; Wu and Wang 2005). 
Recent research has also revealed anti-apoptotic and anti-proliferative activities of CO 
on different cell types. Brouard et al. demonstrated that reduction in TNFα expression 
leads to inhibition of TNFα-initiated apoptosis in fibroblasts and ECs through p38 
MAPK and NF-κB activation (Brouard et al. 2000). Increased levels of cGMP and HO-1 
activity may play an important role in this inhibitory effect on apoptosis, as well. Anti-
apoptotic effects have also been reported in vascular smooth cells and hepatocytes. 
The anti-proliferative properties, on the other hand, were mainly observed in smooth 
muscle cells and are mediated through the activation of guanylyl cyclase and p38 
MAPK, contributing to the general protective actions of CO (Bannenberg and Vieira 
2009). However, anti-apoptotic effects are not observed in all cell types studied and 
this is also true for the reported anti-proliferative effects (Wu and Wang 2005; Ryter 
et al. 2006; Olas 2014). 
Another physiological effect mediated by CO is the inhibition of hypoxia-induced VEGF 
expression (Goldberg and Schneider 1994). CO can also inhibit the cytochrome P450 
family of enzymes, since the level of P450 is affected by the availability of cellular 
haem. In addition, CO is indirectly related to oxidative stress, although it is not a free 
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radical itself. CO can bind to haem proteins and alter their role in oxidative stress 
control, hence indirectly change the cellular redox status. The pro-oxidant effects of 
CO were demonstrated in the vascular endothelium and other cell types (Wu and 
Wang 2005). However, as with most of the effects of CO, the pro-oxidant activity 
remains controversial, since many publications suggest opposite results. In a recent 
study by Wilson et al. (Wilson et al. 2017), CO was found to increase VEGF in LPS-
activated BV2 microglial cells after 3h of treatment with a novel CORM, namely 
CORM-401, although the levels return to normal after 6h. It is also implied to have an 
anti-oxidant effect, contradicting many publications stating the pro-oxidant activity of 
CO. These opposite results are very common in the case of CO and CORMs, as 
highlighted also in other recent publications (Kourti et al. 2017).  
Finally, CO also affects some nervous system functions and expresses neuroprotective 
and neurotherapeutic properties, potentially mediating memory and circadian 
rhythm (Mahan 2012; Wilson et al. 2017). 
The range of systems physiologically affected by and responding to CO is wide as 
evident above and in many publications. Some of these systems and organs are listed 
below, just to demonstrate the complexity of the HO/CO-related signalling networks: 
A. Circulatory System 
B. Nervous System 
C. Respiratory System 
D. Reproductive System 
E. Gastrointestinal System 
F. Liver 
G. Kidneys 
H. Pancreas 
As anticipated from the above list, the physiological functions of CO are various, but 
the clearer image still remains elusive. This is due to the contradicting results acquired 
for different tissues, cell types and in vivo models.  
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1.4.3 Therapeutic applications 
• Inflammatory diseases 
The anti-inflammatory potential of CO observed in vitro was also tested in in vivo 
models of inflammatory diseases, such as sepsis and asthma. CO-pre-treated mice 
injected with LPS showed decreased TNFα levels and increased IL-10 production. This 
result was mediated by MKK3 and suggested a protective role for CO in sepsis via 
inflammatory cytokine production modulation (Ryter et al. 2006). In asthma, CO pre-
treatment in mice resulted in modest increase in the total number of all inflammatory 
cells involved, such as macrophages, eosinophils and neutrophils. Exogenous CO was 
also able to reduce IL-5 production, indicating that CO potentially regulates 
inflammation in asthma too (Ryter et al. 2006). CORM-2 reduced the histamine 
release under immunological conditions, suggesting another potential use of CORMs 
for the treatment of allergies. In a study where UV irradiation was employed for its 
ability to provoke immunosuppression, CO, in the form of CORM-2, could provide 
protection. Finally, neuro-inflammation also seems to be suppressed by CO in a 
variety of conditions, such as autoimmune encephalomyelitis and multiple sclerosis 
(Motterlini et al. 2005a).  
• Cardiovascular diseases 
Several cardiovascular system-related conditions have been tested for treatment via 
CO administration. In myocardial infarction models a CO-donor molecule, CORM-3, 
included in the reperfusion media after ischemia, had a beneficial effect on cardiac 
performance and reduced infarct size. In systemic hypertension in vivo models, CO 
managed to reduce blood pressure. In addition, in vascular injury conditions, CO 
showed an inhibitory effect on the proliferation of smooth muscle cells and lowered 
leukocyte infiltration activity (Ryter et al. 2006). Finally, CORM-2 prevented the 
increase in mean arterial pressure in a rat model of acute hypertension and CORM-3 
and CORM-A1 succeeded in vasorelaxing an isolated aortic ring pre-contracted with 
phenylephrine (Motterlini et al. 2005a).  
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• Ischaemia/Reperfusion 
Ischemia-Reperfusion (I/R) during lung surgery and transplantation can potentially 
lead to tissue injury. CO showed protection against liver and lung I/R injuries by 
exerting antiapoptotic effects through p38, MKK3 and c-Jun N-terminal kinase (JNK) 
activity modulation. The inhibition of apoptosis is also related to a downregulation in 
the expression of apoptosis-related factors, such as caspase-3 (Ryter et al. 2006).  
• Organ transplantation 
Increasing the probability of survival after organ transplantation still remains a 
medical need. Despite the fact that HO-1 expression has mostly been tested against 
organ transplantation models, CO was also proved to have a beneficial effect in 
suppressing graft rejection in a mouse to rat cardiac transplant model. It seems that 
the anti-inflammatory and inhibitory action on platelet aggregation abilities of CO 
contribute to this result (Sato et al. 2001). It has been shown that CO can be useful in 
lung transplantation xenografts, as well. Inhalation of CO reduced lung injury and 
rejection due to the anti-apoptotic and anti-inflammatory properties of CO (Song et 
al. 2003).  
However, all the publications regarding the potential therapeutic applications of CO 
in various disease models raise concerns over the usage of gas mixtures in humans. 
CO must be administered in a controlled and directed manner, which is quite 
problematic, in addition to the difficulties in storing and handling this gas with special 
equipment and in specialized hospital settings. Moreover, the prolonged inhalation of 
CO may lead to intoxication of the oxygen transport and delivery system, hence 
making this approach of limited therapeutic use (Motterlini et al. 2005a).  
1.5 Carbon monoxide – releasing molecules 
1.5.1 General characteristics 
Since CO attracts such major scientific interest in terms of its therapeutic potential, 
large efforts have been made in the past decade to develop safer ways for delivering 
CO to specific body tissues. The direct administration of CO by inhalation could be 
considered in cases of targeting the respiratory tract and the lungs, or for the 
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treatment of a transplant donor or ex vivo treatment of an organ to be transplanted. 
However, as the inhalation of large doses of CO required for sufficient diffusion of 
therapeutically effective concentrations can prove dangerous, interest has turned to 
alternative approaches, the most important being CO-releasing molecules (CORMs) 
(Motterlini et al. 2005a; Bannenberg and Vieira 2009).  
CORMs were first introduced as industrial catalysts and for purification purposes. 
These complexes include a transition metal atom in low oxidation state as core, which 
is surrounded by a certain number of carbonyl groups as coordinated ligands. CORMs 
are capable of releasing CO upon activation. Apart from serving as an alternative to 
the inhalation of CO gas, they have also provided further mechanistic insight into the 
behaviour of CO in biological systems (Ryter et al. 2006). 
The CORM comprises of three parts. First is the metal centre, responsible for the main 
features and toxicity profile of the molecule. The second part is the coordination 
sphere (or CORM sphere – CO groups and ancillary ligands), for determining the 
responsiveness towards specific stimuli and the CO-release mechanism. More 
specifically, this part modulates the number of CO groups that can be released, the 
kinetics of the release process and the trigger mechanism for initiation.  The final part 
is the drug sphere, referring to modifications of the periphery of the ancillary ligands 
pointing away from the metal centre, for tuning the pharmacological parameters of 
the whole molecule, that is solubility, biocompatibility, targeting and ADME 
(absorption, distribution, metabolism and excretion) characteristics (Figure 1.17). The 
ability to manipulate the pharmacological characteristics of the molecule is the most 
important advantage of CORMs over simple CO gas, since it determines the allocation 
between the different body fluids and tissues and the ability of a CORM to actively or 
passively target specific cell subpopulations (García-Gallego and Bernardes 2014; 
Schatzschneider 2015). Furthermore, CORMs also offer a more precise control of the 
concentration of CO even at low levels, compared to CO gas, whose main obstacle in 
in vitro and ex vivo preparations is atmospheric oxygen (Lo Iacono et al. 2011). 
The design and synthesis of novel enhanced CORMs has become the main focus in the 
field recently, however there are still unresolved issues about the appropriate 
features of these molecules. For example, there is still no consensus whether a high 
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or low number of CO ligands per metal complex unit would be more useful and what 
is the optimal speed for the CO release. There is probably not a single profile that 
these molecules should comply with, but instead, different groups of CORMs should 
be designed with favourable properties according to the targeted diseases (García-
Gallego and Bernardes 2014; Schatzschneider 2015). 
 
Figure 1.17: The distinct parts of a CORM. In the middle there is the metal centre, responsible for 
the main features and toxicity profile of the molecule. The second part is the coordination sphere 
(or CORM sphere) referring to CO and ancillary ligands, for determining the CO-release mechanism 
and kinetics. The third part is the drug sphere including the periphery of ancillary ligands, for tuning 
the pharmacological parameters of the whole molecule. Source: (Schatzschneider 2015). 
 
1.5.2 Mechanisms of CO release 
There are several reviews dealing with the potential trigger mechanisms for the CO 
release from CORMs. CORMs have been classified in three groups according to the 
mechanism of CO release: 1) molecules that release CO due to ligand exchange 
reactions with the medium, 2) molecules that need a proper internal or external 
stimulus to induce the release, for example light and 3) molecules that explore the 
differences in cellular microenvironments, such as enzyme expression or pH, to be 
used as alternative trigger mechanisms (Figure 1.18) (Zobi 2013; Simpson and 
Schatzschneider 2014; Schatzschneider 2015).  
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Figure 1.18: Potential trigger mechanisms for CO release from CORMs. Source: (Schatzschneider 
2015). 
An appropriate selection of the metal atom, the number and spatial arrangement of 
CO groups around it and the nature of the ligands completing the outer coordination 
sphere of the molecule allows the tuning of the CO-release properties. Compounds 
with one labile CO group have the simplest release kinetics. In the case of more labile 
groups per molecule, the profile might be entirely different, therefore making kinetic 
analysis and identification of potential intermediates much more complicated.  
Most of the initial metal-carbonyl complexes release CO upon ligand exchange 
reactions with the medium, undergoing thermal activation or hydrolysis. This is the 
case for CORM-2 and CORM-3 (thoroughly discussed in the next section). However, 
these molecules lack a well-defined and assignable pharmacokinetic (PK) profile, 
which becomes the main obstacle for their further clinical development. More recent 
development explores alternative trigger mechanisms for the CO release, such as light 
or magnetic field, generating more drug-like CORMs. These prodrug compounds 
would be stable towards the potential biological ligands, allowing for the CO release 
to occur only upon appropriate internal or external stimulus application (García-
Gallego and Bernardes 2014; Schatzschneider 2015). 
Since light can be well-focused and offer a precise spatial and temporal control of the 
release of CO, it would be a very attractive external stimulus only when and where 
the biological activity is required. An overview of this group of CORMs is discussed in 
section 1.5.4 (Schatzschneider 2011,2015). 
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
47 
 
Another potential stimulus would be magnetic fields, previously described by Kunz et 
al. (Kunz et al. 2013). Kunz and colleagues discovered that biocompatible magnetic 
iron oxide nanoparticles (Fe2O3) (IONPs) can act as carriers for CORMs, which are 
covalently bound to their surface.  For example, a derivative of CORM-3 was anchored 
to the surface of the IONPs, where the ruthenium carbonyl fragment ligates to a dioxy-
phenylalaninato instead of a glycinato group. These particles can be triggered to 
release CO via heating in an alternating magnetic field (Figure 1.19). 
 
Figure 1.19: Induced CO-release from CORM-functionalized IONPs with the application of 
magnetic field. Source: (Kunz et al. 2013). 
Other recent work focuses on the differences in cellular microenvironments for a 
more localized control of the CO release. Several parameters like cellular pH and redox 
environment can be exploited in this context. The group of Schmalz explored an 
alternative approach based on the differences in cellular enzyme expression rates in 
the various tissues (Romanski et al. 2011). The metal carbonyl complexes synthesized 
exploit the two possible tautomeric forms of the organometallic ligand, after the 
exposure of the sensitive group to esterases or phosphatases. A change in the 
hapticity results in increased sensitivity of the molecule to oxidative decomposition 
and subsequent CO release (Schatzschneider 2015). 
1.5.3 First and second generation CORMs 
As mentioned earlier, CORMs were used as an alternative source of CO, because the 
gas itself was proven to be really toxic and unsuitable for patient use. This idea 
evovled when it was shown that CO covalently bound to a metal could be carried and 
released under certain physiological conditions.  
The first CORM to be developed was CORM-1, with the molecular formula 
[Mn2(CO)10]. The limitations of CORM-1 mostly refer to its insolubility in aqueous 
media and the requirement for photo-activation in order to release its CO groups from 
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the manganese metal core. In such context, we can classify CORM-1 to the photo-
CORM group, mentioned in the next section.  
Unlike iron and manganese carbonyl complexes though, which require exposure to 
light to release CO, ruthenium based CORMs could transfer CO spontaneously, even 
in the absence of light, and exerted an almost identical pharmacological effect to that 
observed with CO gas (García-Gallego and Bernardes 2014). 
As a result, the second CORM to be developed was CORM-2, with the molecular 
formula [Ru(CO)3Cl2]2. CORM-2 has a ruthenium core and is insoluble in aqueous 
media, requiring organic solvents such as dimethyl sulfoxide (DMSO) to be dissolved. 
The loss of CO groups occurs upon ligand exchange reactions with the solvent. CORM-
2 has been widely used as a ‘prodrug’ of CO and has been involved in numerous 
studies aiming to elucidate the mechanism of action of CO or its various effects on 
different cellular systems and disease models. However, the water insolubility 
remains an unresolved matter posing limitations and restrictions to its clinical 
applications. The rapid loss of CO upon dissolution in DMSO (< 1min) is also a problem 
to consider of before conducting experiments with CORM-2 (Motterlini et al. 2002). 
Further research of these lipid-soluble systems led to the synthesis of a second 
generation of more water-soluble CORM analogues, which behave more favourably 
in biological systems and confer different CO-release profiles and biological 
properties. One of them includes the amino-acid glycine and a ruthenium core, and is 
named CORM-3 [Ru(CO)3Cl(glycinate)]. CORM-3 is air-stable, water-soluble and 
rapidly releases CO via a hydrolytic mechanism, so upon water exchange reaction 
(Clark et al. 2003). However, due to its instability in aqueous solutions, CORM-3 was 
excluded from further clinical research, despite its benefits in several disease models 
(Kunz et al. 2013; García-Gallego and Bernardes 2014). In more detail, while a distilled 
water solution of CORM-3 at 37°C has a half-life of 98h, this is reduced to just 3.6min 
in human plasma (Schatzschneider 2015). However, studies of the interaction of 
CORM-3 with proteins revealed that this complex reacts rapidly with plasma proteins 
such as human haemoglobin and albumin, hence leading to ruthenium species bound 
to these proteins (Santos-Silva et al. 2011). These species lose one equivalent of CO in 
the form of CO2, thus yielding protein–[Ru(CO)2] adducts. These adducts, which are 
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carried throughout the body via blood circulation, are responsible for the differential 
CO distribution to organs and tissues, through slow loss of CO. This mechanistic 
approach is consistent with the therapeutic versatility of CORM-3 (García-Gallego and 
Bernardes 2014).  
The other prototype water-soluble CORM to be synthesized by the group of Motterlini 
was a borano-carbonate analogue, namely CORM-A1 [Na2H3BCO2]. This CORM 
displays a pH-dependent CO release profile, with a half-life in normal pH conditions of 
~21min (Foresti et al. 2004; Motterlini et al. 2005b) (Figure 1.20).  
  
Figure 1.20: Structures of first and second generation CORMs  
After extensive discussion (Foresti et al. 2008; Zobi 2013; Romão and Vieira 2015; 
Kourti et al. 2017), the field has reached a notion that there are a number of 
prerequisites for an ideal CORM. First of all, it should be effective at low doses, non-
toxic for normal cells, soluble and stable in biological fluids and also biocompatible. 
Moreover, it should have well-defined CO-release kinetics, tissue specificity, stability 
in aerobic aqueous media and appropriate ADME properties.  
The release of CO groups from CORMs is validated mainly by the monitoring of the 
formation of carboxymyoglobin (MbCO) from deoxymyoglobin (Mb) spectroscopically 
(Motterlini et al. 2002; García-Gallego and Bernardes 2014; Schatzschneider 2015). In 
this so-called "myoglobin assay" the conversion of MbCO is followed 
spectrophotometrically by measuring the reduction in intensity of the band of Mb at 
557nm and the increase in intensity of the band of MbCO at 540nm and 577nm, until 
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the measurements reach a plateau value. Although the myoglobin assay remains the 
most popular procedure for the initial screening of the release properties of a novel 
CORM, there are some limitations regarding this assay, which should be taken into 
consideration if an alternative is not possible (Schatzschneider 2015). For example, 
strongly coloured CORMs can interfere with the absorption bands of myoglobin and 
complicated deconvolution techniques would be required for analysis. Another 
limitation is the reducing atmosphere needed to keep the Fe in the +II state (ferrous 
iron), which would be inappropriate for oxidation-activatable CORMs like the ones 
synthesized by the Schmalz group (Romanski et al. 2011).  The aqueous sodium 
dithionite required for the reduction of myoglobin can easily interact with the CORM 
or other components, causing additional issues. Finally, the undefined mechanism of 
interaction between the CO of the CORM with the myoglobin poses extra limitations 
to this technique. So, alternative methods such as gas chromatography (GC) are 
chosen over the traditional method (Schatzschneider 2015).  
1.5.4 Overview of the family of photo-CORMs 
From the first moment that CORMs were considered aspotential pharmaceutical 
agents, the problem of uncontrolled and unspecific delivery of CO arose. For a CORM 
to be used clinically, there should be a well-defined and controlled way of CO release, 
preferably after an appropriate trigger is applied. It was 2008 when the first groups 
started reporting an alternative approach to this problem, and this approach was 
photo-activatable CORMs. Light has been the main and most preferable external 
trigger suggested, because it is usually non-toxic in the used wavelengths and there 
are various devices for light manipulation with a quite straightforward way of 
triggering the release of the carbonyl groups as CO gas into the biological fluids. These 
photo-activatable CORMs, later named photo-CORMs, have the advantage of 
releasing CO in a specific tissue with temporal control, according to where the light 
source is targeted.  
However, there are limitations and challenges for these compounds, as well. An ideal 
photo-CORM should be activated at long wavelengths, with complete stability in 
darkness. The first member of this group was reported by Motterlini and co-workers, 
and it was CORM-1, as described above. Since then, several groups are active in this 
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area, with numerous successful attempts being reported. For instance, the group of 
Schatzschneider have recently developed a novel class of macromolecular photo-
CORMs, namely Mn(CO)3 functionalized metallo-dendrimers, which release CO upon 
activation with light at 410nm (Govender et al. 2013). They have also successfully 
coupled [Mn(CO)3(R-tpm)]+ complexes with target molecules, without affecting the 
photochemical CO-release properties of the complexes (Dördelmann et al. 2012).  
Using light as an external trigger for the internal release of CO in a controlled way 
remains a very active area of CORM research. Most photo-CORMs share common 
characteristics, such as being metal-based, stable in the dark in aqueous solutions and 
able to accumulate in the target tissue before the activation with light. The main 
strategies in the design of new photo-CORMs are three: 1) to shift the release 
wavelength of the photo-CORM towards the infrared area of the spectrum through 
appropriate metal and co-ligand combinations (that is ligands with extended aromatic 
p systems), 2) to attach a photosensitizer for the CO release process to a metal-
carbonyl moiety, such as an organic dye or metal complex, and 3) to use two-photon 
absorption to achieve photolytic liberation of CO from a photo-CORM prodrug. These 
strategies have been applied in order to generate a new generation of photo-CORMs 
which can be activated by visible light (García-Gallego and Bernardes 2014).  
1.5.5 Carbon monoxide and CORMs as anti-cancer agents 
The potential application of CO and CORMs in anti-cancer therapy is still under 
investigation. The relevant findings in the literature showed rather contradictory 
results (Loboda et al. 2015b; Romão and Vieira 2015; Kourti et al. 2017). The molecular 
targets and specific signalling pathways affected by CO remain unclear, being the main 
difficulty in an anti-cancer application of CO (Li Volti et al. 2005; Chatterjee 2007; 
Ahmad et al. 2015). The most plausible scenario is that CO causes opposite effects in 
different biological systems. CO and CORMs have been studied for their effects on cell 
proliferation, apoptosis and angiogenesis, primary processes involved in cancer 
initiation and progression, and the conclusion until now is that this effect is variable 
and seems to be cell–type specific (Loboda et al. 2015a,b). As mentioned already 
though, the anti-cancer potential of CO is a highly active area of research and the near 
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future will be decisive in the elucidation of the exact mechanism of action of this gas 
and its prodrugs, as well as any potential benefits against cancer. 
Examples of a few promising studies are reported here, which could be of interest for 
further development, as they seem to implicate agents that inhibit various aspects of 
cancer and with a diversity of mechanisms and pharmacological profiles. However, 
before any clinical trials are initiated, there should be a more detailed mechanism of 
action elucidated for CO and CORMs. For instance, in his study Lee et al. (Lee et al. 
2014) suggested that CO could attenuate the activity of heat shock protein 90 (HSP90), 
as well as its client proteins, possibly inhibiting cancer progression. The same group 
(Chakraborty et al. 2015) also applied a novel technique for drug delivery, utilizing Al-
MCM-41 mesoporous silica nanoparticles (MSNs) loaded with a newly synthesized 
photo-CORM, namely fac-[Re(CO)3(pbt)(PPh3)](CF3SO3), (ReCO),  for the selective 
delivery of the photo-CORM to breast cancer cells. The anti-cancer activity of the 
endocytosed particles after light-induced CO release in MDA-MB-231 cells measured 
via the MTT assay reached an 80% eradication of the cancer cells. This was a much 
stronger effect than that after the application of the photo-CORM alone, due to the 
extravasation of nano-sized particles occurring in a tumour-selective manner 
(Chakraborty et al. 2015). 
However, the HO-1/CO system is still under investigation and not fully understood. 
This may be the reason why there are so many contradicting publications regarding 
the real role of this system in tumorigenesis and angiogenesis (Kourti et al. 2017). It is 
a possibility that the cytoprotective activities of HO-1 and its by-products could offer 
cancer cells an advantage over the elevated oxidative conditions participating in 
tumorigenesis, but the antioxidant and protecting activities may delay tumour 
initiation (Loboda et al. 2015b).  
The most important aspect to be elucidated is the true role of HO-1 in angiogenesis 
and tumour progression. This role might very well depend on the specific tissue and 
conditions under investigation and if revealed, will also help in the correct application 
of the CO/CORMs in the fight against cancer. The complexity might be related to the 
many products that derive from the enzymatic activity of HO-1 and the plethora of 
interactions of not only the protein itself but also of all the products with the 
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surrounding pathways (Loboda et al. 2015b). Moreover, it seems that the oxidation 
conditions in the relevant area affect the pro- or anti-angiogenic properties of HO-1, 
as the induction of this protein under oxidative stress suggest an involvement in 
angiogenesis linked to inflammation. On the other hand, LPS-induced inflammation 
initiates an angiogenic process that may be inhibited by HO-1 activity (Dulak et al. 
2008). Studies on prostate cancer prove an inhibition of various cell functions by HO-
1, identifying MMP-9 as a potential downstream target of HO-1, whereas the opposite 
results were evident in pancreatic cancer. The general conclusion from all these 
studies was that HO-1 activity is context-dependent and that different steps of the 
angiogenic process may be differentially affected by this system. Other factors such 
as the relative expression levels might also affect the synergistic or antagonistic 
interactions with other signalling pathways. The proposed dual role is that VEGF-
induced angiogenesis may require HO-1 activity but inflammation-derived 
angiogenesis might be inhibited by HO-1 overexpression. Especially in cancer, the role 
is dependent on the type of tumour and other undefined factors (Ferrando et al. 
2011). The only certain prediction is that when the role of HO-1 is elucidated, CO could 
truly be studied and applied as a potent anti-cancer approach.   
1.5.6 CO and CORMs in relation to reactive oxygen species production 
The cellular pathways targeted by CO and CORMs have been shown to be affected by 
the generation of ROS (Bilban et al. 2008). Elevated ROS levels were evident in many 
cancers and associated with increased malignance and regulatory effects on 
angiogenesis (Ushio-Fukai and Nakamura 2008). For example, ROS can mediate cell 
proliferation and migration, including cancer and ECs, by acting as important signalling 
molecules. Furthermore, elevated ROS levels have also been implicated in the 
production and regulation of HIF1α and VEGF, affecting tumour angiogenesis (Tertil 
et al. 2010; Ferrando et al. 2011).  
Two of the main activities of CO, the anti-oxidant and cytoprotective, are through ROS 
generation and signalling, and induce endogenous cellular mechanisms of defence 
linked to anti-inflammatory events (Zuckerbraun et al. 2007; Bilban et al. 2008). It is 
well-known that cancer cells undergo metabolic changes, preferentially using glucose 
and the glycolytic pathway for energy production, which favours their proliferative 
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capacity (Hanahan and Weinberg 2011). The mild uncoupling of mitochondrial 
respiration is a way of avoiding excessive ROS production, especially under stress 
conditions. Mitochondria seem to be the main target of CO, which therefore affects 
cellular metabolism and energy production. Previous studies by Lo Iacono et al. (Lo 
Iacono et al. 2011) showed that low concentrations of CORM-3 are capable of 
increasing mitochondrial respiration, potentially affecting the Warburg effect. Also, as 
it has been suggested that a mild increase in ROS production can activate the cellular 
anti-oxidant machinery, a recent study showed that low CO levels provoke 
mitochondrial ROS generation, inducing the anti-oxidant pathway of glutathione 
(Queiroga et al. 2010). Taken together, it is logical to explore CO-mediated cellular 
metabolism as a potential cancer intervention. 
However, it is well known that the CO/HO-1 system is trivial and has a complex 
relation to cancer initiation and progression. For example, HO-1 was found 
overexpressed in many tumours and was associated to their intrinsic resistance (Yin 
et al. 2014). Contradictory results regarding the regulatory roles of CO/HO-1 levels 
were reported in different cancer types. In particular, the CO/HO-1 system-related 
chemoresistance may depend on the tumour stage and type (Chau 2015; Tan et al. 
2015). Therefore, the effects of CO in tumour development might be tumour type-
specific.  
In summary, the activity of CO, endogenously or exogenously applied, can manipulate 
cell metabolism and favour oxidative phosphorylation. CO can also increase 
mitochondrial respiration and therefore the related ROS production. However, when 
in high amounts, ROS levels can exceed the basal threshold, leading to oxidative stress 
and leak of Ca+2 from the sarcoplasmic reticulum (André et al. 2011). This is indicative 
of how the concentration of CO reaching the cells and the duration of exposure can 
alter the physiological relevance of this small molecule and complicate its study in a 
cancer related environment.  
1.5.7 Designing new CORM analogues 
Over the last decade, the increasing number of publications regarding CO and its 
prodrugs suggest that there is a growing interest in developing novel CO-based 
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therapeutics. As CO biological activities are gradually revealing, we hope that CORMs 
would become a new class of therapeutic agents against various pathological 
conditions in the near future. However, before reaching this goal, we are facing many 
obstacles. In particular, the three parts of a CORM, namely the metal centre, the 
coordination sphere and the drug sphere, play a major role in determining the 
pharmacochemical features as well as the kinetics and toxicity of the molecule.  
As for the metal centre, it has a decisive contribution in the toxic effects observed, 
due to potential uncontrolled distribution and accumulation into unrelated areas. 
Each metal used in CORM designing has unique characteristics that will allow for 
special CO arrangement and a defined number of other ligands, according to its 
coordination number. Choosing a well-characterized metal with reported 
pharmacokinetics and minimum side effects will benefit the whole development 
process and establish a more predictable toxicological profile. 
The ligand coordination sphere determines the kinetics of the molecule, as well as all 
the properties that are related to the CO itself, such as stoichiometry, in terms of 
number of CO groups that can be coordinated, and the mechanism of CO release. This 
would also affect stability against plasma proteins and reactivity with various stimuli, 
namely biologically related ligands, light and magnetic field. To be allowed to 
manipulate not only the mechanism and kinetics of CO release but also the 
appropriate trigger for its initiation, is an additional advantage of CORMs over CO gas.  
Finally, the drug sphere is the most versatile part of a CORM, and can provide the 
whole complex with favourable ADME characteristics and maybe tissue or cell-type 
targeting elements. The pharmacological features of the molecule are a direct 
consequence of the structure of ancillary ligands, which are responsible for important 
drug properties such as solubility in water and biocompatibility. Choosing appropriate 
ligands can benefit the complex with specific tissue spatial distribution and targeting 
moieties. By exploring differences in the distribution of CORMs between normal and 
disease/foreign cells numerous possibilities for therapeutic purposes unravel, with a 
few examples listed below (García-Gallego and Bernardes 2014; Romão and Vieira 
2015; Schatzschneider 2015). 
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During the last decade, a number of different molecules have been reported to be 
able to release CO under certain conditions and their cores belong to a wide variety 
of metals (Ru, Fe, Mn, V, Co, Ir, Cr, Mo, W). This new generation of complexes have 
improved properties over CORM-3, which is often chosen as the lead structure. 
ALF492 and ALF794 are two examples from this new generation of CORMs, which 
present some favourable characteristics (Figure 1.21). ALF492 was synthesized to 
have strong affinity for the liver, and it proved really successful against malaria. It is a 
water-soluble molecule that can transfer CO groups to haem proteins in circulation 
without increasing the amount of HbCO formed (Pena et al. 2012). ALF794 was also 
designed to have high liver specificity, along with other favourable ADME properties, 
as a drug against overdose of paracetamol. It has low acute toxicity in vivo and the 
release of CO is accelerated in the presence of liver microsomes. It can rescue the liver 
after paracetamol intoxication, and is effective even after the 8h initial response 
period (Romão and Vieira 2015). These example show that CORMs can be designed to 
have pharmaceutical profiles and properties similar to those of other regular drugs or 
prodrugs, therefore overcoming most of the problems usually related to metal-based 
drugs. 
One other complex that belongs to the new generation of CORMs is ALF186, which 
has been employed as a good model for the study of the main interactions of 
organometallic complexes with biological fluids. It seems that the CO equivalents of 
ALF186 are released upon O2 trigger, and they are then transported through the 
circulation partly bound to haemoglobin, while the metal by-product forms interact 
weakly with other proteins (García-Gallego and Bernardes 2014) (Figure 1.21).  
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Figure 1.21: Structures of next generation CORMs 
The main representative of the external stimuli application for initiation of CO release 
approach is the group of photo-CORMs. As discussed previously, by controlling the 
initiation of CO release, any therapeutic effects they may have focus only in the area 
where appropriate light excitation occurs, minimizing off-site effects and inadequate 
CO concentration due to systematic circulation of the complex with subsequent loss 
of a signification proportion of the carried CO. For example, in early work, 
Schatzschneider and co-workers synthesized a versatile photo-CORM with a 
[Mn(CO)3(tpm)]+ scaffold (where tpm =tris(pyrazolyl)methane) that undergoes photo-
induced CO release upon irradiation with UV light of 365nm in aqueous buffer. The 
molecule is capable of releasing two out of the three CO ligands and has shown photo-
induced cytotoxicity against human colon cancer cells (Niesel et al. 2008). Based on 
that scaffold, the same group explored the installation of an alkynyl group for further 
functionalization with short peptides, such as part of the transactivation domain of 
p53 with mouse double minute 2 homolog (MDM2), which would give the molecule 
the capability of targeting specific proteins (Pfeiffer et al. 2009) (Figure 1.22). 
 
Figure 1.22: Example of [Mn(CO)3(tpm)]+–peptide conjugate. Source: (Pfeiffer et al. 2009). 
Another example of designing new generation CORMs is the photoCORP-1 (Figure 
1.23), which is the first example of a CO-releasing hydrogel that can release CO upon 
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remote low power visible light excitation and has been proven cytotoxic against 
adenocarcinoma cells. This photoactivatable CORM also employs the approach of 
controlled release of CO, this time with an even more precise way, by using optic fibre 
technology to initiate the release via visible light. Through a specially designed optical 
fibre-based CO catheter, CO can be specifically released in a controlled manner to 
malignant targets in inaccessible cavities and body parts where CO can induce cancer 
cell apoptosis (Pinto et al. 2017).  
 
Figure 1.23: Photo-CORP-1. Source: (Pinto et al. 2017). 
Apart from the photo-CORM group, Zobi and co-workers described a family of Re-
based CORMs whose CO release can be modulated by pH and ligand variation on the 
basis core. These cyanocobalamin (vitamin B12) derivatives show some useful 
features such as water solubility, biocompatibility, aqueous stability and release of a 
minimally toxic metal fragment after the dissociation of CO. These molecules have 
been tested against ischemia-reperfusion injury and can increase cardiomyocyte cell 
survival by up to 83% (Zobi et al. 2012) (Figure 1.24).  
 
Figure 1.24: B12-ReCORM-2. Source: (Zobi et al. 2012). 
There are many other examples of new generation CORMs, most of the research being 
focused on the group of photo-CORMs. Notable examples are the work of Mascharak 
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(Chakraborty et al. 2014), Fairlamb (Ward et al. 2016) and Westerhausen (Mede et al. 
2016) who all try to overcome the main problems of CORMs. However, there are also 
other advances in CORM designing that focus on different releasing mechanisms, with 
the redox-triggered possibility being a novel and highly promising one. 
It is obvious that as with every drug development process, there are many obstacles 
that need to be overcome before a pharmaceutical agent can be clinically useful. The 
development of CORMs is even more challenging, as most of them are still water 
insoluble, unstable in aerobic and aqueous conditions and carry a metal core that 
needs to be thoroughly examined for potential toxicity and favourable 
pharmacokinetics. It is mostly intriguing to design a CORM with the ability of targeting 
the appropriate disease site where CO can be released upon a specific stimulus and 
at the proper concentration and timeframe. Motterlini and Otterbein conclude in a 
number of requirements for CORMs which refer to 1) water solubility and 
biocompatibility, 2) stability in aqueous aerobic environment, 3) slow decay of the 
M(CO)x fragment in the circulation and finally 4) low toxicity and quick metabolism 
and excretion of the remaining metal scaffold after the release of the CO (Motterlini 
and Otterbein 2010). As for the special class of photo-CORMs, additional properties 
are required, such as photoreactivity at specific wavelengths where the penetration 
depth is optimal, that can only be achieved by suitable metal and co-ligand 
combinations (Kourti et al. 2017). 
The final issue that remains unresolved despite the efforts of many research groups 
over the last twenty years, is what exact characteristics are considered desirable for 
such molecules in each disease case. For example, how many CO ligands per metal 
complex unit should be released and should the release be slow or fast, rapid or 
steady? CORMs that dissociate CO rapidly could be beneficial in the study of ion 
channel kinetics, whereas for therapeutic interventions, a more steady and controlled 
release may be desired. Therefore, there are probably more than one profile that 
these molecules should demonstrate, and the different groups of CORMs should be 
designed with specific properties according to the medical application each time in 
mind (García-Gallego and Bernardes 2014; Schatzschneider 2015). 
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1.6 Hypothesis, purpose and aims of the study 
Invasive breast cancer affects more than 1.3 million women worldwide each year, 
with more than 55,000 reported cases in the UK only in 2015. Although some breast 
cancers overexpress HER2, there is a distinct subtype called triple-negative breast 
cancer (TNBC) that does not express ER, PR or HER2. Clinical surveys reveal that 
approximately 15% of all breast cancers are diagnosed as TNBC, which occurs more 
frequently among younger women (<40 years old) and is characterized by high 
histological grade, high risk of recurrence and shorter disease-free survival, alongside 
a more frequent metastasis to bone, lung and brain.  
This unique subtype of breast cancer has yet no established effective therapeutic 
regimens, and the most frequently prescribed drugs are a combination of 
chemotherapeutic agents and RTK inhibitors. However, the results remain 
disappointing and lack long-term effectiveness. The highly regulated process of 
angiogenesis has recently emerged as a promising target for TNBC, where it seems to 
be significantly over-activated and supports the growth and metastasis of the primary 
tumour. It is well established that one of the main growth factors regulating 
angiogenesis is VEGF. VEGF itself is abundantly secreted by breast cancer cells in order 
to promote differentiation and an aggressive phenotype. By overexpressing VEGF, 
cancer cells succeed in stimulating angiogenesis and providing further nourishment 
for the growing tumour. Recent investigations into the use of anti-VEGF therapies 
such as bevacizumab alongside chemotherapy have ultimately proved long-term 
ineffective for patients with invasive breast cancer. Given the status of anti-VEGF 
drugs as one of the few available targeted therapies for TNBC, there remains an urgent 
and unmet need for improving their efficacy.  
For a long time, carbon monoxide (CO) has been best known for its potent toxic effect 
as an air pollutant because of its strong affinity (>220 fold greater than that of oxygen) 
for haemoglobin. Endogenously produced CO was found to regulate various 
endogenous signalling pathways related, among others, also to cellular metabolism, 
and was therefore characterized a gasotransmitter. However, since the 
administration of CO gas can be dangerous and poorly regulated, the discovery of 
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transition metal carbonyls that can act as CO-releasing compounds (CORMs) has 
provided a safer way to control CO release in vivo in a spatial and temporal manner. 
Previous studies suggested that CO can have various and even opposite effects on 
different subtypes of cancer and in the form of its pro-drugs, CORMs, might act as a 
new therapeutic entity. Additional to the observed heterogeneous effects on different 
systems and cell types, recent research has also demonstrated that a first generation 
CORM, that is CORM-2, can exhibit anti-VEGF and anti-angiogenic activity through the 
released CO (Ahmad et al. 2015).  
Therefore this project aimed to determine any potential cytotoxic and anti-angiogenic 
properties of four commercially available CORMs against TNBC. Based on the 
produced results, one of the four CORMs would be chosen for further structural 
modifications following classic medicinal chemistry principles, in order to produce a 
small subset of novel compounds. The new compounds would also be tested for any 
anti-angiogenic potential and one compound would emerge as a proposed leading 
structure for future studies.  
The specific aims of this study were: 
1. To test the cytotoxicity of four currently commercially available CORMs 
against two TNBC cell lines (MDA-MB-231 and MDA-MB-436), one epithelial 
cell line (MCF-10A) and one endothelial cell line (HECV). 
2. To check for alterations in the metabolic activity of TNBC cells upon treatment 
with these compounds using the Seahorse Extracellular Flux Analyser. 
3. To screen for potential anti-angiogenic properties of these compounds by 
quantifying relevant proteins and identifying subsequent effects on EC 
function. 
4. To select one compound, which would be subjected to structural 
modifications in order to synthesize novel analogues. 
5. To carry out the synthesis of a small subset of new compounds. 
6. To test the new analogues for anti-angiogenic properties and effects on ECs. 
From the observations throughout this process, one lead compound would 
eventually be proposed for further studies in the future.  
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Chapter II 
 
Materials & Methods  
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2.1 Materials 
2.1.1 Standard reagents and solutions 
Solutions for cell culture 
• 0.05M Ethylenediaminetetraacetic acid (EDTA) in PBS 
One gram of KCl (Fisons Scientific Equipment, Loughborough, UK), 5.72g Na2HPO4 
(BDH Chemical Ltd., Lutterworth, UK), 1g KH2PO4 (BDH Chemical Ltd.), 40g NaCl 
(Sigma-Aldrich, Dorset, UK) and 1.4g EDTA (Duchefa Biochemie, Haarlem, the 
Netherlands) were dissolved in distilled water and made up to 5L. The solution was 
adjusted to pH 7.4 before it was autoclaved and stored for future use.  
• Trypsin (25mg/mL) 
Five hundred milligrams of trypsin were dissolved in 20mL 0.05M EDTA. The solution 
was mixed and filtered through a 0.2µm minisart filter (Sartorious, Epson, UK), 
aliquoted in 250µL samples and stored at -20oC until required. For routine cell culture 
usage, one aliquot was diluted further in 10mL 0.05M EDTA solution and used for cell 
detachment.  
• 100x Antibiotic cocktail mix 
Five grams of streptomycin, 3.3g penicillin and 12.5g amphotericin B were dissolved 
in 5mL DMSO and then diluted with 495mL of PBS and filtered. In each 500mL media 
bottle, a 5mL aliquot was added.  
• Phosphate buffered saline (PBS) 
Fifty millilitres of 10x stock PBS (Sigma-Aldrich) were diluted in 500mL with distilled 
water, autoclaved and aliquoted in 25mL samples for future use. 
Solutions for cytotoxicity assays 
• 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
(5mg/mL) 
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One hundred milligrams of MTT (Sigma-Aldrich) were dissolved in 20mL of sterile PBS 
and stored at -20oC, protected from light, until required. 
• Acidified isopropanol (0.04M) 
Five millilitres of 2M hydrochloric acid solution (HCl) were diluted in isopropanol (2-
propanol) at a final volume of 250mL and the solution was left into the fume hood at 
room temperature for at least one month before usage.  
• 5x Stock solutions of CO-releasing molecules to be tested 
The calculated milligrams of each compound were weighed and dissolved in 1mL 
DMSO to create a 10mM stock solution. 100µL of this 10mM stock solution were 
further diluted with 1.9mL of normal media to a final volume of 2mL to create a 
500µM stock solution. 100µL of this 500µM solution were added in each well of the 
first two columns of a 96-well plate (triplicates for each different compound or 
DMSO), omitting the outer wells, and columns 2 – 10 were serially diluted with 100µL 
of normal media to obtain 5x the concentration range desired for the experiments. 
From this 5x stock solution, 30µL were transferred into each well of the test plate.  
The calculation of the required milligrams for each compound was based on the 
equations: n= m/MW and 1M= 1mol/L. For example, for CORM-2: 𝑛 =
5.1201𝑚𝑔
512.01𝑔/𝑚𝑜𝑙
=
0.01𝑚𝑚𝑜𝑙. If it is diluted in 1ml of solvent it becomes 0.01mmol/ml= 0.01M= 10mM. 
• 3x Stock solutions of CO-releasing molecules to be tested in IncuCyteTM Cytotox 
reagent 
One IncuCyteTM Cytotox reagent vial (Essen Bioscience, Hertfordshire, UK) was diluted 
with 45µL of full normal media to provide a stock concentration of 100µM, and the 
50µL solution was then transferred to 6.6mL full media to yield a Cytotox reagent 
working solution of 750nM. The 10mM compound stocks prepared as described 
above were diluted at 3x final assay concentrations in the Cytotox reagent working 
solution and 50µL were transferred into each well of the test plate.  
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• 3x Stock solutions of CO-releasing molecules to be tested in CellPlayer Kinetic 
Caspase-3/7 reagent 
The CellPlayer 96-Well Kinetic Caspase-3/7 reagent (Essen Bioscience) was diluted 
with full normal media to provide a stock solution of 15µM. The 10mM compound 
stocks prepared as described above were diluted at 3x final assay concentrations in 
the caspase-3/7 stock solution and 50µL were transferred into each well of the test 
plate.  
Solutions for cell biomass quantification 
• 4% v/v Formalin solution 
To prepare a 4% v/v formalin solution, 500mL of 10% v/v formalin solution (Sigma-
Aldrich) were diluted with 750mL of distilled water to prepare a 1.25L solution of 4% 
v/v.  
• 0.5% v/v Crystal violet solution 
To prepare a 0.5% v/v crystal violet solution, 500mL of 1% v/v crystal violet solution 
(Sigma-Aldrich) were diluted with 500mL of distilled water to prepare a 1L solution of 
0.5% v/v.  
Solutions for metabolic dysfunction detection 
• 1mM Glutamine solution in Seahorse XF Base Medium (Glycolysis medium) 
A 100mM glutamine solution was prepared by dissolving 29.23mg of glutamine 
(Sigma-Aldrich) in 2mL of Seahorse XF Base Medium (Seahorse Bioscience, Agilent 
Technologies, Cheshire, UK). This was further diluted by transferring 500µL of the 
100mM solution to 50mL of Seahorse XF Base Medium (1mM). The Glycolysis medium 
was kept in a warm bath at 37oC for the rest of the experiment.  
• 7x Stock solutions of CO-releasing molecules to be tested 
The calculated milligrams of each compound were weighed and dissolved in 1mL 
DMSO to create a 10mM stock solution. From this high stock, appropriate dilutions 
were performed to obtain a 700µM stock solution for the 100µM treatment, a 350µM 
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stock for the 50µM treatment, a 175µM stock for the 25µM treatment and a 87.5µM 
stock for the 12.5µM treatment. 75µL for the 24-well XF Microplate, or 25µL for the 
96-well XF Microplate were injected to each well during the experiment (working 
concentrations of 100-50-25-12.5µM). Port A for 96-well plate. 
• 80mM Glucose injection solution  
The glucose injection was prepared as a 8x working concentration solution of 80mM. 
43.23mg of glucose (Sigma-Aldrich) were dissolved in 3mL of Seahorse XF Base 
Medium. 75µL for the 24-well XF Microplate, or 25µL for the 96-well XF Microplate, 
were injected to each well during the experiment (working concentration of 10mM).  
Port A for 24-well plate, Port B for 96-well plate. 
• 9µM Oligomycin injection solution  
The oligomycin injection was prepared as a 9x working concentration solution of 9µM. 
1.35µL of a 20mM oligomycin stock solution (Sigma-Aldrich) was diluted in 3mL of 
Seahorse XF Base Medium. 75µL for the 24-well XF Microplate or 25µL for the 96-well 
XF Microplate were injected to each well during the experiment (working 
concentration of 1µM).  Port B for 24-well plate, Port C for 96-well plate. 
• 1000mM 2-Deoxy-Glucose injection solution  
The 2-Deoxy-Glucose injection (2-DG) was prepared as a 10x working concentration 
solution of 1000mM. 492.48mg of 2-DG (Sigma-Aldrich) were dissolved in 3mL of 
Seahorse XF Base Medium and the pH was calibrated to 7.35. 75µL for the 24-well XF 
Microplate or 25µL for the 96-well XF Microplate were injected to each well during 
the experiment (working concentration of 100mM).  Port C for 24-well plate, Port D 
for 96-well plate. 
Solutions for protein assays 
• Lysis Buffer  
Two millimolar (221.96mg) CaCl2, 0.5% Triton X-100, 10µL of 1mg/mL leupeptin, 10µL 
of 1mg/mL aprotinin and 10µL of 10mM stock sodium orthovanadate solution were 
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dissolved in distilled water (final volume 1mL) and stored at 4oC until required. Extra 
phosphatase inhibitors were added right before each experiment.  
• 10% w/v Ammonium Persulfate (APS) 
One gram of ammonium persulfate (Melford Laboratories Ltd., Suffolk, UK) was 
dissolved in 10mL of distilled water and stored at 4oC until required.  
• 10x Running Buffer 
The 1L 10x Tris-Glycine-SDS buffer stock solution (T7777) (Sigma-Aldrich) was diluted 
with 9L of distilled water to prepare a 1x running buffer solution.  
• 10x Transfer buffer 
The 1L 10x Tris-Glycine concentrate stock solution (T4904) (Sigma-Aldrich) was diluted 
with 2L of methanol and 7L of distilled water to prepare a 1x transfer buffer solution.  
• 10x Tris – Buffered Saline (TBS) 
A 10x stock solution (0.2M Tris, 1.38M NaCl) was prepared by dissolving 121g Tris 
(Sigma-Aldrich) and 403.2g NaCl (Melford Laboratories Ltd.) in distilled water up to 5L 
final volume and adjusted to pH 7.4 with HCl. The solution was stored at room 
temperature until required. 
• TBS-Tween 0.1% v/v (TBS-T) 
A 500mL solution was prepared by adding 0.5mL of Tween 20 (Sigma-Aldrich) in 
499.5mL of TBS and left to stir for 10min until complete homogenization.  
Solutions for ELISA 
• 1x Wash buffer for VEGF ELISA kit 
The 25x Wash Buffer Concentrate (Life Technologies Ltd., Paisley, UK) was allowed to 
reach room temperature and then diluted 25 times with deionized water (25mL of 
25x solution diluted with deionized water up to a final volume of 625mL). This 
Working wash buffer was stored at 4oC until required, within 14 days of preparation. 
 
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
68 
 
• Reconstituted human VEGF standards for VEGF ELISA kit 
One vial of Human VEGF Standard (Life Technologies Ltd.) was reconstituted in 1.51mL 
of deionized water (final concentration of 10,000pg/mL), mixed gently and allowed to 
sit for at least 10min to ensure complete reconstitution. 90µL of the reconstituted 
standard were added to a clean Eppendorf tube containing 510µL of Standard Diluent 
Buffer (Life Technologies Ltd.) and this was labelled as ‘standard 1500pg/mL’. This 
standard was serially diluted as follows: 300µL at a time added to a fresh Eppendorf 
tube containing 300µL of Standard Diluent Buffer. The final concentration range 
created was 1500pg/mL – 23.4pg/mL of Hu VEGF.  
• Streptavidin-HRP solution for VEGF ELISA kit 
The 100x Streptavidin-HRP solution (Life Technologies Ltd.) was diluted in HRP 
Diluent,  15min prior to usage. For each 8-well strip used in the assay, 10µL 
Streptavidin-HRP 100x solution were pipetted, the pipette tip was wiped to remove 
any excess solution, and dispensed into a tube containing 990µL of HRP Diluent. The 
solution was mixed thoroughly.  
• 1x Lysis Buffer for pVEGFR2 ELISA kit 
The 10x Cell Lysis Buffer (Cell Signalling Technology, Leiden, The Netherlands) was 
allowed to reach room temperature and then diluted 10 times with deionized water 
(120µL of 10x solution diluted with deionized water up to a final volume of 1.2mL). 
This 1x cell lysis buffer was used to prepare the cell lysates for the pVEGFR2 detection 
with the commercial ELISA kit. The final concentration of the components is as 
follows: 20mM Tris-HCl, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton, 2.5mM 
sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4 and 1µg/mL 
leupeptin. Extra phosphatase and protease inhibitors were added right before each 
experiment. 
• 1x Wash buffer for pVEGFR2 ELISA kit 
The 20x Wash Buffer (Cell Signalling Technology) was allowed to reach room 
temperature and then diluted 20 times with deionized water (5mL of 20x solution 
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diluted with deionized water up to a final volume of 100mL). This 1x Wash buffer was 
prepared fresh before each experiment. 
• Detection antibody solution for pVEGFR2 ELISA kit 
The Phospho-VEGF Receptor-2 (Tyr1175) Rabbit Detection mAb (Cell Signalling 
Technology) was diluted in 1mL of Detection Antibody Diluent and incubated for 5min 
at room temperature with occasional gentle mixing. The final working solution was 
prepared by adding this 1mL of reconstituted Detection Antibody to 10mL of 
Detection Antibody Diluent and stored at 4oC until required.  
• HRP-linked antibody solution for pVEGFR2 ELISA kit 
The Anti-rabbit IgG, HRP-linked Antibody (Cell Signalling Technology) was diluted in 
1mL of HRP Diluent and incubated for 5min at room temperature with occasional 
gentle mixing. The final working solution was prepared by adding this 1mL of 
reconstituted HRP-Linked Antibody to 10mL of HRP Diluent and stored at 4oC until 
required.  
Solutions for ISO Broth Microdilution method  
• Mueller-Hinton broth 
The original formulation was prepared from dehydrated infusion of 300g beef, 17.5g 
of acid digest of casein and 1.5g of corn starch, all made up to 1L QSP distilled water 
and adjusted to pH 7.2-7.4. 
• Mueller-Hinton broth for campylobacter testing 
The formulation was prepared by supplementing the original broth with 5% lysed 
horsed blood (TCS Biosciences, Buckingham, UK) and 20mg/L β-NAD (Sigma-Aldrich). 
• Stock solutions of CO-releasing molecules for testing 
The compounds were provided in sealed containers, protected from light, and kept at 
a -20oC freezer until the day of the experiment. These precautionary measures were 
taken as humidity, light, pH imbalances and high temperature can tamper the 
compounds provoking untimely CO release from the stocks. All stock solutions were 
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made up in either sterile water (in house) or DMSO (Sigma-Aldrich) according to 
provided guidelines. The range of concentrations used was 0.008mg/L – 128mg/L. All 
solutions were prepared freshly on the day of the experiment and they were 
protected from light throughout the handling procedure until in contact with the 
microorganisms. 
2.1.2 Equipment for chemical synthesis and identification 
Analytics  
1H NMR spectra were measured on a Bruker AVANCE 500 UltraShield NMR 
spectrometer (500 MHz) at ambient temperature. Data was recorded as follows: 
chemical shifts in ppm from internal tetramethylsilane, multiplicity (s =singlet; d 
=doublet; t =triplet; m =multiplet), coupling constant (Hz), integration and 
assignment. 13C NMR spectra were measured on a Bruker AVANCE UltraShield NMR 
spectrometer (125 MHz) at ambient temperature. Chemical shifts were recorded in 
ppm from the solvent resonance employed as the internal standard (CDCl3 at 
77.16ppm, MeOD at 49.00ppm, deuterated DMSO at 39.52ppm, THF-d8 at 67.21ppm 
and 25.31ppm). Thin layer chromatography (TLC) was conducted on pre-coated silica 
gel 60 GF254 plates. Preparative TLC plates (20x20cm, 500-2000 silica) were purchased 
from Merck (Southampton, UK). Mass spectrometry analysis (LC-ESI-MS) was 
performed on a Bruker micro-TOF spectrometer. High-resolution mass spectrometry 
(ESI-HRMS) was performed at the School of Chemistry. 
Solvents and chemicals 
All the anhydrous solvents and reagents were purchased from Sigma-Aldrich and they 
were used without further purification. The amino acids and their derivatives used as 
starting materials were purchased from Alfa Aesar (Heysham, UK). Fluka silica gel (35-
70mm) (Bucharest, Romania) was used as the stationary phase for column 
chromatography. 
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2.1.3 Cell lines  
All cell culture work was carried out in class II microflow cabinets. Pipette tips, culture 
medium and all other cell culture equipment were either purchased sterile or 
autoclaved prior to use. All cells were cultured at 37oC in a humidified incubator 
containing 5% CO2. 
In this study, five different cell lines were used, listed in Table 2.1. First, the two 
human TNBC cell lines MDA-MB-231 and MDA-MB-436, obtained from the America 
Type Culture Collection (ATCC, Middlesex, UK), were used. Non-tumorigenic human 
epithelial breast cells MCF-10A (LGC Standards, Lancashire, UK), the human umbilical 
cord endothelial cell line HECV (InterLab, Genova, Italy) and the vascular endothelial 
primary cell line HUVEC (ATCC) were also part of the study.  
Cell line Origin 
Cell 
morphology 
Tissue type 
Metastatic 
site 
Hormone 
receptors 
MDA-MB-
231 
51-year-old 
Caucasian 
female 
Epithelial 
Adenocarcinoma 
(tumorigenic) 
Pleural 
effusion 
ER-/PR-
/HER2- 
MDA-MB-
436 
43-year-old 
Caucasian 
female 
Epithelial 
Adenocarcinoma 
(tumorigenic) 
Pleural 
effusion 
ER-/PR-
/HER2- 
MCF-10A 
36-years-old 
Caucasian 
female 
Epithelial 
Fibrocystic 
disease 
- - 
HECV 
Caucasian 
female 
Endothelial 
Umbilical cord – 
Normal 
immortalized 
- - 
HUVEC 
New-born 
babies 
Endothelial 
Umbilical vein – 
Primary 
- - 
Table 2.1: Cell lines used in this study 
2.1.4 Antibodies  
Full details of primary antibodies used in this study are provided in Table 2.2. The 
secondary antibodies used for Western blotting were horseradish-peroxidase (HRP)- 
conjugated goat derived anti-rabbit IgG or rabbit derived anti-mouse IgG, all supplied 
by Sigma-Aldrich (Product codes: A-9044 and A-0545 respectively).  
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Antibody name 
Molecular 
weight 
(kDa) 
Phosphorylation 
site 
Final concentration 
used 
Product code 
Mouse anti-GAPDH 37 - 0.2 µg/mL SC-32233 
Mouse anti-pERK1/2 42/44 Y204 0.4 µg/mL SC-7383 
Mouse anti-pAKT 62/56/60 S473 0.4 µg/mL SC-81433 
Rabbit anti-pVEGFR2 152 Y1175 1.49 µg/mL Ab-194806 
Rabbit anti-p-p38 38 T180+Y182 1.0 µg/mL Ab-4822 
Rabbit anti-pSrc 60 Y419 0.538 µg/mL Ab-185617 
Rabbit anti-HO-1 32 - 1.0 µg/mL HC3001 
Rabbit anti-pFAK 119 Y397 1.0 µg/mL Ab-81298 
Table 2.2: Primary antibodies used in this study 
2.2 Methods 
2.2.1 Cell culture 
MDA-MB-231, MDA-MB-436 and HECV cell lines were routinely maintained in 
Dulbecco’s Modified Eagle’s medium (DMEM/Ham’s F-12 with L-Glutamine) (Sigma-
Aldrich) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Sigma-
Aldrich) and 1% of antibiotic cocktail mix (working concentrations of 100IU/mL 
penicillin (=0.5988mg/mL), 0.1mg/mL streptomycin and 0.25µg/mL amphotericin B, 
100x stock solution, obtained from Sigma-Aldrich).  
MCF-10A cells were routinely maintained in Mammary Epithelial Basal Medium 
(MEBM, Lonza, Gloucestershire, UK) supplemented with the following growth 
supplements (MEGM kit) (Lonza): 2mL BPE, 0.5mL hEGF, 0.5mL Hydrocortisone, 0.5 
mL GA-1000 and 0.5mL insulin. The medium also contained 1% antibiotic cocktail mix 
(Sigma-Aldrich) and 100ng/mL cholera toxin (Sigma-Aldrich). 
HUVEC cells were routinely maintained in Endothelial Cell Growth Basal Medium-2 
(EBM-2, Lonza) supplemented with 1% antibiotic cocktail mix (Sigma-Aldrich), 2% FBS 
(Lonza) and the following growth supplements (EGM-2 BulletKit) (Lonza): 0.5mL hEGF, 
0.2mL Hydrocortisone, 0.5 mL GA-1000, 2mL hFGF-B, 0.5mL VEGF, 0.5mL R3-IGF-1, 
0.5mL ascorbic acid and 0.5mL heparin.  
All the cells were grown to confluence in 25cm3 or 75cm3 culture flasks loosely capped 
(Greiner Bio-One Ltd., Gloucestershire, UK) at 37oC in 5% CO2 and 95% humidity. The 
flasks were left to reach adequate confluence before starting each experiment, unless 
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otherwise stated. Full media (or normal media) referrs to the optimal media for each 
cell line supplemented with the recommended percentage of FBS.  
2.2.1.1 Trypsinization and counting of cells 
Cells were grown until they reached approximately 80 – 90% confluence, as assessed 
visually evaluating the coverage of cells over the surface of the culture flask using an 
inverted light microscope. The culture medium was aspirated and the cells washed 
once with 1mL of sterile PBS. 1mL of trypsin-EDTA solution (0.01% w/v trypsin-0.05% 
w/v EDTA in PBS buffer) was added and the cells were left in the normal incubator for 
5min to detach. Cells were visualized under a microscope in order to verify if they had 
detached and the flask was also gently tapped to help detachment. The detached cell 
suspension was neutralized with 4mL of normal serum media and transferred to a 
20mL universal container (Greiner Bio-One Ltd.), where it was centrifuged at 1700rpm 
for 5min for the cells to pellet. The supernatant was aspirated and the pellet was 
resuspended in 5mL of normal cell culture medium. The cells were then re-cultured 
by transferring 1/5 of the cell suspension into new culture flasks, counted for 
experimental work or stored under liquid nitrogen for future use.  
For cell counting, a haemocytometer counting chamber was used. Briefly the cell 
pellet after centrifugation was resuspended in 1mL of medium and appropriate 
volume was loaded into the counting chamber. An inverted light microscope was used 
to count the cells for further in vitro cellular assays. The dimensions of each 16 square 
area of the counting chamber was 1mm x 1mm x 0.1mm which allowed the number 
of cells per mL to be determined using the following equation: 
Cell number/mL= (sum number of cells counted in 4 corner squares/4) x 104 cells/mL 
2.2.1.2 Cell storage in liquid nitrogen 
The cell lines were stored in liquid nitrogen after detached from a small T25 flask and 
pelleted as described above. The freezing medium was prepared by supplementing 
standard culture medium with 10% v/v DMSO (Sigma-Aldrich). The cell pellet was 
resuspended in freezing medium at a cell density of 106 cells/mL and aliquoted into 
1.0mL cryopreservation tubes CRYO.S (Greiner Bio-One). The cryo vials were stored 
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for 2h at -20oC before being transferred at a -80oC deep freezer overnight. The vials 
were then stored in liquid nitrogen tanks for long term storage.  
2.2.1.3 Recovery of cells from liquid nitrogen 
Frozen cells were removed from liquid nitrogen and left at room temperature for 2-
3min to facilitate rapid thawing. After complete thawing, the cell suspension was 
transferred to a universal container with 10mL of pre-warmed medium and allowed 
to sit for 2min before centrifugation at 1700rpm for 5min. The supernatant was 
aspirated, the pellet resuspended in 5mL of pre-warmed normal medium and placed 
into a fresh T25 culture flask, followed by normal incubation at 37oC in 5% CO2 and 
95% humidity. Following incubation for 24h, the medium was aspired, the flask 
washed with 1mL of sterile PBS and 5mL of fresh normal medium were added before 
leaving the cells to grow normally.  
2.2.2 Cytotoxicity assays 
2.2.2.1 MTT assay 
Upon reaching adequate confluence (~90%), cells of a T25 flask were trypsinized and 
counted as described above. The cell pellet was resuspended at 500,000cells/12mL 
normal media and 120µL of this suspension were seeded on each well of a 96-well 
plate (Greiner Bio-One Ltd.) leaving the outer wells empty to fill up with 120µL of 
sterile PBS. Another 96-well plate was seeded with 120µL of normal media but no 
cells, following the same layout. The plates were left in a normal incubator for 24h.  
24h after seeding, the treatments were added in the wells as 30µL of 5x stock 
solutions. The final concentration range of the treatments was 100µM – 0.390625µM, 
triplicates each sample and the same concentrations were used for the DMSO 
treatments, which served as controls. The blank plate was treated the same way. The 
plates were then left in a normal incubator for 72h. 
72h after treatment, 20µL of 5mg/mL MTT solution were added in each well of both 
plates and left in a normal incubator for 4h. After that, the medium was aspirated and 
the plates blotted against clean tissue. The remaining purple crystals were dissolved 
in 100µL of acidified isopropanol and the absorbance of both plates was read at 
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540nm using an ELx800 plate reading spectrophotometer (Bio-Tek, Wolf laboratories, 
York, UK). The blank plate absorbance was subtracted from the plate that contained 
cells, in order to eliminate the background interference within the absorbance 
readings.  
2.2.2.2 IncuCyteTM Cytotoxicity assay  
A similar experimental preparation as for the MTT assay was followed in this 
experiment. Confluent T25 flasks were used to obtain a cell pellet, which was 
resuspended at 500,000cells/10mL normal media and 100µL of this suspension were 
seeded on each well of a 96-well plate. The plate was left in a normal incubator 
overnight for cells to adhere.  
24h after seeding, the treatments were added in the 96-well plate wells as 50µL of 
the 3x stock solutions in IncuCyteTM Cytotox reagent. The final concentrations of the 
treatments were 100 – 50 – 25 – 12.5µM, triplicates each sample and the same 
concentrations were used for the DMSO treatments, which served as controls. The 
final assay concentration of the Cytotox reagent was 250nM. The plate was then 
placed into the IncuCyteTM ZOOM® instrument with a 10x objective using the Standard 
Scan Type. The images were captured every 2h until the assay was completed (72h).  
2.2.2.3 IncuCyteTM Caspase-3/7 assay (Apoptosis assay) 
Confluent T25 flasks were used to obtain a cell pellet, which was resuspended at 
1,000,000cells/10mL normal media and 100µL of this suspension were seeded on 
each well of a 96-well plate. The plate was left in a normal incubator overnight for 
cells to adhere.  
A few hours after seeding and upon reaching the desired confluence of 10-20%, the 
treatments were added in the 96-well plate wells as 50µL of the 3x stock solutions in 
CellPlayerTM Caspase 3/7 reagent. The final concentrations of the treatments were 
100 – 50 – 25 – 12.5µM, triplicates each sample and the same concentrations were 
used for the DMSO treatments, which served as controls. The final assay 
concentration of the Caspase 3/7 reagent was 5µM. The plate was then placed into 
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the IncuCyteTM ZOOM® instrument with a 10x objective using the Standard Scan Type. 
The images were captured every 2h until the assay was completed (72h).  
2.2.3 Cell biomass quantification 
2.2.3.1 Crystal violet assay 
To calculate the cell biomass as an indirect way to quantify the number of viable cells, 
a crystal violet assay was performed. The normal media of pre-seeded cells in a 
multiwell plate was aspirated and 100µL of 4% formalin solution were added to each 
well for 15min. After the fixation of the cells, the formalin solution was removed and 
100µL of 0.5% crystal violet solution were added to each well for another 15min. The 
solution was then aspirated and the plate was carefully washed under the tap. The 
plate was left overnight to dry and then the crystal violet dye was resuspended in 
200µL of 10% acetic acid solution (Sigma-Aldrich). The plate was read at 540nm using 
an ELx800 plate reading spectrophotometer (Bio-Tek). 
2.2.4 Metabolic dysfunction detection with the Seahorse Extracellular XFe Flux 
Analyser 
The glycolysis levels of the cells were measured using the Seahorse Extracellular XFe 
Flux Analyser. The cells were seeded in a Seahorse XF24 or XF96 Cell Culture 
Microplate the day before the experiment or as otherwise stated. For the 24-well 
plate 40,000 cells/well were seeded, whereas for the 96-well plate 10,000 cells/well 
were seeded.  
After the supplementation of the Seahorse Base medium with 1mM glutamine, the 
pH was calibrated to 7.35 and the media was kept in a 37oC warm bath after filtration 
through a 0.2µm minisart filter (Sartorious).  
XF24 Cell Culture Microplate: The normal media of the cells was removed and 525µL 
of Glycolysis media were added in each well of the XF Microplate. The plate was then 
left in a CO2-free incubator for 1h.  
Meanwhile, the injections were prepared as indicated in the solution preparation 
section. All the injections were loaded on the injection plate at volumes of 75µL each.  
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After finishing the experiment, the wells were washed with PBS twice and 11µL of lysis 
buffer were added to each well. A protein quantification of the cell lysates was 
performed right after. 
XF96 Cell Culture Microplate: The normal media of the cells was removed and 150µL 
of Glycolysis media were added in each well of the XF Microplate. The plate was then 
left in a CO2-free incubator for 1h.  
Meanwhile, the injections were prepared as indicated in the solution preparation 
section. All the injections were loaded on the injection plate at volumes of 25µL each.  
After finishing the experiment, the wells were washed with PBS twice and a crystal 
violet assay was performed right away for the quantification of the cell biomass. 
2.2.5 Protein detection 
2.2.5.1 Sodium dodecyl sulphate – Polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
Cell lysis and protein extraction 
Upon reaching adequate confluence (~90%), the normal media was removed and the 
cell monolayer of a T25 flask was washed two times with ice-cold sterile PBS. 100µL 
of lysis buffer supplemented with 1µL of 500mM sodium orthovanadate (working 
concentration of 5mM, phosphatase inhibitor) and 1µL of 2.5M sodium fluoride 
(working concentration of 25mM, phosphatase inhibitor) were added on the cell 
monolayer. When preparing the cell lysates for the pVEGFR2 ELISA kit, apart from 
using the 1x Cell Lysis Buffer mentioned previously, 1µL of 1mg/mL aprotinin was also 
added (working concentration of 10µg/mL, serine protease inhibitor). The cells were 
scraped from the base using a disposable cell scraper and everything was kept in ice 
during that procedure. The detached cells were transferred to a 0.5mL Eppendorf 
tube (A laboratories, Hampshire, UK) and placed in ice for 30min in order to extract 
the cell lysate. The Eppendorf was vortexed every 10min on a Vortex-Genie 2 
(Scientific Industries, Cole-Parmer, UK) to enhance the lysis of the cells. The lysed cells 
were then centrifuged at 13,000rpm for 15min at 4oC in an AccuSpin Micro 17R 
microcentrifuge (Fisher Scientific) to remove cellular debris and collect the protein in 
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the supernatant. The supernatant was transferred to a clean Eppendorf tube and 
protein quantification was performed before sample usage in Western blotting or the 
samples were stored at -20oC until future use.  
Protein quantification of cell lysates 
For the standardisation of protein samples when loading on to the SDS-PAGE gel, the 
concentration of protein in each sample was quantified and standardised. This was 
done using the Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories, Hemel Hempstead, 
UK). First, a serial dilution of bovine serum albumin (BSA) standard samples (Sigma-
Aldrich) with known concentrations of protein was prepared in the same cell lysis 
buffer used in protein extraction, to give a working concentration range between 
10mg/mL – 0.156mg/mL. 5µL of either the sample or the standard were pipetted into 
a 96-well plate in duplicate before adding 25µL of "working reagent A/S", followed by 
200µL of "working reagent B" (a dilute Folin Reagent). "Working reagent A/S" was 
prepared by mixing each mL of reagent A (an alkaline copper tartrate solution) with 
20µL of reagent S. If the samples do not contain detergent, this step can be skipped 
and reagent A can be used as supplied. The mixture was left in the dark at room 
temperature for 15min allowing the colorimetric reaction to occur. The absorbance 
of both the samples and the standards was measured at 630nm using an ELx800 plate 
reading spectrophotometer (Bio-Tek). A standard protein curve was constructed for 
the BSA standards and used to correlate the absorbance of each sample with a protein 
concentration.  
All protein concentrations were adjusted to desired working concentrations of 1 – 
2mg/mL by diluting the samples with the same cell lysis buffer used for the protein 
extraction. This was followed by further dilution 1:1 (v/v) with 2x Laemmli sample 
buffer concentrate (Sigma-Aldrich). Samples were then boiled at 100oC for 5min 
allowing the denaturation of the proteins before loaded on an SDS-PAGE gel or stored 
at -20oC until required.  
Loading the samples and running the gel 
SDS-PAGE was carried out using an OmniPAGE VS10 vertical electrophoresis system 
(OmniPAGE, Wolf laboratories). Acrylamide gels were made up at a concentration 
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appropriate to the molecule being analysed. They were prepared in a universal tube 
and added between two clean, dry glass plates and assembled on a casting stand. The 
TEMED was added to the mixture just before loading, as this causes the gel to 
polymerise and set. The amount of each ingredient required to make up 10mL of 10% 
resolving gel (proteins with molecular weight in the range of 30 – 220KDa) are shown 
in the table below: 
Component mL 
Distilled water 4.0 
30% acrylamide mix 3.3 
1.5M Tris (pH 8.8) 2.5 
10% SDS 0.1 
10% ammonium persulfate 0.1 
TEMED 0.004 
Table 2.3: Recipe for 10mL of 10% resolving gel 
Using a disposable plastic pipette, the resolving gel was applied between the glass 
plates and immediately covered with isopropanol (Sigma-Aldrich) to ensure a smooth 
surface for the gel and minimum interaction with the environmental oxygen which 
can cause oxidation of the gel. The gel was left to polymerise at room temperature on 
a flat surface. After approximately 30min the resolving gel was set, the isopropanol 
layer was removed and 3mL of 5% stacking gel were added on top. A well forming 
Teflon comb was placed gently at the top of the stacking gel and the gel was allowed 
to polymerise at room temperature for further 30min. The components and amounts 
used for the 5% stacking gel are indicated below: 
Component mL 
Distilled water 2.1 
30% acrylamide mix 0.5 
1.5M Tris (pH 8.8) 0.38 
10% SDS 0.03 
10% ammonium persulfate 0.03 
TEMED 0.003 
Table 2.4: Recipe for 3mL of 5% stacking gel 
Once the stacking gel had set after approximately 30min, the comb was carefully 
removed without tearing the edges of the wells and the loading cassette was placed 
into an electrophoresis tank filled up with 1x running buffer until the wells were 
completely covered. 
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The samples were loaded into the wells using a 20µL pipette at equal volumes of 
approximately 15µL. Control wells with 10µL of molecular weight marker SDSH2 
(Sigma-Aldrich) were always used to indicate the molecular weight of the bands.  
The proteins were then separated according to their molecular weight using 
electrophoresis at 120V, 80mA and 500W for 1.5h.  
Preparation of membrane and Western Blotting 
Following SDS-PAGE, the protein samples were transferred onto an Immobilon®–P 
PVDF membrane (Merck Milipore, MA, USA) by Western blotting. The electrophoresis 
system was disassembled and the glass plates separated. The gel was removed and 
separated from the glass plates after removing the stacking gel with a plastic edge. 
The nitrocellulose membrane and four sheets of filter paper (Whatman International 
Ltd., Maidstone, UK) were cut (7.5cm x 7.5cm) and immersed into 1x transfer buffer 
for 10min to ensure correct binding of the protein to the membrane. The PVDF 
membrane was then activated by immersing into methanol for 30 seconds and 
transferred immediately back to transfer buffer. Two sheets of filter paper were 
placed on top of the (+) pole of a SD10 SemiDry Maxi System blotting unit, then the 
activated membrane on top, the gel on top of the membrane and finally another two 
sheets of filter paper. The surface of the "sandwich" of papers-nitrocellulose 
membrane-gel-papers was carefully smoothed out to remove air bubbles which may 
interfere with the protein transfer. The (-) pole lid was attached and the sandwich was 
set up for protein transfer from the gel to the membrane via electroblotting at a 
constant current of 15V, 500mA, 8W for 50min – 1h.  
Once completed, the membrane was removed and by forming a roll, it was 
transferred facing upwards into a clean 50mL falcon tube (Nunc, Fisher Scientific). It 
was then incubated in 50mL of 10% milk blocking solution (500mg skimmed milk in 
5mL TBS-T) for 1h with agitation on a roller mixer (Stuart, Wolf Laboratories) at room 
temperature. This solution blocks the proteins on the membrane, disallowing non-
specific binding of the primary antibody. The blocking solution was then discarded and 
5mL of specific primary (1o) antibody (appropriate dilution) made up in 5% milk 
solution (250mg skimmed milk in 5mL TBS-T) were added to the tube and the 
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membrane was left to probe overnight at 4oC with agitation on a roller mixer. After 
this, the 1o antibody solution was discarded and the membrane was washed three 
times for 10min each wash, with 15mL of TBS-T, to ensure complete removal of any 
unbound 1o antibody. The membrane was then incubated in 5mL of HRP-conjugated 
secondary (2o) antibody solution (dilution 1:1000) (Sigma-Aldrich; dependent on the 
species of the primary antibody) made up in 5% milk solution with agitation for 1h at 
room temperature. The 2o antibody solution was discarded and the membrane was 
washed again as previously described.  
Chemiluminescent detection of protein 
The EZ-ECL system (Biological Industries, Cromwell, USA), a highly sensitive chem-
iluminescent substrate for the HRP used for the Western blotting procedure, was used 
for protein detection on the membrane. The two substrates, A and B, were mixed in 
a 1:1 ratio with a final volume of 1mL/membrane and left in the dark for 4min to allow 
the reaction to develop. Once the mixture was ready, the washing solution was 
decanted from the membrane and it was placed on a tray and covered with the 
solution. The membrane was left in the dark for 1 – 3min, any excess solution was 
drained over a piece of clean tissue paper and the chemiluminescent signal was 
captured and visualized on a computer monitor connected to a G:Box Chemi XRQ 
imager (Syngene, Cambridge, UK). Semi-quantitative analysis was undertaken using 
the ImageJ software (National Institutes of Health, NY, USA) in order to assess the 
protein levels in the samples.  
2.2.6 Enzyme – linked immunosorbent assay (ELISA)  
2.2.6.1 ELISA for VEGF quantification 
All the solutions and diluents included in this assay were purchased from Life 
Technologies Ltd., Paisley, UK, unless otherwise stated. The ELISA technique was used 
to detect human VEGF levels in the supernatant of confluent cells. Protein 
concentration of each flask was used to normalize the results of the ELISA.  
Upon reaching adequate confluence (60-70%), the normal media from a culture at a 
T25 flask was collected into Eppendorf tubes and centrifuged at 13,000rpm for 5min 
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in a microcentrifuge to remove cellular debris and cells. The supernatant was 
transferred to clean Eppendorf tubes and kept at a -80oC freezer until required for 
ELISA.  
All the reagents were allowed to reach room temperature before use. 50µL of the 
Incubation Buffer were added to all wells of the provided pre-coated 96-well plate 
except chromogen blanks. 100µL of standards were added to the appropriate 
microtiter wells. For samples and controls, 50µL of Standard Diluent Buffer were 
added to each appropriate well, followed by 50µL of the sample or control. The plate 
was covered and incubated for 2h with constant agitation at room temperature. The 
solution was then thoroughly aspirated and the wells were washed 4 times with 300µL 
diluted (1x) Wash Buffer.  
After the washing, 100µL of the Human VEGF Biotin Conjugate solution were added 
to each well except chromogen blanks. The plate was covered and incubated for 1h 
with constant agitation at room temperature. After this time, the same washing 
procedure described above was followed. 100µL of Streptavidin-HRP solution were 
then added into each well except the chromogen blanks and the plate was covered 
and incubated for further 30min with constant agitation at room temperature. The 
same washing procedure already described was then followed. 100µL of Stabilized 
Chromogen were added to each well and the substrate solution begun to turn blue. 
The plate was covered and incubated for 30min at room temperature in the dark. 
Finally, 100µL Stop Solution were added to each well and all the contents were gently 
mixed until the solution in the wells turns from blue to yellow.  
The absorbance was then read at 450nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek), within 2h of adding the Stop Solution. The standard 
curve was generated using a curve-fitting software (Microsoft Excel 2013) and used 
to associate an absorbance reading with a standard VEGF concentration. The 
background absorbance was subtracted from all data points prior to plotting, and the 
values obtained for the samples (and controls) were multiplied by the appropriate 
factor to correct for the sample dilution.  
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2.2.6.2 ELISA for pY1175 (pVEGFR2) quantification 
All the solutions and diluents included in this assay were purchased from Cell 
Signalling Technology (Leiden, The Netherlands), unless otherwise stated. The 
sandwich ELISA technique was used to detect pVEGFR2 (Tyr1175) levels in the lysate 
of pre-treated cells as described in the corresponding sections.  
Upon reaching adequate confluence (70-80%), the normal media of a culture at a T25 
flask was aspirated and the cells were lysed as described previously. The supernatant 
of the lysate was transferred to a clean Eppendorf tube and kept at a -80oC freezer 
until required for ELISA.  
All the reagents were allowed to reach room temperature before use. Cell lysates 
were diluted before the experiment with the Sample Diluent at a working 
concentration of around 0.2mg/mL. 100µL of each sample were added to the 
corresponding wells of the provided pre-coated 96-well plate. The plate was covered 
and incubated for 2h at 37oC. The solution was then thoroughly aspirated and the 
wells were washed 4 times with 200µL diluted (1x) Wash Buffer.  
After the washing, 100µL of reconstituted Detection Antibody solution were added to 
each well. The plate was covered and incubated for 1h at 37oC. After that, the same 
washing procedure described above was followed. 100µL of reconstituted HRP-Linked 
secondary antibody solution were then added into each well and the plate was 
covered and incubated for further 30min at 37oC. The same washing procedure 
already described was then followed. 100µL of 3,3’,5,5’-Tetramethylbenzidine (TMB) 
substrate were added to each well and the substrate solution begun to turn blue. The 
plate was covered and incubated for 10min at 37oC. Finally, 100µL of the Stop Solution 
were added to each well and all the contents were gently mixed until the solution in 
the wells turns from blue to yellow.  
The absorbance was then read at 450nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek), within 30min of adding the Stop Solution. The values 
obtained for the samples (and controls) were multiplied by the appropriate factor to 
correct for the sample dilution and compared to each other.  
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2.2.7 Tube formation assay 
2.2.7.1 Tube formation assay using conditioned media 
Fifty microliters of Matrigel (BD Biosciences, Oxford, UK) were added in each well of 
a 96-well plate and the plate was left in a normal incubator for the Matrigel to set for 
30min. A 70% confluent T75 flask was used to obtain a cell pellet, which was 
resuspended in normal full media and 35,000cells/100µL were seeded on top of the 
Matrigel in each well. The plate was then left in the normal incubator for 30 – 40min 
for the cells to adhere to the Matrigel. After this, the full media was removed and 
100µL of serum free media were added on top of the cells. 60µL of conditioned media 
from treated MDA-MB-231 cells were also added in each well and the plate was left 
in the incubator for 6h. After 6h the wells were imaged using a Leica DM 1000 LED 
microscope (Leica Microsystems, Milton Keynes, UK) (5x objective) capturing at least 
3 images/well in random areas. Images were analysed using the ImageJ Software 
(National Institutes of Health) and the percentage of total tube length compared to 
the cells that received conditioned media from vehicle treated MDA-MB-231 cells was 
calculated.  
2.2.7.2 Tube formation assay with instant treatments 
Fifty microliters of Matrigel (BD Biosciences) were added in each well of a 96-well 
plate and the plate was left in a normal incubator for the Matrigel to set for 30min. A 
70% confluent T75 flask was used to obtain a cell pellet, which was resuspended in 
normal full media and 35,000cells/100µL were seeded on top of the Matrigel in each 
well. The plate was then left in the normal incubator for 30 – 40min for the cells to 
adhere to the Matrigel. After this, the full media was removed and 100µL of serum 
free media were added on top of the cells. 11.2µL of 10mM CORM stock or 1% DMSO 
stock (diluted in serum free media) or serum free media were added in the 
corresponding wells and the plate was left in the incubator for 6h. After 6h the wells 
were imaged using a Leica DM 1000 LED microscope (Leica Microsystems) (5x 
objective) capturing at least 3 images/well in random areas. Images were analysed 
using the ImageJ Software (National Institutes of Health) and the percentage of total 
tube length compared to the vehicle treated cells was calculated. 
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2.2.8 Migration assays 
2.2.8.1 Traditional Scratch wound healing assay 
Cells were seeded into a 24-well plate at a concentration of 105 cells/well/1mL in 
normal media. Cells were allowed to attach and reach confluence for 3 days in a 
normal incubator. When having reached adequate confluence (>90%), the medium 
was aspirated and the wells were washed with 200µL sterile PBS. A 100µL pipette tip 
was used to scratch down a straight line in the centre of the well. The wells were 
carefully washed again with 200µL PBS and 1.5mL of media supplemented with the 
corresponding treatments of 100µM CORMs or 1% DMSO were added in each well, 
triplicates for each different treatment, and the plate was followed up for 24h. Cells 
were imaged using a Leica DM 1000 LED microscope (Leica Microsystems) (5x 
objective) at 0h, 8h, 12h and 24h, in an area determined by blue lines drawn across 
each well. Images were analysed using the ImageJ Software (National Institutes of 
Health) and the percentage of wound closure (wound confluence) was calculated. 
2.2.8.2 IncuCyteTM Scratch wound assay  
Confluent T25 flasks were used to obtain a cell pellet, which was resuspended in 
normal media and 50,000cells/100µL were seeded on each well of a 96-well 
ImageLock plate (Essen Bioscience). The plate was then left in the IncuCyteTM ZOOM® 
instrument with a 10x objective using the Standard Scan Type. The images were 
captured every 2h until the cells reached adequate confluence of >90% (usually 
overnight).  
Upon reaching adequate confluence, the ImageLock plate was removed from the 
instrument and the Wound Maker was used to scratch all the wells of the plate 
following the manufacturer’s instructions. The wells were immediately washed twice 
with 100µL normal media and then 100µL of normal media supplemented with 
treatments was added to each well for 48h. The ImageLock plate was returned to the 
instrument, where images were captured every 1h or 2h with specific parameters set 
for the experiment. The concentrations used were 100 – 50 – 25 – 12.5µM CORMs or 
corresponding percentages of DMSO, quadruplicates for each different treatment. 
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Images were analysed using the IncuCyte ZOOM 2016A software (Essen Bioscience) 
and the percentage of wound confluence was calculated. 
2.2.9 Antibacterial activity assessment – ISO Broth Microdilution method 
(Described in the Appendix) 
Working solutions of the compounds to be tested were dispensed into microdilution 
trays at 50μl per well with double the desired final concentrations of antimicrobial 
agent. At least one well containing 50μl of antimicrobial agent-free medium was 
included as a growth control for each strain tested. Likewise, a well containing 100μl 
of antimicrobial agent-free medium was included as an uninoculated negative control 
well for each strain tested. The trays were inoculated within 30min of standardizing 
the bacterial suspension, in order to maintain viable cell number concentration. To 
each well containing 50μl of diluted antimicrobial agent in broth, a volume of 50μl of 
bacterial suspension was added. 
Viable counts were performed on the test suspension to ensure that test wells contain 
approximately 5 × 105 CFU/mL (the inoculum is expressed as colony-forming units per 
millilitre (CFU/mL)). This was done by removing 10μl from the growth control well 
immediately after inoculation and diluting it in 10mL of broth. 100μl of the diluted 
growth control were spread over the surface of a suitable agar plate, which was then 
incubated overnight. Twenty to eighty colonies would be expected from an 
acceptable test suspension. If this is not achieved, the results for this strain cannot be 
used. 
After the addition of the bacterial suspension, microdilution trays were sealed in 
polyethylene bags before incubation, in order to prevent desiccation. In order to avoid 
uneven heating, microdilution trays were not to be stacked more than five high. The 
trays were incubated at 37oC in ambient air for (18 ± 2)h. A CO2-enriched atmosphere 
should not be used.  
Results shall only be read when there is sufficient growth of the test organism (that is 
obvious button or definite turbidity in the positive growth control), when there is no 
growth in the uninoculated or negative growth control and when purity and the 
appropriate cell number concentration of the inoculum has been established. The 
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amount of growth in each well is compared with that in the positive growth control, 
and the MIC recorded is the lowest concentration of the agent that completely inhibits 
visible growth.  
2.2.10 Statistical analysis  
Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., 
CA, USA). Each experiment was performed at least three times and the data presented 
shows the mean of the three repeats (unless otherwise stated), with error bars 
showing the standard deviation (SD) or standard error of the mean (SEM). Student’s 
t-test (for rank comparison between two groups) and two-way ANOVA (for more than 
two groups and two factors comparison) were performed to check for statistical 
significance, with a p-value of <0.05 considered statistically significant. Asterisk 
notation (*) was used to identify significances: * p<0.05, ** p<0.01, *** p<0.001 and 
**** p<0.0001.  
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Chapter III 
 
Screening of available 
CORMs 
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3.1 Cytotoxicity Assessment 
3.1.1. Introduction 
In vitro cell-based assays are often used for the screening of anti-cancer compounds 
to determine if they have effects on cell proliferation or show direct cytotoxic effects 
that eventually lead to cell death (Ganot et al. 2013). The preclinical toxicity testing is 
recognised as an essential process during the screening of new molecules by the US 
FDA, in order to reveal any toxic effects of an investigational product on various 
biological systems (Berridge and Tan 1993; Parasuraman 2011). Since the compounds 
related to this project are able to release CO, a potentially lethal gas, the investigation 
of any potential cytotoxicity for the four commercially available CORMs is a useful and 
decisive first analysis. Apart from that, there is a bias among researchers against 
metal-based drug candidates, by assuming that heavy metals cause more harmful 
effects than lighter metals (Egorova and Ananikov 2017). This has not been 
conclusively established in any investigation yet. Nevertheless the screening for 
cytotoxicity was deemed important.  
Meanwhile, previous studies have shown that CORM-2 at 50µM antagonised the 
proliferation of endothelial HUVEC cells after stimulation with increasing 
concentrations of VEGF (Ahmad et al. 2015). Furthermore, Lee et al. revealed that HO-
1 induction or exogenous CO delivered by CORM-2 decreased the proliferation of 
breast cancer cell lines, such as MCF-7 and MDA-MB-231 cells (Lee et al. 2014). Finally, 
anti-proliferative effects of CO in the form of CORM-2 were also demonstrated by the 
group of Vitek et al. (Vítek et al. 2014). Taken together, these studies suggested the 
necessity of a cytotoxicity assessment of the compounds chosen against the different 
cell lines used.  
Tetrazolium dye assays can be used to identify cytotoxicity (loss of viable cells) or 
cytostatic activity (shift from proliferation to quiescence) of potential medicinal 
agents and toxic materials (Berridge et al. 2005). The MTT assay is a colorimetric assay 
for measuring the activity of NAD(P)H–dependent MTT–reducing enzymes (located 
mainly into the mitochondria, but also in the cytosol) to reduce the tetrazolium dye 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its insoluble 
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formazan, which has a purple colour (Figure 3.1). MTT is positively charged and readily 
penetrates viable eukaryotic cells. The formazan form of the MTT accumulates as an 
insoluble purple precipitate inside the cells as well as near the cell surface and in the 
culture medium.  
When cells die, they lose the ability to convert MTT into formazan, thus colour 
formation serves as a useful and convenient indirect marker of the number of viable 
cells. The quantity of formazan (presumably directly proportional to the number of 
viable cells) is measured as absorbance at 540nm in a plate spectrophotometer 
reader. By all means, the formazan must be solubilized prior to the absorbance 
readings, and for the experiments of this chapter, a solubilisation solution of acidified 
isopropanol has been used, as described in section 2.2.2.1. 
The amount of signal generated is dependent on several parameters including the 
concentration of the MTT, the length of the incubation period, the number of viable 
cells and their metabolic activity. All of these parameters should be considered when 
optimizing the assay conditions to generate a sufficient amount of product that can 
be detected above background. The conversion of MTT to formazan by cells in culture 
is also time dependent. 
However, it is worth noting that since MTT reduction is fulfilled by NAD(P)H– 
dependent oxidoreductases, it is a marker reflecting viable cell metabolism and not 
specifically cell proliferation or cell number. Cells with low metabolic rates obviously 
reduce MTT much less compared to rapidly diving cells, such as breast cancer cells. An 
important drawback of this assay is that it could be affected by a number of conditions 
that can alter the metabolic activity and thus MTT reduction, not directly reflecting 
cell viability.  
The IncuCyte® Live-Cell Analysis System enables a real-time, automated viability 
assay. The IncuCyte® Cytotox reagent is an inert, non-fluorescent cyanine nucleic acid 
dye that crosses the cell membrane, when the cells become unhealthy and their 
membrane integrity diminishes. This yields a 100-1000 fold increase in fluorescence 
upon binding to the cell DNA. In this way, cell membrane integrity and cell death in 
response to pharmacological agents can be detected. 
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Caspases are a family of cysteine-dependent aspartate-directed proteases which take 
part in the execution phase of programmed cell death, apoptosis. Their name 
originates from their specific activity to nucleophilically attack and cleave a target 
protein after an aspartic acid residue. Activation of caspases initiates and highly 
regulates apoptosis, which enables the degradation of cellular components in a least 
affecting manner for the surrounding tissues and microenvironment (Porter and 
Jänicke 1999) (depicted in Figure 3.2).  
Caspases are synthesised and exist as inactive pro-enzymes (pro-caspases, zymogens), 
which are activated upon receiving relevant stimuli. Their activation following 
apoptotic signals involves the dimerization of the pro-caspase followed by the 
proteolytic cleavage at inter domain linker regions with conserved aspartic residues 
producing a small and a large subunit. These subunits associate with each other to 
form an active heterotetramer and take up a conformation favourable for enzymatic 
activity (Riedl and Shi 2004).  
Figure 3.1: Tetrazolium bromide dye reduction to purple formazan. Adapted from 
(Mosmann 1983). 
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Figure 3.2: Apoptotic pathways mediated by caspases.  
Source: https://en.wikipedia.org/wiki/Caspase. 
More specifically, caspases are subcategorized into initiator (caspases-2, 8, 9, 10, 11 
and 12) and executioner or effector caspases (caspases-3, 6 and 7). The activation of 
initiator caspases requires the binding to oligomeric activator proteins, and then the 
dimerization can take place. Both initiator caspases of the formed dimer undergo 
cleavage by autocatalysis. The heterotetramer can then proteolytically cleave the 
executioner caspases, which may exist as a homodimer constitutively. The resulting 
small and large subunits associate to form a heterotetramer. The activated effector 
caspase tetramer can then degrade intracellular proteins via proteolysis, in order to 
trigger cell death (McIlwain et al. 2013) (Figure 3.3).  
Caspase-3 is a member of the caspase family and is an effector caspase. When 
activated by caspases-8 or 9 or 10, it can cleave and subsequently activate caspases-
6 and 7. Caspase-3 has a typical role in apoptosis, where it controls chromatin 
condensation and DNA fragmentation. It is also responsible for the cleavage of many 
key cellular proteins that control the process of apoptosis and for some typical 
hallmarks of it (Porter and Jänicke 1999).  
Caspase-3 has also been implicated in tumorigenesis, where increased levels of the 
enzyme cause apoptosis and secretion of paracrine factors, especially in breast cancer 
tissues. This enables compensatory proliferation from the surrounding stromal tissues 
and even tumour cell re-population through increased secretion of prostaglandin E2 
(PGE2), thus complicating effective therapeutic interventions such as radiotherapy 
(O'Donovan et al. 2003; Shalini et al. 2015).  
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Caspase-7 is subsequently activated by caspase-3 and belongs to the effector 
caspases, too. Apart from caspase-3, it can also be cleaved and activated by caspases-
9 and 10. Caspase-7 mediates the cleavage of proteasomes, contributing to the 
reduction of proteasome activity and the accumulation of ubiquitinated proteins 
within the cell. Caspases-3 and 7 are structurally related and present overlapping 
substrate specificity. However, they have distinct roles during apoptosis and are 
differentially regulated, with specific subcellular localizations (Jang et al. 2007; 
Lamkanfi and Kanneganti 2010).  
 
Figure 3.3: Caspase-dependent cell death. Source: (Clarke and Tyler 2009). 
The IncuCyte® Live-Cell Analysis System enables a real-time, automated apoptosis 
assay using the IncuCyte® Caspase-3/7 reagent which is an inert, non-fluorescent 
(DEVD) substrate that freely crosses the cell membrane, where it can be cleaved by 
activated caspase-3 or 7 to release either a green or red DNA-binding fluorescent 
label. Apoptotic cells are identified by the appearance of fluorescently-labelled nuclei. 
In this part of the screening of the four available CORMs the aim was to identify any 
cytotoxic activities of these CORMs against two TNBC, one epithelial and one 
endothelial cell lines. A further aim was to quantify the number of cells undergoing 
apoptosis after treatments with CORMs in different concentrations. These 
experiments were carried out using the MTT assay and the automated IncuCyte® Live-
Cell Analysis System.  
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3.1.2 Materials & Methods  
Cell lines and treatments  
MDA-MB-231, MDA-MB-436 and HECV cell lines, maintained in DMEM media with 
10% FBS and antibiotics, were used for the MTT assay. In addition, MCF-10A cells were 
used and maintained in MEBM media with the necessary MEGM supplements, cholera 
toxin and antibiotics. All cells were maintained at 37°C with 5% CO2. The cells were 
treated with different concentrations of CORMs or DMSO for 72h, when they were 
supplemented with MTT and the absorbance read at 540nm in a plate reading 
spectrophotometer.  
For the IncuCyteTM assays, MDA-MB-231, MDA-MB-436 and MCF-10A cells were used, 
maintained as previously described. The cells were treated with increasing 
concentrations of CORMs or DMSO (12.5 – 25 – 50 – 100µM) diluted in the suggested 
concentration of IncuCyteTM Cytotox reagent or CellPlayerTM Caspase 3/7 reagent for 
72h and the manufacturer’s instructions were followed in each protocol.  
MTT assay 
5x103 cells were seeded in 120µL of normal medium per well in a 96-well plate. The 
number of cells was chosen after appropriate optimisation experiments. Three 
replicates were undertaken per treatment concentration and an identical plate was 
also prepared with no cells (blank). The cells were left to attach overnight and then 
cells were treated with increasing concentrations of CORMs or DMSO. The 
concentration range used was a serial dilution between 100µM and 0.39µM, and the 
vehicle treated cells were used as controls. The blank plate received the same 
treatments. The cells were left in an incubator for 72h and then MTT solution was 
added and both plates were left in the incubator for further 4h. The medium was 
removed and acidified isopropanol was used to dissolve the purple formazan crystals. 
The absorbance of both plates was read at 540nm and the blank plate was used to 
subtract any background absorbance from the test plate absorbance. The method is 
detailed in section 2.2.2.1.  
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IncuCyteTM Cytotoxicity assay  
5x103 cells were seeded in 100µL of normal medium (supplemented with FBS) per well 
in a 96-well plate. The layout of the experiment is the same as in the MTT assay, except 
for the concentration range used, 100 – 12.5µM, and the addition of the Cytotox 
reagent in a final concentration of 250nM in each well, as detailed in section 2.2.2.2. 
Again, vehicle treatments served as controls and the treatment time was 72h.  
IncuCyteTM Caspase-3/7 assay (apoptosis assay) 
10x103 cells were seeded in 100µL of normal medium per well in a 96-well plate. The 
plate was left overnight for the cells to adhere and next day the same treatment 
pattern as the one used in the IncuCyteTM cytotoxicity assay was followed. The 
CellPlayerTM Caspase 3/7 reagent was added along with the CORM or vehicle 
treatments, in a final concentration of 5µM in each well. The method is described in 
section 2.2.2.3. The experiment was followed for 72h.  
IC50 calculation 
Absorbance was normalized to the corresponding absorbance of the vehicle treated 
cells prior to plotting. Data was statistically analysed using non-linear regression 
(curve fit) to calculate the IC50 of each compound against each cell line in GraphPad 
Prism (www.graphpad.com).  
IncuCyteTM data analysis 
The IncuCyteTM data was analysed using the IncuCyte ZOOM 2016A software, kindly 
provided by Essen Biosciences and according to the manufacturer’s guidelines.  
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Two-way ANOVA was 
performed to check for statistical significance, with a p-value of <0.05 considered 
statistically significant. Asterisk notation (*) was used to identify significances:  
* p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
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3.1.3 Results  
The effect of CORM treatments on the viability of different cell lines using the 
MTT assay 
Two TNBC cells, MDA-MB-231 and MDA-MB-436, treated with CORM-1, CORM-2, 
CORM-3 or CORM-A1 in different concentrations, were assessed for their viability 
using the MTT colorimetric assay. No major cytotoxicity compared to the vehicle was 
observed against these cell lines and the calculated IC50 values exceeded 100µM. The 
MCF-10A breast epithelial cells representing the healthy cells in a normal breast 
environment were also assessed. Only CORM-2 appeared to be cytotoxic against 
these cells, with a calculated IC50 of 31.87µM. Finally, the ECs HECV were used, as 
vasculature is mainly lined by ECs. Again, no major cytotoxicity was observed, with 
only CORM-2 having an IC50 just above 100µM (Figure 3.4 A shows the average figures 
for all concentrations and cell lines tested; Figure 3.4 B shows the cytotoxicity of the 
highest concentration tested for all compounds; Figure 3.4 C shows the calculated IC50 
values for these compounds and cell lines). 
In Figure 3.4 C, a red box was used to highlight the CORM with the most favourable 
ratio of cytotoxicity between the cancer and normal cells. CORM-3 was more cytotoxic 
against the two TNBC cell lines than MCF-10A (IC50 not converged, which means that 
a common value could not be generated by the results, but very low cytotoxicity 
suggested by the graph in Figure 3.4 B) or HECV (more than three times higher).   
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A. 
 
 
B. 
 
C. 
 
 
 
 
 
Figure 3.4: Cytotoxicity of CORMs. A. Percentage of cell viability for each concentration of CORM 
tested for all four cell lines used. (Graphs show average % of cell viability normalized to vehicle 
±SEM; n=3, N=4). B. Percentage of cell viability for the highest concentration of CORM tested.  
C. Calculated IC50 values ±SD for all compounds (as calculated in GraphPad Prism).  
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The effect of CORM treatments on the viability of different cell lines using the 
IncuCyteTM 
MDA-MB-231, MDA-MB-436 and MCF-10A cells were assessed for their viability using 
the IncuCyteTM cytotoxicity assay, following treatments with CORM-1, CORM-2, 
CORM-3 or CORM-A1 in four different concentrations. The same result as in the MTT 
assay was observed for all cell lines, that is no major cytotoxicity of the CORM 
treatments compared to vehicle treatments apart from CORM-2 against MCF-10A 
cells (representative images from the experiments in Figures 3.5 A, 3.6 A and 3.7 A). 
However, given the abilities of the IncuCyteTM and its software, an analysis of the 
confluence throughout each experiment was conducted and a difference between the 
treated and untreated cells was observed for some of the treatments.  
More specifically, for the MDA-MB-231 cells, it appeared that 1% DMSO reduced the 
confluence of the cells throughout the experiment in a statistically significant manner 
(p=0.0349). Following the same pattern as their vehicle, all CORMs at 100µM 
concentration reduced the confluence of these cells compared to media treatment, 
with CORM-2 and CORM-3 reaching statistical significance (p=0.0111 and p=0.0225, 
respectively) (Figure 3.5 B shows the average increase of confluence for the 100µM 
CORMs, the 1% DMSO and the media treated cells, N=3). For lower concentrations, 
no such effect was observed (data not shown).  
For MDA-MB-436 cells, there was no observed statistically significant reduction in 
confluence between the 1% DMSO and the media treated cells (p>0.05). Only CORM-
1 and CORM-2 appeared to reduce the confluence of the cells compared to media 
treatment reaching statistical significance (p=0.0383 and p=0.0258, respectively) 
(Figure 3.6 B shows the average increase of confluence for the 100µM CORMs, the 1% 
DMSO and the media treated cells, N=3).  
 
 
 
  
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
99 
 
A.  CORM-1 100µM     CORM-2 100µM 
1.  2.  
CORM-3 100µM     CORM-A1 100µM 
3.  4.  
      Vehicle 1%              Media 
5.  6.  
 
B. 
  
Figure 3.5: Cytotoxicity and confluence of MDA-MB-231 after CORM treatments at IncuCyteTM.  
A. Representative images from the IncuCyteTM cytotoxicity assay in MDA-MB-231 cells, 64h after 
treatment with the highest concentration of CORMs (100µM). 1= CORM-1, 2= CORM-2, 3= CORM-
3, 4= CORM-A1, 5= Vehicle 1%, 6= Media. Objective 10x bar=300µm. B. Confluence change rate for 
the 100µM treatment of CORMs followed for 64h after the treatment. (Average ±SEM; n=4, N=3) 
(All data was statistically analysed against media treated cells using two-way ANOVA: * p<0.05).  
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B. 
 
Figure 3.6: Cytotoxicity and confluence of MDA-MB-436 after CORM treatments at IncuCyteTM. 
A. Representative images from the IncuCyteTM cytotoxicity assay in MDA-MB-436 cells, 72h after 
treatment with the highest concentration of CORMs (100µM). 1= CORM-1, 2= CORM-2, 3= CORM-
3, 4= CORM-A1, 5= Vehicle 1%, 6= Media. Objective 10x bar=300µm. B. Confluence change rate for 
the 100µM treatment of CORMs followed for 64h after the treatment. (Average ±SEM; n=4, N=3) 
(All data was statistically analysed against media treated cells using two-way ANOVA: * p<0.05). 
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There was no observed statistically significant difference in confluence of the MCF-
10A cells between the 1% DMSO and the media treated cells (p>0.05). Only CORM-2 
significantly lowers the confluence of the cells compared to media treatment, but this 
is undoubtedly connected to the toxicity of this compound towards these cells 
(p=0.0452). However, there was no statistical difference between CORM-2 100µM 
and DMSO 1% treated groups (p>0.05) (Figure 3.7 B shows the average increase of 
confluence for the 100µM CORMs, the 1% DMSO and the media treated cells, N=2).  
The effect of CORM treatments on breast cancer apoptosis 
Following the cytotoxicity assessment with both the MTT assay and the IncuCyteTM 
cytotoxicity assay, caspase 3/7 levels were measured for the two TNBC cell lines 
following the IncuCyteTM caspase 3/7 assay. Since the MTT is an indirect way of 
quantifying the number of viable cells by measuring the metabolically active ones, it 
was deemed worthy trying different tests in order to validate the cytotoxicity of these 
compounds.  
None of the cell lines showed any significant differences between the vehicle treated 
and the CORM treated groups. This result confirms the previous observations from 
the MTT and the IncuCyteTM cytotoxicity assays, establishing that the four 
commercially available CORMs show almost no cytotoxicity against the cell lines 
tested. The images also reflect the other observation discussed, that is the reduced 
confluence for the MDA-MB-231 cell line after treatment, especially with CORM-2 and 
CORM-3. (Representative images from the experiments in Figures 3.8 A and 3.9 A. 
Figures 3.8 B and 3.9 B show the change in the number of apoptotic cells for the 
100µM CORMs, the 1% DMSO and the media treated cells  for the two TNBC cell lines, 
N=2).  
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A.  CORM-1 100µM     CORM-2 100µM 
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5.  6.  
 
B. 
 
Figure 3.7: Cytotoxicity and confluence of MCF-10A after CORM treatments at IncuCyteTM.  
A. Representative images from the IncuCyteTM cytotoxicity assay in MCF-10A cells, 72h after 
treatment with the highest concentration of CORMs (100µM). 1= CORM-1, 2= CORM-2, 3= CORM-
3, 4= CORM-A1, 5= Vehicle 1%, 6= Media. Objective 10x bar=300µm. B. Confluence change rate for 
the 100µM treatment of CORMs followed for 64h after the treatment. (Average ±SEM; n=4, N=2) 
(All data was statistically analysed against media treated cells using two-way ANOVA: * p<0.05). 
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Figure 3.8: Caspase 3/7 quantification after CORM treatments in MDA-MB-231 at IncuCyteTM.  
A. Representative images from the IncuCyteTM caspase 3/7 assay in MDA-MB-231 cells, 72h after 
treatment with the highest concentration of CORMs (100µM). 1= CORM-1, 2= CORM-2, 3= CORM-
3, 4= CORM-A1, 5= Vehicle 1%, 6= Media. Objective 10x, scale bar=300µm. B. Change in the 
number of apoptotic cells per well for the 100µM treatment of CORMs followed for 72h after the 
treatment. (Average ±SEM; n=3, N=2) (All data was statistically analysed against media treated cells 
using two-way ANOVA: * p<0.05). 
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B.  
 
Figure 3.9: Caspase 3/7 quantification after CORM treatments in MDA-MB-436 at IncuCyteTM.  
A. Representative images from the IncuCyteTM caspase 3/7 assay in MDA-MB-436 cells, 72h after 
treatment with the highest concentration of CORMs (100µM). 1= CORM-1, 2= CORM-2, 3= CORM-
3, 4= CORM-A1, 5= Vehicle 1%, 6= Media. Objective 10x, scale bar=300µm. B. Change in the 
number of apoptotic cells per well for the 100µM treatment of CORMs followed for 71h after the 
treatment. (Average ±SEM; n=3, N=2) (All data was statistically analysed against media treated cells 
using two-way ANOVA: * p<0.05). 
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3.1.4 Discussion  
According to general opinion, heavy metals and drugs based on them may present 
toxicological concerns not only to the environment in general, but also to different 
cells and organisms. It is generally believed that metals such as palladium and 
platinum are more harmful than lower molecular weight metals such as nickel or 
cobalt. Metal toxicity, however, is tightly correlated with the form in which the metal 
is present, as pure elements may differ greatly from their compounds, that might have 
solubility, oxidation state and bioavailability variations. The same applies to 
organometallic compounds with different metals bound, as the toxic effects derive 
mainly from the intrinsic characteristics of each one, such as the oxidation state, 
ligand sphere or the counter-ion present (Egorova and Ananikov 2017). The prejudice 
against metal-based drugs was partially lifted when cisplatin was discovered, which 
led to numerous other candidates for metal-based drugs (Wang and Lippard 2005). 
Nevertheless, the common conception that the composition of a compound can be 
directly linked to its toxicity is still misleading, especially for metal-based drugs. 
Organometallic compounds consist a special class of compounds and it should be 
acknowledged that it is probably impossible to confidently correlate structure with 
toxicity and metals should not be seen as purely toxic components, but their toxicity 
is rather correlated with the oxidation state, the ligands, the solubility and the 
stereochemistry of each molecule (Egorova and Ananikov 2017).  
Both CORM-2 and CORM-3 are ruthenium (Ru)-based molecules that eventually 
release Ru-bound species to the microenvironment of the tissues (Winburn et al. 
2012). As a matter of fact, Ru-based agents have undergone clinical trials with the first 
one to be tested being NAMI-A with gemcitabine in 2008 (phase I/II) (Alessio 2017). 
Ru compounds are believed to cause fewer and less severe side effects compared to 
other organometallic drugs, due to certain reasons: 1) they have low toxicity because 
Ru can mimic iron (Fe); 2) they have slow ligand exchange rates; 3) they are activated 
by reduction; 4) they may preferably accumulate in cancer tissues and 5) their transfer 
and uptake are mediated by transferrin. However, Ru compounds have eventually 
shown broad diversity in their activity, toxicity and mechanisms of action, surprising 
both their supporters and opponents, and many researchers challenge these 
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attributed advantages (Page 2012; Alessio 2017; Ndagi et al. 2017). In any case, if a 
metal-based compound is designed to be highly selective towards an enzyme and the 
metal core is not toxic itself, then they will probably afford non-toxic compounds that 
are also safer to the general environment (Allardyce and Dyson 2016).  
 Similarly, manganese (Mn) is an essential and biocompatible metal. Mn complexes 
have various medicinal applications. The most significant therapeutic value of Mn 
complexes is their antioxidant application in biological systems, and due to this, three 
Mn-based complexes (AEOL-10150, EUK-134, and M40403) are already under clinical 
trials (Ali et al. 2017).  
In the assessment of cytotoxicity for the four commercially available CORMs, two 
TNBC cell lines were chosen to be tested, MDA-MB-231 and MDA-MB-436, because 
this is the targeted cancer subtype, along with a control epithelial breast cell line, 
MCF-10A and an endothelial cell line, HECV. As shown in the graphs (Figure 3.4), these 
compounds had a moderate cytotoxicity against the cell lines, with the most potent 
compound in general being CORM-2.  
As discussed earlier, CORM-2 has been previously shown to exert toxicity against 
different cell subtypes at around 50µM (Lee et al. 2014; Vítek et al. 2014; Ahmad et 
al. 2015). Similar to these results, CORM-2 at 100µM reduced the viability of MDA-
MB-231 by ~50% and of MDA-MB-436 by ~30%, with calculated IC50 values of 117µM 
and 400µM, respectively. However, CORM-2 was also the most toxic CORM against 
the control MCF-10A cell line, with a low IC50 of 32µM. The toxicity of CORM-2 against 
the ECs along with the TNBC cells might be desired, but the quite high toxicity against 
the breast epithelial cells is definitely a drawback.  
Since the MTT assay offers an indirect measurement of cell viability that might be 
affected by the interference of CORMs with the mitochondria, another more direct 
assay was also conducted. When considering the results of the IncuCyte cytotoxicity 
assay, even though the cell viability results were very similar to the previous ones, 
CORM-2 obviously affects the proliferation of MDA-MB-231, pointing towards a 
cytostatic rather than a cytotoxic profile. Even though there was no statistical 
significance upon a two-way ANOVA analysis between the vehicle and the CORM-2 
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group, when comparing CORM-2 with the media treated group, significance could be 
obtained with a p-value of 0.0111. Furthermore, the vehicle itself reduced the 
confluence of the cells after 44h, and when comparing with media treated cells, this 
trend reached significance (p=0.0349). Anyway, CORM-2 remains the only one with 
such low confluence after 72h of treatment in MDA-MB-231. Similar results were 
reported also in MDA-MB-436, where again CORM-2 was not very cytotoxic, but 
reduced cell confluence significantly when compared with media treated cells 
(p=0.0258). Finally, the high toxicity of CORM-2 against MCF-10A was most probably 
responsible for the inhibition of their proliferation in a notable manner.  
CORM-3 on the other hand, even though sharing many common features with CORM-
2, such as the Ru core and the similar ligand sphere, exerted a considerably lower 
toxicity against the tested cells. It appeared to be more potent against MDA-MB-231 
with an IC50 value of 312.5µM, closely followed by MDA-MB-436, and almost no 
cytotoxicity was reported against epithelial or ECs. It was the only CORM with such as 
big difference (almost three times) between the toxicity against TNBC cells and normal 
cells, which suggests a kind of selectivity for this CORM. CORM-3 did not affect the 
proliferation of the cells at significant levels, apart from MDA-MB-231, where 
p=0.0225 when compared to media treated cells.  
CORM-1 was the only Mn CORM tested, which also belongs to the photo-CORM 
family. Even though no specific light excitation was used for this compound, the stock 
solutions were prepared and kept in the dark until they reached the cells, under 
ambient daylight. For this compound, a desirable toxicity profile was reported, where 
the two TNBC cells were more sensitive compared to the epithelial or endothelial 
ones. However, the toxicity against MCF-10A was very close to the toxicity against 
MDA-MB-436. The lowest IC50 was measured for the MDA-MB-231 cells, although a 
little higher than CORM-2’s. CORM-1 significantly reduced the proliferation of only 
MDA-MB-436 cells when compared to media (p=0.0383).  
Finally, CORM-A1 did not show any cytotoxicity against these cells or any inhibition of 
their proliferation rates. It is also the only one without a heavy metal core, potentially 
responsible for the total lack of toxicity.  
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Since the highest concentration tested for the MTT assay was 100µM, all the 
calculated IC50 values exceeding 100µM are extrapolated values, which poses certain 
limitations. The safest way to determine an IC50 value is by experimental testing of all 
the relevant concentrations until the half point is reached. However, due to time 
restrictions only a few concentrations were explored, and the calculation was 
performed by the statistical software Graphad, which means that the true 
experimental value could be a lot different than the calculated one. It is also worth 
considering that the projected sigmoid curves could follow another pattern after the 
100µM concentration, but since this was not experimentally determined, the 
extrapolated calculated IC50 values could not be used as a concluding result but rather 
as an indication of where the IC50 could lie. Nevertheless, for the purposes of this 
study, these values were used to imply potential selectivity of some CORMs and for 
comparison reasons, even though they should be viewed rather sceptically.  
At this point, another relevant issue must be addressed, and that is the solvent used 
in these experiments. Dimethyl sulfoxide (DMSO) is a common chemical solvent for 
pharmaceutical preparations, although it has certain disadvantages compared to 
water. As discussed in many publications, low concentrations of DMSO have no 
deleterious effects on cell viability or cytology, however when the concentration goes 
up to 1% (used as the highest concentration in my experiments) the effects become 
more significant and increased apoptosis is reported (Winburn et al. 2012). Although 
many studies try to deal with this problem, by using both a low and a high 
concentration of DMSO and comparing their results with both as well as the media 
itself, most of the studies seem to deliberately ignore this phenomenon and use a 
much lower concentration of DMSO as control compared to the one used to dissolve 
the CORMs (Winburn et al. 2012). In my experiments I chose to use the correct 
concentration of DMSO, that is 1%, as the highest one, since this is exactly how much 
is needed to dissolve the CORMs. Even then though, CORM-1 was challenging, 
because even in pure DMSO it is not completely or easily soluble. 
The caspase 3/7 quantification experiment showed no statistically significant 
difference between the treated groups, even though the trend could be seen for 
increased apoptosis following DMSO 1% treatment in MDA-MB-231.  
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In summary, the metal core may be partly responsible for the moderate toxicity 
associated with CORMs -1, -2 and -3, although no major cytotoxicity was reported for 
any of the cells tested. This is also an indication that the heavy metal core is not 
necessarily toxic in all potential forms, and that other characteristics may affect this 
behaviour.  
3.2 Metabolic dysfunction detection 
3.2.1. Introduction 
In 1924 Otto Warburg realized that cancer cells depend on aerobic glycolysis to 
metabolize glucose and generate ATP. This is a less efficient pathway to produce 
energy, since with oxidative phosphorylation the yield is 36 molecules of ATP per 
glucose molecule, but with aerobic glycolysis the yield falls to only 2 molecules of ATP. 
This is also the case for cancer cells with plenty of oxygen and no apparent oxygen 
deprivation, which is more common in the cores of solid tumours. This phenomenon 
is referred to as the “Warburg effect” (Gatenby and Gillies 2004). The up to 200 times 
higher rate of glycolysis in cancer cells is followed by lactic acid fermentation in the 
cytosol, unlike normal cells which oxidize pyruvate in mitochondria (Kim and Dang 
2006).  
The Warburg effect was initially thought as a cause for the transition of normal cells 
to cancerous ones, but today it is viewed more as a consequence of damaged 
mitochondrial function or a simple adaptation of the cancer cells to unfriendly 
environments with low oxygen concentrations and nutrient supply (López-Lázaro 
2008; Alfarouk et al. 2014). This metabolic switch is useful for the tumour also for 
other reasons, one of them being the generation of a unique pH gradient between the 
low extracellular pH and the alkaline or near neutral pH environment within the 
tumour, that serves as a determining factor for the ability of the tumour to invade and 
metastasize, surpassing the immune system (Alfarouk 2016).  
Nevertheless, this observation of high glycolysis levels of cancer cells compared with 
normal cells, which produce energy via the oxidation of pyruvate in mitochondria, was 
deemed a promising target for new anti-cancer therapies (Alfarouk et al. 2014; 
Alfarouk 2016). Inhibition of glycolysis would deprive cancer cells of energy, reducing 
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their rapid growth and proliferation. Cancer cells seem to be completely dependent 
on the glycolytic pathway for energy production, and oxidative phosphorylation was 
found to be suppressed in them. Thus, activating the mitochondrial respiration back 
could be a potential alternative approach for anti-cancer therapy, leading cancer cells 
to apoptosis (Upadhyay et al. 2013). In that scope, it has also been reported that 
aerobic glycolysis seems more efficient during rapid cell growth – as in cancer cells – 
compared with normal glycolysis linked to the tricarboxylic acid (TCA) cycle and 
oxidative phosphorylation, therefore switching to an oxidative metabolism could lead 
cancer cells to ineffective growth and death (Shyh-Chang et al. 2013). 
There are many publications dealing with the alterations in cell metabolism caused by 
the administration of exogenous CO. One study in astrocytes reports a reduction in 
the ratio between lactate production and glucose consumption, while oxygen 
consumption and mitochondrial population were increased. This could indicate a CO-
induced enhancement of oxidative phosphorylation for these cells, promoting 
cytoprotection (Almeida et al. 2012). Moreover, the group of Wegiel has 
demonstrated an inhibition in prostate cancer progression by CO, which seems to 
induce an anti-Warburg effect also promoting chemotherapeutic effectiveness. 
Mitochondria seem to be the main target of CO, as assessed by higher oxygen 
consumption levels and elevated ROS generation, leading to mitochondrial 
dysfunction and cell growth inhibition induced by the combined chemotherapy 
(Wegiel et al. 2013). Finally, another study supports the ability of CORM-A1 to induce 
differentiation in neurons due to increased mitochondrial population and enhanced 
oxidative phosphorylation levels, which suggest a metabolic modulation driven by CO 
towards a more oxidative profile (Almeida et al. 2016). 
With these in mind, investigation into whether this metabolic modulation was evident 
in TNBC cells and if different treatment options and durations would affect these 
observations was desired. A way to measure glycolysis levels in treated and untreated 
cells is by using the Seahorse XF Glycolysis Stress Test. This test illustrates the three 
key parameters of glycolytic function: glycolysis, glycolytic capacity and glycolytic 
reserve. The Seahorse XFe Extracellular Flux Analyser can measure glycolytic levels by 
measuring the extracellular acidification rate (ECAR) of cells inserted in the 
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instrument. These cells can be previously treated for a certain time period with agents 
that can potentially alter their metabolism, or the treatment can be injected during 
the experiment directly on the cells (instant treatment).  
In this section, the aim was to identify if 72h pre-treated or instantly treated cancer 
cells show differences in their glycolytic metabolism compared to untreated or vehicle 
treated cells. There was also a desire to spot any differences the co-treatment with 
10g/mL or 100g/mL of Avastin® could induce to their glycolysis levels.  
In order to achieve that, the cells were either pre-treated with increasing 
concentrations of CORMs for 72h prior to the experiment or the treatments were 
injected during the experiment. Glycolysis levels can be calculated after the increase 
in glycolysis induced by the precursor glucose injected directly on the cells. Glycolytic 
capacity is measured after injecting the antibiotic oligomycin, which is well known for 
its inhibitory activity on the ATP synthase. This way, cells are forced to use glycolysis 
only for the production of energy. Finally, the glucose competitor 2-deoxy-D-glucose 
(2-DG) is injected to stop glycolysis and cells return to their original levels, which 
indicates the glycolytic reserve.  
 3.2.2 Materials & Methods  
Cell lines and treatments  
MDA-MB-231 cells maintained in DMEM media with 10% FBS and antibiotics were 
used for these experiments. All cells were maintained at 37°C with 5% CO2 prior to the 
assay. Cells were treated with increasing concentrations of CORMs or DMSO and 
standard concentrations of Avastin® in the corresponding experiments. 
Glycolysis Stress test with the Seahorse Extracellular XFe Flux Analyser 
The glycolysis levels of the cells were measured using the Seahorse Extracellular XFe 
Flux Analyser. For the Seahorse XF24 Cell Culture Microplate, 40,000 cells/well were 
seeded. The Seahorse Base medium included 1mM glutamine, had a pH of 7.35 and 
was kept at 37oC after filtration. The normal media of the cells was removed and 
525µL of Glycolysis media were added before the plate was left in a CO2-free incubator 
for 1h. All the injections prepared meanwhile were loaded on the injection plate at 
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volumes of 75µL each. After the experiment, wells were washed with PBS twice and 
11µL of lysis buffer were added to each well. A protein quantification assay was 
performed right after. 
For the Seahorse XF96 Cell Culture Microplate, 10,000 cells/well were seeded. The 
procedure was the same apart from changes in concentrations and volumes: the 
normal media of the cells was removed and 150µL of Glycolysis media were added in 
each well. All the injections were loaded on the injection plate at volumes of 25µL 
each. After finishing the experiment, the wells were washed with PBS twice and a 
crystal violet assay was performed right away for the quantification of the cell 
biomass. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Two-way ANOVA was 
performed to check for statistical significance, with a p-value of <0.05 considered 
statistically significant. Asterisk notation (*) was used to identify significances:  
* p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
3.2.3 Results 
Glycolysis Stress test for pre-treated MDA-MB-231 (72h) 
MDA-MB-231 cells were pre-treated with three different concentrations of CORMs or 
1% DMSO for 72h and then subjected to a glycolysis stress test in the Seahorse 
Analyser. As observed in Figure 3.10 A, no statistically significant difference between 
the CORM and vehicle treated groups was measured in this experiment for any of the 
concentrations tested.  
Glycolysis Stress test for instant treatments on MDA-MB-231 
MDA-MB-231 cells were subjected to a glycolysis stress test in the Seahorse Analyser. 
The treatments were added directly on the cells as the first injection, and then the 
protocol was followed as previously described. Four different concentrations of 
CORMs were tested, along with matching vehicle concentrations and media 
treatments as controls. As observed in Figure 3.10 B, for the highest concentration 
tested (100µM), only CORM-2 raised a statistically significant reduction in the 
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glycolysis change rate compared to the vehicle group (p=0.0006). Again for the 50µM 
treatment, only CORM-2 reduced the levels of glycolysis significantly, with a p-value 
of 0.0184. However, for both lower concentration treatments, nearly all CORMs 
produced such an effect, with the media treated group also appearing to perform 
glycolysis in a significantly lower level than the vehicle group (p=0.0108 for the 25µM 
treatment and p<0.0001 for the 12.5µM treatment). More specifically, for the 25µM 
treatment, CORMs -1, -2 and -3 reduced glycolysis compared to vehicle with p-values 
of 0.0326, 0.0399 and 0.046, respectively. Finally, for the 12.5µM treatment, CORMs 
-1, -3 and -A1 significantly decreased glycolysis with p-values of 0.0297, 0.0133 and 
0.0018, respectively.  
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A.  
 
B. 
 
Figure 3.10: Glycolysis stress test in MDA-MB-231 after CORM treatments. A. Change rate in the 
glycolysis levels of pre-treated MDA-MB-231 cells, measured as ECAR (mpH/min). (Average ±SEM; 
n=3, N=2). B. Change rate in the glycolysis levels of instantly treated MDA-MB-231 cells, measured 
as ECAR (mpH/min). (Average ±SEM; n=3, N=2) (All data was statistically analysed against vehicle 
treated cells using two-way ANOVA: * p<0.05, ** p<0.01 and *** p<0.001). 
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Glycolysis stress test for CORM combined with Avastin® 10µg/mL treatments 
on MDA-MB-231 
Avastin® was the first anti-angiogenic drug to be marketed as discussed earlier in 
section 1.3.3.1. Since the general aim was to examine if these four CORMs had any 
anti-angiogenic effects against TNBC and could be eventually combined with Avastin® 
in order to enhance its efficacy, it was considered interesting to look for any 
differences in the glycolytic levels of MDA-MB-231 cells after treatment with CORMs 
and a standard concentration of Avastin®. Two concentrations of Avastin® were 
chosen for this study, 10µg/mL and 100µg/mL, although the highest one (100µg/mL) 
interfered with the experiment and no useful results were obtained.  
As shown in Figure 3.11, the addition of Avastin® (10µg/mL) dissimulated the 
previously observed decrease in the glycolytic levels of these cells, reducing any 
differences between the vehicle and CORM treated groups. Only CORM-A1 managed 
to raise statistical significance in the highest concentration tested (p=0.0349), 
whereas CORM-3 was the only different in the 50µM treatment group (p=0.0246).  
Glycolysis stress test for CORM combined with Avastin® 100µg/mL treatments 
on MDA-MB-231 
Unfortunately, the results of this experiment were not appropriate for analysis, since 
after the addition of this high concentration of Avastin®, the pH of the wells was 
severely derailed, not allowing for the detection of changes. Most of the wells showed 
pH values in the sub-zero area, so the results were not deemed worth of analysis, and 
the experiment was not repeated. 
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Figure 3.11: Glycolysis stress test in MDA-MB-231 after CORM treatments combined with 
Avastin®. Change rate in the glycolysis levels of instantly treated with combination of CORMs and 
Avastin® (10µg/mL) MDA-MB-231 cells, measured as ECAR (mpH/min). (Average ±SEM; n=3, N=2) 
(All data was statistically analysed against vehicle treated cells using two-way ANOVA: * p<0.05). 
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3.2.4 Discussion 
Cancer has been linked to mitochondrial dysfunctions even from studies carried out 
many years ago. Several studies have shown decreased mitochondrial number and 
the reduced efficiency of Krebs’ cycle compels cancer cells to use glycolysis for the 
production of energy. Aerobic glycolysis (Warburg effect) can be more efficient in 
supporting the rapid growth of cancer cells, compared to normal glycolysis linked to 
the TCA cycle and oxidative phosphorylation. In addition, diminishing mitochondrial 
activity offers cancer cells a way to reduce apoptosis, therefore provides an 
evolutionary advantage. The reprogramming of cellular metabolism and the shift of 
the environmental pH towards the acidic region during malignant transformation 
suppresses the growth of normal cells and potentially supports cancer cell growth and 
migration (Shyh-Chang et al. 2013; Alfarouk 2016).  
Carbon monoxide has been shown to exert a variety of effects on mitochondrial 
function and cell metabolism, depending on its concentration, the duration of 
exposure and the specific cell subtype studied. It is generally accepted that CO can 
inhibit cellular mitochondrial respiration via inhibition of complex IV (cytochrome c 
oxidase). CO has also been implicated with increased ROS production, which is also a 
mechanism for its signalling activity. Even though low concentrations can activate 
survival pathways, high concentrations of CO can increase mitochondrial oxidative 
stress, inhibit mitochondrial electron transport chain and protein synthesis and 
maybe activate apoptotic pathways in predisposed cells (Alonso et al. 2003; D'Amico 
et al. 2006; Piantadosi et al. 2006; Zuckerbraun et al. 2007; Winburn et al. 2012; Szabo 
2016). 
As shown in many studies, exogenous CO reduces glucose consumption and at the 
same time increases oxygen consumption, indicating a CO-induced improvement in 
oxidative phosphorylation levels (R. Oliveira et al. 2016). CO can also limit prostate 
cancer progression by manipulating cell metabolism, thus sensitizing cancer cells to 
chemotherapy via promoting an anti-Warburg effect. Indeed, CO can target the 
mitochondrial activity, inducing higher oxygen consumption levels and free radical 
generation, thus leading to mitochondrial collapse, cancer cell growth inhibition and 
maybe apoptosis, induced potentially by chemotherapy (Wegiel et al. 2013). Finally, 
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in another study by Kaczara et al. (Kaczara et al. 2015), it has been demonstrated that 
CO released from a novel CORM (CORM-401) induced uncoupling of mitochondrial 
respiration and repression of glycolysis, which could lead to the inhibition of 
pathological angiogenesis.  
In the first experiment, a 72h pre-treatment with CORMs was tested for any effects 
on the metabolism of MDA-MB-231 in three different concentrations. As expected, 
no major differences were observed between the CORM and vehicle treated cells. This 
was probably due to the long treatment, where all CO released would have the time 
to escape from the cell media, therefore no long-time effects would be measurable. 
If indeed the CO is responsible for any inhibition of the glycolytic metabolism of the 
cancer cells, this would be an instantaneous incident and a shorter treatment would 
be more appropriate to measure it. It should also not be forgotten that the CORMs 
chosen for this study have a very short half-life, except for CORM-A1 (~21min). 
Thus, a different scheme was also tested, that is an instant treatment with CORMs as 
the first injection during the experiment. As shown in Figure 3.10 B, in the highest 
concentration tested, only CORM-2 managed to raise a statistically significant 
reduction in the glycolysis levels of TNBC cells compared to vehicle treatment, and 
more specifically in the actual glycolysis and the glycolytic capacity. However, an 
anomaly during the first measurements could be seen, which would probably diminish 
if the experiment was repeated further and may be linked to changes in the pH due 
to the addition of the treatment in such high concentration.  
When the concentration halved (50µM), again only CORM-2 reduced the metabolism 
of the cancer cells in a significant manner, although less compared to the higher 
concentration. Again the reduction was reported in the glycolysis and the glycolytic 
capacity of the TNBC cells.  
On the contrary, when the concentrations of the treatments decreased, a difference 
between the vehicle and media treated cells was observed, where the vehicle seemed 
to increase the glycolytic metabolism of the cells, and especially their glycolytic 
capacity. All CORMs in the 25µM treatment, apart from CORM-A1, managed to reduce 
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this reported increase and resembled the media treated cells, raising statistical 
significance over the vehicle.  
Finally, in the lowest concentration used (12.5µM), again the vehicle and the media 
treated cells showed a highly statistically significant difference in the glycolysis and 
glycolytic capacity (p<0.0001), and all CORMs, apart from CORM-2 this time, managed 
to reduce this increase and resemble the media treatment. This unexpected effect of 
low concentrations of the vehicle might be due to the limited time of repeats for this 
experiment or due to other unidentified reasons. In any case, if such observations are 
close to the truth, then CORMs managed to reduce the glycolytic levels of TNBC cells 
even against the increasing influence of their vehicle, which suggests a notable 
reduction.  
It has been previously shown that CO release from low concentrations of CORM-3 
interact with the mitochondrial respiratory chain by uncoupling proteins and also with 
adenine dinucleotide transporters leading to disruption of the membrane potential. 
Ruthenium compounds have demonstrated significant mitochondrial toxicity 
suggesting that the Ru core of CORM-2 and CORM-3 might also be responsible for the 
impairment of complex I and IV activity (Lo Iacono et al. 2011; Winburn et al. 2012; 
Long et al. 2014; Kaczara et al. 2015). Therefore, these results could be explained, 
especially for CORM-2 and CORM-3, by supporting the hypothesis that the Ru core 
along with the CO reduce the glycolytic metabolism of TNBC cells by interfering with 
the mitochondrial activity, inhibiting proteins of the respiratory chain and leading to 
electron leakage and ROS production.  
Avastin® is a well-known anti-VEGF-A monoclonal antibody, which has been approved 
for different cancer subtypes. Since CORMs were studied for any anti-angiogenic 
effects for a potential combination with Avastin® in TNBC, the glycolytic levels of 
MDA-MB-231 cells after instant treatment with CORMs in combination with a 
standard concentration of Avastin® (10µg/mL) were also tested.  
The same concentrations of CORMs were chosen (100µM, 50µM 25µM), and as 
depicted in Figure 3.11, no major differences were reported between the CORMs and 
the vehicle treated cells. Only CORM-A1 managed to significantly reduce the glycolysis 
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and glycolytic capacity of the cells compared to vehicle. This has also been shown for 
neuronal cells, that CORM-A1 can enhance their mitochondrial metabolism by 
increasing oxidative phosphorylation and decreasing lactate production per molecule 
of glucose consumed (Almeida et al. 2016). In the 50µM, only CORM-3 was different 
from the vehicle, although CORM-A1 showed the same trend but barely missed 
significance (p=0.0563). Finally in the lowest concentration tested, no differences 
were observed between the CORM treatments and the vehicle. 
In principle, all experiments should be repeated at least three times in order to be 
statistically analysed safely. However, due to restrictions in the use of the Seahorse 
equipment, as well as other unforeseen circumstances, these experiments were only 
repeated twice, which might partially explain the few inconsistencies observed and 
the noticeable error bars for some of them. In the 72h pre-treatment and in the 
combination with Avastin® experiments, no media treated group was included, which 
largely affects the overall picture, as a very interesting increasing trend was reported 
for the low concentrations of vehicle during the instant treatments, which could not 
be assessed for the other experiments too. Especially in the combination of CORMs 
with Avastin®, it would be very interesting to study the change in glycolysis levels for 
normal media treated cells and compare with the vehicle and other treatments. This 
may have indicated a similar increasing trend for the vehicle, which would explain the 
lack of reduction in glycolysis after CORM treatments. All in all, CORMs seem to have 
effects on the glycolytic ability of TNBC cells, but more experiments and various 
protocols would be needed in order to safely reach conclusions.  
3.3 Protein expression quantification 
3.3.1. Introduction 
In order for tumour angiogenesis to take place, two important steps must be 
accomplished. First, the tumour cells should be able to express high concentrations of 
VEGF and other growth factors, in order to induce pro-angiogenic signals. Second, ECs 
around the tumour area should express effective VEGFRs (RTKs) that upon binding 
with VEGF will initiate the pro-angiogenic signal through activation of their 
downstream signalling pathways. This activation cascade involves the 
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phosphorylation of several kinases that manipulate EC survival, proliferation, 
migration and vessel formation. Therefore, an anti-angiogenic agent could potentially 
inhibit several different steps of this process that is either the ability of cancer cells to 
express elevated stimulant levels or the ability of ECs to execute an efficient signal 
transduction that will lead to new vessel formation.   
Endothelial cells are equipped with surface VEGFRs that upon stimulation with VEGF 
activate their downstream signalling pathway. This pathway is quite complicated, as 
depicted in Figure 3.12. Numerous proteins are involved in the successful signalling 
towards EC survival, proliferation, migration and capillary formation, but in this study 
the focus was on a few of them, depicted more clearly in Figure 3.13.  
 
Figure. 3.12: VEGFR2 signalling cascade upon stimulation with VEGF-A. Source: http://www.bio-
rad.com/en-cn/prime-pcr-assays/pathway/development-vegf-signaling-via-vegfr2-generic-
cascades. 
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Figure. 3.13: Summarized version of VEGFR2 signalling cascade upon stimulation with VEGF. 
Source: http://www.oapublishinglondon.com/article/471# 
Upon VEGFR2 stimulation with VEGF, diverse signalling proteins are activated in ECs, 
including the non-catalytic region of tyrosine kinase adaptor protein (NCK), Shc-
related adaptor protein (SCK), phospholipase C-γ (PLC-γ), protein kinase C (PKC), 
protein kinase B (PKB/AKT), p38 mitogen-activated protein kinases (p38 MAPK), focal 
adhesion kinase (FAK) and extracellular signal-regulated kinases (ERK). The cross talk 
between these molecules successfully modulates the process of angiogenesis. Upon 
activation with VEGF, VEGFR2 undergoes autophosphorylation and seven important 
phosphorylation sites have been identified; Y1054, Y1214, Y801, Y1175, Y951, Y1059 
and Y996. Each of them is correlated with a different downstream signalling pathway 
towards a specific EC function. More specifically, Y1214 phosphorylation modulates 
signalling events towards cell migration. Y801 phosphorylation regulates cell survival. 
Y1175 is linked to cell proliferation and migration. Y951 and Y1059 phosphorylation 
regulates cell survival, migration and proliferation. Finally, Y1054 interacts with 
integrins and regulates signalling events involved in cell migration (Wu et al. 2000; 
Abhinand et al. 2016). 
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An important pathway linked to EC proliferation appears to be correlated with the p-
Y1175-PLC-γ mediated activation of PKC and downstream induction of the ERK 
through the PLC-γ-PKC-Raf-MEK-ERK pathway. The VEGF-mediated activation of ERK 
depends on the activation of Ras and both are important for EC proliferation (Bruce 
and Tan 2011; Shibuya 2013). Cell survival is mainly regulated by the VEGFR2-
dependent activation of the PI3K-AKT signalling pathway. AKT is a serine/ threonine-
specific protein kinase involved in multiple cellular processes such as cell metabolism, 
apoptosis, proliferation, transcription, permeability and migration. It has three 
isoforms, AKT1, AKT2 and AKT3. AKT1 is mainly involved in the PI3K/AKT/mTOR 
pathway (Wu et al. 2000; Somanath et al. 2006; Abhinand et al. 2016). On the other 
hand, several signalling pathways downstream of VEGFR2 are induced by VEGF and 
contribute towards EC migration, but particularly important is the complementary 
role of the signalling through the p38 MAPK for actin polymerization and stress fibre 
reorganisation and the FAK for focal adhesion turnover. FAK is activated through two 
complementary downstream pathways, one involving the Src kinase (Bruce and Tan 
2011; Abhinand et al. 2016). 
In that scope, CORMs were subjected to relevant experiments in order to assess their 
ability to affect the two required steps for successful angiogenesis. First, TNBC cells 
were treated with CORMs and the expression levels of VEGF were quantified at three 
different time points. Any reduction in the expressed VEGF could lead to a decreased 
pro-angiogenic signal towards the surrounding ECs. Complementary to this, HO-1 
levels of TNBC cells were also quantified after treatment with CORMs, in order to 
detect any potential decrease in the levels of this anti-oxidant and cyto-protective 
enzyme. Reduced HO-1 could lead to more sensitive cancer cells that are more prone 
towards oxidative stimuli. Finally, ECs were subjected to CORM treatments and 
phosphorylation levels of Y1175 and other relevant downstream proteins were 
assessed both upon and without VEGF stimulation.  
The concentration of CORMs chosen to be tested in these experiments was the 
100µM based on previous literature. CORM-related papers use a wide range of 
concentrations according to the activity to be explored, but the 50µM and 100µM 
were the most common. A few examples can be found in these references (Megías et 
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al. 2007; Vadori et al. 2009; Winburn et al. 2012; Lee et al. 2014; Patterson et al. 2014; 
Vítek et al. 2014; Ahmad et al. 2015).  
3.3.2 Materials & Methods  
Cell lines and treatments  
MDA-MB-231 and MDA-MB-436 maintained in DMEM media with 10% FBS and 
antibiotics (full media), were used for the quantification of VEGF expression after 
CORM treatments. All cells were maintained at 37°C with 5% CO2. Cells were treated 
with 100µM CORMs or 1% DMSO or normal media for 6h, 12h or 24h before collecting 
the supernatant.  
MDA-MB-231 maintained in DMEM media with 10% FBS and antibiotics (full media), 
were used for the quantification of HO-1 expression after CORM treatments. All cells 
were maintained at 37°C with 5% CO2. Cells were treated with 100µM CORMs or 1% 
DMSO or normal media for 12h before collecting the cell lysate.  
HECV maintained in DMEM media with 10% FBS and antibiotics (full media), were 
used for the quantification of pVEGFR2 and other downstream phosphorylated 
proteins after CORM treatments. All cells were maintained at 37°C with 5% CO2. Cells 
were treated with 100µM CORMs or 1% DMSO or normal media for 6h, 12h or 24h 
before collecting the cell lysate.  
HUVEC maintained in serum free EBM-2 media (SFM) were stimulated with 50ng/mL 
or 100ng/mL VEGF for 5min or 20min and the levels of their phosphorylated proteins 
were assessed in order to find the best protocol for VEGFR2 pathway stimulation. 
Upon finding the appropriate protocol, HUVEC were treated with CORM-2 or CORM-
3 or 1% DMSO and then stimulated with 100ng/mL VEGF in order to be used for the 
quantification of pY1175 of VEGFR2 and other downstream phosphorylated proteins. 
All cells were maintained at 37°C with 5% CO2. Cells were treated with 100µM CORM-
2 or CORM-3 or 1% DMSO or serum free media (SFM) for 15min and then stimulated 
with 100ng/mL VEGF for 5min. After that, the cell lysate was collected. An 
unstimulated sample was also obtained.  
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VEGF expression after treatment with CORMs 
Upon reaching adequate confluence (~70%), the normal media of a T25 flask was 
removed and the flask washed twice with PBS. Fresh media containing the 
corresponding concentration of CORMs or 1% DMSO or no treatment was added to 
each flask and the cells were left in the normal incubator for 6h, 12h or 24h. After the 
indicated incubation time, the supernatant of the flask was collected, centrifuged and 
aliquoted in 1mL Eppendorf tubes that were kept at -80oC until required. Protein was 
also extracted from each flask using 100µL lysis buffer, quantified using the Bio-Rad 
DC Protein Assay kit (Bio-Rad laboratories) and used for normalization of the results. 
Each aliquot was thawed and used only once and the VEGF content was quantified 
using the human VEGF ELISA kit (Life Technologies Ltd.) following the manufacturer’s 
instructions. The assay is described in section 2.2.6.1 
HO-1 expression in MDA-MB-231 after treatment with CORMs 
Upon reaching adequate confluence (~70%), the normal media of a T25 flask was 
removed and the flask washed twice with PBS. Fresh media containing 100µM CORMs 
or 1% DMSO or no treatment was added to each flask and the cells were left in the 
normal incubator for 12h. After that, the supernatant of the flask was discarded and 
the total protein was extracted from each flask using 100µL lysis buffer and was 
quantified using the Bio-Rad DC Protein Assay kit. After the SDS-PAGE, the proteins 
were transferred onto nitrocellulose membrane which was then blocked and probed 
with the relevant primary and the corresponding peroxidase-conjugated secondary 
antibodies. All of the antibodies used in this study are listed in Table 2.2. The protein 
bands were eventually visualized using the chemiluminescence detection system EZ-
ECL (Biological Industries). 
Expression of phosphorylated proteins in HECV after treatment with CORMs 
Upon reaching adequate confluence (~70%), the normal media of a T25 flask was 
removed and the flask washed twice with PBS. Fresh media containing 100µM CORMs 
or 1% DMSO or no treatment was added to each flask and the cells were left in the 
normal incubator for 6h, 12h or 24h. After that, the supernatant of the flask was 
discarded and the total protein was extracted from each flask using 100µL lysis buffer 
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and was quantified using the Bio-Rad DC Protein Assay kit. After the SDS-PAGE, the 
proteins were transferred onto nitrocellulose membranes which were then blocked 
and probed with the specific primary and the corresponding peroxidase-conjugated 
secondary antibodies. The protein bands were eventually visualized using the 
chemiluminescence detection system EZ-ECL. 
Expression of phosphorylated proteins in VEGF stimulated HUVEC after 
treatment with CORMs 
HUVEC cells were seeded in 6-well plates and upon reaching adequate confluence 
(~80%), the normal media was replaced with serum free media for 12h. 50ng/mL or 
100ng/mL VEGF was added to each well for 5min or 20min. The supernatant of the 
well was then discarded, and the total protein was extracted from each well using 
100µL lysis buffer and quantified. The lysate was used for Western blot analysis.  
For the CORM treatments, HUVEC cells were seeded in 6-well plates and upon 
reaching adequate confluence (~80%), they were serum starved for 12h. Treatments 
of 100µM CORMs or 1% DMSO or no treatment were added to each well and the cells 
were left in the normal incubator for 15min. After that, 100ng/mL VEGF was added 
for further 5min. The supernatant of the well was then discarded and the total protein 
was extracted from each well using 100µL lysis buffer and quantified. The lysate was 
used either for ELISA (diluted 1:3 with Sample Diluent) or for Western blot analysis.  
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Unpaired Student’s t-test 
with Welch’s correction and nonparametric Mann-Whitney t-test were performed to 
check for statistical significance, with a p-value of <0.05 considered statistically 
significant. Asterisk notation (*) was used to identify significances: * p<0.05, ** 
p<0.01, *** p<0.001 and **** p<0.0001. 
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3.3.3 Results 
VEGF expression in MDA-MB-231, MDA-MB-436 and MCF-10A cells  
Before studying the effect of CORM treatments on the expression of VEGF from TNBC 
cells, an initial experiment aiming to estimate a rough concentration of VEGF in the 
supernatants of confluent cultures of the two TNBC cell lines along with the control 
breast cell line MCF-10A was conducted. As evident from the graph and table shown 
in Figures 3.14 A and B respectively, MDA-MB-231 cells expressed a much higher 
amount of VEGF compared to the other two cell lines. This was an expected 
observation, since these cells are known to be quite aggressive and highly metastatic 
(Browne et al. 2016; Takeda et al. 2017). Hence, this cell line was used for most of the 
further studies.  
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A.       B. 
 
 
Figure 3.14: VEGF expression in different cell lines. A. Quantification of VEGF levels in the 
supernatants of confluent cultures of MDA-MB-231, MDA-MB-436 and MCF-10A cells. B. Levels of 
VEGF expressed in picograms (pg) in the supernatants of confluent cultures of MDA-MB-231, MDA-
MB-436 and MCF-10A cells quantified using the human VEGF ELISA kit.  
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VEGF expression in MDA-MB-231 cells after CORM treatments  
In order to investigate any potential anti-angiogenic properties of the four 
commercially available CORMs, MDA-MB-231 cells were treated with 100µM CORMs 
for three different time periods and the concentration of VEGF excreted in the cell 
supernatants was then quantified. As established in the previous experiment, MDA-
MB-231 cells express a high concentration of VEGF, so any decrease in this 
concentration might make them less aggressive and metastatic. Taking this into 
consideration, three different treatment periods were chosen to be tested, that is 6h, 
12h and 24h, as any changes in the expression of VEGF were expected to be fast and 
last for a limited time.  
As observed in Figure 3.15 A, all four CORMs indeed reduced the excreted VEGF. More 
specifically, in the 6h treatment, CORM-3 reduced VEGF by more than 55%, reaching 
high statistical significance (p=0.0017). For other CORMs the significance was slightly 
lower, with p-values of 0.0141 for CORM-1, p=0.0171 for CORM-2 and p=0.0278 for 
CORM-A1.  
At this point, it is useful to point out that all these values were calculated comparing 
the CORM treated cells with normal media treated ones. In all other experiments, the 
treatments were compared to the vehicle, as was logical from the plan of each 
experiment. Due to unforeseen circumstances and uncertain reasons though, in this 
experiment, the vehicle treated cells presented a highly variable expression of VEGF, 
especially for the 6h treatment. The experiment was repeated many times, but the 
outcomes were very similar and many values were excluded in order for the graphs 
to be designed. Hence, it was decided to include the corresponding values for the 
vehicle treated cells, but compare the treatments with media treated cells instead 
(control). Here, it has to be noted that the values obtained and depicted for the 
vehicle treated cells are not statistically different from the control, with p>0.05.  
The reduction in the expression of VEGF in MDA-MB-231 cells remained evident even 
in the longer time treatments. As depicted in the same graph for the 12h treatment, 
CORM-2 managed to reduce VEGF by 60% with the greatest statistical significance 
among the others (p=0.0012). For other CORMs the p-values also indicated high 
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statistical significance, that is p=0.0303 for CORM-1, p=0.0025 for CORM-3 and 
p=0.0098 for CORM-A1.  
Finally, in the 24h treatment, the pattern was similar, with CORMs -2 and -3 reducing 
VEGF expression by 65% and 50%, respectively, with statistical significance (p=0.0255 
and p=0.0055, respectively). For the other CORMs -1 and -A1, the reduction was 
between 30% and 40% and they were also different from the control (p=0.0258 and 
0.0139, respectively).  
With these above encouraging results, it was also decided to test these CORMs at a 
higher concentration (250µM), to seek for concentration-dependent effects (Figure 
3.15 B). However, only CORM-2 appeared to reduce VEGF expression vastly more 
compared to its lower concentration, but this could also be linked to a higher 
cytotoxicity of this concentration. This experiment was only conducted once, as 
concentrations much higher than 100µM are not clinically relevant, so just a potential 
pattern was pursued. Nevertheless, it should be noted that CORM-2 managed to 
reduce VEGF expression in MDA-MB-231 cells at all time points by more than 90% 
compared to control. Especially for the 12h treatment, there was a very high statistical 
difference between these two groups, with p=0.001. 
VEGF expression in MDA-MB-436 cells after CORM treatments 
The other TNBC cell line, MDA-MB-436, was also studied for similar reduction effects 
of the CORMs in the concentration of excreted VEGF. The results of 100µM 
treatments at three different time points are depicted in Figure 3.15 C. All four CORMs 
reduced the excreted VEGF, as observed also in the other TNBC cell line. In the 6h 
treatment, only CORM-2 managed to reach statistical significance, reducing VEGF by 
80% (p=0.0485). In the 12h treatment, CORM-1 was statistically different compared 
to control and decreased the expression by 70% (p=0.0234). Finally, in the 24h 
treatment, CORM-3 had the greatest effect, with an observed reduction of more than 
65% (p=0.0121). For other CORMs, even though the reduction pattern was still 
evident, the results did not reach significance, and this might have been a 
consequence of the fewer repeats and the higher SEMs observed for all the 
treatments and time points.  
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Figure 3.15: VEGF expression after CORM treatments. A. Quantification of VEGF levels in the 
supernatants of treated MDA-MB-231 cells with 100µM CORMs or 1% DMSO or normal media for 
6h, 12h or 24h. (% compared to media treated cells (control) +SEM; n=3, N=4). B. Quantification of 
VEGF levels in the supernatants of treated MDA-MB-231 cells with 250µM CORMs or 1% DMSO or 
normal media for 6h, 12h or 24h. (% compared to media treated cells (control) +SD; n=3, N=1). C. 
Quantification of VEGF levels in the supernatants of treated MDA-MB-436 cells with 100µM 
CORMs or 1% DMSO or normal media for 6h, 12h or 24h. (% compared to media treated cells 
(control) +SEM; n=3, N=3) (All data was statistically analysed against media treated cells using 
unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001).  
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HO-1 expression in MDA-MB-231 cells after CORM treatments for 12h 
As discussed previously, HO-1 is a well-characterised cytoprotective enzyme that 
defends the cell in conditions of oxidative stress and excessive ROS production. 
CORMs have been reported to increase ROS production, especially in bacterial, but 
also in eukaryotic cells. Therefore, this study aimed to investigate if CORMs could 
potentially alter the expression of this enzyme, affecting the redox status of the 
cancer cells and their antioxidant defending systems. MDA-MB-231 cells were treated 
with 100µM CORMs for 12h and the expression of HO-1 was quantified via Western 
blot analysis.  
As observed in Figures 3.16 A and B, CORMs -1 and -2 could reduce the expression of 
HO-1 after 12h of treatment, reaching statistical significance (p=0.0079 and 
p=0.0179), whereas CORM-3 failed to reach this level. On the other hand, CORM-A1 
increased the expression of this enzyme by 40% (p=0.0079), indicating a different 
mechanism of interaction from the other CORMs.  
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A.  
 
 
B.  
 
Figure 3.16: HO-1 expression after CORM treatments. A. Western blot of HO-1 expression 
following CORM or vehicle or media treatment for 12h in MDA-MB-231 cells. (Blot shows 
representative data; N=4). B. Assessment of HO-1 levels in MDA-MB-231 cells following 12h of 
treatment with CORM or vehicle or media (control) treatment. (Graph shows % compared to 
vehicle +SEM; N=4) (Data statistically analysed using nonparametric (Mann-Whitney) t-test with * 
p<0.05, ** p<0.01).   
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Downstream proteins of the VEGFR2 signalling pathway in HECV cells after 
CORM treatments  
Before investigating the ability of the four available CORMs to inhibit the 
phosphorylation and activation of downstream molecules of the VEGFR2 signalling 
pathway following VEGF stimulation, an initial study was conducted, to determine the 
relative expression levels of phosphorylated Y1175 of VEGFR2, p38, Src, AKT and 
ERK1/2 proteins in unstimulated CORM treated ECs.  
The experiment was carried out once for each different time point, but it was evident 
in the corresponding Western blots in Figures 3.17 A and B, that there was a trend for 
all CORMs to reduce the phosphorylation of some these proteins in unstimulated ECs. 
More specifically, the phosphorylation of VEGFR2 at Y1175 was investigated in cell 
lysates of CORM treated HECV cells and compared to vehicle treated cells at three 
different time points (Figure 3.17 A). CORM-3 appeared to be the most potent, 
reducing the activation of VEGFR2 at all time points by more than 40%. CORM-2 also 
showed similar effects, whereas CORM-A1 significantly increased the phosphorylation 
of this tyrosine residue on VEGFR2, especially after 24h of treatment (representative 
bar graph in Figure 3.17 C).  
Different trends were observed for the other downstream proteins tested, including 
p-p38 (T180/Y182), p-Src (Y419), p-AKT (S473) and p-ERK1/2 (S473) (Figure 3.17 B). 
The levels of these proteins were quantified after 6h of treatment with CORMs or 
vehicle or normal media (control). In the case of p-p38, CORM-1 reduced its 
expression by more than 50%, closely followed by CORM-2, whereas CORM-A1 
increased the activation of this protein to some extent (Figure 3.17 C). 
For Src, all CORMs seemed to slightly increase its phosphorylation, whereas p-AKT was 
reduced after treatment with CORM-1 (Figure 3.17 C).  
Finally, CORM-1 remained the one with the highest effect on p-ERK1/2 in HECV cells, 
although all CORMs seemed to reduce the levels of p-ERK1/2, as well (Figure 3.17 C).  
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Figure 3.17: Expression of VEGFR2 pathway proteins in HECV after CORM treatments. A. Western 
blots of pY1175 expression following CORM or vehicle or media treatment for 6h, 12h or 24h in 
HECV cells. B. Western blots of VEGFR2 pathway protein expression following CORM or vehicle or 
media treatment for 6h in HECV cells. (All blots show the obtained data; N=1). C. Assessment of 
pY1175, pERK1, pERK2, p-p38, pSrc and pAKT levels in HECV cells following the indicated duration 
of treatment with CORM or vehicle or media (control) treatment. (Graphs show % compared to 
vehicle; N=1).    
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Downstream proteins of the VEGFR2 signalling pathway in VEGF stimulated 
HUVEC cells  
As evident from the previous experiment, even unstimulated EC seemed to react to 
CORM treatments by altering the activation levels of several proteins of the VEGFR2 
pathway. Since within the tumour microenvironment the concentration of VEGF is 
significantly elevated compared to normal tissues, more relevant results would be 
obtained if VEGF stimulated ECs were treated with CORMs and any differences in the 
activation of proteins of the VEGFR2 pathway were assessed.  
The first few attempts were made with HECV cells. However, the few protocols tried 
with these cells seemed not to produce the expected stimulation for all the tested 
proteins, therefore other ECs were adopted, where the differences would be more 
profound. These ECs were HUVEC, that have been vastly explored in the literature for 
similar purposes, for example (Ahmad et al. 2015).  
The main difference between primary ECs and EC lines is the limited lifespan of the 
primary cells, that can be grown for up to 10 serial passages. Thereafter they enter a 
senescence stage halting their proliferation and changing their morphology (Bouïs et 
al. 2001). Even within the same primary ECs though, a disparate behaviour during 
experiments can be observed, since the different donor origin for their harvest can 
alter several responses, for example the response towards IL-8 stimulation (Watson 
et al. 1995).  
Moreover, the molecular characteristics of the cells can vary greatly, as for example 
some EC lines such as the HMEC-1 (human microvascular endothelial cells), have been 
shown to express growth factors including VEGF and bFGF, but others do not express 
these factors (for example the telomerase-immortalized human microvascular 
endothelial cell line, TIME) (Ng et al. 2015). HECV is an EC line that secretes high 
concentrations of VEGF-A even under normal conditions (643.3 ± 72.37pg/ml secreted 
in the supernatant of a 24h confluent cell culture (Puddu et al. 2016)), whereas HUVEC 
express very low concentrations of VEGF. This leads to a divergent growth factor 
dependence, as also suggested by the different optimal growth media for each cell 
line. Following this, another very relevant point to be made is the differential 
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expression of VEGFRs by primary ECs and EC lines, as for example HUVEC have been 
shown to express elevated levels of VEGFRs (300%-1000% increase) compared to 
HECV (Martin T.A., unpublished data). These observations of different growth factor 
dependence and uneven VEGFR expression might be the reason why HECV did not 
respond to VEGF stimulation as much as HUVEC did in this study.  
The different conditions reported in literature vary in the concentration of VEGF and 
the duration used for stimulation, therefore relevant experiments were conducted to 
find the appropriate protocol. Results are depicted in Figure 3.18 for four different 
protocols. After 12h serum starvation, both 50ng/mL and 100ng/mL VEGF were used 
for either 5min or 20min stimulation. As shown in the Western blot data, the best 
protocol was obtained with 100ng/mL VEGF for 5min. Although pAKT was very mildly 
activated under these conditions, this protocol was used anyway for further 
experiments. A longer time treatment might have been useful for pAKT, but all other 
proteins tested responded at the expected level.  
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Figure 3.18: Western blot analysis for the different conditions tested.  
The chosen condition is highlighted in the red box.  
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For the next experiment, 100µM CORMs or 1% DMSO or serum free media treatments 
were added to the cells for 15min prior to stimulation. After the 5min stimulation 
period, cell lysate was isolated and used either for ELISA for pY1175 of VEGFR2 or for 
Western blot analysis for pSrc (Y419), pERK1/2 (Y204), pFAK (Y397) and pAKT (S473) 
proteins.  
As shown in Figures 3.19 A and C, all proteins were activated by VEGF at different 
levels. CORM-2 and CORM-3 downregulated both pERK1 and pERK2 at baseline levels, 
very close to the unstimulated control (Figure 3.19 A). This reduction reached 
significance for both CORMs (pERK1; p=0.079 for CORM-2 and p=0.0317 for CORM-3, 
pERK2; p=0.0173 for CORM-2 and p=0.0079 for CORM-3). On the contrary, pSrc was 
not affected by the two CORMs, which failed to lower the phosphorylation levels of 
this protein, although upon stimulation with VEGF only a moderate increase in the 
phosphorylation of ~50% for the control and ~25% for the vehicle was observed 
(Figure 3.19 B).  
The other two proteins, pAKT and pFAK also responded mildly to the stimulation with 
VEGF, and due to the experiment having been repeated only twice, no quantification 
was performed. However, an obvious reduction in the phosphorylation levels of both 
proteins was observed for CORM-2, whereas CORM-3 decreased only pAKT and did 
not affect pFAK levels (Figure 3.19 C).  
Finally, ELISA quantification was performed for the phosphorylation levels of VEGFR2 
at Y1175, and as shown in Figure 3.20 A, only CORM-2 managed to return the 
phosphorylation at the baseline levels of the unstimulated control. This reduction 
reached statistical significance with p=0.0067. CORM-3 failed to decrease these levels, 
and the same result was also verified with a Western blot analysis, where it was 
obvious that only CORM-2 can inhibit the phosphorylation and activation of Y1175 of 
VEGFR2 (Figure 3.20 B).   
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A.       
 
 
B.  
 
 
C.       
 
 
Figure 3.19: Expression of VEGFR2 pathway proteins in HUVEC after CORM pre-treatments and 
VEGF stimulation. A. Western blot of pSrc and pERK1/2 following 15min of CORM or vehicle pre-
incubation and then stimulation with VEGF (100ng/ml) for 5 min. The first sample is the 
unstimulated control (Control) and the second is the stimulated control (SFM=serum free media). 
(Blots show representative data; N≥4). B. Quantitative assessment of pERK1/2 and pSrc levels in 
HUVEC following the same protocol. (Graphs show % compared to Control +SEM; N≥4) (Data 
statistically analysed using nonparametric (Mann-Whitney) t-test with * p<0.05, ** p<0.01).  
C. Western blot of pAKT and pFAK following the same protocol. (Blots show representative data; 
N=2). 
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A. 
 
 
B.  
 
 
Figure 3.20: pY1175 levels. A. Expression levels of pY1175 of VEGFR2 in HUVEC after 15min of 
CORM or vehicle pre-incubation and then stimulation with VEGF (100ng/ml) for 5 min, as measured 
with the human pY1175-VEGFR2 ELISA kit. The first sample is the unstimulated control (Control) 
and the second is the stimulated control (SFM=serum free media). (Graph shows % compared to 
Control +SEM; N=3) (Data statistically analysed using unpaired Student’s t-test with Welch’s 
correction * p<0.05, ** p<0.01). B. Western blot of pY1175 of VEGFR2 following 15min of CORM 
or vehicle pre-incubation and then stimulation with VEGF (100ng/ml) for 5 min, which verifies the 
results of the ELISA. (Blot shows the obtained data; N=1). 
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3.3.4 Discussion 
Angiogenesis is linked to the expression of several proteins, both by the cancer cells 
themselves and by the ECs that line the surrounding blood vessels and execute the 
process of neovascularization. In that scope, the next step of the screening of the four 
commercially available CORMs was to measure the expression of proteins related to 
angiogenesis and are responsible for its successful accomplishment.  
As suggested by other studies, several chemotherapeutics may have a complementary 
anti-angiogenic activity, along with any other in vitro and in vivo effects. For example, 
paclitaxel, doxorubicin and thalidomide can also inhibit VEGF expression, 
bisphosphonates may also reduce VEGF serum levels and celecoxib can also decrease 
circulating angiogenic markers. A logical approach would be to combine agents that 
can reduce the expression of angiogenic factors with ones that target these factors 
per se, or their receptors. The principle behind this combination involves the potential 
enhancement of the delivery of cytotoxic agents to the tumour site, as well as the 
possible interference with the ability of the tumour to recover from the effects of the 
accompanying chemotherapeutic agent (Wang et al. 2015).  
The main pro-angiogenic factor, VEGF, participates in the angiogenic process by 
increasing vascular permeability and stimulating EC survival, proliferation, migration 
and expression of MMPs, among others (Abhinand et al. 2016). Previous literature 
suggested an increase in VEGF expression induced by CORMs in several in vitro 
models. More specifically, ECs seemed to stimulate their VEGF expression upon 
treatment with CORMs, CORM-2 and CORM-3 in most studies, and this pointed 
towards an increased angiogenic potential for these cells (Jözkowicz et al. 2003; Li 
Volti et al. 2005). Other cells showed a similar behaviour, that is CORM-2 caused an 
increase in VEGF secretion in astrocytes (Choi et al. 2010) and CORM-401 and CORM-
A1 led to an enhanced expression of VEGF in microglia cells after 3h of treatment, 
whereas after 6h the levels returned back to normal (Wilson et al. 2017). However, 
there are also studies contradicting these results, such as the study from Ahmad et al. 
(Ahmad et al. 2015) where HUVEC – primary vascular ECs – were reported to 
downregulate the phosphorylation and activation of both VEGFR2 and AKT upon 
treatment with CORM-2, suggesting a potential anti-angiogenic ability of this 
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compound. Nevertheless, none of these studies used cancer cells, and since CO and 
CORMs have extensively been reported to have contradicting effects that are cell and 
tissue-type specific, it was deemed useful to study the effects of the commercially 
available CORMs on the expression of VEGF from TNBC cells.  
As shown in the relevant figures, MDA-MB-231 cells are more aggressive, thus express 
a higher concentration of VEGF compared to MDA-MB-436. When MDA-MB-231 cells 
were treated with CORMs for 6h, 12h and 24h, VEGF secretion was reduced, especially 
for CORM-2 and CORM-3 treatments. The reduction reached a level of 50-60%, 
suggesting a very promising profile for these complexes that can potentially halt the 
elevated expression of VEGF by TNBC cells, possibly also decreasing the angiogenic 
stimulation reaching the surrounding ECs. It would be important to mention that 
these results were significant, and all four CORMs seemed to share the same tendency 
to reduce the VEGF expression of TNBC cells at the used concentration of 100µM.  
The same pattern was observed also for a higher concentration of CORMs, where 
CORM-2 was surprisingly effective at reducing the expression of VEGF. However, it 
should be considered whether this reduction was a direct effect of CORM-2 or it was 
linked to potential toxicity of this compound against MDA-MB-231 at higher 
concentrations than 100µM.  
The more sensitive TNBC cell line, MDA-MB-436, seemed to be erratically affected by 
the four CORMs, with patterns not complying to the increase in the treatment 
duration and CORM-A1 showing ineffectiveness. This might have been a consequence 
of small differences in the confluence of the flasks during the treatments and between 
the experiments, the different passage numbers of the cells used or other unidentified 
factors. MDA-MB-436 cells are less aggressive and resilient compared to MDA-MB-
231, therefore a more unpredicted behaviour might be observed. More repeats of this 
experiment would help in establishing a more robust pattern for the effects of the 
four CORMs on VEGF expression by MDA-MB-436 cells.  
Thus, the main observation of this experiment was the reduction in the excreted VEGF 
from TNBC cells at all time points tested, leading to potentially decreased angiogenic 
stimulation towards ECs. These complexes were shown to interfere with the 
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expression pathway of VEGF in TNBC cells, possibly leading to lower stimulation 
signals to the surrounding tissues. Observing that these results contradict previous 
literature, it should be again pointed out that the in vitro models of none of these 
studies were cancer cells, and CO and CORMs have repeatedly been reported to have 
cell and tissue-type specific effects. There are differences in the physiological 
procedures of normal and TNBC cells, hence this result might be a consequence of a 
divergent VEGF expression mechanism in TNBC cells that is prone to CORM 
interference.  
It has been previously shown that suppression of HO-1 expression can impede the 
proliferation and viability of pancreatic cancer cells (Berberat et al. 2005), as well as 
the survival and growth of hepatocellular carcinoma (Sass et al. 2008) and prostate 
cancer cells (Li et al. 2011). However, in other studies HO-1 silencing was oppositely 
reported to increase tumour growth (Zou et al. 2011), pointing towards a rather 
complex and tumour type-specific role. Most of the increasing evidence though, 
suggest a link between lower expression of HO-1 and higher sensitivity of cancer cells 
(Szabo 2016). Therefore, it would be useful to study the effect of CORMs on HO-1 
expression in TNBC cells. A study by Taillé et al. (Taillé et al. 2005) suggested no change 
in HO-1 expression after 24h treatment with up to 10µM CORM-2 in airway smooth 
muscle cells, so a shorter incubation time was chosen, that is 12h.  
The result of the study showed a downregulating activity of CORMs towards HO-1 that 
was significant for CORMs -1 and -2, but failed to reach significance for CORM-3. 
However, the pattern observed for these complexes was not shared by CORM-A1, 
which markedly increased HO-1 expression in TNBC cells. These observations suggest 
two different concepts: 1) that transition-metal based CORMs can decrease the 
expression of HO-1 in TNBC, a mechanism not followed by the non-transition metal 
based CORM-A1, and 2) that this downregulation might lead to a higher sensitivity of 
these cells towards other chemotherapeutic or anti-angiogenic agents, based on 
previous observations for other tumour types. 
Another important aspect of angiogenesis is the successful pro-angiogenic signal 
transduction from the surface receptor VEGFR2 to its complicated network of 
downstream proteins. As discussed in Chapter 1, VEGF has a higher affinity for VEGFR-
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1, but the effects of activation are much more profound for VEGFR2, regulating EC 
functions. VEGFR2 has also been found upregulated in TNBC. As an RTK, VEGFR2 
undergoes dimerization and oligomerization, which results into auto- and trans-
phosphorylation on specific tyrosines in the cytoplasmic domain. Two of the most 
important tyrosine residues (autophosphorylation sites) are Y1175 and Y1214 
(Lamalice et al. 2007; Jansson et al. 2014). Therefore, CORMs were studied for their 
ability to reduce the phosphorylation of one of these tyrosine residues of VEGFR2, in 
order to investigate any inhibitory activity on the activation of this major receptor. 
The ELISA technique is more sensitive than a Western blot analysis, therefore it was 
chosen for measuring the phosphorylation levels of Y1175 after appropriate 
stimulation with VEGF.  
The effective concentration (EC50) of VEGF for the stimulation of VEGFR2 has been 
reported to be around 650pM (≈27ng/mL) (Akeson et al. 2010). However, most 
published papers utilise this or higher concentrations of VEGF, as a cell line is only an 
in vitro model that can represent the in vivo situation with modest accuracy and 
usually requires higher concentrations of stimulants to induce a measurable 
activation. Following this, the optimization experiment for the stimulation of the 
VEGFR2 pathway in HUVEC aimed to determine the best concentration and duration 
of stimulation between 50ng/mL and 100ng/mL concentrations and 5-minute and 20-
minute stimulation durations. These values were chosen based on previous literature, 
for example the published work of Cai et al. (Cai et al. 2003) and Ahmad et al. (Ahmad 
et al. 2015), whereas a very comprehensive study was conducted by Akeson et al. 
(Akeson et al. 2010) where several concentrations and durations were explored and 
the 50ng/mL for 4-6min was shown to stimulate most of the proteins tested. In more 
detail, a good ratio between phospho-VEGFR2/VEGFR2 was shown for stimulatory 
concentrations of VEGF ≥20ng/mL, with 50ng/mL for 4min being the most effective. 
Moreover, for PLC-γ and MAPK the best stimulation was achieved with 50ng/mL of 
VEGF for 6min, whereas for AKT the longer the duration the higher stimulation was 
observed. It must be noted here that 50ng/mL was the highest concentration tested 
in the cited study (Akeson et al. 2010). Therefore, 50ng/mL was chosen as the 
reference concentration and the higher 100ng/mL was used for comparison purposes, 
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even though it proved to be more effective in the conducted experiments and used 
further. The 20-minute stimulation was tested mostly to prove that VEGF achieves 
significant stimulation very quickly that fades with time, as also shown by the obtained 
results.  
Only CORM-2 appeared to inhibit the activation of this receptor on Y1175, reducing 
the phosphorylation almost to baseline levels, whereas CORM-3 failed to produce 
such an inhibition. This was a particularly interesting finding that correlates well with 
previous literature (Cudmore et al. 2007; Ahmad et al. 2015) and suggests an 
impairment of the angiogenic signal transduction after treatment with CORM-2, even 
upon stimulation with a high dose of VEGF.  
As a proof of concept, more downstream proteins were investigated upon stimulation 
with VEGF, in order to shed light on any potential targets of CORM-2 and CORM-3 
(Abhinand et al. 2016). Different studies reported contradictory results. The work by 
Otterbein et al. (Otterbein et al. 2000) and Brouard et al. (Brouard et al. 2000) 
suggested an upregulation of pERK1/2 in stimulated macrophages, fibroblasts and ECs 
upon treatment with CO gas, whereas a study by Song et al. (Song et al. 2011) showed 
an inhibition of ERK phosphorylation in stimulated human gingival fibroblasts upon 
treatment with CORM-3. The group of Taillé et al. (Taillé et al. 2005) found decreased 
ERK1/2 phosphorylation in airway smooth muscle cells upon treatment with CORM-
2, which implicated ROS production. Therefore, HUVEC cells were studied for the 
phosphorylation levels of different proteins of the VEGFR2 pathway upon VEGF 
stimulation and it was found that both CORM-2 and CORM-3 had an inhibitory activity.  
CORM-3 seemed to be more effective towards pERK1/2 whereas CORM-2 was 
effective against all tested proteins. This suggested a different mechanism of action 
for the two similar CORMs, but anyway confirmed their potential as anti-angiogenic 
agents. Not all proteins were affected by the two CORMs though, for example Src 
phosphorylation was not downregulated upon treatment. This observation proved 
some type of preferential inhibition on ERK activation and maybe also on AKT 
activation for CORM-3, but not on the whole pathway, whereas for CORM-2 a more 
holistic inhibition might be the case. 
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3.4 Migratory ability assessment 
3.4.1 Introduction 
Angiogenesis is directly linked to the capability of ECs to proliferate and migrate in 
response to growth factor activation (Potente and Carmeliet 2017). As discussed in 
the introduction, there is a fine balance between pro- and anti-angiogenic factors that 
determines the formation of new blood vessels, not only in a normal environment but 
also in a cancerous one. In this process, migration of capillary ECs plays a main role 
and it follows the stimulation induced by the secreted and circulating VEGF. ECs are 
equipped with VEGFRs and VEGFR2 is the most potent of them. The next step is the 
selection of an EC as a tip cell, which will lead the vascular sprout towards the 
angiogenic signal produced by avascular tissue. The tip cell is followed by trailing 
proliferative stalk cells that will subsequently form a vascular lumen, create links 
between adjacent cells and build the basement membrane (Lamalice et al. 2007; 
Missiaen et al. 2017). The angiogenic cascade is also tightly correlated with ROS 
production and signalling, as discussed earlier (Lamalice et al. 2007). 
Finding agents that can disrupt the migration of ECs would be a promising alternative 
approach towards the inhibition of cancer-mediated angiogenesis. Since ECs are the 
major contributors to the formation of new blood vessels that can sustain the growth 
of tumours, targeting their vital functions could prove helpful.  
In that scope, the four available CORMs were tested for their ability to inhibit the 
migration of ECs following a wound formation on their monolayer.  
3.4.2 Materials & Methods 
Cell lines and treatments  
HECV cells maintained in DMEM with 10% FBS and antibiotics, were used for the 
scratch wound assay. All cells were maintained at 37°C with 5% CO2 prior to and during 
the experiments. Cells were treated with 100µM of CORMs or 1% DMSO or normal 
media.  
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MDA-MB-231 cells maintained in DMEM with 10% FBS and antibiotics, were used for 
the IncuCyteTM Scratch wound assay. All cells were maintained at 37°C with 5% CO2 
prior to and during the experiments. Cells were treated with increasing 
concentrations of CORMs or vehicle.  
Scratch wound assay 
1x105 cells were seeded in 1mL of normal media per well in a 24-well plate and left to 
form a confluent monolayer. Three replicates were undertaken per different 
treatment tested. The cells were washed with PBS, wounded with a pipette tip and 
then treated with 100µM of CORMs or 1% DMSO or normal media for 24h. Photos 
were taken at 0h, 8h, 12h and 24h after wounding. Migration distances were 
measured using ImageJ software. The process is detailed in section 2.2.8.1. 
IncuCyteTM Scratch wound assay 
5x104 cells were seeded in 100µL of normal media per well in a 96-well ImageLock 
plate (Essen Bioscience) and left to reach >90% confluence (usually overnight). Four 
replicates were undertaken per different treatment tested. The Wound Maker was 
used to make the scratches. The wells were washed twice with media and then 
treatments were added to each well for 48h. Images were taken every 2h after 
wounding. The process is detailed in section 2.2.8.2.   
IncuCyteTM data analysis 
The IncuCyteTM data was analysed using the IncuCyte ZOOM 2016A software, kindly 
provided by Essen Biosciences.  
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Unpaired Student’s t-test 
with Welch’s correction and two-way ANOVA were performed to check for statistical 
significance, with a p-value of <0.05 considered statistically significant. Asterisk 
notation (*) was used to identify significances: * p<0.05, ** p<0.01, *** p<0.001 and 
**** p<0.0001. 
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3.4.3 Results 
Endothelial cell migratory ability tested with the Scratch Wound assay 
In order for angiogenesis to take place, migration of ECs must occur, so that the new 
blood vessels will start to form. As extensively discussed in section 1.3.1, the migration 
of a tip cell towards the angiogenic signal is the initiating step allowing for the 
formation of immature tubes and branches between pre-existing blood vessels. 
Therefore, it was worth investigating if the treatment of ECs with CORMs could affect 
their ability to migrate. Inhibiting this process would prove very useful in the blockade 
of the neovascularization process as a whole. 
Figures 3.21 A – C present the results of a scratch wound assay in ECs after CORM, 
vehicle or normal media treatments, as quantified from images captured 8h, 12h and 
24h after the scratch. As observed, CORMs -1, -2 and -3 blocked the migration of ECs, 
leaving the induced wound still open, even 24h after the scratch (Figure 3.21 A). More 
specifically, although after treatment of ECs with normal media, vehicle and CORM-
A1, the wound managed to close due to successful migration of ECs, the result was 
totally different after treatment with CORMs -1, -2 and -3. These differences reached 
statistical significance with p-values of 0.0092, 0.0003 and 0.0045, respectively (Figure 
3.21 B). It should be noted though, that the vehicle treated cells showed slower 
migration than the media treated ones, and this difference was significant with 
p=0.0056, as calculated in a two-way ANOVA test. Figure 3.21 C depicts the 
percentage of wound confluence in the final time point tested (24h), and again these 
three CORMs reached significance (p=0.0323, p=0.0003, p=0.0092 for CORMs -1, -2 
and -3). In this time point, vehicle and control treatments did not show statistically 
different results, as calculated in an unpaired t-test with Welch’s correction.  
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Figure 3.21: Migratory ability of HECV after CORM treatments. A. Representative images from the 
scratch wound assay in HECV cells, at 0h and 24h after treatment with 100µM CORMs or 1% DMSO 
or normal media. Objective 5x. B. Assessment of the healing, expressed as % wound confluence, 
at three time points after treatments. (% wound confluence ±SEM; n=3, N=3) (All data was 
statistically analysed against vehicle treated cells using two-way ANOVA: * p<0.05, ** p<0.01,  
*** p<0.001). C. Average % wound confluence at the final time point (24h) for all treatments. (All 
data was statistically analysed against vehicle treated cells using un-paired t-test with Welch’s 
correction: * p<0.05, ** p<0.01, *** p<0.001).  
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Cancer cell migratory ability tested with the IncuCyteTM Scratch Wound assay 
MDA-MB-231 cells are capable of migrating, hence their metastatic and aggressive 
nature. Therefore, any inhibitory activity of CORMs on the migration of these cells was 
tested, as well. Blocking their capability to travel long distances might help in reducing 
their aggressive phenotype. 
In an IncuCyteTM Scratch Wound assay, MDA-MB-231 cells were treated with 100µM 
CORMs following a scratch induced by a wound maker. As observed in Figure 3.22 A, 
none of the CORMs succeeded in blocking the migration of these TNBC cells, allowing 
the wound to close 48h after the scratch. However, as depicted in the corresponding 
images 26h after the scratch, for CORMs -1, -2 and -3 treated cells the migration was 
slightly slower compared to vehicle or media treated cells. The overall result may not 
have raised statistical significance in a two-way ANOVA test (Figure 3.22 B), but it 
could imply a negative effect on the migratory ability of these cells, that could possibly 
reach significance in higher concentrations.  
When the results for the intermediate time point (26h) were plotted separately 
(Figure 3.22 C) though, a significant difference between the percentage wound 
confluence of the vehicle versus the media treated group in an unpaired t-test with 
Welch’s correction (p=0.0108) could be observed. None of the CORM treatments 
raised significance compared to the vehicle group, but when compared to the media 
treated group, CORMs -2, -3 and -A1 were shown to be very significantly different 
(p=0.0037, p=0.0009 and p=0.0010, respectively).  
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Figure 3.22: Migratory ability of MDA-MB-231 after CORM treatments. A. Representative images 
from the IncuCyteTM scratch wound assay in MDA-MB-231 cells at 0h, 26h and 48h after treatment 
with 100µM CORMs or 1% DMSO or normal media. Objective 10x. B. Assessment of the healing, 
expressed as % wound confluence, at all time points tested after treatments. (% wound confluence 
±SEM; n=4, N=2) (All data was statistically analysed against vehicle treated cells using two-way 
ANOVA: * p<0.05). C. Average % wound confluence at an intermediate time point (26h) for all 
treatments. (All data was statistically analysed against control treated cells using un-paired t-test 
with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001).  
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3.4.4 Discussion 
Angiogenesis refers to the highly organized process of the formation of new blood 
vessels from pre-existing ones. A whole cascade of events take part in this process, 
but capillary EC migration is one of the most decisive components. Angiogenesis has 
traditionally been viewed from the perspective of how ECs coordinate migration and 
proliferation in response to growth factors,  in order to form new vessel branches, and 
molecules that are capable of inhibiting EC migration were deemed promising for 
novel anti-angiogenic therapies (Lamalice et al. 2007; Missiaen et al. 2017; Potente 
and Carmeliet 2017). In the widely used experiment of scatch wound assay (Menyhárt 
et al. 2016), ECs are grown in a monolayer and when confluent, a scratch is induced 
on their surface. Molecules that can inhibit the closure of this wound, thus the 
migration of ECs, could be considered for anti-angiogenic therapies. 
However, since the effects of proliferation cannot be excluded from this experiment 
a more useful assay to explore would have been a trans-well migration assay. 
Especially when considering the fast proliferation of HECV, it is not clear whether the 
obtained results represent just the impairement of the migratory ability of the cells or 
effects on their proliferation also contribute to the observed inhibition of wound 
closure. This poses a limitation on interpreting the results.  
According to the obtained results for HECV, all CORMs apart from CORM-A1 managed 
to inhibit the closure of the wound in a statistically significant manner. Even though 
the vehicle treated ECs were slower in closing the wound compared to control, 
eventually both groups, vehicle and control, succeeded in providing a fully confluent 
monolayer of ECs. On the contrary, ECs treated with CORMs -1, -2 and -3 never 
recovered from the wound and almost no EC migration took place during the 24h of 
the experiment. Especially for CORM-2, this result was highly significant when 
compared to the vehicle group. Even when plotting the end point results (24h) and 
performing a different statistical test, the result was the same, that is CORMs -1, -2 
and -3 managed to inhibit the migration of ECs in a notable level.  
Although the delay in EC migration induced by the vehicle itself should not be 
overlooked, CORMs seem to have a strong inhibiting effect on EC migration that raised 
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significance over the vehicle. This points towards a potentially anti-aniogenic profile 
of these molecules, since EC migration is key process for the formation of new blood 
vessels. 
MDA-MB-231 are a well-characterized aggressive and highly metastatic TNBC cell line, 
which has the ability to migrate and invade distant areas, such as the bones and the 
brain, where secondary tumour niches can be formed (ECACC catalogue No. 
92020424). Therefore, it was considered interesting to look for potential anti-
migratory effects of CORMs on MDA-MB-231 cells. For this experiment, the 
IncuCyteTM ZOOM® instrument and the Wound Maker were used, that provide higher 
consistency in the produced wounds and in the areas from where the photos can be 
captured.  
The results showed a minimal inhibition of the migration of TNBC cells that did not 
reach significance when compared to the vehicle group in a two-way ANOVA analysis. 
However, the plotted results for the intermediate time point (26h) revealed a 
difference between the vehicle and control groups, strongly resembling the one for 
HECV cells, suggesting a delay in the migration of the tested cells caused by the vehicle 
itself. This effect was even greater with CORM treatments, and more specifically with 
CORMs -2, -3 and -A1. This result might have been enhanced by the vehicle at some 
level, but CORMs reduced the percentage wound confluence even more and in a 
statistically significant manner when compared to the control group. This suggests a 
modest inhibition in the migration of MDA-MB-231 cells that is short-lived and may 
have been even more profound if the dosing was repeated every 24h. 
In summary, a strong inhibition in the migration of ECs was observed, that could 
potentially point towards an anti-angiogenic profile for CORMs -1, -2 and -3 but should 
be re-tested with more relevant assays. The slight but significant inhibition of 
migration of TNBC cells for the first 26h could also indicate an impairment of their 
aggressive nature, and it would be interesting to study if there would be an additional 
effect if the dosing was repeated, since TNBC cells are far more aggressive and less 
sensitive than ECs and they have the ability to overcome malfunctions caused by 
inhibitors.  
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
155 
 
3.5 Angiogenic potential 
3.5.1. Introduction 
As outlined thoughout this study, angiogenesis is central to many normal physiological 
processes, but has also been linked to tumour growth, progression and metastasis. It 
is essential for the rapidly dividing cancer cells to be able to draw oxygen and nutrients 
from the body’s blood supply in order to support their survival and growth. Malignant 
angiogenesis has been recognised as a required step for the transition from a small 
cluster of faster dividing cells to a primary tumour (Carmeliet and Jain 2011; Bishayee 
and Darvesh 2012). The prevalent form of pathological angiogenesis is sprouting 
angiogenesis, which participates in tumour neovascularization (Hillen and Griffioen 
2007). 
Mature blood vessels are the main type of vessels formed during pathological 
angiogenesis, although they have many differences compared to normal vessels, such 
as hyperpermeability, heterogeneous morphology and reduced efficiency in tissue 
perfusion (Gacche and Meshram 2014; Falcon et al. 2016; Missiaen et al. 2017). 
Moreover, angiogenesis has a contributory role in the ability of a tumour to spread 
and metastasize. Single cancer cells can be detached from an original established 
tumour site and circulate through the blood vessels towards a secondary tumour site. 
Considering the morphology of tumour vessels, which are mosaic vessels with 
irregular shapes and consist of both endothelial and cancer cells, tumour cells may be 
facilitated in circulating towards distant areas and establishing new tumour sites 
(Shan et al. 2014).  
Since VEGF is the basic mediator of pathological angiogenesis and arising evidence 
shows that the interaction between VEGF and its receptors facilitates angiogenesis 
and promotes tumour growth especially in TNBC, the study could not ommit a test for 
the ability of ECs to form tubes after VEGF stimulation and CORM treatments. 
Therefore, conditioned media from MDA-MB-231 cells which had been treated with 
CORMs or vehicle or media for different durations, was used to stimulate tube 
formation in HECV cells. In addition, a separate experiment was conducted, where 
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HECV cells were directly treated with CORMs and assessed for their ability to create 
tube-like formations. 
3.5.2. Materials & Methods 
Cell lines and treatments  
HECV cells maintained in DMEM with 10% FBS and antibiotics, were used for the tube 
formation assay. All cells were maintained at 37°C with 5% CO2 prior to and during the 
experiments. Cells were treated with conditioned media from MDA-MB-231 cells 
incubated with 100µM of CORMs or 1% DMSO or normal media for 6h, 12h or 24h. 
For the instant treatments, the same cells and conditions were used, and the cells 
were directly treated with 100µM of CORMs or 1% DMSO or normal media. 
Tube formation assay using conditioned media 
3.5x104 cells were seeded on top of a pre-set layer of Matrigel in each well of a 96-
well plate. The plate was left in the normal incubator for cells to adhere and then the 
full media was replaced with serum free media containing conditioned media from 
treated MDA-MB-231 cells. After 6h, the wells were imaged using a Leica DM 1000 
LED microscope capturing at least 3 images/well in random areas. The images were 
analysed using the ImageJ Software and the percentage of total tube length compared 
to the wells that received conditioned media from vehicle treated MDA-MB-231 cells 
was calculated. 
Tube formation assay with instant treatment 
3.5x104 cells were seeded on top of a pre-set layer of Matrigel in each well of a 96-
well plate. The plate was left in the normal incubator for cells to adhere and then the 
full media was replaced with serum free media containing 100µM of CORMs or 1% 
DMSO or serum free media. After 6h, the wells were imaged using a Leica DM 1000 
LED microscope capturing at least 3 images/well in random areas. The images were 
analysed using the ImageJ Software and the percentage of total tube length compared 
to the vehicle treated cells was calculated. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Unpaired Student’s t-test 
with Welch’s correction was performed to check for statistical significance, with a p-
value of <0.05 considered statistically significant. Asterisk notation (*) was used to 
identify significances: * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
3.5.3. Results 
Tube formation after treatment with conditioned media from cancer cells 
As the main objective of this study was to search for potential anti-angiogenic 
properties of commercially available CORMs, a tube formation assay was considered 
very useful towards this aim. The previous observation that these compounds can 
possibly decrease the expression of VEGF from TNBC cells, in conjunction with the fact 
that VEGF is the main inducer of angiogenesis in tumour environments, directed the 
search for any possible reduction in the formation of tube-like structures by ECs 
treated with cancer conditioned media.  
Isolated media from CORM or vehicle or full media treated MDA-MB-231 cells was 
used to supplement ECs and check for angiogenic capability. As shown in Figure 3.23 
A, all CORMs managed to reduce the formation of tubes by ECs to some extent. More 
specifically, conditioned media from CORM-2 treated MDA-MB-231 cells for 6h, 12h 
or 24h, stimulated fewer and longer tubes compared to conditioned media from 
vehicle and media treated cells. These differences reached statistical significance with 
p-values of 0.00486, 0.0313 and 0.0279 for 6h, 12h and 24h, respectively (Figure 3.23 
B).  
Conditioned media from 12h CORM-3 treated cancer cells reduced the formation of 
tube-like structures by 30%, whereas the conditioned media from 24h treatment 
reduced it by only 20%, although reaching higher significance (p=0.0169 and  
p=0.0006, respectively).  
Finally, conditioned media from CORM-1 and CORM-A1 treatments did not induce 
statistically different tube formation capability, with only the media from 24h 
treatment with CORM-A1 causing a reduced response with p=0.0158.  
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Tube formation after treatment with CORMs 
To investigate if the observed reduction was due to lower concentrations of VEGF 
contained in the conditioned media from CORM treated cancer cells or due to the 
compounds themselves, a separate tube formation experiment was conducted, 
where ECs were directly treated with the CORMs (100µM) or vehicle or serum free 
media and their tube formation capability was assessed by quantifying total tube 
length in images taken 6h after treatments. 
As shown in Figure 3.23 C, treatments did not affect the tubes as much as previously 
observed, and only CORM-2 had a vastly different result compared to the former one, 
which reached high statistical significance (p=0.0026) (Figure 3.23 D).  
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Figure 3.23: Tube formation ability of HECV after conditioned media or CORM treatments.  
A. Representative images from tube formation assay with HECV cells treated with conditioned 
media from variable duration incubation of MDA-MB-231 cells with 100µM CORMs or 1% DMSO 
or normal media. Objective 5x. B. Tube formation capacity of HECV cells after treatment with 
conditioned media from variable duration incubation of MDA-MB-231 cells with 100µM CORMs or 
1% DMSO or normal media. (% total tube perimeter compared to vehicle +SEM; n=3, N=3) (All data 
was statistically analysed against the conditioned media from corresponding duration vehicle 
treated MDA-MB-231 cells using un-paired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** 
p<0.001). C. Representative images from tube formation assay with HECV cells treated with 100µM 
CORMs or 1% DMSO or serum free media. Objective 5x. D. Tube formation capacity of HECV cells 
after treatment with 100µM CORMs or 1% DMSO or serum free media. (% total tube perimeter 
compared to vehicle +SEM; n=3, N=2) (All data was statistically analysed against vehicle treated 
cells using un-paired t-test with Welch’s correction: * p<0.05, ** p<0.01).  
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3.5.4 Discussion 
Pathological angiogenesis has been found to support tumour growth, progression and 
metastasis via the supplementation of oxygen and nutrients to the rapidly diving 
cancer cells. The formation of the primary tumour itself has been linked to the 
potential of cancer cells to induce angiogenesis, and from a pathophysiological point 
of view, in the absence of malignant neovascularization, tumour size cannot exceed 
certain limits or undergo metastasis. Malignant angiogenesis has been deemed an 
appropriate target and there are several benefits attributed to anti-angiogenic 
therapies, which are well-established for different tumour subtypes (Bishayee and 
Darvesh 2012; Gacche and Meshram 2014).  
The formation of capillary-like structures by ECs has been used as a clinically relevant 
and solid indication of the potential of different factors to affect angiogenesis. ECs 
rapidly form tube structures when plated on top of a basement membrane 
extracellular matrix. In this experiment, Matrigel was used, which stimulated the 
attachment, migration and differentiation of ECs into capillary-like structures, 
resembling the in vivo environment (Menyhárt et al. 2016).  
As presented in the relevant figures, commercially available CORMs seemed to induce 
a mild reduction in the levels of VEGF expressed by TNBC cells. Following this, it was 
speculated that these decreased levels of growth factor would have a subsequent 
decreasing effect on the ability of ECs to form tubes. Therefore, conditioned media 
from CORM treated TNBC cells was used to stimulate angiogenesis on ECs and was 
compared to vehicle and normal media treatments. The media from all CORMs 
stimulated angiogenesis in a lower level compared to vehicle or media treated cells, 
suggesting a potential inhibition of the capability of ECs to form tubes.  
CORM-2 had the most profound effect, since conditioned media from 6h CORM-2 
treated TNBC cells lowered the length and complexity of the formed tubes by more 
than 30% compared to the vehicle. This did not mirror the results from the relevant 
VEGF expression experiment though, where CORM-2 seemed to lower the expression 
of VEGF in a time-dependent manner in treated MDA-MB-231 cells and the reduction 
reached 65%. However, this opposite trend might have just been coincidental, due to 
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the small differences between the levels of expressed VEGF at the different times 
checked.  
The second best CORM was CORM-3, which reduced the formation of tubes by 25- 
30%, depending on the duration of cancer cell treatment. The best result was 
obtained with the 12h conditioned media, once again opposing the VEGF expression 
pattern, although the differences in the expressed VEGF were similarly small between 
each time point (all around 50% reduction). In any case, 12h and 24h CORM-3 
conditioned media managed to significantly reduce the tube formation activity of ECs.  
CORM-1 and CORM-A1 failed to reduce tube formation in a statistically significant 
manner, reflecting the VEGF expression results, where they had only a moderate 
effect in reducing the expression of the growth factor compared to CORM-2 and 
CORM-3 (around 35%). However, a trend of decreased tube formation was also 
evident for these compounds.  
One limitation of this experiment that might explain the smaller reduction in tube 
formation compared to the significant reduction in VEGF expression was the use of 
normal media for the seeding of ECs on top of the Matrigel. The Matrigel used had a 
normal concentration of growth factors, which in combination with the normal media 
(10% FBS) used for the seeding, could have stimulated the tube formation process 
prior to the replacement with serum free media and the addition of treatments. Thus, 
any differences in the concentration of VEGF in the conditioned media could have 
been obscured. Moreover, the conditioned media was diluted almost 1:3 in each well, 
making the differences in VEGF concentration even more subtle. In any case, the same 
trend was observed, that is conditioned media from CORM treated TNBC cells 
stimulated a reduced angiogenic behaviour in ECs compared to conditioned media 
from vehicle and normal media treated TNBC cells. 
When the same experiment was repeated with instant CORM treatments instead of 
conditioned media, the results were almost expected. CORMs -1, -3 and -A1 did not 
reduce tube formation in a significant manner, suggesting a minimal interference with 
the ECs themselves. However, CORM-2 treatment surprisingly reduced tube 
formation by 100% and no tubes were formed at any time point. On the contrary, the 
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cells remained stable and were unable to migrate and create capillary-like formations. 
The same phenomenon was observed in all the repetitions of the experiment and for 
all replicates of the treatment. This was a solid indication of the interference of CORM-
2 with the ECs themselves that correlated well with the inhibition in migration 
previously shown for this compound. This result suggested a strong anti-angiogenic 
behaviour of CORM-2 when in direct contact with ECs and should not be linked to the 
moderate toxicity of this compound towards HECV cells, since the corresponding IC50 
was more than 100µM and the duration of the tube formation assay was by far shorter 
than that of the cytotoxicity assays reported.  
Another interesting protocol that could have been tested if more time was available 
would include the treatment of ECs with both CORMs and a high concentration of 
VEGF in order to identify any inhibition offered by the CORMs. However, as the main 
observation of the previous experiments was the downregulation of VEGF expression 
from TNBC cells, the protocol of using conditioned media from CORM-treated TNBC 
cells to stimulate tube formation in ECs was found more relevant and closer to the in 
vivo situation and was therefore explored. Nevertheless, this poses a limitation in the 
interpretation of the results, as a more wholistic view would have been available if 
that protocol would have also been included in this study.    
In summary, conditioned media from CORM treated TNBC cells induced lower tube 
formation activity in Matrigel coated ECs, that reached significance for CORM-2 and 
CORM-3. The tubes formed were less and more elongated compared to the complex, 
highly organised tubes in the vehicle and media groups. However, when direct 
treatments of CORMs were administered on ECs, no significant inhibition was 
observed, apart from CORM-2, which managed to eliminate all tube-like structures 
and prevented ECs from creating a network of tubes completely.  
3.6 Lead compound for structural modification and further studies 
The first milestone of this study was to screen the commercially available CORMs for 
effects against various cell functions and any effects related to an anti-angiogenic 
potential they might have against TNBC. With this in mind, several experiments were 
conducted trying to relate these complexes to anti-angiogenic activities, such as 
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effects on the stimulant activity of TNBC cells per se or on the signalling and migratory 
activity of ECs that are responsible for the angiogenic process.  
According to these experiments, many conclusions were drawn. First of all, none of 
the CORMs showed major cytotoxicity against TNBC, endothelial or epithelial cells. 
However, CORM-2 was significantly more toxic than the others and highly toxic 
towards non-tumorigenic breast epithelial cells. CORMs -1 and -3 on the other hand, 
had a more favourable profile, showing higher toxicity against TNBC than other cells, 
especially CORM-3. Moreover, CORMs -2 and -3 appeared to be cytostatic against 
MDA-MB-231 cells, whereas CORM-2 also inhibited the growth of MDA-MB-436 and 
MCF-10A cells, as expected by its inherent toxicity towards epithelial cells.  
Cancer cells are known to use glycolysis over oxidative phosphorylation in order to 
meet their high demands in energy production, a phenomenon called the "Warburg 
effect". When the glycolytic activity of cancer cells was assessed, instant treatments 
were more effective in lowering the metabolism of MDA-MB-231. However, due to 
the experimental procedure itself, it might be possible that during the almost 20min 
period between preparing the treatments and the treatments actually reaching the 
cells, most of the CO would have been released, therefore instantaneous effects could 
not be detected following this protocol. Anyway, CORM-2 had the most profound 
reducing impact on the glycolysis of MDA-MB-231, whereas CORMs -1 and -3 also 
showed some inhibition at certain concentrations.  
The main stimulatory activity on angiogenesis exhibited by cancer cells is the 
production of elevated levels of VEGF, which subsequently activate corresponding 
pathways in ECs initiating angiogenic behaviour. It was shown that upon treatment 
with all CORMs, but especially CORMs -2 and -3, this expression was reduced at 
significant levels. MDA-MB-231 cells were affected more than MDA-MB-436, but the 
same trend was observed in both cell lines.  
The cytoprotective enzyme HO-1 is responsible for the endogenous production of CO. 
However, it is also responsible for the protection of cells against oxidative damage 
and ROS. It was found that upon 12h treatment with CORMs -1, -2 and -3, the 
expression of this enzyme was reduced, even though treatment with CORM-3 did not 
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show statistical significance. Therefore, cancer cells might be more vulnerable 
towards oxidative stress and increased ROS production. 
Upon receiving VEGF from cancer cells, ECs execute several processes leading to 
vessel formation, which depend on the successful signal transduction from the surface 
receptor VEGFR2 to other downstream proteins. It was shown that CORM-2 inhibited 
both VEGFR2 activation and the activation of other downstream proteins such as 
ERK1/2 and FAK, whereas CORM-3 was more successful towards ERK1/2 protein. 
The ability of ECs to migrate is tightly correlated with their capability to form new 
vessels.  CORMs -1, -2 and -3 were shown to inhibit the migration of ECs, preventing 
the closure of the induced wound on the cell monolayer.  
Finally, the tube formation ability of non-primary ECs was reported to be reduced 
after treatment with conditioned media from CORM-treated cancer cells. CORMs -2 
and -3 had the most profound effect, followed by CORM-1 with good but not 
significant activity. CORM-2 on the other hand, was the only one to affect ECs directly, 
totally inhibiting their tube formation activity upon direct treatment.  
Based on these observations, and taking into consideration previous literature, 
CORM-3 was chosen as the basis for the design of novel analogues based on its 
monomeric Ru core. This decision was a conflation of data and inherent limitations of 
the study. In general, a molecule that provided good results in the previous screening, 
is water soluble and contains modification handles with a variety of possible ligands 
to be explored would be desired as the parent structure. An ideal lead CORM should 
present several useful effects in the conducted screening: it should be selectively toxic 
against TNBC cells with very limited toxicity against normal breast epithelial cells, it 
should affect the glycolytic metabolism of these cells reducing their energy 
production, it should decrease VEGF expression by TNBC cells limiting the pro-
angiogenic signals, it should downregulate HO-1 expression in order to limit the 
protection offered by this enzyme, it should inhibit the phosphorylation of VEGFR2 
and downstream proteins reducing the pro-angiogenic signal transduction and it 
should halt EC migration and tube formation capability.     
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The first choice would have been to proceed with CORM-2 which presented a variety 
of favourable results and proved to be effective in nearly all the tested activities. 
However, CORM-2 is a dimer with limited handles for structural modification, as the 
only ligands that could be replaced are the chloride atoms pointing away from the 
metal centres, in order not to affect the dimeric structure. Since a strong inorganic 
chemical background would be necessary for the design of such modifications, this 
was not possible in the timeframe of this study. Apart from that, the dimeric structure 
itself complicates the synthetic procedure because most reactions would result in the 
destruction of the dimer and the formation of a monomer. Another important 
drawback is CORM-2’s insolubility in water, which would probably lead to water 
insoluble derivatives that need DMSO as a solvent for their administration. Finally, its 
inherent toxicity against normal breast tissue as proved in the cytotoxicity assessment 
against MCF-10A cells, is yet another limiting factor pointing towards its inappropriacy 
as a lead structure for further modifications.  
As discussed previously, CORM-1 was the first photo-CORM to be characterised, but 
was soon abandoned due to insolubility in water and uncontrolled photo-activatable 
release of CO. Many groups over the recent years started to explore the family of 
photo-CORMs and have produced notable new molecules. Nevertheless, the design 
of structural modifications on a photo-CORM again requires a strong background in 
inorganic chemistry and specific equipment would be necessary for further 
experiments, in order to validate the wavelength for the initiation of CO release and 
to use this wavelength to stimulate the release upon cell treatment, therefore CORM-
1 could not be further pursued due to several limitations.  
As a consequence, CORM-3 was chosen for structural modifications, because it 
presents several desired characteristics. First of all, it is water soluble, a feature that 
would be highly appreciated in the new analogues. Second, it has shown many 
positive results, such as selective toxicity against TNBC cells, potential reduction in 
glycolytic metabolism of cancer cells, decrease in VEGF expression from MDA-MB-231 
cells, a trend of downregulation on HO-1 expression, inhibition of activation of ERK1/2 
upon VEGF stimulation, EC migration inhibition and finally EC tube formation ability 
reduction. Furthermore, CORM-3 has been proven safe for in vivo applications, not 
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leading to substantial increase in carboxyhaemoglobin (HbCO) levels upon 
intravenous injections in mice (Davidge et al. 2009). Finally, it has a well-characterized 
but yet complicated aqueous chemistry, interacting extensively with blood proteins 
and forming Ru-adducts that have not been proven toxic per se (Johnson et al. 2007; 
Santos-Silva et al. 2011; Chaves-Ferreira et al. 2015).  
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Main findings and impact: 
• Commercially available CORMs are moderately cytotoxic against TNBC cells with 
potential to be cytostatic – these cells never explored before with first and second 
generation CORMs. 
• Glycolytic capacity of MDA-MB-231 is affected by all CORMs in a low level – 
CORMs known to affect metabolism but no literature on glycolysis for TNBC. 
• VEGF expression of TNBC cells is significantly reduced by CORMs, especially 
CORMs -2 and -3 – contradicting results with other publications about 
upregulation of VEGF expression in shorter treatments and other cell lines. 
• HO-1 expression is reduced after CORMs -1, -2 and -3 treatments – difference 
with other cells in literature, where upregulation of HO-1 evident. 
• Reduction of pY1175 of VEGFR2 upon CORMs -2 and -3 treatments in 
unstimulated ECs, other downstream proteins also affected by all CORMs – no 
previous literature in unstimulated HECV. 
• Reduction of pY1175 of VEGFR2 upon CORM-2 treatment in VEGF stimulated 
HUVEC, similar reduction for pERK1/2, pSrc, pAKT, pFAK – agreement with 
previous literature.  
• Reduction of ERK1/2 and AKT activation upon treatment with CORM-3 in VEGF 
stimulated HUVEC – different mechanism of action with CORM-2, no similar 
comparison in previous literature. 
• EC migration inhibited by CORMs -1, -2 and -3 – existence of previous literature 
for CORM-2, but not for this EC line and not for other CORMs. 
• No significant inhibition in the migration of TNBC cells – no previous literature for 
migration of TNBC cells upon CORM treatments. 
• Conditioned media from CORM -2 and -3 treated TNBC cells stimulated lower 
tubule formation in ECs – studies on a more aggressive EC line than previous 
literature, with high tube formation activity. 
• Total inhibition of tubule formation in ECs by direct treatment with CORM-2 – 
confirmation of previous literature but with different more aggressive cell line. 
• Only CORM-2 had minor antibacterial activity – contradicting results with 
previous literature about effectiveness of CORM-2 and CORM-3 but in higher 
concentrations than tested here.   
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Chapter IV 
 
Design & Synthesis of  
new compounds 
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4.1 Design of new analogues 
Based on the previous experiments described in Chapter 3, one of the four 
commercially available CORMs was selected as the parent compound for the design 
and synthesis of a small series of new analogues. CORM-3 was chosen as the lead 
structure, hence the design should be based on which Ru ligands could be replaced 
and which potential new ligands with desired characteristics could take their place. 
Since metal carbonyls are defined as organometallic complexes containing one or 
more CO ligands (Gasser et al. 2011), the three CO ligands could not be replaced with 
other groups. The same stands for the Ru core, since the attributed effects observed 
previously for both CORM-2 and CORM-3 may very well be a direct consequence of 
not only the CO released, but also the metal core per se. Therefore, the only ligands 
possible to be replaced were the chloride atom (Cl) and the amino acid moiety. 
 
Figure 4.1: Synthetic scheme of CORM-3. Adapted from (Clark et al. 2003). 
The synthetic scheme reported for CORM-3 and subsequently used by all relevant 
publications describes the synthetic reaction starting from commercially available 
CORM-2 (Clark et al. 2003). CORM-2 is a binuclear metal carbonyl that upon reaction 
with glycine forms two mononuclear adducts of the Ru core bound to the amino acid 
through the amine and the carboxylic groups. The two Cl ligands of each Ru are 
substituted by the groups of the amino acid and the last Cl remains on the molecule 
(Figure 4.1).  Therefore, the most labile part of the molecule is the amino acid moiety, 
which can be replaced by a variety of other ligands.  
In general, amino acids are favourable ligands, because they can form complexes with 
many transition metals and may enhance the water solubility of the resulting metal 
complexes (Mohr et al. 2012). Apart from that, amino acids are well-characterized and 
can be obtained in high chemical purity, thus make ideal starting materials. As a result, 
the first idea was to replace the glycine moiety of CORM-3 with other amino acids, 
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most of them more lipophilic than glycine, and explore differences in activity rising 
from their different distribution in water. 
The distribution coefficient of a molecule (logP) can affect its ability to reach its target, 
the efficiency upon interaction with the intended target, as well as the half-life inside 
the body. Therefore, logP (or ClogP) is a critical feature determining the likelihood of 
a molecule to become a drug candidate (Leeson and Springthorpe 2007). ClogP 
influences the pharmacokinetics of a drug, in terms of its ADMET properties and its 
pharmacodynamics, in terms of the ability to reach and bind to the target receptor. It 
is also important in order to determine the potential toxicity of a compound, because 
more hydrophobic molecules tend to be retained longer, have a wider and less 
controlled distribution, bind extensively to blood proteins and get broadly 
metabolized (Pliška et al. 2008). 
The topological polar surface area (tPSA) of a molecule is defined as the sum of all its 
polar atoms’ surface, mainly oxygen and nitrogen, including their attached hydrogens. 
This feature is commonly used in medicinal chemistry to indicate the potential cell 
membrane permeability of a drug and has partially replaced the "molecular mass less 
than 500 Daltons" rule of Lipinski's rule of five (Veber et al. 2002).  
Eight different amino acids were chosen from the 20 natural standard amino acids, 
and the relevant derivatives were synthesized (amino acids and properties shown in 
Table 4.1). The first of them was glycine, as in CORM-3, in order to standardize the 
method and determine any differences between the commercially available and the 
laboratory synthesized one.  
Ligand CLogP tPSA 
Glycine -3.21 63.32 
Alanine -3.124 63.32 
Serine -2.811 83.55 
Phenylalanine -1.556 63.32 
Tyrosine -2.223 83.55 
Histidine -3.727 87.71 
Tryptophan -1.566 75.35 
Aspartic acid -2.412 100.62 
Table 4.1: Common amino acids as ligands of the new CORMs and their chemical properties 
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The next approach was based on the substitution of glycine with uncommon amino 
acids, two α,α-dialkylated ones and five derivatives of tyrosine, phenylalanine and 
serine. The α,α-dialkylated amino acids introduce conformational constraints to the 
whole complex, due to the alicyclic ring and the quaternary α-carbon atom, thereby 
they might stabilize a pre-set conformation. In the case of 1-aminocyclopentane-
carboxylic acid (ACPC) and 1-aminocyclohexane-carboxylic acid (ACHC) that will be 
used in this study, it has been shown that a folded conformation was preferred, that 
might help in creating a packed complex structure (Staykova et al. 2015). This way, 
both complexes will exhibit higher lipophilicity (ClogP) but similar polar surface (tPSA) 
with CORM-3. These two uncommon amino acids have been used extensively in 
research, since the strain of their rings may change the ability of the final molecule to 
adapt to the targeted position and the more atoms are included in the ring, the less 
constrained the molecule becomes (Rodríguez-Ropero et al. 2008).  
More specifically, ACPC has been studied from very early on as an unnatural and 
antitumor amino acid. It was proven to be toxic to rats at certain small concentrations 
and was widely distributed in the tissues where it remained in the cellular fluid, 
without being incorporated into the proteins. ACPC was also shown to have a selective 
uptake by tumour tissue and react with amino acid transport systems A and L. Several 
derivatives aimed to inhibit tumour growth have been prepared from then on, based 
on the observation that ACPC inhibited a variety of carcinomas, such as Walker 
carcinoma 256 and adenocarcinoma 755 (Connors et al. 1960; Connors and Ross 1960; 
Berlinguet et al. 1962a; Berlinguet et al. 1962b; Hayes et al. 1976).  
ACHC, similarly to ACPC, drew scientific attention due to its conformational restriction 
and its lipophilicity. Conformationally restricted ligands can fix the functional groups 
in an active conformation, therefore could be more efficient ligands for various 
targets. Apart from this, ACHC is also symmetric and achiral, so there is no formation 
of optically active compounds that need extra separation and purification. Finally, the 
cyclohexane ring imparts lipophilicity to the final molecule, potentially adding to its 
efficacy. As a consequence, there are many pharmacologically relevant derivatives of 
ACHC already known and some of them have also been approved by the FDA 
(Cyclacillin, Spiromustine, Balicatib) (Mykhailiuk et al. 2013).  
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The other ligands chosen were simple phenylalanine, tyrosine and serine derivatives. 
The nitro group seemed particularly interesting as a substituent of the aromatic ring 
of both phenylalanine and tyrosine, due to its innate toxicity linked also to ROS 
production. 4-Nitro-phenylalanine has previously been shown to inhibit amino acid 
activation and the transfer of phenylalanine into the microsomes during protein 
synthesis. The same was also observed for 3-nitro-tyrosine, and the nitro group was 
held responsible for these effects. Both compounds had moderate toxicity against HT-
29 colorectal adenocarcinoma cells, but specifically for the 3-nitro-tyrosine, 
promotion of DNA degradation was observed, indicating important toxicological 
implications (Tamemasa et al. 1968; Prütz 1986; Zhao et al. 2015).  
Therefore, some nitro ligands were chosen, including 4-nitro-phenylalanine, 3-nitro-
tyrosine and 3,5-dinitro-tyrosine, in order to correlate any observed activities with the 
number of nitro groups on the molecule and the existence or not of the hydroxyl 
group. Finally, the 4-amino-derivative of phenylalanine was chosen, to compare with 
the corresponding nitro-derivate and the O-benzyl-serine, for comparison reasons 
with the simple serine analogue, as a more hydrophobic molecule.   
The final designing strategy tried to exploit differences between cancer and healthy 
cells, in order to attribute some kind of specificity to the new molecules. As described 
previously, the four commercially available CORMs do not show any specificity 
towards certain tissues or cell subtypes, and as a consequence CO toxicity might affect 
healthy cells along with disease ones. Even though CORM-3 has successfully been 
administered to animals without elevating the concentration of carboxyhaemoglobin 
to toxic levels (Clark et al. 2003; Vadori et al. 2009), benefiting from the distinct 
characteristics of healthy and cancer cells is highly favourable in order to keep the 
general toxicity of a CORM health issues to a minimum.    
Most cancer cells generally exhibit higher levels of ROS compared to healthy cells, 
which may promote tumour development and progression. In rapidly proliferating 
cells, the existence of oncogenic mutations promotes unusual metabolism and 
protein translation, resulting in elevated ROS production (Liou and Storz 2010; Gorrini 
et al. 2013; Li et al. 2013; Pinto et al. 2017). Usually, tumour cells also express higher 
levels of antioxidant defence mechanisms, however there is a relatively fragile 
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balance of intracellular ROS status. In general, oxidative stress-mediated signalling has 
been shown to affect cancer cell behaviour in processes like cell cycle progression, 
proliferation, survival, apoptosis, energy metabolism, adhesion, motility and 
angiogenesis (Liou and Storz 2010; Gorrini et al. 2013; Kruk and Aboul-Enein 2017). 
The threshold at which ROS can become toxic is not clear, but disproportional increase 
in ROS production could induce cell cycle arrest or even apoptosis (Liou and Storz 
2010; Gorrini et al. 2013; Potente and Carmeliet 2017). The strategy to induce 
irreparable damages subsequently leading to apoptosis has been exploited by many 
modern chemotherapeutic agents. The apoptosis could be initiated by random 
damaging functions of ROS or by specific stimulation of death signalling pathways. The 
main advantage of this strategy is that cancer cells are already compromised by the 
higher inner ROS levels compared to normal cells, thus are more prone to oxidative 
stress than healthy cells. This characteristic offers a therapeutic window that could be 
explored by agents that further induce ROS production (Liou and Storz 2010; Gorrini 
et al. 2013).  
Based on very early studies, CORMs were shown to possess antimicrobial activities 
based on their capability to inhibit respiratory oxidases and increase ROS production 
beyond manageable levels (Nobre et al. 2007). This hypothesis has not been 
abandoned over the more recent years, and most of the publications still agree on 
this mechanism of action involving ROS overproduction (Ward et al. 2017). In fact, 
eukaryotic cells have also been shown to respond to CORM treatments by increasing 
the levels of produced ROS, for example polymorphonuclear leukocytes augmented 
their LPS-induced ROS production upon treatment with CORM-3 (Mizuguchi et al. 
2009). Taillé et al. (Taillé et al. 2005) suggested a potential target signalling pathway 
for CO involving NAD(P)H oxidase inhibition, leading to ERK1/2 downregulation, 
reduced cyclin D expression and therefore elevated mitochondrial ROS formation. 
Cancer cells are extensively exposed to oxidative stress as a consequence of their 
change in cellular redox balance. Thus, treatment of cancer cells with CORMs might 
lead to increased mitochondrial ROS formation that could stimulate apoptotic 
pathways and eventually lead to cancer cell death, due to the tip of the redox balance 
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towards an oxidative status (Chin et al. 2007; Piantadosi 2008; Üstün et al. 2016; Pinto 
et al. 2017).  
CORMs sensitive to a redox environment have been explored before (Seixas et al. 
2015; Aucott et al. 2017). In the work from Aucott et al. (Aucott et al. 2017), three 
CORMs were synthesized and fully characterized, based on the parent structure of 
Mn(CO)4(2-phenylpyridine) photo-CORM with a ferrocenyl substitution. These 
compounds are yet to be tested in vitro, however the redox approach seems more 
appealing in recent years.   
This study used the research done by the group of Simić et al. (Simić et al. 2007) to 
decide on the antioxidant and pro-oxidant activity of some natural phenolics, where 
molecules with first oxidation potential (Epa) value greater than 0.45 were deemed 
pro-oxidants and less than 0.45 antioxidants (Table 4.2).  
Phenolics Epa (V) 
Lipid peroxidation 
(percent inhibition) 
Salicylic acid 0.94 -12.1 ± 1.8 
m-Hydroxy-benzoic acid 0.83 -10. 1± 3.0 
p-Hydroxy-benzoic acid 0.87 -11.4 ± 2.0 
Protocatechuic acid 0.41 +15.5 ± 0.3 
Vanillic acid 0.73 -12.5 ± 1.1 
Syringic acid 0.49 -5.4 ± 1.1 
o-Coumaric acid 0.75 -13.0 ± 1.0 
m-Coumaric acid 0.78 -10.6 ± 1.1 
p-Coumaric acid 0.67 -23.3 ± 3.1 
Caffeic acid 0.45 +11.2 ± 2.2 
Quercetin 0.10 +67.8 ± 2.0 
Rutin 0.23 +10.0 ± 3.6 
Table 4.2: Epa values and antioxidant activity of phenolics. Source: (Simić et al. 2007). 
Based on these observations, the p-hydroxy-benzoic acid was chosen to be used and 
ligated to tyrosine or serine, in order to create a hybrid molecule with the Ru core of 
CORM-3, a different amino acid moiety than glycine and an extra pro-oxidant moiety 
that might help in elevating the production of ROS, thus changing the redox status of 
cells potentially leading to greater toxicity for the whole complex against cancer cells. 
As shown in Table 4.2, p-hydroxy-benzoic acid is the second most pro-oxidant phenol, 
with a high Epa value and a stimulatory activity over lipid peroxidation. o-Hydroxy-
benzoic acid is the most efficient one, but potential cyclization reactions made it more 
inappropriate than the p-derivative, therefore it was not chosen.  
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In summary, the uncommon amino acids chosen to replace glycine are depicted in 
Table 4.3, along with the two hybrid molecules aimed to act more pro-oxidatively than 
the others. One of the last two ligands (serine analogue) has an acetyl protection on 
its phenolic hydroxyl group, in order to delay the metabolism of the final complex and 
to moderate the very high polarity imparted by a free hydroxyl group. The tyrosine 
analogue did not need extra protection, as it is less polar.  
Ligand CLogP tPSA 
1-Aminocyclopentane-carboxylic acid -2.254 63.32 
1-Aminocyclohexane-carboxylic acid -1.695 63.32 
3-Nitro-Tyrosine -1.844 135.36 
3,5-Dinitro-Tyrosine -1.878 187.17 
4-Nitro-Phenylalanine -1.813 115.13 
4-Amino-Phenylalanine -2.887 87.12 
O-Benzyl-Serine -0.819 72.55 
O-(4-Acetoxybenzoyl)-Serine -1.173 115.92 
O-(4-Hydroxybenzoyl)-Tyrosine -0.204 109.85 
Table 4.3: Uncommon amino acids as ligands of the new CORMs and their chemical properties 
For the last two analogues, the ligand had to be prepared separately before the final 
conjugation with CORM-2, because the amino acid derivative was not commercially 
available. Therefore, these ligands had to be prepared by the closest possible 
analogue using known reactions. For the serine analogue, the N-benzyloxycarbonyl-L-
serine benzyl ester was used and conjugated with 4-acetoxybenzoic acid, whereas 
there was an attempt to synthesize the free hydroxyl molecule, using 4-
hydroxybenzoic acid. The conjugated compound was subjected to hydrogenolysis to 
remove the benzyloxy protecting group. Finally, for the synthesis of the tyrosine 
analogue, the N-Boc-L-Tyrosine methylester was used, which after the conjugation 
with 4-acetoxybenzoic acid, had to be deprotected in several steps, due to the 
different protecting groups of the starting molecule.  
4.2 Synthesis and Characterization 
Procedures and spectral data 
Described below are the standard procedures followed in the synthesis of new CORM 
analogues and the spectral data for each new compound. CORM-2 was purchased 
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from Sigma-Aldrich and the different amino acids from Alfa Aesar, unless otherwise 
stated.  
Standard procedure for CORM synthesis 
The new analogues were synthesized starting from the commercially available 
tricarbonyl dichloro ruthenium(II) dimer (CORM-2) [Ru(CO)3Cl2]2. In general, CORM-2 
(1.0mol equivalent) was dissolved in dry methanol (MeOH) in a round-bottomed flask 
at room temperature (r.t.) under nitrogen (N2) atmosphere. The appropriate amino 
acid (2.0mol equivalent) and sodium methoxide (2.0mol equivalent) (MeONa) were 
suspended in dry MeOH in a separate conical flask and left to stir for a few minutes at 
r.t. The suspension was then added to the CORM-2 solution under N2 atmosphere 
maintained by a Schlenk line, and the reaction was allowed to stir for 24h at r.t. with 
a N2 balloon and protected from light. The solvent was removed in vacuo and the 
yellow residue re-dissolved in dry tetrahydrofuran (THF); this was precipitated with 
excess diethyl ether (Et2O) or light petroleum ether (PE) 40 – 60. The new CORMs were 
stored in closed vials at -20°C and used fresh on the day of the experiments (Clark et 
al. 2003). 
In some cases, all the powders (CORM-2, amino acid and MeONa) were transferred 
into a round-bottomed flask, which was continuously kept under N2 and dry MeOH 
was added last. The reaction was allowed to stir for 24h at r.t. with a N2 balloon and 
protected from light. The solvent was removed in vacuo and the yellow residue re-
dissolved in dry THF; this was triturated with excess Et2O or light PE 40 – 60 and the 
precipitated solid was dried under vacuum or N2 after removal of the supernatant 
liquid.  
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Figure 4.2: Schlenk line apparatus 
 
 
 
 
Figure 4.3: Synthetic scheme for CORM-3 analogues 
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Tricarbonyl chloro (glycinato) ruthenium(II) (CORM-3) 
 
MF: C5H4ClNO5Ru 
MW: 294.61 
Tricarbonyl chloro (glycinato) ruthenium(II) ([Ru(CO)3Cl(glycinate)] or CORM-3) was 
synthesized in order to test the synthetic protocol (Clark et al. 2003), starting from the 
commercially available CORM-2 (Sigma Aldrich). Briefly, CORM-2 (1mol eq, 100mg, 
0.195mmol), glycine (2.05mol eq, 30mg, 0.4mmol) and sodium methoxide (MeONa) 
(2.1mol eq, 22.16mg, 0.41mmol) were dissolved in dry MeOH (7mL) in a round-
bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk line. The reaction 
was allowed to stir for 24h at r.t. with a N2 balloon and protected from light. The 
solvent was then removed in vacuo and the yellow residue re-dissolved in dry THF 
(1mL); this was filtered through a syringe filter (Nylon) and excess light PE added until 
precipitation started. The supernatant yellow liquid was continuously transferred to 
another flask using a glass pipette and the remaining powder was dried under N2 or 
under the vacuum pump. In the transferred liquid, more PE was added, until no solid 
could be further isolated. The different fractions of the solid were mixed together to 
yield the final CORM-3 (45mg, 39% yield). CORM-3 was stored in closed vials at -20°C, 
but the commercially available one was selected for use in further experiments.  
For characterization purposes, 1H and 13C NMR and MS spectra were obtained and 
compared to the commercially available one’s (reference): 
1H NMR (500MHz, DMSO-d6)  ppm 3.64 – 3.60 (m, 2H, CH2) Reference: 3.64 – 3.60 
(m, 2H, CH2)  
1H NMR (500MHz, THF-d8)  ppm 5.81 (s broad, 1H, NH) 5.14 (s broad, 1H, NH) 4.70 
– 4.59 (m, 1H, CH) 3.90 – 3.88 (m, 1H, CH) Reference: 5.77 – 5.54 (m, 2H, NH2) 4.00 – 
3.93 (m, 2H, CH2)   
13C NMR (125MHz, THF-d8)  ppm 44.66 (CH2) 184.27 (C=O) Reference: 42.89 (CH2)  
MS (ESI) ES+ m/z 317.25 [M+Na+] 289.17 [M-CO+Na+] 259.93 [M-Cl-+H+] 239.18  
[M-2CO+H+] Reference: 317.25 [M+Na+] 289.17 [M-CO+Na+] 259.93 [M-Cl-+H+] 
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
179 
 
239.17 [M-2CO+H+] Expected: 317.59, 289.59, 260.16, 239.59  
ES- m/z 293.88 [M-H+] 265.16 [M-CO-H+] 237.89 [M-2CO-H+] Reference: 293.88  
[M-H+] 265.16 [M-CO-H+] 237.89 [M-2CO-H+] Expected: 293.60, 265.59, 237.58  
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Tricarbonyl chloro (alaninato) ruthenium(II) (CORM-Ala) 
 
MF: C6H6ClNO5Ru 
MW: 308.64 
Tricarbonyl chloro (alaninato) ruthenium(II) ([Ru(CO)3Cl(alaninate)] or CORM-Ala) was 
synthesized starting from the commercially available CORM-2. Briefly, CORM-2 (1mol 
eq, 85mg, 0.166mmol), alanine (2mol eq, 29.58mg, 0.332mmol) and MeONa (2.1mol 
eq, 22.16mg, 0.41mmol) were dissolved in dry MeOH (7mL) in a round-bottomed flask 
at r.t. under N2 atmosphere maintained by a Schlenk line. The reaction was allowed 
to stir for 24h at r.t. with a N2 balloon and protected from light. The solvent was then 
removed in vacuo and the yellow residue re-dissolved in dry THF (2mL) where solid 
started precipitating. The precipitation was enhanced with excess Et2O. The 
supernatant liquid was transferred to another flask using a glass pipette and the 
remaining powder was dried under N2. The remaining crude was dried and upon 
addition of excess Et2O and light PE more solid could be isolated. The different 
fractions of the solid were mixed together to yield the final CORM-Ala (95mg, 90% 
yield). CORM-Ala was stored in closed vials at -20°C and used freshly on the day of the 
experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.4 (broad s, 2H, NH2) 3.77 – 3.72 (q, J= 7Hz, 1H, 
CH) 1.38 – 1.36 (d, J= 7Hz, 3H, CH3)  
1H NMR (500MHz, THF-d8)  ppm 3.62 – 3.59 (m, 1H, CH) 1.40 – 1.15 (m, 3H, CH3)  
13C NMR (125MHz, DMSO-d6)  ppm 199.21, 197.74, 191.01 (3 CO), 181.24 (C=O), 
50.95 (CH), 20.89 (CH3) 
MS (ESI) ES+ m/z 331.992 [M+Na+] 303.999 [M-CO+Na+] 268.018 [M-CO-HCl+Na+] 
Expected: 331.891, 303.893, 267.916 (Accurate MS) 
ES- m/z 307.90 [M-H+] 279.91 [M-CO-H+] 251.91 [M-2CO-H+] Expected: 307.63, 
279.62, 251.61  
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Tricarbonyl chloro (serinato) ruthenium(II) (CORM-Ser) 
 
MF: C6H6ClNO6Ru 
MW: 324.64 
Tricarbonyl chloro (serinato) ruthenium(II) ([Ru(CO)3Cl(serinate)] or CORM-Ser) was 
synthesized starting from the commercially available CORM-2. Briefly, CORM-2 (1mol 
eq, 85mg, 0.166mmol), serine (2mol eq, 34.9mg, 0.332mmol) and MeONa (2mol eq, 
17.94mg, 0.332mmol) were dissolved in dry MeOH (7mL) in a round-bottomed flask 
at r.t. under N2 atmosphere maintained by a Schlenk line. The reaction was allowed 
to stir for 24h at r.t. with a N2 balloon and protected from light. The solvent was then 
removed in vacuo and the yellow residue re-dissolved in dry THF (2mL) where solid 
started precipitating. The precipitation was enhanced with light PE. The supernatant 
yellow liquid was transferred to another flask using a glass pipette and the remaining 
powder was washed with light PE twice and dried under the vacuum pump. In the 
supernatant transferred liquid, no solid could be further isolated, even with excess 
Et2O, because it kept forming a sticky and dark residue that could not be worked up 
any further. The solid was the final product CORM-Ser (34mg, 32% yield). CORM-Ser 
was stored in closed vials at -20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.78 – 7.80 (s broad, 2H, NH2) 3.81 – 3.69 (m, 
2H, CH2)  
13C NMR (125MHz, DMSO-d6)  ppm 169.85 (C=O) 60.21 (CH2) 55.32 (CH)  
MS (ESI) ES+ m/z 325.8 [M+H+] 347.8 [M+Na+] 289.8 [M-Cl-+H+] 311.8 [M-Cl-+Na+] 
Expected: 325.6, 347.6, 290.2, 312.17 
ES– m/z 323.8 [M-H+], 295.9 [M-CO-H+]  Expected: 323.6, 295.6  
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Tricarbonyl chloro (phenylalaninato) ruthenium(II) (CORM-Phe) 
 
MF: C12H10ClNO5Ru 
MW: 384.73 
Tricarbonyl chloro (phenylalaninato) ruthenium(II) ([Ru(CO)3Cl(phenylalaninate)] or 
CORM-Phe) was synthesized starting from the commercially available CORM-2. 
Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol) was dissolved in dry MeOH (2mL) in a 
round-bottomed flask at r.t. under N2. Phenylalanine (2mol eq, 54.92mg, 0.332mmol) 
and MeONa (2.1mol eq, 18.8mg, 0.348mmol) were added in dry MeOH (5mL) in a 
separate flask and left to stir for a few minutes at r.t. The suspension was then added 
to the CORM-2 solution and the reaction was allowed to stir for 24h at r.t. connected 
to a Schlenk line for continuous N2 atmosphere and protected from light. The solvent 
was then removed in vacuo and the yellow residue re-dissolved in dry THF (5mL); this 
was filtered through a syringe filter (Nylon) and excess Et2O added. The yellow 
solution was evaporated down to give a pale yellow solid (99mg, 77.5% yield). CORM-
Phe was stored in closed vials at -20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 7.37 – 7.22 (m, 5H, Ar-H) 3.22 – 3.09 (m, 2H, 
CH2) 3.03 – 2.64 (m, 1H, CH) 
13C NMR (125MHz, DMSO-d6)  ppm 135.74 (Ar-C1) 129.95, 129.71, 129.00, 128.80, 
127.57 (Ar-C2,3,4,5,6) 53.93 (CH) 36.35 (CH2) 
MS (ESI) ES+ m/z 408.0 [M+Na+] 386.1 [M+H+] Expected: 407.7, 385.7 
ES– m/z 384.0 [M-H+] Expected: 383.7 
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Tricarbonyl chloro (tyrosinato) ruthenium(II) (CORM-Tyr) 
 
MF: C12H10ClNO6Ru 
MW: 400.73 
Tricarbonyl chloro (tyrosinato) ruthenium(II) ([Ru(CO)3Cl(tyrosinate)] or CORM-Tyr) 
was synthesized starting from the commercially available CORM-2. Briefly, CORM-2 
(1mol eq, 85mg, 0.166mmol), tyrosine (2mol eq, 60.16mg, 0.332mmol) and MeONa 
(2mol eq, 17.94mg, 0.332mmol) were dissolved in dry MeOH (7mL) in a round-
bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk line. The reaction 
was allowed to stir for 24h at r.t. with a N2 balloon and protected from light. The 
solvent was then removed in vacuo and the yellow residue re-dissolved in dry THF 
(2mL) where solid started precipitating. The precipitation was enhanced with excess 
light PE. The yellow suspension was evaporated down to give a yellow solid (132mg, 
99.2% yield). CORM-Tyr was stored in closed vials at -20°C and used freshly on the day 
of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 9.41 (s, 1H, OH), 7.07 – 7.02 (m, 2H, Ar-H2, H6), 
6.73 – 6.65 (m, 2H, Ar-H3, H5), 4.15 – 4.02 (m, 1H, CH), 3.04 – 2.95 (m, 2H, CH2) 
13C NMR (125MHz, DMSO-d6)  ppm 170.91 (C=O ester), 157.08 (Ar-C4), 130.96, 
130.72 (Ar-C2, C6), 125.21 (Ar-C1), 115.84, 115.64 (Ar-C3, C5), 53.98 (CH), 35.5 (CH2) 
MS (ESI) ES+ m/z 402.0 [M+H+] 388.1 [M-Cl-+Na+] 374.1 [M-CO+H+] 366.1 [M-Cl-+H+] 
Expected: 401.7, 388.3, 373.7, 366.3 
ES– m/z 400.0 [M-H+] 372.0 [M-H+-CO] Expected: 399.7, 371.7  
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Tricarbonyl chloro (histidinato) ruthenium(II) (CORM-His) 
 
MF: C9H8ClN3O5Ru 
MW: 374.70 
Tricarbonyl chloro (histidinato) ruthenium(II) ([Ru(CO)3Cl(histidinate)] or CORM-His) 
was synthesized starting from the commercially available CORM-2. Briefly, CORM-2 
(1mol eq, 85.1mg, 0.166mmol) was dissolved in dry MeOH (2mL) in a round-bottomed 
flask at r.t. under N2. Histidine (2mol eq, 51.51mg, 0.332mmol) and MeONa (2.1mol 
eq, 18.8mg, 0.348mmol) were added in dry MeOH (5mL) in a separate flask and left 
to stir for a few minutes at r.t. The suspension was then added to the CORM-2 solution 
and the reaction was allowed to stir for 24h at r.t. connected to a Schlenk line for 
continuous inert atmosphere and protected from light. The solvent was then removed 
in vacuo and the white residue re-dissolved in dry THF (5mL); this was filtered through 
a syringe filter (Nylon) and excess Et2O added. The white suspension was evaporated 
down to give an off-white solid (75mg, 60% yield). CORM-His was stored in closed vials 
at -20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 13.15 – 13.00 (m, 1H, NH), 8.09 – 7.85 (m, 1H, 
Ar- H4), 7.34 – 7.10 (m, 1H, Ar-H2), 3.91 – 3.85 (m, 1H, CH) 3.27 – 3.19 (m, 1H, CH2) 
3.06 – 3.01 (m, 1H, CH2) 
13C NMR (125MHz, DMSO-d6)  ppm 203.24, 202.47, 201.41 (3 CO) 180.84 (C=O 
ester) 140.89 (Ar-C4) 134.71 (Ar-C1) 115.31 (Ar-C2) 52.44 (CH) 28.27 (CH2) 
MS (ESI) ES- m/z 373.853 [M-H+] 345.866 [M-CO-H+] 309.910 [M-CO-2H2+-Cl-] 
Expected: 373.912, 345.917, 309.939 (Accurate MS) 
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Tricarbonyl chloro (tryptophanato) ruthenium(II) (CORM-Trp) 
 
MF: C14H11ClN2O5Ru 
MW: 423.77 
Tricarbonyl chloro (tryptophanato) ruthenium(II) ([Ru(CO)3Cl(tryptophanate)] or 
CORM-Trp) was synthesized starting from the commercially available CORM-2. Briefly, 
CORM-2 (1mol eq, 85.1mg, 0.166mmol) was dissolved in dry MeOH (2mL) in a round-
bottomed flask at r.t. under N2. Tryptophan (2mol eq, 67.8mg, 0.332mmol) and 
MeONa (2.1mol eq, 18.8mg, 0.348mmol) were added in dry MeOH (5mL) in a separate 
flask and left to stir for a few minutes at r.t. The suspension was then added to the 
CORM-2 solution and the reaction was allowed to stir for 24h at r.t. connected to a 
Schlenk line for continuous inert atmosphere and protected from light. The solvent 
was then removed in vacuo and the yellow residue re-dissolved in dry THF (5mL) 
where excess Et2O was added. The yellow solution was evaporated down to give a 
pale yellow solid (100mg, 71% yield). CORM-Trp was stored in closed vials at -20°C 
and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 11.13 – 10.93 (m, 1H, NH), 7.61 – 7.52 (m, 1H, 
Ar- H7), 7.40 – 7.33 (m, 1H, Ar-H4), 7.26 – 7.19 (m, 1H, Ar-H2), 7.11 – 6.96 (m, 2H, 
Ar-H6, H5) 4.31 – 4.00 (m, 1H, CH) 3.30 – 2.91 (m, 2H, CH2) 
1H NMR (500MHz, THF-d8)  ppm 10.25 – 10.13 (m, 1H, NH), 7.66 – 7.61 (m, 1H, Ar- 
H7), 7.39 – 7.28 (m, 2H, Ar-H4, H2), 7.14 – 6.97 (m, 2H, Ar-H6, H5) 4.09 – 3.83 (m, 
1H, CH) 3.61 – 3.18 (m, 2H, CH2) 
13C NMR (125MHz, THF-d8)  ppm 135.17 (Ar-C3) 126.02 (Ar-C8) 122.07 (Ar-C2) 
119.38 (Ar-C5) 116.83 (Ar-C6) 116.34 (Ar-C7) 109.18 (Ar-C4) 107.74 (Ar-C1) 53.57 
(CH) 27.06 (CH2) 
MS (ESI) ES+ m/z 411.064 [M-HCl+Na+] 419.038 [M-CO+Na+] 361.084 [M-HCl-CO+H+] 
355.081 [M-2CO-HCl+Na+] Expected: 410.952, 418.934, 360.975, 354.963 (Accurate 
MS) ES- m/z 422.95 [M-H+] 394.95 [M-CO-H+] Expected: 422.76, 394.75 
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Tricarbonyl chloro (aspartato) ruthenium(II) (CORM-Asp) 
 
MF: C7H6ClNO7Ru 
MW: 352.65 
Tricarbonyl chloro (aspartato) ruthenium(II) ([Ru(CO)3Cl(aspartate)] or CORM-Asp) 
was synthesized starting from the commercially available CORM-2. Briefly, CORM-2 
(1mol eq, 85mg, 0.166mmol), aspartic acid (2mol eq, 44.2mg, 0.332mmol) and 
MeONa (2mol eq, 17.94mg, 0.332mmol) were dissolved in dry MeOH (5mL) in a 
round-bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk line. The 
reaction was allowed to stir for 24h at r.t. with a N2 balloon and protected from light. 
The solvent was then removed in vacuo and the yellow residue re-dissolved in dry THF 
(2mL) where solid started precipitating. The precipitation was enhanced with excess 
Et2O and light PE. The yellowish supernatant was transferred to another flask and the 
off white solid was dried under N2. Excess light PE was added to the supernatant until 
no more solid could be isolated. Both solids were dried under N2 to yield the final 
CORM-Asp (115mg, 98.2% yield). CORM-Asp was stored in closed vials at -20°C and 
used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.34 (s broad, 2H, NH2) 4.08 – 4.06 (t, J= 5.5Hz, 
1H, CH) 2.85 – 2.83 (m, 2H, CH2)  
13C NMR (125MHz, DMSO-d6)  ppm 196.28, 191.02, 187.02 (3 CO) 171.40 (C=O 
ester) 170.48 (C=O acid) 51.67 (CH) 35.08 (CH2) 
MS (ESI) ES– m/z 323.91 [M-CO-H+] Expected: 323.63 
ESI+ m/z 317.95 [M-Cl-+H+] 340.29 [M-Cl-+Na+] Expected: 318.2, 340.18 
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Tricarbonyl chloro (cyclopentanato) ruthenium(II) (CORM-Cyclopent) 
 
MF: C9H10ClNO5Ru 
MW: 348.70 
Tricarbonyl chloro (cyclopentanato) ruthenium(II) ([Ru(CO)3Cl(cyclopentanate)] or 
CORM-Cyclopent) was synthesized starting from the commercially available CORM-2. 
Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 1-aminocyclopentane-carboxylic acid 
(2mol eq, 42.9mg, 0.332mmol) and MeONa (2mol eq, 17.94mg, 0.332mmol) were 
dissolved in dry MeOH (6mL) in a round-bottomed flask at r.t. under N2 atmosphere 
maintained by a Schlenk line. The reaction was allowed to stir for 24h at r.t. with a N2 
balloon and protected from light. The solvent was then removed in vacuo and the 
yellow residue re-dissolved in dry THF (2mL) where solid started precipitating. The 
precipitation was enhanced with excess Et2O. The supernatant yellow liquid was 
continuously transferred to another flask using a glass pipette and the remaining 
powder was dried under N2. In the transferred liquid, more Et2O was added and 
fractions of solid isolated, until no solid could be further isolated. The different 
fractions of the solid were mixed together to yield the final CORM-Cyclopent (67mg, 
57.8% yield). CORM-Cyclopent was stored in closed vials at -20°C and used freshly on 
the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.5 (broad, 2H, NH2) 2.08 – 1.73 (m, 8H, (CH2)4) 
13C NMR (125MHz, DMSO-d6)  ppm 201.30, 186.99, 185.11 (3 CO), 174.43 (C=O 
ester), 64.79 (C1), 36.58 (2C, CH2 (2, 5)), 25.55 (2C, CH2 (3, 4)) 
MS (ESI) ES+ m/z 335.97 [M-Cl-+Na+] Expected: 336.24 
ES– m/z 347.94 [M-H+] 319.95 [M-H+-CO] 291.95 [M-H+-2CO] Expected: 347.69, 
319.68, 291.67  
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Tricarbonyl chloro (cyclohexanato) ruthenium(II) (CORM-Cyclohex) 
 
MF: C10H12ClNO5Ru 
MW: 362.73 
Tricarbonyl chloro (cyclohexanato) ruthenium(II) ([Ru(CO)3Cl(cyclohexanate)] or 
CORM-Cyclohex) was synthesized starting from the commercially available CORM-2. 
Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 1-aminocyclohexane-carboxylic acid 
(2mol eq, 47.54mg, 0.332mmol) and MeONa (2mol eq, 17.94mg, 0.332mmol) were 
dissolved in dry MeOH (7mL) in a round-bottomed flask at r.t. under N2 atmosphere 
maintained by a Schlenk line. The reaction was allowed to stir for 24h at r.t. with a N2 
balloon and protected from light. The solvent was then removed in vacuo and the 
yellow residue re-dissolved in dry THF (2mL) where solid started precipitating. The 
precipitation was enhanced with light PE. The supernatant yellow liquid was 
transferred to another flask using a glass pipette and the remaining powder was dried 
under N2. In the transferred liquid, excess Et2O was added and yellow solid was 
isolated. The different fractions of the solid were mixed together to yield the final 
CORM-Cyclohex (87mg, 72.3% yield). CORM-Cyclohex was stored in closed vials at -
20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.5 (s broad, 2H, NH2) 1.93 – 1.34 (m, 10H, 
(CH2)5) 
13C NMR (125MHz, DMSO-d6)  ppm 191.02 (CO), 65.37 (C1), 35.45 (CH2 (6)), 31.89 
(CH2 (2)), 24.83 (CH2 (4)), 20.99 (CH2 (3)), 20.67 (CH2 (5)) 
MS (ESI) ES+ m/z 357.25 [M-CO+Na+] Expected: 357.70 
ES– m/z 361.95 [M-H+] 333.96 [M-H+-CO] Expected: 361.72, 333.71  
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Tricarbonyl chloro (3-nitrotyrosinato) ruthenium(II) (CORM-Nitro-Tyr) 
 
MF: C12H9ClN2O8Ru 
MW: 445.73 
Tricarbonyl chloro (3-nitro-tyrosinato) ruthenium(II) ([Ru(CO)3Cl(3-nitrotyrosinate)] 
or CORM-Nitro-Tyr) was synthesized starting from the commercially available CORM-
2. Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 3-nitro-L-tyrosine (2mol eq, 75mg, 
0.332mmol) and MeONa (2mol eq, 17.94mg, 0.332mmol) were dissolved in dry MeOH 
(5mL) in a round-bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk 
line. The reaction was allowed to stir for 24h at r.t. with a N2 balloon and protected 
from light. The solvent was then removed in vacuo and the yellow residue re-dissolved 
in dry THF (1mL) and triturated with excess Et2O until solid started precipitating. The 
supernatant yellow liquid was transferred to another flask using a glass pipette and 
the remaining powder was air dried to yield the final CORM-Nitro-Tyr (112mg, 75.6% 
yield). CORM-Nitro-Tyr was stored in closed vials at -20°C and used freshly on the day 
of the experiments. 
1H NMR (500MHz, MeOD)  ppm 8.14 -8.04 (m, 1H, Ar-H2) 7.66 – 7.58 (m, 1H, Ar-
H6) 7.19 – 7.12 (m, 1H, Ar-H5) 3.99 – 3.93 (m, 1H, CH) 3.40 – 3.35 (m, 1H, CH2) 3.26 – 
2.96 (m, 1H, CH2) 
13C NMR (125MHz, MeOD)  ppm 187.77, 186.01, 184.06 (3 CO) 181.77 (C=O ester) 
153.26 (Ar-C4) 137.64 (Ar-C6) 129.01 (Ar-C3) 128.70 (Ar-C1) 125.42 (Ar-C2) 120.09 
(Ar-C5) 56.60 (CH) 37.54 (CH2) 
MS (ESI) ES– m/z 444.93 [M-H+] 416.93 [M-H+-CO] 388.93 [M-H+-2CO]  
Expected: 444.72, 416.72, 388.70 
 
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
190 
 
Tricarbonyl chloro (3,5-dinitrotyrosinato) ruthenium(II) (CORM-Dinitro-Tyr) 
 
MF: C12H8ClN3O10Ru 
MW: 490.73 
Tricarbonyl chloro (3,5-dinitro-tyrosinato) ruthenium(II) ([Ru(CO)3Cl(3,5-
dinitrotyrosinate)] or CORM-Dinitro-Tyr) was synthesized starting from the 
commercially available CORM-2. Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 3,5-
dinitro-L-tyrosine (2mol eq, 90mg, 0.332mmol) and MeONa (2mol eq, 17.94mg, 
0.332mmol) were dissolved in dry MeOH (5mL) in a round-bottomed flask at r.t. under 
N2 atmosphere maintained by a Schlenk line. The reaction was allowed to stir for 24h 
at r.t. with a N2 balloon and protected from light. The solvent was then removed in 
vacuo and the orange residue re-dissolved in dry THF (2mL) and triturated with excess 
Et2O until solid started precipitating. The solid was dried in vacuo to yield the final 
CORM-Dinitro-Tyr (120mg, 73.7% yield). CORM-Dinitro-Tyr was stored in closed vials 
at -20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, MeOD)  ppm 8.20 (s, 2H, Ar-H2, H6) 3.92 – 3.82 (m, 1H, CH) 3.22 
– 3.103 (m, 2H, CH2)  
13C NMR (125MHz, MeOD)  ppm 198.47, 196.50, 188.05 (3 CO) 186.26 (C=O ester) 
148.82 (Ar-C4) 140.00, 139.80 (Ar-C3, C5) 139.47 (Ar-C1) 131.87, 131.53 (Ar-C2, C6) 
56.71 (CH) 38.14 (CH2) 
MS (ESI) ES– m/z 489.93 [M-H+] 461.94 [M-H+-CO] Expected: 489.72, 461.71  
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Tricarbonyl chloro (4-nitrophenylalaninato) ruthenium(II) (CORM-Nitro-Phe) 
 
MF: C12H9ClN2O7Ru 
MW: 429.73 
Tricarbonyl chloro (4-nitro-phenylalaninato) ruthenium(II) ([Ru(CO)3Cl(4-
nitrophenylalaninate)] or CORM-Nitro-Phe) was synthesized starting from the 
commercially available CORM-2. Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 4-
nitro-L-phenylalanine (2mol eq, 69.8mg, 0.332mmol) and MeONa (2mol eq, 17.94mg, 
0.332mmol) were dissolved in dry MeOH (5mL) in a round-bottomed flask at r.t. under 
N2 atmosphere maintained by a Schlenk line. The reaction was allowed to stir for 24h 
at r.t. with a N2 balloon and protected from light. The solvent was then removed in 
vacuo and the yellow residue was re-dissolved in dry THF (1mL) and triturated with 
excess Et2O until solid started precipitating. Each fraction of solid isolated was washed 
with excess Et2O and the different fractions were combined to yield the final CORM-
Nitro-Phe (135mg, 94.7% yield). CORM-Nitro-Phe was stored in closed vials at -20°C 
and used freshly on the day of the experiments. 
1H NMR (500MHz, DMSO-d6)  ppm 8.51 (s broad, 2H, NH2) 8.22 – 8.08 (m, 2H, Ar-
H3, H5) 7.71 – 7.46 (m, 2H, Ar-H2, H6) 4.18 – 4.17 (m, 1H, CH) 3.09 – 2.97 (m, 1H, 
CH2, second hydrogen obscured by traces of H2O in the NMR solvent) 
13C NMR (125MHz, DMSO-d6)  ppm 176.62 (CO) 170.45 (C=O ester) 147.22 (Ar-C4) 
144.22 (Ar-C1) 131.45 (Ar-C2) 131.28 (Ar-C6) 123.96 (Ar-C3) 123.78 (Ar-C5) 53.43 
(CH) 35.91 (CH2) 
MS (ESI) ES– m/z 428.94 [M-H+] 400.95 [M-H+-CO] 372.95 [M-H+-CO]  
Expected: 428.72, 400.71, 372.70  
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Tricarbonyl chloro (4-aminophenylalaninato) ruthenium(II) (CORM-Am-Phe) 
 
MF: C12H11ClN2O5Ru 
MW: 399.75 
Tricarbonyl chloro (4-amine-phenylalaninato) ruthenium(II) ([Ru(CO)3Cl(4-
aminophenylalaninate)] or CORM-Am-Phe) was synthesized starting from the 
commercially available CORM-2. Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), 4-
amine-L-phenylalanine (2mol eq, 59.8mg, 0.332mmol) and MeONa (2mol eq, 
17.94mg, 0.332mmol) were dissolved in dry MeOH (5mL) in a round-bottomed flask 
at r.t. under N2 atmosphere maintained by a Schlenk line. The reaction was allowed 
to stir for 24h at r.t. with a N2 balloon and protected from light. The solvent was then 
removed in vacuo and the yellow residue was re-dissolved in dry THF (1mL) and excess 
Et2O was added. The solid was then dried in vacuo to yield the final CORM-Am-Phe 
(139mg, 97.9% yield). CORM-Am-Phe was stored in closed vials at -20°C and used 
freshly on the day of the experiments. 
1H NMR (500MHz, MeOD)  ppm 7.4 – 7.03 (m, 4H, Ar-H2, H3, H5, H6) 4.87 (s, 2H, 
NH2, obscured by traces of H2O in the NMR solvent) 4.13 – 3.93 (m, 1H, CH) 3.30 – 
2.94 (m, 2H, CH2)  
13C NMR (125MHz, MeOD)  ppm 187.74, 186.04, 184.61 (3 CO) 183.99 (C=O ester) 
144.42 (Ar-C4) 130.85 (Ar-C6) 130.39 (Ar-C2) 120.90 (Ar-C5) 119.97 (Ar-C3) 56.70 
(CH) 38.07 (CH2) 
MS (ESI) ES– m/z 398.97 [M-H+] 370.98 [M-H+-CO] 342.97 [M-H+-2CO]  
Expected: 398.74, 370.73, 342.72  
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Tricarbonyl chloro (O-benzyloserinato) ruthenium(II) (CORM-Benz-Ser) 
 
MF: C13H12ClNO6Ru 
MW: 414.76 
Tricarbonyl chloro (O-benzyl-serinato) ruthenium(II) ([Ru(CO)3Cl(O-benzyloserinate)] 
or CORM-Benz-Ser) was synthesized starting from the commercially available CORM-
2. Briefly, CORM-2 (1mol eq, 85mg, 0.166mmol), O-benzyl-L-serine (2mol eq, 64.8mg, 
0.332mmol) and MeONa (2mol eq, 17.94mg, 0.332mmol) were dissolved in dry MeOH 
(5mL) in a round-bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk 
line. The reaction was allowed to stir for 24h at r.t. with a N2 balloon and protected 
from light. The solvent was then removed in vacuo and the yellow residue was re-
dissolved in dry THF (1mL) and small excess of Et2O was added. The solid was then 
dried in vacuo to yield the final CORM-Benz-Ser (120mg, 87.1% yield). CORM-Benz-
Ser was stored in closed vials at -20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, THF-d8)  ppm 7.36 – 7.22 (m, 5H, Ar-H) 4.62 – 4.47 (m, 2H, CH2-
2) 3.95 – 3.69 (m, 3H, CH2-1, CH) 
13C NMR (125MHz, THF-d8)  ppm 187.4, 185.16, 182.98 (3 CO), 175.34 (C=O ester) 
136.36 (Ar-C1), 126.12 (Ar-C5) 126.06 (Ar-C3) 125.75 (Ar-C6) 125.68 (Ar-C2) 125.44 
(Ar-C4) 71.20 (CH2-2) 69.57 (CH2-1) 53.35 (CH) 
MS (ESI) ES– m/z 413.97 [M-H+] 385.97 [M-H+-CO] 357.97 [M-H+-2CO]  
Expected: 413.75, 385.74, 357.73  
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Tricarbonyl chloro (O-(4-acetoxybenzoyl)serinato) ruthenium(II) (CORM-MK4a) 
 
MF: C15H12ClNO9Ru 
MW: 486.78 
Tricarbonyl chloro (O-(4-acetoxybenzoyl)serine) ruthenium(II) ([Ru(CO)3Cl(O-(4-
acetoxybenzoyl)serinate)] or CORM-MK4a) was synthesized starting from the 
commercially available CORM-2 and the synthesized MK4a. Briefly, CORM-2 (1mol eq, 
95mg, 0.185mmol), O-(4-acetoxybenzoyl)-serine (MK4a) (2mol eq, 88mg, 0.37mmol) 
and MeONa (2mol eq, 20mg, 0.37mmol) were dissolved in dry MeOH (5mL) in a 
round-bottomed flask at r.t. under N2 atmosphere maintained by a Schlenk line. The 
reaction was allowed to stir for 24h at r.t. with a N2 balloon and protected from light. 
The solvent was then removed in vacuo and the off-white residue was re-dissolved in 
dry THF (2mL) and excess Et2O was added. The solid was then dried in vacuo to yield 
the final CORM-MK4a (156mg, 86.6% yield). CORM-MK4a was stored in closed vials at 
-20°C and used freshly on the day of the experiments. 
1H NMR (500MHz, THF-d8)  ppm 8.22 – 8.07 (m, 2H, Ar-H2, H6) 7.22 – 7.19 (m, 2H, 
Ar-H3, H5) 4.71 – 4.65 (m, 2H, CH2) 4.12 – 3.98 (m, 1H, CH) 2.25 (s, 3H, CH3)  
13C NMR (125MHz, THF-d8)  ppm 184.21 (CO) 174.70 (C=O ester) 165.91 (C=O 2) 
163.30 (C=O 1) 153.1 (Ar-C4) 129.32 (Ar-C2) 129.00 (Ar-C6) 125.2 (Ar-C1) 119.75 (Ar-
C3) 119.62 (Ar-C5) peak of CH2 within the solvent signal (expected around 64) 52.68 
(CH) 17.90 (CH3) 
MS (ESI) ES– m/z 485.31 [M-H+] Expected: 485.77  
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Synthesis of Ligands 
Procedures and spectral data 
Described below are the standard procedures followed in the synthesis of the ligands 
for the new CORM analogues and the spectral data for each compound. Everything 
was purchased from Alfa Aesar and used without further purification unless otherwise 
stated.  
4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl 4-acetoxy-
benzoate (MK1) 
 
MF: C24H27NO8 
MW: 457.48 
This compound was synthesized starting from the commercially available 4-
acetoxybenzoic acid and N-Boc-L-Tyrosine methyl ester. N-Boc-L-Tyrosine 
methylester was activated by reacting with NaH dispersed in 60% mineral oil (Sigma-
Alrich). Briefly NaH (1mol eq, 753.12mg, 2.55mmol) was dissolved in dry 
dichloromethane (CH2Cl2) (1mL) in a round-bottomed flask in ice and under N2 
atmosphere. N-Boc-L-Tyrosine methyl ester (1.2mol eq, 123mg, 3.06mmol) was 
dissolved in dry CH2Cl2 (2mL) and added dropwise in the NaH suspension, keeping 
everything in ice. After the addition, the reaction was left to stir for 30min at r.t. 4-
Acetoxybenzoic acid (1mol eq, 306.26mg, 1.7mmol) was activated by reacting with 
hydroxybenzotriazole (HOBt) (1.2mol eq, 276mg, 2.04mmol) (Sigma-Aldrich) and 1-
ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDC) (1.2mol eq, 391mg, 2.04mmol) 
in dry CH2Cl2 (5mL) in a separate flask under N2 and left to stir for 30min at r.t. The 
first reaction was then added to the second under N2 and the reaction was allowed to 
stir for 3h at r.t. The crude was filtered and the organic layer washed twice with H2O 
and once with Brine. It was left to dry over Na2SO4 for more than 2h and after the 
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filtration of the Na2SO4, the solvent was removed in vacuo. The white residue was 
further purified by column chromatography using CHCl3:EtOAc 99-1% – 90-10% 
gradient system. The product was isolated as a white oil – solid (593mg, 76% yield).  
1H NMR (500MHz, CDCl3)  ppm 8.34 – 8.23 (m, 1H, Ar-H2’), 7.43 – 7.25 (m, 1H, Ar-
H3’), 7.22 – 7.15 (m, 3H, Ar-H2, H3, H6), 7.05 – 7.03 (m, 1H, Ar-H5), 4.64 – 4.58 (m, 
1H, CH), 3.75 – 3.73 (m, 3H, COOCH3), 3.18 – 3.04 (m, 2H, CH2), 2.38 – 2.29 (m, 3H, 
OCOCH3), 1.48 – 1.44 (m, 9H, (CH3)3)  
13C NMR (125MHz, CDCl3)  ppm 172.22 (C=O, COOCH3), 169.41 (C=O, OCOCH3), 
168.79 (C=O, middle ester), 164.31 (Ar-C4’), 154.85 (C=O, Boc), 149.73 (Ar-C4), 
132.01 (Ar-C1), 131.92 – 131.78 (2C-H, Ar-C2’, C6’), 130.37 – 130.27 (2C-H, Ar-C2, 
C6), 127.05 (Ar-C1’), 122.16 – 121.62 (4C-H, Ar-C3, C5, C3’, C5’), 80.02 (C(CH3)3), 
54.37 (CH), 52.28 (COOCH3), 37.71 (CH2), 28.30 (C(CH3)3), 21.13 (OCOCH3)   
MS (ESI) ES+ m/z  480.17 [M+Na+] Expected: 480.47  
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4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl 4-hydroxy-
benzoate (MK1a) 
 
MF: C22H25NO7 
MW: 415.44 
This compound was synthesized starting from the synthesized MK1 with the following 
two methods: 
1. MK1 (1mol eq, 400mg, 0.874mmol) was dissolved in MeOH (5mL) in a round-
bottomed flask and sodium bicarbonate (NaHCO3) (6mol eq, 440.68mg, 5.25mmol) 
was added in the flask. After the addition, the reaction was left to stir for 24h at r.t. 
The solvent was then removed in vacuo and the crude was dissolved in water, where 
it was acidified with a few millilitres of 1M HCl. The aqueous layer was extracted twice 
with CHCl3 and once with ethyl acetate (EtOAc). It was then left to dry over Na2SO4 for 
more than 2h and after the filtration of the Na2SO4, the solvent was removed in vacuo. 
The crude was further purified by column chromatography using CHCl3:EtOAc 99-1% 
– 50-50% gradient system. The product was isolated as a white waxy oil (326mg, 90% 
yield).  
2. MK1 (1mol eq, 593mg, 1.29mmol) was dissolved in MeOH (5mL) in a round-
bottomed flask and potassium hydroxide (KOH) (1.5mol eq, 109.1mg, 1.94mmol) 
dissolved in 1mL H2O and 3mL of CH3OH was added in the flask. After the addition, 
the reaction was left to stir for 2h at r.t. The solvent was then removed in vacuo and 
the crude was dissolved in water, where it was acidified with a few millilitres of 1M 
HCl. The aqueous layer was extracted three times with CH2Cl2 and the organic layer 
was left to dry over Na2SO4 for more than 2h. After the filtration of the Na2SO4, the 
solvent was removed in vacuo and the crude was further purified by column 
chromatography using CHCl3:EtOAc 99-1% – 80-20% gradient system. The product 
was isolated as a white waxy oil (446mg, 83% yield).  
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1H NMR (500MHz, CDCl3)  ppm 8.12 – 8.09 (m, 1H, Ar-H3’), 7.20 – 7.18 (d, J= 
10MHz, 1H, Ar-H3), 7.14 – 7.13 (d, J= 5MHz, 1H, Ar-H5), 7.00 – 6.99 (d, J= 5MHz, 1H, 
Ar-H2), 6.92 – 6.90 (d, J= 10MHz, 1H, Ar-H6), 6.77 – 6.76 (d, J= 5MHz, 1H, Ar-H2’), 
4.64 – 4.54 (m, 1H, CH), 3.76 – 3.74 (m, 3H, COOCH3), 3.18 – 2.98 (m, 2H, CH2), 1.46 
– 1.45 (d, J=5.5MHz, 9H, (CH3)3)  
13C NMR (125MHz, CDCl3)  ppm 172.39 (C=O, COOCH3), 165.13 (C=O, middle ester), 
161.19 (Ar-C4’), 155.37 (C=O, Boc), 150.12 (Ar-C4), 133.44 (Ar-C1), 132.69 – 132.56 
(2C-H, Ar-C2’, C6’), 131.89 (Ar-C5), 130.40 – 130.27 (2C-H, Ar-C2, C6), 121.95 (Ar-
C1’), 115.60 – 115.51 (2C-H, Ar-C3’, C5’), 80.44 (C(CH3)3), 54.63 (CH), 52.30 
(COOCH3), 37.53 (CH2), 28.32 (9C, C(CH3)3)  
MS (ESI) ES+ m/z 438.15 [M+Na+] Expected: 438.43  
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2-((tert-butoxycarbonyl)amino)-3-(4-((4-hydroxybenzoyl)oxy)phenyl)propanoic 
acid (MK1b) 
 
MF: C21H23NO7 
MW: 401.42 
This compound was synthesized starting from the synthesized MK1a with the 
following method: 
MK1a (1mol eq, 560mg, 1.35mmol) was dissolved in 1,4-dioxane (5mL) in a round-
bottomed flask and lithium hydroxide (LiOH) (6mol eq, 193.7mg, 8.09mmol) dissolved 
in 1mL H2O and 3mL of 1,4-dioxane was added in the flask. After the addition, the 
reaction was left to stir for 24h at 35oC. The solvent was then removed in vacuo and 
the crude was redissolved in water, where it was neutralized with a few millilitres of 
1M HCl (pH=6). The aqueous layer was extracted three times with EtOAc and dried in 
vacuo. The product MK1b was isolated as a white waxy solid from the aqueous phase 
(500mg, 92.4% yield).  
1H NMR (500MHz, MeOD)  ppm 7.89 – 7.87 (m, 1H, Ar-H2’), 7.29 – 2.28 (m, 1H, Ar-
H3), 7.06 – 7.05 (m, 2H, Ar-H2, H6), 6.69 – 6.68 (m, 2H, Ar-H5, H3’), 4.24 – 4.14 (m, 
1H, CH), 3.21 – 2.82 (m, 2H, CH2), 1.42 – 1.33 (m, 9H, (CH3)3)  
13C NMR (125MHz, MeOD)  ppm 177.19 (C=O, COOH), 166.58 (C=O, middle ester), 
156.08 (Ar-C4’), 155.60 (C=O, Boc), 149.95 (Ar-C4), 135.45 (Ar-C1), 132.11 (2C-H, Ar-
C2’, C6’), 130.15 (2C-H, Ar-C2, C6), 128.82 (Ar-C1’), 121.14 (Ar-C5’) 117.91 (2C-H, Ar-
C3, C5), 114.71 (Ar-C3’), 78.81 (C(CH3)3), 56.92 (CH), 37.71 (CH2), 27.40 (C(CH3)3) 
MS (ESI) ES+ m/z 424.16 [M+Na+] 408.19 [M-OH+Na+] Expected: 424.40, 408.40  
ES- m/z 400.15 [M-H+] Expected: 400.41  
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
200 
 
2-amino-3-(4-((4-hydroxybenzoyl)oxy)phenyl)propanoic acid (MK1c) 
 
MF: C16H15NO5 
MW: 301.29 
This compound was attempted to be synthesized starting from MK1b with the 
following method: 
MK1b (1mol eq, 150mg, 0.373mmol) was suspended in dry CH2Cl2 (1mL) and dry 
MeOH (1mL) in a round-bottomed flask and 0.3mL trifluoroacetic acid (TFA) (10mol 
eq, 447mg, 3.8mmol) were added in the flask. After the addition, the reaction was left 
to stir for 2h at r.t. The solvent was then removed in vacuo. The product was 
attempted to be purified with flash chromatography and preparative TLC using 8:2:1 
iPrOH:MeOH:NH4OH as the eluent system. However, MK1c could not be purified 
completely, so only a mixed product was isolated as a white sticky solid (38mg, 34% 
yield). NMR and MS spectra of the isolated crude were taken and the final product 
was detected in them, even though impure (only MS spectra reported here). 
MS (ESI) ES+ m/z 302.13 [M+H+] Expected: 302.31  
ES- m/z 300.10 [M-H+] Expected: 300.29 
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3-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)-3-oxopropyl 4-acetoxybenzoate  
(MK4) 
 
MF: C27H25NO8 
MW: 491.50 
MK4 was synthesized starting from the commercially available N-benzyloxycarbonyl-
L-serine benzyl ester and 4-acetoxybenzoic acid. The ester (1mol eq, 548.43mg, 
1.665mmol) along with the acid (1mol eq, 300mg, 1.665mmol) and 
dimethylaminepyridine (DMAP) (0.3mol eq, 61.5mg, 0.5mmol) were dissolved in dry 
CH2Cl2 (2mL) in a round-bottomed flask under N2 and kept in ice. N,N’-
dicyclohexylcarbodiimide (DCC) (1mol eq, 343.58mg, 1.665mmol) was dissolved in 
6mL of dry CH2Cl2 and added in the flask. After the addition, the reaction was left to 
stir for 5min in ice and for 4h at r.t. under N2. The mixture was then filtrated to remove 
the formed dicyclohexylurea (DCU) and the filtrate was concentrated in vacuo. The 
crude was redissolved in dry CH2Cl2, and a new filtration was performed to remove 
any residual DCU. The filtrate was washed twice with 1M HCl and once with 0.1M 
NaOH and the organic layer was dried over Na2SO4 for more than 2h. After the 
filtration of the Na2SO4, the solvent was removed in vacuo and the crude was 
dissolved in i-PrOH with medium heating. The solution was left in the freezer for the 
final product to crystallize as a white waxy solid (600mg, 73.3% yield).  
1H NMR (500MHz, MeOD)  ppm 7.93 – 7.92 (d, J= 7Hz, 2H, Ar-H3, H5), 7.34 – 7.23 
(m, 11H, NH, Ar-H2’, H3’, H4’, H5’, H6’, H2’’, H3’’, H4’’, H5’’, H6’’) 7.16 – 7.15 (d, J= 
7Hz, 2H, Ar-H2, H6), 5.26 – 5.11 (m, 4H, COOCH2Ph, NHCOOCH2Ph), 4.75 – 4.56 (m, 
3H, CH2-CH), 2.34 – 2.30 (m, 3H, CH3)  
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
202 
 
13C NMR (125MHz, CDCl3)  ppm 169.33 (C=O, CH3COO), 168.77 (C=O, COOCH2Ph), 
165.09 (C=O, Ar-COO-CH2-CH), 155.70 (C=O, NH-COO-CH2Ph), 154.59 (Ar-C1), 135.97 
(Ar-C1’’), 134.84 (Ar-C1’), 131.92 (2C, Ar-C3, C5), 131.39 (2C, Ar-C3’, C5’), 131.30 (2C, 
Ar-C3’’, C5’’), 128.64 (2C, Ar-C4’, C4’’), 128.58 (Ar-C2’), 128.46 (Ar-C6’), 128.31 (Ar-
C2’’), 128.19 (Ar-C6’’), 126.73 (Ar-C4), 122.01 (Ar-C2), 121.71 (Ar-C6), 67.86 (NH-
COO-CH2Ph), 67.32 (CH-COO-CH2Ph), 64.86 (Ar-COO-CH2-CH), 53.59 (CH), 21.17 (CH3) 
MS (ESI) ES+ m/z 492.19 [M+H+] 514.17 [M+Na+] Expected: 492.50, 514.49  
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O-(4-acetoxybenzoyl)serine (MK4a) 
 
MF: C12H13NO6 
MW: 267.24 
MK4a was synthesized starting from the synthesized MK4. 
MK4 (1mol eq, 239mg, 0.486mmol) was dissolved in dry MeOH (5mL) and dry CH2Cl2 
(1mL) in a round-bottomed flask. 28% of the starting material weight in 10% Pd/C 
were added and the mixture was stirred for a few minutes under N2. The stirring stops 
and the N2 balloon is replaced with a H2 balloon and the reaction is left to stir at r.t. 
for 3h under H2 (1 atmosphere). The mixture was then filtrated through a pad of cellite 
and washed many times with dry MeOH. The filtrate and the washings were combined 
and concentrated in vacuo to yield the final product MK4a as a white solid. (100mg, 
77% yield).  
1H NMR (500MHz, MeOD)  ppm 8.17 – 8.15 (d, J = 9Hz, 2H, Ar-H5, H3) 7.27 – 7.25 
(d, J = 9Hz, 2H, Ar-H2, H6) 4.79 – 4.76 (dd, J = 3Hz, 12Hz, 1H, CH2) 4.69 – 4.66 (dd, J = 
6.5Hz, 12.5Hz, 1H, CH2) 4.03 – 4.01 (m, 1H, CH) 2.32 (s, 3H, CH3) 
 13C NMR (125MHz, MeOD)  ppm 169.38 (C=O acid) 169.07 (C=O Ac) 165.36 (C=O 
ester) 154.95 (Ar-C1) 131.07 (Ar-C3, C5) 126.83 (Ar-C4) 121.59 (Ar-C2, C6) 63.69 
(CH2) 53.90 (CH) 19.49 (CH3)  
MS (ESI) ES+ m/z 268.0820 [M+H+] Expected: 268.0816 (Accurate MS) 
ES+ m/z 268.10 [M+H+] 290.10 [M+Na+] Expected: 268.24, 290.20  
ES- m/z 266.08 [M-H+] Expected: 266.24  
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3-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)-3-oxopropyl 4-hydroxybenzoate  
(MK5) 
 
MF: C25H23NO7 
MW: 449.46 
MK5 was attempted to be synthesized starting from the commercially available N-
benzyloxycarbonyl-L-serine benzyl ester and 4-hydroxybenzoic acid. The ester (1mol 
eq, 272.9mg, 0.828mmol) along with the acid (1mol eq, 114.47mg, 0.828mmol) and 
DMAP (0.3mol eq, 30.37mg, 0.249mmol) were dissolved in dry CH2Cl2 (2mL) in a 
round-bottomed flask under N2 and kept in ice. DCC (1mol eq, 170.98mg, 0.828mmol) 
was dissolved in 6mL of dry CH2Cl2 and added in the flask. After the addition, the 
reaction was left to stir for 5min in ice and for 6h at r.t. under N2. The mixture was 
then filtered to remove the formed DCU and the filtrate was concentrated in vacuo. 
The crude was redissolved in dry CH2Cl2, and a new filtration was performed to 
remove any residual DCU. The filtrate was washed twice with 1M HCl and once with 
0.1M NaOH and the organic layer was dried over Na2SO4 for more than 2h. After the 
filtration of the Na2SO4, the solvent was removed in vacuo and the crude was 
dissolved in i-PrOH for the final product to crystallize. The solution was left in the 
freezer for long time, but the final product was never recovered.  
MS (ESI) ES+ m/z 472.15 [M+Na+] Expected: 472.45  
ES- m/z 448.15 [M-H+] Expected: 448.49 
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4.3 Discussion 
CORM synthesis 
As discussed in detail in section 4.1, 15 new CORMs were synthesized starting from 
the commercially available CORM-2 and different amino acids, either purchased or 
synthesized. The protocol used for the synthesis has been reported in all the relevant 
publications, and all studies using synthesized CORM-3 agree on that (Clark et al. 
2003). The mechanism of the reaction is a nucleophilic substitution, where the pairs 
of electrons of the nitrogen (amine group) and oxygen (hydroxyl group of the 
carboxylic acid) attack both ruthenium cores in subsequent steps and replace the 
middle chorines creating two monomers (Figure 4.4).  
 
Figure 4.4: Mechanism of reaction for the synthesis of CORM-3 analogues 
However, during the synthesis, some problems were encountered concerning the 
purification and characterization of the final products. In the corresponding protocol, 
there is no further purification step, apart from the crystallization of the final product 
inside the mixture. After the formation of the crystals, the solvent is removed in 
vacuo, which is quite uncommon, since all the impurities will eventually end up on the 
surface of the formed crystals. Therefore, several techniques were employed in order 
to remove the solvent and the dissolved by-products all together. Filtration under N2 
or normal atmosphere and through normal paper filter or glass filters with different 
pore sizes were employed, but none of the methods provided pure CORM-3 crystals. 
A different technique was also tried, to pipette out the supernatant and dry the solid 
under N2 atmosphere or vacuum. The best product isolated was the one after removal 
of the supernatant in successive steps, following crystallization of CORM-3.   
The synthesized product was subsequently compared to the commercially available 
one via 1H and 13C NMR spectra and the results are shown in Figures 4.5 and 4.6, 
respectively. The solvent used for the 1H spectra was DMSO-d6, which has some 
inherent limitations, such as the existence of water within the solvent, which 
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produces a quite broad 1H NMR peak at δ 3.33 and the very strong and sharp signal of 
DMSO-d6 itself at δ 2.50. THF-d8 was preferred for the 13C spectra because its peaks 
do not interfere with the expected signals of the molecule (THF-d8 61.50, 126.28ppm).  
 
A.  
 
B.  
 
Figure 4.5: A. 1H NMR spectra of reference and B. synthesized CORM-3 in DMSO-d6. 
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A.  
 
B.  
 
C.  
 
D.  
 
Figure 4.6: 13C NMR spectra of purchased CORM-3 in THF-d8 at A. 256 scans, B. 3072 scans and  
C. 9216 scans. D. 13C NMR spectrum of synthesized CORM-3 in THF-d8.  
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As observed in the figures, both products had very similar NMR spectra. In the 1H 
NMR, both compounds showed a peak for two protons at around δ 3.60 and there 
were also the peaks of DMSO, H2O and in both situations there were traces of THF 
solvent originating from the synthetic procedure. This means that the products cannot 
be completely dry, a phenomenon observed also in the other synthesized CORMs. 
Apart from that, there were some minor peaks further downfield that did not 
integrate into protons and a small broad peak resembling the ones produced by amine 
groups at around δ 8.00.  
A few unexpected observations were reported for the 13C NMR spectra, which were 
obtained using THF-d8 as the solvent. The first spectrum was taken at 256 scans, but 
as expected the carboxyl group or the 3 carbonyl groups were not visible. When the 
number of scans was increased to 3072, more peaks started to come out, that do not 
originally belong to the molecule per se. More specifically, two extra peaks showed at 
44.04 and 42.61ppm, and further downfield one peak showed at 123.03ppm and five 
peaks at around 185.00ppm. These peaks could not be assigned to specific carbons in 
the molecule, since there should be only one peak at around 42.00ppm for the CH2 
group and four peaks downfield of 180.00ppm for the one carboxyl and three carbonyl 
groups. This was quite unexpected, since the purchased product was confirmed to be 
more than 98% pure and even though the company was contacted, no extra 
information could be obtained. Taking a longer 13C NMR spectrum at 9216 scans 
revealed one more peak at 47.03ppm, however the ratios between the pre-existing 
peaks was different than in the shorter spectrum.  
For the synthesized CORM-3, at low number of scans two peaks were visible at 44.66 
and 40.03ppm, very close to the commercially available ones, and one peak existed at 
184.27ppm, probably belonging to the carboxyl group. The spectrum was very similar 
to the purchased CORM-3’s and since the MS were also identical, no further 
characterization was carried out. Moreover, during the work up of the synthesized 
CORM-3 some well-structured crystals formed, that were subsequently characterized 
by Dr. B. Kariuki in the School of Chemistry and found to be a by-product of the 
synthesis containing Ru, with the structure Ru(CO)3Cl3Na·1.5(H2O) (Figure 4.7).  
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Figure 4.7: Crystal structure of by-product from synthesis of CORM-3 
This unusual behaviour could suggest a potential change in the molecule while in the 
NMR tube, maybe as a consequence of its interaction with the solvent or other 
impurities. It could also imply a higher polymeric structure and not a monomeric one. 
This has also been proposed by other researchers (Johnson et al. 2007; Kunz et al. 
2013; Seixas et al. 2015), where problematic spectra were again obtained for CORM-
3 and derivatives, and isomers or a complex oligomeric structure were proposed, 
along with potential interactions with solvents and an extensive aqueous chemistry.  
In the next step, other derivatives of CORM-3 were synthesized, using alternative 
amino acids. During these procedures all the different methods of crystallization and 
isolation of the final product were explored and the reported ones were the most 
effective for each individual derivative. Most of the times, a successive titration of the 
formed solid with PE or Et2O and removal of the supernatant was used to obtain as 
pure products as possible. Most of them were dried under N2 or vacuum, but certain 
times this drying step resulted in complete loss of the crystals, which had to be re-
precipitated. In summary, each individual CORM had to be worked up in a different 
way in order to obtain the best possible result. 
Three of the synthesized CORMs have been reported before in the literature. In the 
work of Kunz et al, CORM-Phe was synthesized for comparison purposes with its 
functionalized counterpart on the surface of maghemite nanoparticles. In the work of 
Wang et al, several CORM-3 derivatives were synthesized and evaluated, including 
CORM-Phe and CORM-Ala (Kunz et al. 2013; Wang et al. 2014). Finally, CORM-Ser has 
been briefly mentioned in a patent that was not readily available at the time of the 
production of this thesis. Neither the exact experimental procedure, nor the full 
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compound characterization was provided, therefore no comparison could be made 
for the CORM-3 derivatives. 
The same problems that occurred during the characterization of CORM-3 were also 
experienced in the characterization of its derivatives. In short 13C NMR scannings (low 
scan number), the peaks of the carboxyl or carbonyl groups were not visible most of 
the times, whereas when longer duration was used, more peaks arose for each 
carbon. This event resembled the observation for the purchased CORM-3, where 
longer spectra showed more peaks for the CH2 or CO groups. For all CORM derivatives, 
several durations of 13C NMR were employed and a study for each CORM was 
conducted, where the highest number of scans used were 10240 (10h) (a selection of 
spectra is attached in the Appendix). The same unusual observation was also reported 
in the 1H NMR spectra, where apart from the peaks originating from the molecule 
itself, other little peaks were also visible and most of them had traces of THF. When 
the three reported CORMs were compared with the literature, similar peaks were 
found, but no publication referred to problems with the NMR spectra. However, in 
both these studies referenced here, NMR peaks were reported for the three 
complexes, but no spectrum was attached in the publication itself or the supporting 
material.   
As a consequence of the unusual problems with the NMR spectra, certain purification 
methods were employed, in order to further purify the solids. Along with the 
exploration of different synthetic procedures and work up steps described previously, 
both high-performance liquid chromatography (HPLC)/UV and HPLC/MS were used to 
purify the final products in a variety of conditions and different ratios of the eluent 
system, but the products were never recovered.  
Due to these unforeseen circumstances, and since all the MS confirmed the prevalent 
existence of the desired products in the isolated solids, the products were used as 
crudes and without further purification.  
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Ligand synthesis 
Two ligands were aimed to be synthesized starting from the amino acid serine or 
tyrosine and the p-hydroxy-benzoic acid, in order to add an extra pro-oxidant moiety 
to the final complex. 
As for the first ligand, 2-amino-3-(4-((4-hydroxybenzoyl)oxy)phenyl)propanoic acid 
(MK1c), the designed synthetic pathway is shown in Figure 4.8.  
 
 
Figure 4.8: Synthetic pathway of MK1c. a) 1. NaH, CH2Cl2, N2, 0oC-rt, 30min 2. HOBt, EDC, CH2Cl2, 
N2, rt, 30min 3. N2, rt, 3h, 76% b) 6eq NaHCO3, MeOH, rt, 24h, 90% OR 1.5eq KOH, MeOH-H2O, rt, 
2h, 83% c) 6eq LiOH, 1,4-dioxane-H2O, 35oC, 24h, 92.4% d) TFA, CH2Cl2-MeOH, rt, 2h, 34% 
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The first step includes the activation of both the carboxylic acid and the hydroxyl 
group of the protected tyrosine. The mechanisms of both activations are depicted in 
Figure 4.9 A and B.  
A.  
 
B. 
 
Figure 4.9: Activation of starting materials. A. Activation of p-hydroxy-benzoic acid with HOBt 
and EDC. B. Activation of tyrosine derivative with NaH. 
 
After the activation, the two reactions are added together and the final product is 
yielded following the mechanism shown in Figure 4.10. 
Figure 4.10: Mechanism of reaction for the synthesis of MK1 
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Product MK1 is then deprotected from the acetyl group in basic conditions and two 
different bases were explored, that is 6eq NaHCO3, a relatively soft base, and 1.5eq 
KOH, a stronger base. Both methods formed the final product MK1a in good yields. 
The next step is the deprotection of the carboxyl group from the methyl ester under 
basic conditions, using an even stronger base, LiOH, in excess. This step required 
moderate heating, and different conditions were explored. However, during the work 
up, the final product MK1b was unexpectedly isolated from the aqueous phase and 
was not possible to be completely dried from the remaining water. Nevertheless, the 
NMR and MS confirmed its formation, and it was subjected to the next step without 
further purification.  
Finally, the final product MK1c was attempted to be synthesized from MK1b using an 
acidic hydrolysis of the Boc group (Figure 4.11). However, the final product yielded 
was not completely pure and the subsequent flash chromatography or preparative 
TLC employed to purify it were not successful. This product is very polar, which might 
be the reason why the chromatography did not succeed, even though a very polar 
eluent system was used for both, reported previously in literature for the purification 
of amino acids (Mota et al. 2003).  
 
Figure 4.11: Mechanism of deprotection of the Boc group under acidic conditions for the 
synthesis of MK1c 
The second ligand, O-(4-acetoxybenzoyl)serine (MK4a), was synthesized using the 
synthetic pathway shown in Figure 4.12.  
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Figure 4.12: Synthetic pathway of MK4a. A. Steglich esterification for the synthesis of MK4.  
B. Hydrogenolysis for the synthesis of MK4a. 
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This ligand was successfully synthesized with very good yields of 73.3% for the first 
step and 77% for the second. The corresponding 1H and 13C NMR spectra for MK4a are 
attached in the Appendix (Figures A.1 and A.2, respectively).  
The same technique was employed also for the synthesis of the free hydroxyl 
derivative of MK4a (MK5a), however the first step did not yield the desired product, 
probably due to its high lipophilicity, or possibly a different purification method other 
than crystallization should have been explored. Nevertheless, the free hydroxyl 
derivative would have gone through an extensive metabolism within the cells or the 
organism, therefore a protecting group such as an ester could prove useful in delaying 
the rapid excretion and MK4a was used further.  
Calculated lipophilicity data for all 15 new analogues of CORM-3 is shown in Table 4.4 
(as calculated in ChemDraw Professional 15.0).  
CORM CLogP tPSA 
CORM-3 -2.318 94.61 
CORM-Ala -1.799 94.61 
CORM-Ser -2.768 97.77 
CORM-Phe -0.381 94.61 
CORM-Tyr -1.048 114.84 
CORM-His -2.782 119.00 
CORM-Trp -0.391 106.64 
CORM-Asp -2.329 131.91 
CORM-Cyclopen -0.886 94.61 
CORM-Cyclohex -0.327 94.61 
CORM-Nitro-Tyr -1.305 166.65 
CORM-Dinitro-Tyr -1.562 218.46 
CORM-Nitro-Phe -0.638 146.42 
CORM-Am-Phe -1.71 120.63 
CORM-Benz-Ser -0.259 103.84 
CORM-MK4a -0.792 147.21 
Table 4.4: Lipophilicity data of new CORM-3 analogues 
As observed, all the complexes have polar characteristics and their CLogP values are 
negative, with CORM-His having the most hydrophilic and CORM-Benz-Ser the most 
lipophilic structure. However, CORM-Ala, CORM-Phe, CORM-Cyclopent and CORM-
Cyclohex share the same tPSA with CORM-3. The other CORMs have more extended 
polar areas and the one with the highest tPSA is CORM-Dinitro-Tyr, due to its two nitro 
groups. These different characteristics also indicate different solubility in the various 
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solvents. As this was critical for further experiments, the new CORMs were tested for 
their solubility in different solvents, and the results are shown in Table 4.5: 
CORM H2O MeOH DMSO THF 
CORM-3 +  + + 
CORM-Ala   + + 
CORM-Ser   +  
CORM-Phe   +  
CORM-Tyr   +  
CORM-His +  +  
CORM-Trp   + + 
CORM-Asp   +  
CORM-Cyclopen   +  
CORM-Cyclohex   +  
CORM-Nitro-Tyr  + +  
CORM-Dinitro-Tyr  + +  
CORM-Nitro-Phe   +  
CORM-Am-Phe  + +  
CORM-Benz-Ser   + + 
CORM-MK4a   + + 
Table 4.5: Solubility of new CORMs in different solvents 
As observed, none of the new complexes is soluble in water apart from CORM-His, 
even though they are all very hydrophilic and with significant polar areas. This was 
quite unexpected, however since they are all very well soluble in DMSO, this was the 
solvent chosen for further experiments.  
In summary, a set of 15 new analogues of CORM-3 were synthesized, 12 of them 
novel. These complexes were subsequently subjected to in vitro evaluation, in order 
to reveal any potential anti-angiogenic properties related to tumour angiogenesis in 
TNBC. The molecules were kept in tightly sealed vials at -20oC and fresh stocks were 
prepared for each individual experiment. The stocks were kept in dark until tested and 
were diluted seconds before their addition on the cells.  
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Chapter V 
 
Screening of new 
analogues 
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5.1 Cytotoxicity Assessment 
5.1.1. Introduction 
It has been extensively discussed that cell-based assays can be used for the 
assessment of cytotoxicity of anti-cancer compounds against diseased and normal 
cells (Ganot et al. 2013). The preclinical toxicity testing is a necessary step, as 
determined by the FDA, and it should include various biological systems (Berridge and 
Tan 1993; Parasuraman 2011). Any potential cytotoxicity of the novel compounds 
may be related to their capability to release CO, a lethal gas, as well as their metal 
core, that could also be responsible for toxicity (Egorova and Ananikov 2017).  
Based on previous studies on the commercially available CORMs, it was considered 
useful to compare the novel compounds to the parent compound and look for any 
differences in the toxicological profile. Therefore, all the 15 newly synthesized 
candidates were screened against the aggressive MDA-MB-231 TNBC cell line and the 
most potent analogues were also screened against endothelial (HECV) and epithelial 
(MCF-10A) cells.  
For the toxicological testing, the MTT assay was chosen, as a colorimetric assay for 
measuring the activity of NAD(P)H–dependent MTT–reducing enzymes to reduce MTT 
to its insoluble  formazan, which has a purple colour. The quantity of formazan 
(presumably directly proportional to the number of viable cells) is measured by 
recording changes in absorbance at 540nm using a plate reading spectrophotometer.  
5.1.2 Materials & Methods  
Cell lines and treatments  
MDA-MB-231 and HECV cell lines, maintained in DMEM media with 10% FBS and 
antibiotics, were used for the MTT assay. In addition, MCF-10A cells were used and 
maintained in MEBM media with the necessary MEGM supplements, cholera toxin 
and antibiotics. All cells were maintained at 37°C with 5% CO2. The cells were treated 
with various concentrations of CORMs or DMSO for 72h. Then they were subjected to 
MTT assay.  
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MTT assay 
5x103 cells were seeded in 120µL of normal medium per well in a 96-well plate. Three 
replicates were undertaken per treatment concentration and an identical plate was 
also prepared with no cells (blank). The cells were left to attach overnight and then 
were treated with various concentrations of CORMs as indicated or DMSO as the used 
vehicle. The concentration range used was a serial dilution between 100µM and 
0.39µM, and the vehicle treated cells were used as controls. The blank plate received 
the same treatments. The cells were left in an incubator for 72h and then 
supplemented with MTT solution. The plates were incubated for further 4h and then 
the medium was removed and acidified isopropanol was used to dissolve the purple 
formazan crystals. The absorbance of both plates was read at 540nm and the blank 
plate was used to subtract any background absorbance from the test plate 
absorbance. The method is detailed in section 2.2.2.1.  
IC50 calculation 
The absorbance was normalized to the corresponding absorbance of the vehicle 
treated cells prior to plotting. Data was statistically analysed using non-linear 
regression (curve fit) to calculate the IC50 of each compound against each cell line in 
GraphPad Prism (www.graphpad.com).  
5.1.3 Results  
The effect of CORM treatments on the viability of different cell lines using the 
MTT assay 
Consistent with previous experiments, the cytotoxicity of the novel compounds was 
assessed using an MTT colorimetric assay. MDA-MB-231 TNBC cells, MCF-10A 
epithelial cells and HECV ECs, following treatments with the new CORMs in different 
concentrations, were assessed for their viability.  
No major cytotoxicity against the TNBC cells was observed for the new compounds 
compared to the vehicle. All calculated IC50 values exceeded 100µM, except for 
CORM-Cyclopent, which had an IC50 at 89µM. However, many values were very close 
to 100µM, that is for CORM-Ala, CORM-His, CORM-Nitro-Tyr, CORM-Dinitro-Tyr and 
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CORM-MK4a. Therefore, these compounds, along with CORM-Phe, CORM-Tyr, CORM-
Cyclohex and CORM-Am-Phe, were chosen to be tested against the two other cell 
lines, as well.  
First of all, the MCF-10A breast epithelial cells were assessed, representing the control 
cells in a normal breast environment. Almost all the newly synthesized CORMs tested 
had IC50 values of more than 200µM, although CORM-Cyclopent, CORM-Nitro-Tyr and 
CORM-Dinitro-Tyr appeared to be more cytotoxic than the others (IC50 of 71µM, 
107µM and 156µM, respectively). For CORM-His an IC50 could not be calculated. 
Following up, HECV cells were checked for cytotoxicity representing normal ECs, and 
all novel CORMs showed very low toxicity (Figure 5.1 shows the calculated IC50 values 
for all the compounds and cell lines tested). 
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IC50 (µM) MDA-MB-231 HECV MCF-10A 
CORM-3 312.5 996.3 Not converged 
CORM-Ala 198.8 4866 787.4 
CORM-Phe 325.3 1857 340.7 
CORM-Trp 448.9 n.d. n.d. 
CORM-Ser 1429 n.d. n.d. 
CORM-Tyr 320.5 1681 373.3 
CORM-Asp 353.4 n.d. n.d. 
CORM-His 162.1 1340 Not converged 
CORM-Cyclopent 89.07 530.5 71.14 
CORM-Cyclohex 460.9 n.d. 219.7 
CORM-Benz-Ser 376.4 n.d. n.d. 
CORM-Nitro-Tyr 151.8 892.8 106.6 
CORM-Dinitro-Tyr 171 1031 156 
CORM-Nitro-Phe 273.4 n.d. n.d. 
CORM-Am-Phe 278.7 1642 339.5 
CORM-MK4a 232.9 700.3 698.2 
 
Figure 5.1: Cytotoxicity of novel CORMs. Mean IC50 values for all compounds and cell lines tested 
(calculated in GraphPad Prism) (n=3, N=3). The compounds which were significantly more cytotoxic 
against MDA-MB-231 compared to HECV and MCF-10A cells are highlighted in red boxes. (n.d.=not 
determined) 
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5.1.4 Discussion 
Following previous experiments, the novel compounds were initially subjected to a 
cytotoxicity assessment. Since Ru has been the chosen metal for the new CORMs and 
heavy metals are generally believed to be more toxic compared to lighter ones, it was 
necessary to determine any potential toxicity of the new compounds against TNBC, 
epithelial and ECs.  
The MTT assay was chosen for the cytotoxicity assessment, since previous results 
showed no difference between the three endpoint methods used. MDA-MB-231 cells 
were chosen to represent the target cancer subtype, that is TNBC, along with the 
control epithelial breast cells, MCF-10A and HECV as ECs. As shown in Figure 5.1, these 
compounds had a moderate cytotoxicity against the cell lines tested. 
The most potent compound against MDA-MB-231 was CORM-Cyclopent, with an IC50 
of 89µM. However, the IC50 against MCF-10A cells was also very low, namely 71µM, 
thus showing no selectivity between the cancer and normal cells. This agrees with 
previous literature, stating the cytotoxicity of ACPC, even though it has also been 
reported to be selectively taken up by tumour tissue (Connors et al. 1960). CORM-
Cyclohex did not share the same cytotoxicity as CORM-Cyclopent, and this might be 
explained by the greater freedom in the conformation of its ring, making it less rigid 
and probably inducing less interaction with other cell components.  
Other CORMs with elevated toxicity against MDA-MB-231 compared to the parent 
structure were CORM-Ala, CORM-His, CORM-Nitro-Tyr and CORM-Dinitro-Tyr, all with 
IC50 values between 100µM and 200µM. This toxicity was expected for CORM-Nitro-
Tyr and CORM-Dinitro-Tyr, since as discussed earlier, the addition of nitro groups 
amplifies the ability of a compound to induce ROS production, and after a certain 
threshold, these levels might become toxic for the cells. Apart from that, nitro 
compounds are known toxicants that share toxicological effects with aromatic 
amines, since the nitro group can be readily reduced to amine group. These aromatic 
amines can yield reactive intermediates after metabolic activation that leads to 
toxicity (Lai and Woo 2015). However, CORM-Nitro-Tyr and CORM-Dinitro-Tyr were 
also toxic against MCF-10A cells, with lower IC50 values compared to the ones against 
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cancer cells. Therefore, no selectivity was observed for these CORMs, probably 
making them inappropriate candidates for further study. At this point, it should be 
also noted that the addition of an extra nitro group in the CORM-Dinitro-Tyr compared 
to CORM-Nitro-Tyr did not enhance the cytotoxicity of this compound, but on the 
contrary, its IC50 values were slightly lower than the corresponding ones for CORM-
Nitro-Tyr. This might suggest an additional mechanism of toxicity for these two 
CORMs that does not rely solely on the existence of the nitro group. 
The compounds that had a very favourable selectivity profile were CORM-MK4a, 
CORM-His and CORM-Ala, highlighted in red boxes (Figure 5.1). These three CORMs 
had a significantly higher cytotoxicity against MDA-MB-231 cells compared to ECs or 
MCF-10A. For CORM-Ala this result was unexpected, as there is nothing in its structure 
to correlate it with increased toxicity compared to other novel CORMs. Its relatively 
simple structure and small substituent (one methyl group) would make it less bulky 
and more versatile than others, but no specific characteristics are attributed to this 
one, apart from the major similarity with the parent compound, CORM-3. 
Nevertheless, CORM-Ala seemed to be more potent in killing TNBC cells than CORM-
3 (198.8µM vs 312.5µM).  
The same result was observed also for CORM-His that had a vast difference of almost 
9-times between the toxicity against MDA-MB-231 and against HECV, whereas for 
MCF-10A the IC50 value was not converged. A big advantage of this complex is its 
solubility in water like CORM-3, while the imidazole ring may also confer a favourable 
interaction with any potential cellular target. The increased cytotoxicity compared to 
the parent complex may be related to the imidazole ring or the higher tPSA of this 
compound compared with CORM-3, although it is not the only one with a more 
extended polar surface. Nevertheless, CORM-His is the most potent of the three, 
having a relatively low IC50 value of 162.1µM against the MDA-MB-231.       
As for CORM-MK4a, this result was expected to some extent, as from the design point 
of view, it was targeted to be more toxic due to the ability to enhance ROS production. 
The addition of the p-hydroxy-benzoic acid as an ester with serine could probably 
amplify the pro-oxidant activity of the whole complex compared to the simple CORM-
Ser analogue. Thus, CORM-MK4a could potentially establish oxidative stress in cancer 
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cells over normal cells, since cancer cells are energetically challenged and their 
reduction defence mechanisms are more easily depleted due to their rapid division 
(Gorrini et al. 2013). This hypothesis was very well supported by the fact that CORM-
MK4a was selectively cytotoxic against MDA-MB-231 cells and not against MCF-10A 
or HECV, where the IC50 values were as high as 700µM.   
5.2 Protein expression quantification 
5.2.1. Introduction 
Tumour angiogenesis is linked to the expression of several proteins-enzymes that play 
various roles in the pro-angiogenic signalling and the formation of new capillaries. In 
line with the studies conducted for the commercially available CORMs, the new 
molecules were assessed for their ability to affect two main events implicated in 
angiogenesis. The first event was the ability of TNBC cells to express high 
concentrations of VEGF and the second one was the successful transduction of the 
pro-angiogenic signal starting from the EC surface receptor VEGFR2, in order to 
stimulate the angiogenic behaviour in ECs. Therefore, TNBC cells were treated with all 
novel CORMs and the expression levels of VEGF were quantified at three different 
time points. Two of them were chosen for further studies, based on the degree of 
VEGF reduction. HO-1 levels of TNBC cells were also quantified after treatment with 
the two chosen CORMs, in order to detect any potential decrease in the levels of this 
anti-oxidant and cyto-protective enzyme. Finally, ECs were subjected to treatments 
with the two CORMs and phosphorylation levels of Y1175 and other relevant 
downstream proteins were assessed upon VEGF stimulation.  
5.2.2 Materials & Methods 
Cell lines and treatments  
MDA-MB-231 maintained in DMEM media with 10% FBS and antibiotics, were used 
for the quantification of VEGF expression after novel CORM treatments. All cells were 
maintained at 37°C with 5% CO2. Cells were treated with 100µM CORMs or 0.1% 
DMSO or normal media 6h, 12h or 24h before collecting the supernatant. 
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MDA-MB-231 maintained in DMEM media with 10% FBS and antibiotics, were used 
for the quantification of HO-1 expression after CORM treatments. All cells were 
maintained at 37°C with 5% CO2. Cells were treated with 100µM CORM-Phe or CORM-
Tyr or 0.1% DMSO or normal media 12h before collecting the supernatant.   
HUVEC maintained in EBM-2 media were treated with CORM-Phe or CORM-Tyr and 
then stimulated with 100ng/mL VEGF in order to be used for the quantification of 
pVEGFR2 and other downstream phosphorylated proteins. All cells were maintained 
at 37°C with 5% CO2. Cells were treated with 100µM CORM-Phe or CORM-Tyr or 0.1% 
DMSO or serum free media for 15min and then stimulated with VEGF for 5min before 
the cell lysate was collected. An unstimulated sample was also obtained.  
VEGF expression after treatment with CORMs 
Upon reaching adequate confluence (~70%), the normal media of a T25 flask was 
removed and the cells were washed twice with PBS. Fresh media containing the 
corresponding concentration of CORMs or 0.1% DMSO or no treatment was added to 
each flask and the cells were left in the normal incubator for 6h, 12h or 24h. After the 
indicated incubation time, the supernatants of the cultures were collected, 
centrifuged and aliquoted in 1mL Eppendorf tubes that were kept at -80oC until 
required. Protein was also extracted from the cells using 100µL lysis buffer, quantified 
using the Bio-Rad DC Protein Assay kit (Bio-Rad laboratories) and used for 
normalization of the results. Each aliquot was thawed and used only once and the 
VEGF content was quantified using the human VEGF ELISA kit (Life Technologies Ltd.) 
following the manufacturer’s instructions. The assay is described in section 2.2.6.1. 
HO-1 expression in MDA-MB-231 after treatment with novel CORMs 
Upon reaching adequate confluence (~70%), the normal media of a T25 flask was 
removed and the cells were washed twice with PBS. Fresh media containing 100µM 
CORMs or 0.1% DMSO or no treatment was added to each flask and the cells were left 
in the normal incubator for 12h. After that, the supernatant of the culture was 
discarded and the total protein was extracted from the cells using 100µL lysis buffer, 
quantified and used for Western blot analysis.  
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Expression of phosphorylated proteins in VEGF stimulated HUVEC after 
treatment with novel CORMs 
HUVEC cells were seeded in 6-well plates and upon reaching adequate confluence 
(~80%), the normal media was replaced with serum free media for 12h. Treatments 
of 100µM CORMs or 0.1% DMSO or no treatment were added to each well and the 
cells were left in the normal incubator for 15min. After that, 100ng/mL VEGF was 
added for further 5min. The supernatant of the cells was then discarded and the total 
protein was extracted from the cells using 100µL lysis buffer and quantified. The lysate 
was used either for ELISA (diluted 1:3 with Sample Diluent) or for Western blot 
analysis.  
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Unpaired Student’s t-test 
with Welch’s correction and nonparametric Mann-Whitney t-test were performed to 
check for statistical significance, with a p-value of <0.05 considered statistically 
significant. Asterisk notation (*) was used to identify significances: * p<0.05, ** 
p<0.01, *** p<0.001 and **** p<0.0001. 
5.2.3 Results 
VEGF expression in MDA-MB-231 cells after CORM treatments  
In line with the screening of the four commercially available CORMs, the novel 
compounds were tested for any effects on the VEGF expression from TNBC cells. MDA-
MB-231 cells were treated with 100µM CORMs for three different time periods and 
the concentration of VEGF excreted in the cell culture media was then quantified. As 
discussed in detail previously, MDA-MB-231 cells excrete a high concentration of 
VEGF, hence behave aggressively on angiogenesis and have a high metastatic 
capability. If this expression could be reduced, angiogenic signals towards tumour 
microenvironment could be potentially limited. Taking this into consideration, three 
different treatment periods were tested, that is 6h, 12h and 24h.  
For matters of consistency, all the percentage values were calculated comparing the 
CORM treated cells with normal media treated ones. As explained for the four initial 
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
227 
 
CORMS, due to high variations throughout the experiments in the vehicle treated 
group the results were normalised to the media treated ones. Even though the 
concentration of the vehicle was now lower and very high variations were not 
observed in the vehicle groups, the decision to proceed this way was made in order 
to make the data comparable to the previous results and reach conclusions.  
As depicted in Figures 5.2 A, B and C, all the novel CORMs could reduce the VEGF 
excreted from TNBC cells in the three time points tested. In each graph, the three 
CORMs that reduced VEGF by the highest percentage compared to the corresponding 
control group, were highlighted in red boxes. In the 6h treatment (Figure 5.2 A), 
CORM-Ala, CORM-Tyr and CORM-Nitro-Phe reduced VEGF expression by more than 
50% each, reaching high statistical significance (p=0.011, p=0.009, p=0.006 
respectively). Even though at a lower level, CORM-Asp, CORM-His and CORM-MK4a 
also managed to reduce VEGF with a higher statistical significance compared to the 
three above (p-values of 0.001, 0.0009 and 0.0008, respectively).  
The reduction in the expression of VEGF in MDA-MB-231 cells was also observed in 
the longer time treatments. As depicted in Figure 5.2 B, in the 12h treatment, again 
all CORMs decreased the levels of VEGF expressed, although for most of the 
treatments this did not reach statistical significance. The three best CORMs in this 
subset were CORM-Phe, CORM-Benz-Ser and CORM-Nitro-Tyr, which reduced VEGF 
by almost 50% with statistical significance reached only for CORM-Benz-Ser 
(p=0.0081). However, other CORMs such as CORM-Ala and CORM-Asp showed similar 
reduction levels but more significant differences compared to the above mentioned 
ones, with p-values of 0.0072 and 0.0065, respectively.  
Finally, in the 24h treatment (Figure 5.2 C), CORMs showed higher reduction rates, 
with the best ones, CORM-Phe, CORM-Tyr and CORM-His, reducing VEGF expression 
by 50%, 60% and 55%, respectively (p=0.0309, p=0.0002 and p=0.00815, respectively). 
Other CORMs did not induce such a reduction or reach any higher statistical 
significance than the ones highlighted.  
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Figure 5.2: VEGF expression after novel CORM treatments. A. VEGF expression quantification in 
MDA-MB-231 cells 6h after treatment with 100µM CORMs, 0.1% DMSO or normal media, using a 
human VEGF ELISA kit. B. VEGF expression quantification in MDA-MB-231 cells 12h after treatment 
with 100µM CORMs, 0.1% DMSO or normal media, using a human VEGF ELISA kit.  
C. VEGF expression quantification in MDA-MB-231 cells 24h after treatment with 100µM CORMs, 
0.1% DMSO or normal media, using a human VEGF ELISA kit. (All data is presented as % compared 
to control +SEM; n=3, N=3) (All data was statistically analysed against the corresponding duration 
normal media treated MDA-MB-231 cells (control) using un-paired t-test with Welch’s correction: 
* p<0.05, ** p<0.01, *** p<0.001. In each time point, the three CORMs that reduce VEGF 
expression the most are highlighted in red boxes).  
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HO-1 expression in MDA-MB-231 cells after CORM treatments for 12h 
Since HO-1 is a well-characterised cytoprotective enzyme in conditions of oxidative 
stress and excessive ROS production, any reduction in its expression would possibly 
sensitize cancer cells towards elevated production of ROS or other chemotherapeutic 
and anti-angiogenic agents. Thus, CORM-Phe and CORM-Tyr that were the most 
successful in reducing VEGF expression were also evaluated for their effects on HO-1 
expression from TNBC cells after 12h of each CORM treatment at 100µM.  
As observed in Figures 5.3 A and B, CORM-Phe and CORM-Tyr could both reduce the 
expression of HO-1 ~20% after 12h of treatment, reaching statistical significance 
(p=0.0268 for both).  
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A.  
 
 
B.  
 
 
Figure 5.3: HO-1 expression after novel CORM treatments. A. Western blot of HO-1 expression 
following CORM or vehicle or media treatment for 12h in MDA-MB-231 cells. (Blot shows 
representative data; N=3). B. Assessment of HO-1 levels in MDA-MB-231 cells following 12h of 
treatment with CORM or vehicle or media (control) treatment. (Graph shows % compared to 
vehicle +SEM; N=3) (Data statistically analysed using nonparametric (Mann-Whitney) t-test with  
* p<0.05).   
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Expression of phosphorylated proteins in VEGF stimulated HUVEC after 
treatment with CORMs 
For this experiment, 100µM CORMs or 0.1% DMSO or serum free media treatments 
were added to the cells for 15min prior to stimulation. After the 5min stimulation 
period, cell lysates were isolated and used either for ELISA against pY1175 of VEGFR2 
or for Western blot analysis against pSrc (Y419), pERK1/2 (Y204), pFAK (Y397) and 
pAKT (S473) proteins.  
As shown in Figure 5.4 A, CORM-Phe and CORM-Tyr reduced the phosphorylation of 
both pERK1 and pERK2 to baseline levels, reaching high statistical significance for both 
proteins (pERK1: p=0.0043 for CORM-Phe and p=0.0043 for CORM-Tyr, pERK2: 
p=0.0079 for CORM-Phe and p=0.0079 for CORM-Tyr). The levels of pSrc were both 
decreased to baseline, although they did not reach significance for the two new 
CORMs when compared to vehicle (Figure 5.4 B).  
For pAKT levels, there was an obvious reduction induced by both CORMs, and the 
same trend was also observed for pFAK, even though more repeats would have 
generated a more robust result (Figure 5.4 C).  
Finally, the phosphorylation levels of VEGFR2 at Y1175 were measured via ELISA and 
as shown in Figure 5.5 A both new CORMs managed to reduce phosphorylation at 
some level. However, this decrease reached statistical significance only for CORM-Tyr 
with p=0.0268. A similar outcome was also obtained by a Western blot analysis, where 
it was again shown that only CORM-Tyr moderately inhibited the activation of Y1175 
of VEGFR2 (Figure 5.5 B).   
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A.       
 
 
B. 
  
 
 
C.       
 
 
Figure 5.4: Expression of VEGFR2 pathway proteins in HUVEC after novel CORM pre-treatments 
and VEGF stimulation. A. Western blot of pSrc and pERK1/2 following 15min of CORM or vehicle 
pre-incubation and then stimulation with VEGF (100ng/ml) for 5 min. The first sample is the 
unstimulated control (Control) and the second is the stimulated control (SFM=serum free media). 
(Blot shows representative data; N≥4). B. Assessment of pERK1/2 and pSrc levels in HUVEC 
following the same protocol. (Graphs show % compared to Control +SEM; N≥4) (Data statistically 
analysed using nonparametric (Mann-Whitney) t-test with * p<0.05, ** p<0.01). C. Western blot 
of pAKT and pFAK following the same protocol. (Blot shows representative data; N=2). 
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A.  
 
 
B.   
 
 
Figure 5.5: pY1175 levels for novel CORMs. A. Expression levels of pY1175 of VEGFR2 in HUVEC 
after 15min of CORM or vehicle pre-incubation and then stimulation with VEGF (100ng/ml) for 5 
min, as measured with the human pY1175-VEGFR2 ELISA kit. The first sample is the unstimulated 
control (Control) and the second is the stimulated control (SFM=serum free media). (Graph shows 
% compared to Control +SEM; N=3) (Data statistically analysed using unpaired Student’s t-test with 
Welch’s correction * p<0.05). B. Western blot of pY1175 of VEGFR2 following the same protocol, 
which verifies the results of the ELISA. (Blot shows the obtained data; N=1). 
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5.2.4 Discussion 
Angiogenesis depends on the expression of several proteins both by the cancer cells 
and the ECs that will line the new blood vessels. Based on previous experiments for 
the commercially available CORMs, all the synthesized analogues were screened for 
their ability to affect the expression of the main angiogenic signal from TNBC cells – 
VEGF – and the expression of downstream targets of the VEGF/VEGFR2 signalling 
pathway of ECs.   
Previous literature suggested an increase in VEGF expression induced by CORMs in 
several in vitro models (Jözkowicz et al. 2003; Li Volti et al. 2005; Choi et al. 2010; 
Wilson et al. 2017), but other studies found an opposite effect for these complexes 
(Ahmad et al. 2015). Therefore, a study for any reduction in VEGF expression from 
TNBC cells was conducted, in line with the previous experiments for the commercially 
available CORMs (shown in Chapter 3).  
When the aggressive MDA-MB-231 cell line was treated with the new CORMs for 6h, 
12h and 24h, VEGF secretion was found reduced, and the three most successful 
CORMs for each time point were highlighted in red in Figure 5.2. The reduction was 
evident for all compounds, and for some of them managed to reach statistical 
significance. For the three most successful CORMs at each time point, the decrease 
reached a level of 45-65%, compared to the 47-57% for the parent complex, CORM-3. 
This suggests a potential anti-angiogenic profile for the new complexes, proving that 
the substitution of glycine with other amino acid moieties did not impair the ability to 
interfere with the VEGF expression from TNBC cells, possibly also decreasing the 
stimulation signals to the surrounding ECs.   
Due to time restrictions limiting this study, only two CORMs were chosen for further 
exploration, based on their activity on lowering VEGF expression. CORM-Phe and 
CORM-Tyr were considered the most successful among the 15 new analogues and 
were therefore pursued further.  
As limiting HO-1 expression in various cells may impair their proliferation and growth 
(Sass et al. 2008; Li et al. 2011; Szabo 2016), it would be useful to investigate how the 
two chosen CORMs affect HO-1 expression in MDA-MB-231 cells. In line with previous 
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experiments, a 12h incubation time was chosen and the concentration of 100µM, for 
comparison reasons with the commercial CORMs.  
There was a downregulating activity observed for the two CORMs that was statistically 
significant. Both complexes reduced HO-1 expression by ~20%, almost at the same 
level as the parent compound which however failed to reach significance. A decrease 
in HO-1 expression might lead to more sensitive TNBC cells to chemo- or anti-
angiogenic therapy and maybe also promote a less aggressive behaviour. Once again, 
the substitution of glycine did not impair this ability of the complex but did not 
significantly enhance it either.  
Finally, the two chosen CORMs were subjected to experiments investigating any 
inhibitory activity on the VEGF/VEGFR2 pathway of ECs. As a successful pro-
angiogenic signal transduction is linked to the effective new capillary formation, this 
pathway was explored as a potential target of the new molecules.  
Some downstream proteins of VEGFR2 were investigated upon stimulation with VEGF 
that is pERK1/2, pSrc, pAKT and pFAK, in order to detect any inhibition induced by 
CORM-Phe and CORM-Tyr. It was found that both chosen CORMs had a decreasing 
activity on the activation of all studied proteins, even though specifically for ERK1/2, 
this inhibition was highly successful and statistically significant. The results for pSrc 
were not significant, although both CORMs managed to reduce the activation. It 
should be noted though that the activation achieved with VEGF was not very high, and 
the vehicle was less stimulated than the control, therefore this might have been the 
reason why they failed to reach significance.  
As for pAKT and pFAK proteins, again both chosen CORMs seemed quite effective in 
reducing the activation induced by VEGF at such a high concentration, although this 
data needs to be confirmed via additional repeats in order to be statistically analysed 
and produce a trustworthy result.  
In any case, the new CORMs showed better inhibitory activity than the parent 
compound CORM-3 that failed to reduce pSrc and pFAK levels at all. This suggests an 
enhanced anti-angiogenic activity for the new analogues, as well as a mechanism of 
action potentially involving ERK1/2, AKT and FAK proteins.   
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Finally, the activation of VEGFR2 upon stimulation with VEGF was explored, using the 
sensitive ELISA technique for the quantification of the results. Both chosen CORMs 
showed the same trend of reducing the activation of this receptor at Y1175, although 
the result was significant only for CORM-Tyr. The results were also verified by Western 
blot analysis. As CORM-3 failed to produce such an inhibition, the new analogues 
appeared to be more effective in this experiment altogether. This was a particularly 
interesting finding that needs further investigation, but definitely points toward an 
inhibition on the pro-angiogenic signal transduction after treatment especially with 
CORM-Tyr, even upon stimulation with a high dose of VEGF.  
5.3 Angiogenic potential 
5.3.1. Introduction 
In line with previous experiments, the novel CORMs were tested for their potential to 
inhibit or reduce the ability of HECV cells to form tube-like structures. Since 
angiogenesis is involved in tumour growth, progression and metastasis, novel anti-
angiogenic agents should be able to reduce tube formation induced in ECs, therefore 
less, or disrupted tube formations would be visible in the corresponding images. 
The interaction between VEGF and its receptors promotes angiogenesis and tumour 
growth and data confirms this especially for TNBC, thus this study focuses on anti-
angiogenic indications from the new molecules. Conditioned media from MDA-MB-
231 cells which had been treated with the two chosen novel compounds or vehicle or 
media for three different durations, was used to stimulate tube formation in HECV 
cells. In addition, a separate experiment was conducted, where HECV cells were 
directly treated with the two chosen CORMs and their ability to form tube-like 
structures was measured. 
5.3.2. Materials & Methods 
Cell lines and treatments  
HECV cells maintained in DMEM media with 10% FBS and antibiotics, were used for 
the tube formation assay. All cells were maintained at 37°C with 5% CO2 prior to and 
during the experiments. Cells were treated with conditioned media from MDA-MB-
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231 cells incubated with 100µM of CORMs or 0.1% DMSO or normal media for 6h, 12h 
or 24h. For the instant treatments, the same cells and conditions were used. 
Tube formation assay using conditioned media 
3.5x104 cells were seeded on top of a pre-set layer of Matrigel in each well of a 96-
well plate. The plate was left in the normal incubator for cells to adhere and then the 
full media was replaced with serum free media containing conditioned media from 
treated MDA-MB-231 cells. After 6h, the wells were imaged using a Leica DM 1000 
LED microscope capturing at least 3 images/well in random areas. Images were 
analysed using the ImageJ Software and the percentage of total tube length compared 
to the cells that received conditioned media from vehicle treated MDA-MB-231 cells 
was calculated. 
Tube formation assay with instant treatment 
3.5x104 cells were seeded on top of a pre-set layer of Matrigel in each well of a 96-
well plate. The plate was left in the normal incubator for cells to adhere and then the 
full media was replaced with serum free media containing 100µM of CORMs or 0.1% 
DMSO or serum free media. After 6h, the wells were imaged using a Leica DM 1000 
LED microscope capturing at least 3 images/well in random areas. Images were 
analysed using the ImageJ Software and the percentage of total tube length compared 
to the vehicle treated cells was calculated. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Unpaired Student’s t-test 
with Welch’s correction was performed to check for statistical significance, with a p-
value of <0.05 considered statistically significant. Asterisk notation (*) was used to 
identify significances: * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
5.3.3. Results 
Tube formation after treatment with conditioned media from cancer cells 
As the new CORMs were being screened for potential anti-angiogenic properties, a 
tube formation assay was deemed necessary for the characterization of their anti-
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
238 
 
angiogenic capability. As a reduction of excreted VEGF from MDA-MB-231 cells was 
previously observed, any effects on the formation of tube-like structures from cancer 
conditioned media treated ECs were sought. As these compounds were not majorly 
cytotoxic against ECs, any effect observed should be a consequence of the lower 
concentration of VEGF expressed and excreted by the cancer cells.  
After isolating media from CORM-Phe, CORM-Tyr, vehicle or media treated MDA-MB-
231 cells, it was used to supplement ECs and check for angiogenic capability. As shown 
in Figure 5.6 A, both CORMs managed to reduce the formation of tubes. More 
specifically, conditioned media from CORM-Phe treated MDA-MB-231 cells for 6h, 
12h or 24h, stimulated lower tube formation compared to conditioned media from 
vehicle and media treated cells. These differences reached statistical significance with 
p-values of 0.0197, 0.0302 and 0.005 for 6h, 12h and 24h, respectively (Figure 5.6 B).  
Conditioned media from 6h and 24h CORM-Tyr treated cancer cells reduced the 
formation of tube-like structures by 40% and 30%, respectively, whereas the 
conditioned media from 12h treatment did not show a significant trend. For the 6h 
and 24h treatments, the differences were statistically significant with p-values of 
0.0153 and 0.0019, respectively.  
Tube formation after treatment with CORMs 
Another tube formation experiment was carried out, where ECs were directly treated 
with the CORMs (100µM) or vehicle or serum free media and their tube formation 
activity was assessed by quantifying total tube length in images taken 6h after the 
treatments.  
As shown in Figure 5.6 C, direct treatments did not affect the tubes and the images 
obtained were quite similar. The quantification of the total tube length did not reveal 
any statistically significant differences, with p-values calculated via t-test with Welch’s 
correction exceeding p=0.05 (Figure 5.6 D).  
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Figure 5.6: Tube formation ability of HECV after conditioned media or novel CORM treatments.  
A. Representative images from tube formation assay with HECV cells treated with conditioned 
media from variable duration incubation of MDA-MB-231 cells with 100µM CORMs or 0.1% DMSO 
or normal media. Objective 5x. B. Tube formation capacity of HECV cells after treatment with 
conditioned media from variable duration incubation of MDA-MB-231 cells with 100µM CORMs or 
0.1% DMSO or normal media. (% total tube perimeter compared to vehicle +SEM; n=3, N=3) (All 
data was statistically analysed against the conditioned media from corresponding duration vehicle 
treated MDA-MB-231 cells using un-paired t-test with Welch’s correction: * p<0.05, ** p<0.01).  
C. Representative images from tube formation assay with HECV cells treated with 100µM CORMs 
or 0.1% DMSO or serum free media. Objective 5x. D. Tube formation capacity of HECV cells after 
treatment with 100µM CORMs or 0.1% DMSO or serum free media. (% total tube perimeter 
compared to vehicle +SEM; n=3, N=2) (All data was statistically analysed against vehicle treated 
cells using un-paired t-test with Welch’s correction: * p<0.05). 
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5.3.4. Discussion 
Cancer cells are known to induce the expression of several growth factors, in order to 
support their rapid growth and potential to metastasize. One of these factors, VEGF, 
is mainly responsible for the induction of angiogenesis that will supply cancer cells 
with a functional network of blood vessels. VEGF excreted from TNBC cells reaches 
VEGFRs on the surface of ECs and stimulates pro-angiogenic pathways leading to 
increased angiogenic activity. ECs will eventually form tubules that will mature into 
fully functional blood vessels (Zhu and Zhou 2015). The in vitro formation of capillary-
like structures by ECs seeded on basement matrix has been used as a reliable 
indication of the potential of different factors to affect angiogenesis (Menyhárt et al. 
2016).  
As shown also with previous CORMs, the newly synthesized CORMs seemed to induce 
a notable reduction in the levels of VEGF expressed by MDA-MB-231 cells. Following 
previous experiments, the effect of reduced growth factor expression caused by these 
compounds on the activation and angiogenic behaviour of ECs was studied, that is the 
ability of ECs to form tubes. Therefore, conditioned media from CORM treated MDA-
MB-231 cells was used to stimulate angiogenesis on ECs and was compared to vehicle 
and normal media treatments.  
Both CORMs managed to reduce the tube formation activity of ECs to some extent. 
Conditioned media from CORM-Phe treated cancer cells caused a small (15-20%) but 
significant decrease in the length and complexity of the formed tubes. The same was 
observed also with the conditioned media from CORM-Tyr treated TNBC cells, apart 
from the 12h treatment, which did not raise statistical significance. However, CORM-
Tyr appeared to have a higher activity than CORM-Phe and the reduction after 
treatment with conditioned media from 6h pre-treated TNBC cells reached 35%.  
These results correlated very well with the determined VEGF levels for each 
conditioned media. More specifically, CORM-Phe treated MDA-MB-231 cells 
appeared to have similar concentrations of VEGF after the three different treatment 
durations that resulted in a comparable reduction in the tube formation by ECs. 
CORM-Tyr on the other hand, showed a significant lowering effect at 6h and 24h, thus 
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these media were more efficient in reducing tube formation. Indeed, even though 6h 
and 24h pre-treated MDA-MB-231 cells expressed 60% less VEGF than vehicle treated 
cells, the 12h treatment resulted in only 20% decrease. This was reflected in the tube 
formation assay, where conditioned media from 6h and 24h inhibited tube formation 
by 35% and 25%, respectively, whereas the 12h media managed only a 10% reduction 
that did not reach significance. This anomaly might be a consequence of the 
differential expression of other pro-angiogenic factors that may have been more 
elevated at the 12h time point, resulting in a lower efficiency of the CORM treatment.  
The same limitations discussed earlier for the four commercial CORMs also apply to 
these results. These are that the low level reduction in tube formation compared to 
the significant reduction in VEGF expression might be explained by the use of full 
normal media for the seeding of ECs on top of the Matrigel, the dilution of the 
conditioned media and the non-reduced concentration of growth factors of the 
Matrigel used. Thus, the mild inhibition of the tube formation activity of ECs did not 
reflect the big differences in the concentration of VEGF determined for these 
conditioned media. Another limiting factor might be other pro-angiogenic factors 
apart from VEGF that also regulate the formation of tube-like structures. In any case, 
the same trend was observed, that is TNBC cells expressed lower levels of VEGF 
because of CORM treatments and as a result there was a limited stimulation of ECs 
towards fewer and less complex tubes. 
Finally, when instant CORM treatments were checked for inhibitory activity, the 
results were as expected. None of the CORMs managed to reduce tube formation in 
a significant manner, reflecting the lack of direct toxicity against HECV and the 
minimal interference with these cells.  
In summary, the modest inhibition in the tube formation ability of ECs was a direct 
result of the reduced VEGF expression by TNBC cells because of CORM treatments. 
This observation suggests a potential of these CORMs to ablate the aggressiveness of 
MDA-MB-231 cells by limiting their growth factor expression and therefore their 
chemotactic ability.  
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Main findings and impact: 
• Some novel CORMs more cytotoxic against TNBC cells and with more favourable 
cytotoxicity profiles compared to parent structure confirming the design strategy.  
• VEGF expression of TNBC cells significantly reduced by most of the novel CORMs, 
especially CORMs -Phe and -Tyr – design did not affect parent compound’s 
activity. 
• HO-1 expression reduced after CORM-Phe and CORM-Tyr treatments – difference 
with previous literature about upregulation of HO-1 upon CORM treatment. 
Novel CORMs better than parent compound.  
• Reduction of pY1175 of VEGFR2 upon CORM-Tyr treatment in VEGF stimulated 
HUVEC, similar reduction for pSrc and pFAK, much higher reduction in pERK1/2 
and pAKT – novel analogue more efficient than parent compound.  
• Reduction of ERK1/2, Src, AKT and FAK activation upon treatment with CORM-Phe 
in VEGF stimulated HUVEC – similar activity with CORM-Tyr, failure to inhibit 
VEGFR2 activation. New complex better than the parent complex CORM-3. 
• Conditioned media from CORMs -Phe and -Tyr treated TNBC cells stimulated less 
tubule formation in ECs – studies on a more aggressive EC line than previous 
literature, with high tube formation activity. 
• No inhibition in EC tube formation after direct treatment with novel CORMs – ECs 
not directly affected by novel CORMs. 
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Chapter VI 
 
Final Discussion 
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6.1 First and second generation CORMs as anti-angiogenic agents 
Carbon monoxide has been studied both as a toxic agent known to provoke death, 
and as a therapeutic agent used in low concentrations for its beneficial contribution 
to many pathological conditions (Maruyama et al. 2012). CORMs have been 
developed as alternative sources of CO for a safer and better controlled application 
(Motterlini et al. 2005a). Recent studies report contradicting results about the effects 
of CORMs on different pathologies and they conclude that CORMs act in a tissue and 
cell type-specific manner, as well as depend on different factors in order to exert their 
therapeutic activities (Ferrando et al. 2011).  
First and second generation CORMs have been developed and studied against various 
diseases, but this study focuses on their potential as anti-angiogenic agents in TNBC. 
Being a highly aggressive and metastatic breast cancer subtype, TNBC has high 
recurrence rates and increased mortality, therefore new more targeted therapies are 
urgently needed (Marmé and Schneeweiss 2015). Angiogenesis is a necessary 
procedure that supplies tumour cells with oxygen and nutrients needed to sustain 
their rapid development (Carmeliet and Jain 2011). Therapies targeting angiogenesis, 
which appears elevated in TNBC, are not entirely successful, since they have several 
side effects and limited effectiveness, especially against TNBC. The insufficient 
efficacy can be attributed to the escape mechanisms via alternative growth factor 
signalling and the developing resistance. Thus, new therapies are under investigation 
and combination of different agents with complementary modes of action may prove 
a useful therapeutic intervention (Falcon et al. 2016; Missiaen et al. 2017).  
The four CORMs that were commercially available at the time of initiating this study 
were investigated as potential anti-angiogenic agents in TNBC. These CORMs were 
CORM-1, CORM-2, CORM-3 and CORM-A1. Since heavy metal-based drugs present 
toxicological concerns to the living organisms (Egorova and Ananikov 2017), the 
cytotoxicity of the four analogues was first explored. CORM-1 is a Mn-based CORM, 
and Mn is known as an essential and biocompatible metal (Ali et al. 2017). Moreover, 
CORM-2 and CORM-3 are Ru-based, and have not been reported as highly toxic 
against any cell type tested (Winburn et al. 2012). Finally CORM-A1 does not have a 
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heavy metal core, instead boron serves as the metalloid centre (Motterlini et al. 
2005b).  
In this study, the four CORMs were shown moderately cytotoxic against the two TNBC 
cell lines, MDA-MB-231 and MDA-MB-436, with CORM-2 being the most effective 
one. However, this complex was also toxic against the control epithelial breast cells, 
MCF-10A and the ECs, HECV. A more favourable profile was found for CORM-1 and 
CORM-3 that were more toxic against TNBC cells than against the non-tumorigenic 
cell lines. These results fall in line with previous studies, where CORM-2 was shown to 
be toxic against various cell types (Lee et al. 2014; Vítek et al. 2014). Despite of the 
lack of high cytotoxicity, CORM-2 and CORM-3 were shown to be moderately 
cytostatic against MDA-MB-231 cells. Furthermore, caspase-3 and caspase-7 levels 
were not significantly affected by these compounds.  
Following cancer cells’ preference towards a glycolytic metabolism over an oxidative 
phosphorylation one (Alfarouk et al. 2014), these four CORMs were tested for any 
ability to alter or inhibit the glycolytic metabolism of MDA-MB-231 cells. CO has been 
shown to affect mitochondrial function and cell metabolism in a concentration-
dependent manner (Szabo 2016), therefore four different concentrations of CORMs 
were tested. When the treatments were injected directly onto the cells at the 
beginning of the experiment, a reduction in the glycolytic metabolism of these cells 
was found at different concentrations for each compound, with CORM-2 being the 
most effective one at the highest concentrations used. When Avastin® was combined 
with CORMs no significant enhancement was observed, but rather a loss of activity 
for the CORMs. Thus, CORMs can potentially interfere with the glycolytic metabolism 
of TNBC cells, although higher concentrations than 100µM might be more effective.  
Angiogenesis is a complex procedure that is vital for the survival and growth of the 
tumour. It is linked to the expression of several proteins that can either sustain the 
pro-angiogenic signal towards the surrounding tissues, or execute the angiogenic 
process itself (Abhinand et al. 2016). In line with that, CORMs were tested for their 
effects on the expression of proteins critical for angiogenesis. First of all, the two TNBC 
cell lines were quantified for their VEGF expression after CORM treatments, in order 
to reveal any reduction in the angiogenic signal originating from the tumour. Indeed, 
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all CORMs were shown to decrease the expressed and excreted VEGF from both MDA-
MB-231 and MDA-MB-436, although more consistent results were reported for the 
first cell line. This result contradicted previous literature that suggested an increase in 
VEGF expression in different cell types upon treatment with CORMs and suggested 
the potential interference of other pro-angiogenic growth factors (Jözkowicz et al. 
2003; Li Volti et al. 2005; Choi et al. 2010; Wilson et al. 2017).  
The successful pro-angiogenic signal transduction within the ECs that are going to 
execute angiogenesis, involves the phosphorylation and activation of subsequent 
proteins, starting from the surface receptor VEGFR2 and following its complex 
downstream pathway. One important phosphorylation site on VEGFR2 is the tyrosine 
residue Y1175, but each site is linked to several functions (Lamalice et al. 2007). Taking 
this into consideration, the four CORMs were studied for their ability to interfere with 
the activation of the VEGFR2 signal pathway in a primary EC line, HUVEC, and upon 
VEGF stimulation. The obtained results suggested that CORM-2 inhibited the VEGF-
induced phosphorylation on Y1175 of VEGFR2, whereas CORM-3 was more successful 
in reducing the activation of ERK1/2 proteins. In fact, CORM-2 was effective against 
all proteins tested, correlating well with previous literature (Ahmad et al. 2015), which 
pointed towards a different mechanism of action for CORM-2 and CORM-3. The 
inherent toxicity of CORM-2 against ECs might have also been a reason why this 
complex was more successful, whereas CORM-3 was shown to preferentially inhibit 
ERK proteins and maybe AKT, as well. In any case, both compounds seem to have anti-
angiogenic potential and as suggested by other researchers, the combination of 
agents that can reduce the expression of angiogenic factors with ones that target 
these factors and their signalling pathways might provide future therapeutic regimens 
for TNBC (Wang et al. 2015).  
Another important protein linked to CO and CORMs is HO-1. HO-1 is responsible for 
the endogenous production of CO and is also involved in the cytoprotective 
mechanisms against oxidative stress (Dulak et al. 2008). Since suppression of HO-1 
could impair the proliferation of cancer cells (Li et al. 2011), CORMs were also studied 
for their effects on HO-1 expression in TNBC cells. It was shown that CORMs 
downregulated HO-1 expression in MDA-MB-231, with CORM-1 and CORM-2 being 
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the most effective ones, although CORM-A1 showed a completely opposite effect. 
This might have been a consequence of the non-transition metal core of CORM-A1 
but the result pointed towards a reduced protection for TNBC cells after transition 
metal CORM treatments.  
The angiogenic process depends highly on the ability of ECs to migrate to distant 
areas, and there are many therapeutic agents that block this function (Missiaen et al. 
2017; Potente and Carmeliet 2017). The four available CORMs were tested for any 
inhibitory activity against the migration of HECV cells, and three of them were found 
to inhibit this process at a significant level. The only unsuccessful CORM was CORM-
A1, again showing a different behaviour than the other complexes. When TNBC cells 
were tested in the same experimental set up, in the scope of the high metastatic 
nature of MDA-MB-231 cells, they were found not affected by CORMs, so probably 
there would be minor interference with the ability of these cells to induce metastasis.  
The final angiogenesis-related investigation involved the ability of ECs to form tube-
like structures upon treatment with conditioned media from CORM-treated TNBC 
cells (Menyhárt et al. 2016). As VEGF is the main angiogenic stimulant that initiates 
vessel formation, the VEGF reducing activity of CORMs in TNBC cells might be 
translated into a decreased stimulation for ECs. Indeed, both CORM-2 and CORM-3 
limited the tube-formation activity of HECV cells, even though the reduction was not 
of the same level as the reduction in VEGF expression from cancer cells. This was an 
expected result, as VEGF is not the only pro-angiogenic stimulant and HECV cells are 
more aggressive than other similar EC lines expressing many growth factors (Puddu et 
al. 2016). In a similar experiment, the ability of direct treatments of CORMs to inhibit 
tube formation in ECs was assessed, and it was revealed that only CORM-2 interfered 
with these cells directly, reflecting the previous results about the inhibition in 
activation of the VEGFR2 pathway in ECs upon VEGF stimulation. This meant that 
CORM-2 affected the ECs per se, whereas CORM-3 probably interfered with the VEGF 
expression mechanism in TNBC cells and directly inhibited only the ERK 
phosphorylation and activation in ECs.  
In summary, there are clear indications of anti-angiogenic activity for CORM-2 and 
CORM-3, which appear to have a different but similar mechanism of action.  
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6.2 Design and synthesis of new analogues 
Based on the obtained data, CORM-3 was chosen as the lead compound for structural 
modifications. This decision was based on several favourable characteristics, such as 
water solubility and good inhibiting activity on the VEGF expression from TNBC cells, 
the activation of downstream proteins of VEGFR2 and the migration of ECs. It was also 
based on several limitations of the other complex with good results, CORM-2, such as 
being water insoluble, toxic against breast epithelial cells and a Ru-based dimer that 
could not be easily modified without affecting the general structure. Hence, a set of 
15 new analogues based on CORM-3 were designed and synthesized, and most of 
them were novel structures not reported before in literature. 
These complexes explored different strategies for the substitution of the glycine 
moiety of CORM-3, such as amino acids with various lipophilicity features, addition of 
nitro and amino groups and ligation with an additional pro-oxidant substituent. Even 
though the purification of the synthesized products proved challenging, the crudes 
used were very close to purity and higher polymeric structures might explain the 
abnormalities shown in the NMR spectra, instead of the existence of impurities. 
All the new molecules were isolated as white to yellow powders, kept in tightly sealed 
vials in the dark at -20oC and used fresh on the day of the experiments. Only CORM-
Ser appeared to be heavily affected by light and humidity, as from yellow powder it 
transformed to a dark yellow waxy solid, probably owing to its free hydroxyl group 
that can be easily oxidized by the atmospheric oxygen. 
6.3 Third generation CORMs as anti-angiogenic agents 
The 15 new analogues were first subjected to cell viability tests, in order to determine 
their toxicity against the cell lines used in this study. The results showed a better 
cytotoxicity profile for the new CORMs, especially for CORM-Ala, CORM-His and 
CORM-MK4a, which pointed towards a favourable selectivity profile. The other 
analogues correlated well with the designing strategies, and molecules that were 
expected to be more toxic had indeed lower IC50 values.  
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In line with previous experiments, the new CORMs were tested for their ability to 
reduce VEGF expression in MDA-MB-231 cells. In fact, all new CORMs showed very 
promising results, and the decrease of the excreted VEGF reached a high point of 65%.  
Based on the data, only two CORMs were chosen for further studies, that is CORM-
Phe and CORM-Tyr. This was inevitable due to time restrictions for this study, and the 
choice of the two analogues derived from their ability to reduce VEGF expression in 
TNBC cells more effectively than the other analogues.  
Another effect of the two chosen analogues on MDA-MB-231 cells was that they were 
both proven to lower the expression of the cytoprotective HO-1 enzyme in these TNBC 
cells, possibly interfering with their defence mechanisms against oxidative stress and 
excess ROS production. 
Taking into consideration that angiogenesis involves the successful signal 
transduction from VEGFR2 on the surface of ECs towards the cell nucleus, the two 
chosen CORMs were investigated for their ability to interfere with the VEGFR2 
pathway in HUVEC upon VEGF stimulation. The data showed that both CORMs 
inhibited the activation of ERK1/2, Src, AKT and FAK proteins at some level. In fact, 
CORM-Tyr was the most effective, especially against ERK1/2 and AKT 
phosphorylation. It was also the most successful of the two in reducing the activation 
of Y1175 of VEGFR2 upon stimulation with VEGF.  
Finally, the new CORMs were tested for their ability to reduce the tube-formation 
activity of HECV cells, as an in vitro model imitating the process of angiogenesis in vivo. 
Conditioned media from CORM-treated TNBC cells was used to stimulate tube 
formation in ECs and both CORMs had a modest inhibitory effect, with CORM-Tyr 
showing a higher reduction when 6h and 24h conditioned media was used. 
Nevertheless, both CORMs showed similar results that pointed towards anti-
angiogenic ability. None of them had a direct effect on the ECs per se, meaning that 
the reduction in VEGF from TNBC cells was probably the reason for the decreased 
tube formation observed in the treated ECs.  
Combining CORMs with anti-VEGF therapy for TNBC therapy | Malamati Kourti 
 
250 
 
In summary, there are several features of the new analogues which are favourable for 
an anti-angiogenic behaviour, and the two chosen CORMs were shown to be effective 
in limiting certain events crucial for a successful angiogenic process.  
6.4 Comparison between old and new analogues and selection of the 
final lead compound 
Four commercially available CORMs were chosen to be investigated in this study, for 
their potential as anti-angiogenic agents. Based on the obtained data and other 
important characteristics, one of them was chosen for further modification; hence 15 
new CORMs were successfully designed and synthesized. The new complexes were 
subjected to in vitro evaluation and a comparison made between the old and the new 
molecules. 
Three of the newly synthesized CORMs showed a more favourable cytotoxicity profile 
than the parent compound, CORM-3, and the more toxic CORM-2. CORM-Ala, CORM-
His and CORM-MK4a were all more effective in reducing the viability of TNBC cells 
than the other non-tumorigenic cell lines. This selectivity was not observed for the 
other more toxic analogues, such as CORM-Nitro-Tyr and CORM-Cyclopent, but 
CORM-Cyclopent was more cytotoxic than CORM-2 against MDA-MB-231 cells and 
less toxic against MCF-10A. 
The new CORMs were similarly able to reduce the VEGF expression in TNBC cells when 
compared with CORM-2 and CORM-3. No major enhancement was observed, but all 
new analogues retained this activity, which means that the substitution of the glycine 
moiety of the parent CORM with other amino acids did not impair the ability of the 
new CORMs to interfere with the VEGF expression mechanism in MDA-MB-231 cells. 
This is an indication that the common characteristic between all these CORMs – the 
released CO – might be responsible for the reduction of this growth factor. Otherwise, 
the change in the conformation of the complex by substituting a specific ligand would 
have severe impact on the activity of the whole molecule.  
In line with this observation, the two new CORMs, CORM-Phe and CORM-Tyr, had the 
same downregulating activity over HO-1 expression as the parent compound CORM-
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3, CORM-2 and CORM-1. This might be an indication that this downregulation in both 
VEGF and HO-1 expression is a result of the CO released and not of the whole 
molecule. The Ru core, which is also a common characteristic between CORM-2, 
CORM-3, CORM-Phe and CORM-Tyr might also play a role in the observed effects, 
especially for the downregulation of VEGF, since the new analogues are slightly more 
active than CORM-1. 
As for the ability to inhibit the activation of the VEGFR2 pathway, CORM-Phe and 
CORM-Tyr were far more successful than CORM-3 in halting the phosphorylation of 
VEGFR2 in Y1175 upon VEGF stimulation. However, none of them was better than 
CORM-2, which managed to return the phosphorylation levels to baseline. Similarly 
for the rest of the pathway proteins tested, the new CORMs were more effective than 
CORM-3 in all cases, and especially for ERK1/2 and Src, they managed to decrease the 
activation even more than CORM-2, reaching significance for the ERK1/2 data.    
Finally, when conditioned media from CORM-treated TNBC cells was used to stimulate 
tube formation in ECs, CORM-Tyr managed to reduce the tubes by 40% at 6h 
treatment, whereas CORM-2 and CORM-3 reached 30% and 20% reduction, 
respectively. Even though CORM-Phe was less successful in decreasing the length of 
the tubes formed, both new analogues showed a consistent inhibition. Only CORM-2 
was shown to affect ECs directly, whereas the activities of the other molecules were 
merely attributed to their ability to reduce VEGF expression from cancer cells. 
All in all, it seems that CORM-2 is the best analogue of the original series, but its 
activities might also be related to its inherent toxicity against ECs and its higher 
toxicity against MDA-MB-231 cells compared to CORM-3. On the other hand, CORM-
Phe and CORM-Tyr have lower toxicities that would be quite improbable to affect the 
observed abilities, pointing towards a mechanism of action targeting VEGF expression 
in TNBC cells and the activation of ERK1/2 proteins in ECs. As they are both better 
than CORM-3 in most of the experiments conducted, it seems that the new amino 
acid substituents are more suitable in reaching their cellular targets due to different 
lipophilicity or because they force the complex to a different conformation in space. 
In any case, CORM-Tyr showed an enhanced activity over the parent compound 
CORM-3, but they both share a similar mechanism of action slightly different to the 
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one of CORM-2. Therefore, the observed abilities cannot be solely attributed to the 
released CO, otherwise a very similar effect would have been reported for all tested 
CORMs. The Ru core might also play an important role in these results, as well as the 
possible higher polymeric formation of CORM-Tyr compared to the dimer CORM-2. 
Hence, CORM-2 can be suggested for a more holistic approach against angiogenesis, 
due to its interference with several steps of the process, whereas CORM-Tyr could be 
explored as a more targeted CORM against specific proteins.  
6.5 Future work 
In the present study commercially available and newly synthesized CORMs were 
assessed for their effects on different cell function and for their anti-angiogenic 
potential. Since it was shown that they interfere with the molecular mechanisms 
executing angiogenesis, it would be interesting to investigate their exact mechanism 
of action. CORM-2 seemed to have a slightly different behaviour than CORM-3 and its 
analogues, hence both cases would have to be explored and any different targets 
identified and characterized. The clear indication of interference of CORM-2 with ECs 
was not shared by CORM-3 or its analogues, so different targets could be expected 
for these cases.  
Another important aspect of this study would be to examine the ability of newly 
synthesized CORMs to induce ROS production in TNBC cells and maybe correlate this 
activity with the mechanism of action for each complex.  In any case, more pro-oxidant 
CORMs should be synthesized in order to get a clear indication of ROS participation in 
the observed effects.  
Other EC lines could also be tested against these CORMs, since it was shown that even 
though HECV and HUVEC are both ECs, they respond diversely to CORM treatments, 
hence they have distinctive characteristics that are differently affected by CORMs. It 
would be useful to show these differences discussed earlier in this study and their 
impact on the in vitro and in vivo anti-angiogenic activities of these complexes.   
Finally, another interesting exploration would involve the combination of the lead 
CORMs with other chemotherapeutic or anti-angiogenic agents, for example Avastin® 
as suggested by the title of this study. Depending on the accompanying agent, the 
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combination might present higher cytotoxic or anti-angiogenic efficiency against 
TNBC and help with the reduction of the recommended dose for the combined agent, 
as well. For example, it is known that Avastin® provokes serious side-effects which 
would be reduced or avoided if the necessary therapeutic dose could be lowered. A 
combination of drugs that leads to synergy is particularly welcome when it comes to 
anticancer therapies, since anticancer drugs have severe and frequent adverse effects 
that derive from the high doses recommended for the desired activity.  
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Antibacterial activity assessment 
Introduction 
In the early 2000’s, the newly characterized group of CORMs started receiving major 
scientific interest. One of the first studies to investigate potential applications of these 
compounds revealed a potent anti-microbial profile, which was originally attributed 
to the released CO. In the study of Nobre et al. (Nobre et al. 2007), cell growth 
experiments showed an interesting bactericidal effect of CORM-2 and CORM-3 
against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) at 250µM for 
CORM-2 and 400µM for CORM-3. The effectiveness of CORMs appeared to be much 
greater in near-anaerobic environments, resembling the anaerobic nature of the 
microorganisms themselves and the most common pathogen colonization 
environments. The researchers ascribed the results to the preferential binding of the 
released CO to the ferrous haem proteins and the impairment of the respiratory chain 
due to the inhibition of cytochrome oxidase, even though the latter might also 
conveniently explain the bactericidal activity of CORMs under aerobic conditions too. 
In the following years, many groups studied the anti-microbial activity of CORMs, for 
example CORM-3 was shown to inhibit Pseudomonas aeruginosa (P. aeruginosa) at 
0.1-100µM, probably through inhibition of cysteine moieties on respiratory proteins 
and independently of the overproduction of ROS caused by the inhibition of the 
respiratory chain (Desmard et al. 2009). CORM-3 was also investigated against E. coli 
under aerobic conditions in a separate study by Davidge et al. (Davidge et al. 2009) 
and inhibition of electron transfer to cytochrome c oxidase, generation of ROS and 
redox modulation of cysteine residues were identified as potential targets of the 
strong anti-microbial activity of CORM-3, even at low concentrations. Moreover, this 
study revealed a gene expression profile extensively modified by CORM-3, correlated 
with metal metabolism, homeostasis and transporting proteins, as well as respiratory 
complexes.  
Other investigations include the work against Campylobacter jejuni (C. jejuni), which 
was not inhibited with up to 100µM of CORM-3. However this insensitivity was not 
due to failure of CORM-3 to inhibit membrane-associated respiratory oxidases, and 
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even at almost 200µM oxygen, CORM-3 could inhibit formate-dependent respiration 
and lead to generation of hydrogen peroxide (H2O2) (Smith et al. 2011).  
CORM-2 was also shown to have antibacterial activity, for example against 
uropathogenic E. coli and other strains, at 500µM (Sahlberg Bang et al. 2016). 
Interestingly, CORM-2 was also combined with other antibiotics, such as 
metronidazole, amoxicillin and clarithromycin and found to enhance their effect 
against Helicobacter pylori (H. pylori) and with tobramycin against P. aeruginosa 
(Murray et al. 2012; Tavares et al. 2013).  
Most of these studies suggest the ROS hypothesis, that is CORMs based on Ru such as 
CORM-2 and CORM-3, induce the generation of ROS due to the inhibition of 
respiratory oxidases and thioredoxin reductase. The produced ROS contribute to the 
killing properties of CORMs and CORMs should not be solely seen as CO delivery 
systems, but rather that the whole molecule contributes to the observed properties 
(Tavares et al. 2011; Tavares et al. 2013). In fact, transcriptomics revealed that both 
CORM-3 and the CO-depleted molecule affected several systems linked to energy 
metabolism, membrane transport, motility and metabolism of sulphur species 
(McLean et al. 2013). All in all, it seems that ROS play an important role not only in the 
bactericidal activity of CORMs but also in their general properties, hence ROS 
formation should be considered when using this class of organometallic compounds 
(Wareham et al. 2015).  
Following this, CORMs -2, -3 and -A1 were subjected to an anti-microbial testing using 
a broth microdilution method. The strains tested were NCTC/ATCC control strains 
both sensitive and resistant, as well as strains that belong to the strain collection of 
the laboratory. An anti-microbial activity of CORMs may be unrelated to TNBC, 
however the involvement of ROS production and the opportunity to check the CORMs 
against a wide collection of microorganisms were considered interesting, therefore 
these experiments were chosen to be included in this study. 
Dilution procedures were used to determine the minimum inhibitory concentrations 
(MICs) of antimicrobial agents as they are the reference method for antimicrobial 
susceptibility testing. MIC methods are used in several cases, such as resistance 
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surveillance or comparative testing of new agents. In dilution tests, microorganisms 
are tested for their ability to produce visible growth in broth-containing serial 
dilutions of the antimicrobial agent. The lowest concentration of an antimicrobial 
agent (mg/L) that under defined in vitro conditions prevents the appearance of visible 
growth of a microorganism within a defined period of time is known as the MIC.  
In the broth microdilution technique, containers filled with identical volumes of broth 
and antimicrobial agent solution in incrementally (two-fold) increasing concentrations 
are inoculated with a known number of microorganisms.  
Materials & Methods 
ISO broth microdilution method 
Working solutions of the compounds to be tested were dispensed into microdilution 
trays with double the desired final concentrations of antimicrobial agent. The trays 
were inoculated within 30min of standardizing the bacterial suspension, in order to 
maintain viable cell number concentration. To each well with diluted antimicrobial 
agent in broth, the same volume of bacterial suspension was added. 
After the addition of the bacterial suspension, microdilution trays were sealed in 
polyethylene bags before incubation, in order to prevent desiccation. The trays were 
incubated at 37oC in ambient air for (18 ± 2)h. The amount of growth in each well was 
compared with that in the positive growth control, and the MIC recorded was the 
lowest concentration of the agent that completely inhibited visible growth.  
Results 
Several bacterial strains were used in this study, both sensitive and resistant to 
specific antibiotics. The well-known antibiotic ampicillin was used as a control 
antibiotic to ensure reliable results. 
In contrast with many other reports (as will be discussed further), in these 
experiments only CORM-2 managed to kill most of the strains tested, with MIC values 
from 64 to 128mg/L (Table 1, Table 2). In more detail, Klebsiella pneumoniae and S. 
aureus resistant strains appeared to be affected by CORM-2 with MIC of 128mg/L, 
whereas C. coli and jejuni were not affected by this compound. Enterococcus faecalis 
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resistant to vancomycin was inhibited by CORM-2 with MIC= 64mg/L and also other 
sensitive bacteria, such as Salmonella enteritidis and Burkholderia cepacia were killed 
by it with MIC values of 128mg/L. CORM-3 and CORM-A1 were not effective against 
these microorganisms. 
It must be stressed here that the highest concentration used for these experiments 
(128mg/L) corresponds to different molar concentrations of CORMs. More 
specifically, 128mg/L are equivalent to 250µM CORM-2, 434µM CORM-3 and 
1.233mM CORM-A1.   
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Organism ID Resistances 
CORM-A1 
MIC 
(mg/L) 
CORM-2 
MIC 
(mg/L) 
CORM-3 
MIC 
(mg/L) 
Amp 
MIC 
(mg/L) 
Escherichia coli Sensitive strain >128 128 >128 8 
Klebsiella pneumoniae Sensitive strain >128 >128 >128 >128 
Proteus mirabilis Sensitive strain >128 128 >128 >128 
Pseudomonas aeruginosa Sensitive strain >128 128 >128 >128 
Salmonella enteritidis Sensitive strain >128 128 >128 4 
Acinetobacter baumannii Sensitive strain >128 128 >128 128 
Burkholderia cepacia Sensitive strain >128 128 >128 >128 
Staphylococcus aureus Sensitive strain >128 128 >128 4 
Enterococcus faecalis Sensitive strain >128 128 >128 2 
Escherichia coli Ampicillin >128 >128 >128 >128 
Klebsiella pneumoniae Carbapenems >128 128 >128 >128 
Escherichia coli 
3rd gen 
Cephalosporins 
>128 128 >128 >128 
Escherichia coli Nitro / Trim >128 >128 >128 >128 
 
Table 1: Anti-bacterial assessment expressed as MIC of each CORM against different bacterial 
strains. Results from antibacterial assessment of CORM-A1, CORM-2 and CORM-3. Organism 
identity, known resistances and MIC in mg/L for each compound are given at the table. Ampicillin 
(Amp) was used as the control antimicrobial. MIC values ≤128mg/L are highlighted in blue. 
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Organism ID Resistances 
CORM-A1 
MIC 
(mg/L) 
CORM-2 
MIC 
(mg/L) 
CORM-3 
MIC 
(mg/L) 
Amp 
MIC 
(mg/L) 
Klebsiella pneumoniae 
4th gen 
Cephalosporins 
>128 128 >128 >128 
Klebsiella pneumoniae Carbapenems >128 128 >128 >128 
Staphylococcus aureus Flucloxacillin >128 128 >128 >128 
Staphylococcus aureus ERY/CLIND >128 128 >128 64 
Staphylococcus aureus Vancomycin >128 >128 >128 >128 
Staphylococcus aureus Tetracycline >128 >128 >128 >128 
Enterococcus faecalis Vancomycin >128 64 >128 4 
Enterococcus faecalis Vancomycin >128 64 >128 8 
Campylobacter coli Sensitive strain >128 >128 >128 - 
Campylobacter coli Sensitive strain >128 >128 >128 - 
Campylobacter jejuni Sensitive strain >128 >128 >128 - 
Campylobacter jejuni Sensitive strain >128 >128 >128 - 
Campylobacter jejuni Sensitive strain >128 >128 >128 - 
 
Table 2: Anti-bacterial assessment expressed as MIC of each CORM against different bacterial 
strains. Results from antibacterial assessment of CORM-A1, CORM-2 and CORM-3. Organism 
identity, known resistances and MIC in mg/L for each compound are given at the table. Ampicillin 
(Amp) was used as the control antimicrobial. MIC values ≤128mg/L are highlighted in blue. 
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Discussion  
The findings of this experiment were quite unexpected. Based on previous literature, 
it was expected to find lower MIC values for both CORM-2 and CORM-3 against some 
of the tested bacteria, but instead only CORM-2 showed some anti-microbial activity 
in this experiment. These observations may have various explanations. 
First of all, as discussed extensively in the work by Smith et al. (Smith et al. 2011), 
complex media such as broth may have abolished the effects of CORM-3 due to 
components acting as scavengers of CO or inhibiting CO release. Sulphur-containing 
species such as cysteine and glutathione may have also abrogated the effects of 
CORM-3, as shown in other studies (Sawle et al. 2005; Desmard et al. 2009). The 
potential existence of certain reductases that can metabolize CO in these bacteria 
could be another explanation of the atypical results observed in this study. Finally, 
some of the tested bacteria may have had a CO-insensitive respiratory pathway that 
can induce micro-aerobic proliferation and growth.  
In any case, these results might need further optimization before conclusions can be 
drawn, however the bactericidal activity of CORM-2 was indeed confirmed and for 
CORM-3 a different method might have been better and more effective. These results 
do not contradict previous literature though, that has decisively shown a good anti-
microbial activity for both CORM-2 and CORM-3 against a variety of microorganisms. 
The ROS hypothesis is still involved in studies about CORMs and might also prove 
useful in the fight against TNBC.  
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Figure A.1: 13C NMR spectrum of MK4a 
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Figure A.2: 1H NMR spectrum of MK4a 
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Figure A.3: 13C NMR spectrum of CORM-Phe 
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Figure A.4: 1H NMR spectrum of CORM-Phe 
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Figure A.5: 13C NMR spectrum of CORM-Tyr 
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Figure A.6: 1H NMR spectrum of CORM-Tyr 
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Figure A.7: 13C NMR spectrum of CORM-Cyclopent 
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Figure A.8: 1H NMR spectrum of CORM-Cyclopent 
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Figure A.9: 13C NMR spectrum of CORM-Dinitro-Tyr 
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Figure A.10: 1H NMR spectrum of CORM-Dinitro-Tyr 
